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Abstract	  	  Macrophages	   are	   key	   cellular	   mediators	   of	   the	   innate	   immune	   system.	   During	   an	  infection,	   phagocytosis	   of	   microorganisms	   delivers	   them	   to	   the	   macrophage	  phagolysosome	  where	  they	  are	  targeted	  for	  destruction	  by	  immediate	  antimicrobial	  responses.	   In	  parallel	  with	   this,	   signalling	  via	  pattern	  recognition	  receptors	   such	  as	  the	   Toll-­‐like	   Receptors	   (TLRs)	   turns	   on	   expression	   of	   a	   set	   of	   genes	   to	   enable	   a	  second	   wave	   of	   inducible	   antimicrobial	   responses.	   Such	   responses	   enable	  macrophages	   to	   combat	   microorganisms	   that	   can	   evade	   immediate	   antimicrobial	  pathways.	  Mouse	  models	  have	  provided	  a	  powerful	  tool	  to	  study	  the	  innate	  immune	  system	   in	   the	   context	   of	   infection	   and	   inflammation,	   however	   some	   antimicrobial	  pathways	   are	   divergently	   regulated	   between	   human	   and	   mouse.	   This	   may	   partly	  reflect	   divergent	   evolution	   between	   species,	   due	   to	   selection	   pressure	   to	   co-­‐evolve	  with	  rapidly-­‐evolving	  pathogens.	  In	  view	  of	  this,	  this	  project	  aimed	  to	  explore	  novel	  aspects	  of	  human	  macrophage	  antimicrobial	  pathways.	  	  	  In	  Chapter	  3	  of	  this	  thesis,	  genetic	  analysis	  was	  conducted	  to	  validate	  the	  differential	  expression	   of	   novel	   TLR4-­‐inducible	   genes	   in	   primary	   human	   versus	   mouse	  macrophages.	   From	   this	   initial	   analysis,	   four	   genes	   (RNF144B,	   BATF3,	   G0S2	   and	  
SLC41A2)	  were	  chosen	  for	  further	  functional	  analysis.	  In	  addition	  to	  their	  differential	  regulation,	  these	  genes	  were	  chosen	  based	  on	  novelty	  and	  biological	  functions	  in	  the	  context	   of	   innate	   immunity.	   Functional	   analysis	   by	   gene	   knockdown	   focused	   on	  investigating	   potential	   roles	   in	   macrophage	   inflammatory	   and	   antimicrobial	  responses.	  These	  studies	  led	  to	  the	  identification	  of	  the	  E3	  ubiquitin	  ligase	  RNF144B	  as	  a	  novel	  regulator	  of	  NLRP3	  inflammasome	  activation.	  Further	  analysis	  (Chapter	  4)	  revealed	   that	   RNF144B	   broadly	   affected	   inflammasome	   function	   by	  mediating	   LPS	  inducible	   expression	   of	   the	   inflammasome	   substrate,	   IL-­‐1β.	   Consequently,	   p21WAF1	  was	   investigated	   as	   a	   potential	   RNF144B	   target	   that	   controls	   regulated	   IL-­‐1β	  expression	  in	  human	  macrophages.	  	  	  The	   second	   approach	   to	   investigate	   novel	   human	   macrophage	   antimicrobial	  mechanisms	  was	   to	   examine	   the	   effect	   of	   pharmacological	   agents,	   currently	   under	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investigation	   as	   modulators	   of	   inflammation	   and	   innate	   immunity,	   on	   human	  macrophage	   antimicrobial	   responses	   against	   Gram-­‐negative	   bacteria	   (Chapter	   5).	  Previous	   studies	   utilising	   histone	   deacetylase	   inhibitors	   (HDACi)	   in	   mouse	  macrophages	   had	   demonstrated	   that	   HDACi	   impair	   macrophage	   phagocytosis	   and	  antimicrobial	   responses.	   However,	   I	   found	   that,	   while	   pre-­‐treatment	   of	   primary	  human	  macrophages	  with	  HDACi	  did	  compromise	  phagocytic	  uptake	  of	  bacteria,	  co-­‐treatment	  with	  HDACi	  actually	  enhanced	  clearance	  of	  S.	  Typhimurium	  and	  E.	  coli	  by	  promoting	   the	   generation	   of	  mitochondrial	   reactive	   oxygen	   species.	   The	  G	   protein-­‐coupled	   receptor,	   C5aR,	   was	   also	   revealed	   to	   amplify	   antimicrobial	   responses	   in	  human	  macrophages	  via	  an	  ERK-­‐dependent	  pathway.	  These	  pharmacological	  studies	  thus	   provided	   new	   insights	   into	   regulation	   of	   human	   macrophage	   antimicrobial	  responses	  against	  Gram-­‐negative	  bacteria.	  	  In	   summary,	   findings	   from	   this	   thesis	   revealed	  RNF144B	  as	  a	  novel	  human-­‐specific	  regulator	   of	   TLR-­‐inducible	   IL-­‐1β	   expression	   in	  macrophages,	   and	   the	   potential	   for	  HDACi	  and	  C5aR	  agonists	  to	  boost	  the	  clearance	  of	  intracellular	  pathogens	  by	  human	  macrophages.	  Thus,	  knowledge	  generated	  from	  this	  thesis	  provides	  new	  insight	  and	  avenues	   for	   future	   research	   on	   the	   molecular	   mechanisms	   that	   regulate	   both	  inflammatory	  and	  antimicrobial	  responses	  in	  human	  macrophages.	  	  	  	  	  	   	  
	   iv	  	  
	  
Declaration	  by	  Author	  	  This	   thesis	   is	   composed	   of	   my	   original	   work,	   and	   contains	   no	  material	   previously	  published	  or	  written	  by	  another	  person	  except	  where	  due	  reference	  has	  been	  made	  in	  the	   text.	   I	   have	   clearly	   stated	   the	   contribution	   by	   others	   to	   jointly-­‐authored	  works	  that	  I	  have	  included	  in	  my	  thesis.	  	  I	   have	   clearly	   stated	   that	   contribution	   of	   others	   to	  my	   thesis	   as	   a	  whole,	   including	  statistical	   assistance,	   survey	   design,	   data	   analysis,	   significant	   technical	   procedures,	  professional	  editorial	  advice,	  and	  any	  other	  original	  research	  work	  used	  or	  reported	  in	  my	  thesis.	  The	  content	  of	  my	  thesis	  is	  the	  result	  of	  work	  I	  have	  carried	  out	  since	  the	  commencement	   of	   my	   research	   higher	   degree	   candidature	   and	   does	   not	   include	   a	  substantial	  part	  of	  work	  that	  has	  been	  submitted	  to	  qualify	  for	  the	  award	  of	  any	  other	  degree	  or	  diploma	  in	  any	  university	  or	  other	  tertiary	  institution.	  I	  have	  clearly	  stated	  which	  parts	  of	  my	  thesis,	  if	  any,	  have	  been	  submitted	  to	  qualify	  for	  another	  award.	  	  I	   acknowledge	   that	   an	   electronic	   copy	   of	   my	   thesis	   must	   be	   lodged	   with	   the	  University	   Library	   and	   subject	   to	   the	   General	   Award	   Rules	   of	   The	   University	   of	  Queensland,	   immediately	  made	  available	   for	  research	  and	  study	   in	  accordance	  with	  the	  Copyright	  Act	  1968.	  	  	  I	  acknowledge	  that	  copyright	  of	  all	  material	  contained	  in	  my	  thesis	  resides	  with	  the	  copyright	   holder(s)	   of	   that	  material.	  Where	   appropriate	   I	   have	   obtained	   copyright	  permission	  from	  the	  copyright	  holder	  to	  reproduce	  material	  in	  this	  thesis.	  
	   	  
	   v	  	  
Publications	  during	  Candidature	  	  
Peer	  reviewed	  papers:	  Review:	  1) Ariffin,	   J.K.,	   and	  Sweet,	  M.J.	   (2013).	  Differences	   in	   the	   repertoire,	   regulation	  and	   function	   of	   Toll-­‐like	   Receptors	   and	   inflammasome-­‐forming	   Nod-­‐like	  Receptors	   between	   human	   and	   mouse.	   Curr	   Opin	   Microbiol,	   doi:	  10.1016/j.mib.2013.03.002.	  
	  Journal	  Article:	  1) Vernon	   Seow,	   Junxian	   Lim,	   Abishek	   Iyer,	   Jacky	   Y	   Suen,	   Juliana	   K	   Ariffin,	  Daniel	  M	  Hohenhaus,	  Matthew	  J	  Sweet,	  David	  P	  Fairlie.	  (2013).	  Inflammatory	  Responses	   Induced	   by	   Lipopolysaccharide	   Are	   Amplified	   in	   Primary	   Human	  Monocytes	   but	   Suppressed	   in	   Macrophages	   by	   Complement	   Protein	   C5a.	  
Journal	  of	  Immunology.	  15;191(8):4308-­‐16.	  doi:	  10.4049/jimmunol.1301355.	  
 
Book	  chapter:	  1) Ronan	  Kapetanovic,	   Juliana	  K.	  Ariffin,	  Matthew	  J.	  Sweet	   (2014).	  Evolutionary	  Divergence	   in	   Human	   Versus	   Mouse	   Innate	   Immune	   Gene	   Regulation	   and	  Function.	   Pontarotti,	   Pierre	   (Ed.)	   EvolutionaryBiology:	   Genome	   Evolution,	  
Speciation,	  Coevolution	  and	  Origin	  of	  Life.	  doi:	  10.1007/978-­‐3-­‐319-­‐07623-­‐2_6.	  	  	  	  	  	  	  	   	  
	   vi	  	  
Conference	  abstracts	  
	  
Oral	  conference	  presentations:	  1) Characterization	   of	   human-­‐restricted	   TLR4	   responses	   identifies	   a	   novel	  ubiquitin	   ligase	   required	   for	   NLRP3	   inflammasome	   responses	   in	   human	  macrophages.	  Juliana	  K.	  Ariffin,	  Kate	  Schroder,	  Matthew	  J.	  Sweet.	  Presented	  at	   the	   44th	   Annual	   Scientific	   Meeting	   of	   the	   Australiasian	   Society	   for	  Immunology	  (ASI),	  1-­‐4	  December	  2014,	  Wollongong,	  NSW,	  Australia.	  
	  
Poster	  presentations:	  1) Characterization	   of	   human-­‐restricted	   TLR4	   responses	   identifies	   a	   novel	  ubiquitin	   ligase	   required	   for	   NLRP3	   inflammasome	   responses	   in	   human	  macrophages.	  Juliana	  K.	  Ariffin,	  Kate	  Schroder,	  Matthew	  J.	  Sweet.	  Cytokines	  Down	  Under	  Conference,	  26-­‐29	  October	  2014,	  Lorne,	  Melbourne,	  Australia.	  	  2) Characterization	   of	   human-­‐restricted	   TLR4	   responses	   identifies	   a	   novel	  ubiquitin	   ligase	   required	   for	   NLRP3	   inflammasome	   responses	   in	   human	  macrophages.	   Juliana	   K.	   Ariffin,	   Kate	   Schroder,	   Matthew	   J.	   Sweet.	   Lorne	  Infection	  and	  Immunity	  Conference,	  19-­‐21	  February	  2014,	  Lorne,	  Melbourne,	  Australia	  	   3) Novel	   Human	   Macrophage	   Antimicrobial	   Mechanisms.	   Juliana	   K.	   Ariffin,	  Nilesh	   J.	   Bokil,	   Vernon	   Seow,	   Kate	   Stacey,	   David	   Fairlie,	   Kate	   Schroder,	  Matthew	  J.	  Sweet.	  Brisbane	  Immunology	  Group,	  16-­‐17	  August	  2012,	  Kingscliff,	  New	  South	  Wales,	  Australia.	  	   4) Novel	   Human	   Macrophage	   Antimicrobial	   Mechanisms.	   Juliana	   K.	   Ariffin,	  Nilesh	   J.	   Bokil,	   Vernon	   Seow,	   Kate	   Stacey,	   David	   Fairlie,	   Kate	   Schroder,	  Matthew	   J.	   Sweet.	   UQ-­‐SBMS	   Postgraduate	   Symposium,	   The	   University	   of	  Queensland,	  24-­‐26	  August	  2012,	  Brisbane,	  Australia.	  	  	   	  
	   vii	  	  
Publications	  included	  in	  this	  thesis	  
	  
Ariffin,	   J.K.,	   and	   Sweet,	   M.J.	   (2013).	   Differences	   in	   the	   repertoire,	   regulation	   and	  function	   of	   Toll-­‐like	   Receptors	   and	   inflammasome-­‐forming	   Nod-­‐like	   Receptors	  between	  human	  and	  mouse.	  Curr	  Opin	  Microbiol,	  doi:	  10.1016/j.mib.2013.03.002.	  Partially	  incorporated	  as	  paragraphs	  in	  Chapter	  1.	  Table	  1,	  Figure	  1	  and	  Figure	  2	  from	  this	  review	  were	  also	  included	  as	  Table	  1.2,	  Figure	  1.1	  and	  Figure	  1.2	  in	  this	  thesis.	  	  
Contributor	   Statement	  of	  contribution	  Ariffin,	  J.K.	   Wrote	  and	  edited	  manuscript	  (50%)	  Sweet,	  M.J.	   Wrote,	  edited	  and	  reviewed	  manuscript	  (50%)	  	  Vernon	  Seow,	   Junxian	  Lim,	  Abishek	   Iyer,	   Jacky	  Y	   Suen,	   Juliana	   K	   Ariffin,	  Daniel	  M	  Hohenhaus,	   Matthew	   J	   Sweet,	   David	   P	   Fairlie.	   (2013).	   Inflammatory	   Responses	  Induced	   by	   Lipopolysaccharide	   Are	   Amplified	   in	   Primary	   Human	   Monocytes	   but	  Suppressed	   in	   Macrophages	   by	   Complement	   Protein	   C5a.	   Journal	   of	   Immunology.	  15;191(8):4308-­‐16.	  doi:	  10.4049/jimmunol.1301355.	  Data	  used	  to	  generate	  Figure	  8	  in	  this	  paper	  was	  included	  in	  this	  thesis	  as	  Figure	  5.11	  and	  Figure	  5.12.	  	  
Contributor	   Statement	  of	  contribution	  Vernon	  Seow	   Data	   acquisition	   and	   analysis,	   writing	   and	   editing	   of	  manuscript	  (45%)	  Junxian	  Lim	   Provided	   experimental	   reagents,	   reviewing	   of	   manuscript	  and	  analysis	  (5%)	  Abishek	  Iyer	   Project	  direction,	  reviewing	  of	  manuscript	  (5%)	  Jacky	  Y	  Suen	   Project	  direction,	  reviewing	  of	  manuscript	  (5%)	  Juliana	  K	  Ariffin	   Data	  acquisition	  and	  analysis	  (5%)	  Daniel	  M	  Hohenhaus	   Provided	  experimental	  reagents	  (2%)	  Matthew	  J	  Sweet	   Edited	  and	  reviewed	  manuscript	  (10%)	  David	  P	  Fairlie	   Project	  conception,	  edited	  and	  reviewed	  manuscript	  (23%)	  	   	  
	   viii	  	  
Contributions	  by	  others	  to	  the	  thesis	  	  Assoc.	   Prof.	   Matthew	   Sweet	   made	   significant	   contributions	   to	   the	   conception	   and	  design	  of	  these	  projects	  as	  well	  as	  interpretation	  of	  data	  and	  critical	  revision	  of	  this	  thesis.	   Dr.	   Kate	   Schroder	   provided	   input	   into	   project	   design	   and	   interpretation	   of	  data,	   and	   contributed	   cells	   and	   reagents	   used	   in	   these	   studies.	   Prof.	   David	   Fairlie	  provided	   reagents	   used	   in	   these	   studies	   and	   Dr.	   Vernon	   Seow	   provided	   input	   into	  technical	  work	  for	  C5a-­‐related	  studies.	  Dr.	  Dominique	  Gorse	  provided	  assistance	  with	  access	  and	   training	   for	  use	  of	   Ingenuity	  Pathway	  Analysis.	  Dr.	  Nilesh	  Bokil	  provided	  support	   in	   technical	   work	   related	   to	   culturing	   human	   monocyte-­‐derived	  macrophages,	   microscopy	   and	   statistical	   analysis.	   Dr.	   Ronan	   Kapetanovic	   provided	  technical	   support	  with	   FACs	   analysis	   and	   training	   for	   use	   of	  Geneious	  software.	  Dr.	  Melanie	   Shakespear	   provided	   support	   with	   obtaining	   and	   culturing	   murine	  thioglycollate-­‐elicited	   peritoneal	   macrophages.	   Dr.	   Divya	   Ramnath	   provided	  assistance	  with	   protein	   prediction	  modelling	   and	   use	   of	   the	   ECR	   browser.	   Kathryn	  Tunny	  provided	  support	  related	  to	  cloning	  of	  plasmid	  constructs.	  The	  Australian	  Red	  Cross	  Blood	  Service	  provided	  buffy	  coats	  used	  for	  culturing	  human	  monocyte-­‐derived	  macrophages.	  Where	  others	  have	  made	  specific	  contributions	  towards	  the	  generation	  of	  data	  contained	  within	   this	   thesis,	   this	  has	  been	  acknowledged	  at	   the	  appropriate	  point	  in	  the	  thesis.	  	  Statement	  of	  parts	  of	  the	  thesis	  submitted	  to	  qualify	  for	  the	  award	  of	  another	  degree	  	  Data	   used	   to	   generate	   Figure	   5.11	   and	   Figure	   5.12	   was	   incorporated	   into	   a	   thesis	  submitted	  by	  Dr.	  Vernon	  Seow	  to	  qualify	  for	  the	  award	  of	  his	  PhD	  degree.	  	   	   	  
	   ix	  	  
Acknowledgments	  	  I	  would	  first	  like	  to	  thank	  my	  supervisor,	  Assoc.	  Prof.	  Matt	  Sweet	  for	  the	  opportunity	  to	  do	  a	  PhD	  in	  his	  lab.	  If	  not	  for	  his	  guidance,	  encouragement,	  support	  and	  financial	  assistance	  throughout	  my	  degree,	  I	  would	  not	  have	  learned	  as	  much	  as	  I	  have,	  and	  I	  definitely	  would	   not	   have	   been	   able	   to	   complete	   this	   degree!	   I	   am	   very	   grateful	   to	  have	  such	  a	  great	   supervisor,	  who	  has	  been	   there	   for	  me	  every	  step	  of	   the	  way.	   I’d	  also	   like	   to	   thank	   my	   co-­‐supervisor	   Dr.	   Kate	   Schroder	   for	   her	   words	   of	  encouragement,	  support	  and	  guidance	  during	  my	  project,	  and	  for	  checking	  up	  on	  me	  to	  make	  sure	  everything	  was	  still	  ok.	  	  	  The	   last	   four	   years	   has	   been	   such	   a	   period	   of	   growth	   for	   me	   and	   I	   have	   many	  wonderful	  memories	   of	  my	   time	   here.	   I’d	   like	   to	   thank	   the	  members	   of	   the	   Sweet,	  Schroder	   and	   Stacey	   lab,	   past	   and	   present,	   who	   have	   taught	   me	   and	   shared	   their	  advice,	  suggestions	  and	  camaraderie.	  Many	  of	  you	  are	  my	  friends	  both	  in	  and	  out	  of	  the	   lab!	   So,	   thanks,	   Greg,	   Nilesh,	   Ronan,	   Kolja,	  Mel,	   Steve,	   Nabilah,	   Tam,	   Dan,	   Sian,	  Katja	  and	  Divya.	  Thanks	  also	  to	  Kai	  Wen,	  Dave,	  Leo,	  Flor,	  Vita	  and	  Nazarii.	  Thank	  you,	  Alina,	   for	   the	   yoga	   lessons	   –	   they	  were	   so	   good	   after	   hours	   of	   sitting	   down	   in	   the	  Dungeon!	  And	  I	  will	  always	  remember	  how	  much	  fun	  we	  all	  had	  in	  the	  Fishbowl.	  To	  my	  other	  friends	  at	  IMB	  and	  UQ,	  especially	  Selwin,	  Xin	  Yan,	  Kelly,	  Darshani	  and	  Peter	  Yee,	  thank	  you	  for	  your	  friendship,	  advice	  and	  support,	  	  Finally,	   thank	   you	   to	   my	   family,	   for	   your	   love,	   support	   and	   encouragement	  throughout	  the	  late	  nights,	  the	  floods,	  the	  haunted	  houses,	  and	  the	  long	  years	  away.	  Thanks	  also	  to	  Alex	  for	  loving	  me	  and	  for	  being	  the	  brightest	  spark	  in	  my	  life	  on	  many	  challenging	  days.	  My	  biggest	  thanks	  goes	  to	  God,	  for	  everything.	  	   	  
	   x	  	  
Keywords	  	  Inflammation,	  inflammasome,	  immune,	  antimicrobial,	  macrophage,	  toll-­‐like	  receptor,	  histone	   deacetylase,	   G	   protein-­‐coupled	   receptor,	   complement,	   C5a,	   ubiquitin,	  interleukin-­‐1β,	  RNF144B	  	  	   	  
	   xi	  	  
Australian	  and	  New	  Zealand	  Standard	  Research	  
Classifications	  (ANZSRC)	  	  ANZSRC	  code:	  110707,	  Innate	  Immunity,	  80%	  ANZSRC	  code:	  110706,	  Immunogenetics,	  20%	  	  	  






	   	  
	   xii	  	  
Table	  of	  Contents	  
	  
CHAPTER	  1	  ....................................................................................................................................	  1	  
Introduction	  .................................................................................................................................	  1	  
1.1.	   Macrophages	  and	  the	  Innate	  Immune	  System	  ...............................................................	  2	  1.1.1.	   Monocyte/Macrophage	  Differentiation	  ...................................................................................	  2	  1.1.2.	   GM-­‐CSF-­‐	  and	  M-­‐CSF-­‐differentiated	  macrophages	  ...............................................................	  5	  1.1.3.	   Microbial	  Recognition	  Systems	  ...................................................................................................	  7	  1.1.3.1.	   Toll-­‐like	  receptors	  .....................................................................................................................................	  8	  1.1.3.2.	   TLR	  signalling	  ...........................................................................................................................................	  11	  1.1.3.3.	   Downstream	  consequences	  of	  TLR	  signalling	  ............................................................................	  13	  1.1.4.	   Macrophage	  antimicrobial	  responses	  ....................................................................................	  13	  1.1.4.1.	   Lysosomal	  enzymes	  and	  antimicrobial	  peptides	  ......................................................................	  14	  1.1.4.2.	   Reactive	  oxygen	  species	  .......................................................................................................................	  15	  1.1.4.3.	   Reactive	  nitrogen	  species	  ....................................................................................................................	  16	  1.1.4.4.	   Nutrient	  deprivation	  ..............................................................................................................................	  17	  1.1.4.5.	   Autophagy	  ..................................................................................................................................................	  17	  1.1.4.6.	   Cell	  death	  ....................................................................................................................................................	  18	  
1.2.	   Inflammasomes	  .....................................................................................................................	  19	  1.2.1.	   Inflammasome	  activation	  ............................................................................................................	  20	  1.2.2.	   Role	  of	  ubiquitination	  in	  inflammasome	  activation	  ........................................................	  22	  
1.3.	  Species-­‐Specific	  Immunity	  .....................................................................................................	  23	  1.3.1.	   Differences	  in	  Pathogen-­‐sensing	  mechanisms	  ...................................................................	  25	  1.3.2.	   Differences	  in	  PRR-­‐regulated	  gene	  expression	  ..................................................................	  28	  
1.4.	  Immunoregulatory	  effects	  of	  pharmacological	  agents	  ................................................	  31	  1.4.1.	   Histone	  Deacetylases	  ....................................................................................................................	  31	  1.4.1.1.	   HDACi	  as	  anti-­‐cancer	  drugs	  ................................................................................................................	  32	  1.4.1.2.	   HDACi	  as	  anti-­‐inflammatory	  agents	  ................................................................................................	  33	  1.4.1.3.	   HDACi	  and	  effects	  on	  host	  defence	  ..................................................................................................	  34	  1.4.2.	  G	  protein-­‐Coupled	  Receptors	  ........................................................................................................	  36	  1.4.2.1.	   GPCR	  structure,	  activation	  and	  regulation	  ...................................................................................	  36	  1.4.2.2.	   GPCR	  and	  TLR	  signalling	  crosstalk	  ..................................................................................................	  37	  1.4.2.3.	   C5aR	  and	  host	  defence	  ..........................................................................................................................	  38	  
1.5.	  Scope	  of	  thesis	  and	  Aims	  ........................................................................................................	  40	  
CHAPTER	  2	  .................................................................................................................................	  42	  
Materials	  and	  Methods	  ..........................................................................................................	  42	  
	   xiii	  	  
2.1.	  Reagents	  .......................................................................................................................................	  43	  2.1.1.	   General	  reagents	  .............................................................................................................................	  43	  2.1.2	  	   TLR	  agonists	  and	  recombinant	  cytokines	  ............................................................................	  43	  2.1.3	  	   HDAC	  inhibitors	  ...............................................................................................................................	  44	  2.1.4.	   GPCR	  agonists/antagonists	  ........................................................................................................	  44	  2.1.5.	   Oligonucleotides	  ..............................................................................................................................	  44	  2.1.6.	   Antibodies	  ..........................................................................................................................................	  46	  2.1.7.	   siRNAs	  ..................................................................................................................................................	  48	  
2.2.	  Methods	  ........................................................................................................................................	  49	  2.2.1.	   Cell	  lines	  and	  culture	  conditions	  ..............................................................................................	  49	  2.2.2.	   Primary	  cells	  .....................................................................................................................................	  50	  2.2.3.	   Storage	  of	  cell	  lines	  and	  primary	  cells	  ...................................................................................	  51	  2.2.4.	   Bacterial	  culture	  ..............................................................................................................................	  53	  2.2.5.	   Bacterial	  growth	  assays	  ...............................................................................................................	  53	  2.2.6.	   Bacterial	  infection	  assays	  ............................................................................................................	  54	  2.2.7.	   Macrophage	  viability	  assays	  ......................................................................................................	  55	  2.2.8.	   siRNA-­‐mediated	  gene	  knockdown	  ..........................................................................................	  56	  2.2.9.	   Quantification	  of	  mRNA	  expression	  .......................................................................................	  56	  2.2.10.	   Enzyme-­‐linked	  immunosorbent	  assays	  ................................................................................	  57	  2.2.11.	   Inflammasome	  activation	  assays	  .............................................................................................	  58	  2.2.12.	   Western	  Blotting	  .............................................................................................................................	  59	  2.2.13.	   Flow	  Cytometry	  ...............................................................................................................................	  60	  2.2.14.	   Statistical	  analysis	  ..........................................................................................................................	  61	  2.2.15.	   Standard	  Solutions	  .........................................................................................................................	  61	  
CHAPTER	  3	  .................................................................................................................................	  62	  
Human	  versus	  mouse	  differences	  in	  TLR4-­‐regulated	  gene	  expression	  ...............	  62	  
3.1.	  	   Introduction	  ...........................................................................................................................	  63	  
3.2.	  	   Results	  ......................................................................................................................................	  66	  3.2.1	  	   Species-­‐specific	  regulation	  of	  LPS	  target	  genes	  in	  human	  versus	  mouse	  macrophages.	  ....................................................................................................................................................	  66	  3.2.2.	  	   siRNA-­‐mediated	  knockdown	  of	  selected	  TLR4	  target	  genes	  does	  not	  impact	  intracellular	  survival	  of	  E.	  coli	  or	  S.	  Typhimurium	  in	  primary	  human	  macrophages	  .......	  70	  3.2.3.	  	   Effect	  of	  siRNA-­‐mediated	  gene	  knockdown	  on	  cytokine	  and	  chemokine	  release	  from	  primary	  human	  macrophages.	  .......................................................................................................	  75	  3.2.4.	  	   Silencing	  of	  RNF144B	  expression	  attenuates	  NLRP3-­‐mediated	  inflammasome	  responses	  in	  human	  primary	  macrophages.	  .......................................................................................	  80	  
	   xiv	  	  
3.2.5.	  	   LPS	  and	  S.	  Typhimurium-­‐regulated	  expression	  of	  RNF144B	  in	  PMA-­‐differentiated	  THP-­‐1	  cells	  ............................................................................................................................	  83	  3.2.6.	  	   Silencing	  of	  RNF144B	  expression	  attenuates	  NLRP3-­‐mediated	  inflammasome	  responses	  in	  PMA-­‐differentiated	  THP-­‐1	  macrophages.	  .................................................................	  85	  
3.3	  Discussion	  .....................................................................................................................................	  88	  3.3.1.	  	   Divergent	  regulation	  of	  TLR4	  target	  genes	  in	  human	  versus	  mouse	  macrophages	  populations.	  .......................................................................................................................................................	  88	  3.3.2.	  	   Gene	  silencing	  screen	  fails	  to	  identify	  regulators	  of	  macrophage	  antimicrobial	  responses.	  ...........................................................................................................................................................	  89	  3.3.3.	  	   RNF144B	  regulates	  IL-­‐1β	  release	  from	  human	  macrophages.	  ...................................	  90	  
CHAPTER	  4	  .................................................................................................................................	  92	  
Role	  of	  RNF144B	  in	  inflammasome	  responses	  in	  human	  macrophages	  ..............	  92	  
4.1.	   Introduction	  ............................................................................................................................	  93	  
4.2	  Results	  ...........................................................................................................................................	  98	  4.2.1.	  	   Silencing	  of	  RNF144B	  expression	  with	  multiple	  siRNAs	  inhibits	  IL-­‐1β	  secretion	  from	  THP-­‐1	  cells.	  .............................................................................................................................................	  98	  4.2.2.	  	   Silencing	  of	  RNF144B	  expression	  reduces	  IL-­‐1β	  secretion	  in	  human	  macrophages	  activated	  via	  the	  NLRP3	  and	  NLRC4	  inflammasomes.	  .......................................	  99	  4.2.3.	  	   Proteasome	  inhibition	  reduces	  NLRP3-­‐triggered	  IL-­‐1β	  release	  in	  both	  human	  and	  mouse	  primary	  macrophages.	  ........................................................................................................	  100	  4.2.4.	  	   RNF144B	  knockdown	  reduces	  LPS-­‐induced	  pro-­‐IL-­‐1β	  protein	  expression	  in	  primary	  human	  macrophages.	  ................................................................................................................	  103	  4.2.5.	  	   RNF144B	  knockdown	  inhibits	  LPS-­‐induced	  IL-­‐1β	  mRNA	  expression	  in	  primary	  human	  macrophages.	  ..................................................................................................................................	  105	  4.2.6.	  	   p21	  protein	  expression	  is	  more	  tightly	  regulated	  by	  proteasomal	  degradation	  in	  primary	  human	  macrophages	  as	  compared	  to	  primary	  mouse	  macrophages.	  ..................	  107	  4.2.7.	  	   Silencing	  of	  RNF144B	  expression	  does	  not	  affect	  LPS-­‐regulated	  p21WAF1	  mRNA	  and	  protein	  expression	  in	  primary	  human	  macrophages.	  ..........................................................	  109	  
4.3.	  Discussion	  .................................................................................................................................	  111	  4.3.1.	  	   RNF144B	  regulates	  LPS-­‐inducible	  pro-­‐IL-­‐1β	  expression	  in	  human	  macrophages.	  ..	  111	  4.3.2.	  	   p21WAF1	  as	  a	  candidate	  target	  of	  RNF144B	  in	  human	  macrophages.	  .............................	  112	  
CHAPTER	  5	  ...............................................................................................................................	  116	  
Pharmacological	  modulation	  of	  human	  macrophage	  antimicrobial	  responses
	  .....................................................................................................................................................	  116	  
5.1.	  Introduction	  .............................................................................................................................	  117	  
5.2.	  Results	  .......................................................................................................................................	  119	  
	   xv	  	  
5.2.1.	   IFNγ	  priming	  effectively	  reduces	  E.	  coli	  intracellular	  survival	  in	  human	  macrophages	  ...................................................................................................................................................	  119	  5.2.2.	   Priming	  with	  SAHA	  reduces	  S.	  Typhimurium	  intracellular	  survival	  in	  M-­‐CSF-­‐derived	  HMDM.	  ..............................................................................................................................................	  121	  5.2.3.	   SAHA	  does	  not	  affect	  bacterial	  proliferation	  ....................................................................	  123	  5.2.4.	   Priming	  or	  co-­‐treatment	  with	  SAHA	  reduces	  intracellular	  survival	  of	  S.	  Typhimurium	  	  and	  E.	  coli	  in	  HMDM.	  .....................................................................................................	  124	  5.2.5.	   Comparison	  of	  efficacy	  of	  TSA	  and	  SAHA	  as	  HDAC	  inhibitors	  in	  HMDM	  ..............	  126	  5.2.6.	   Priming	  with	  HDAC	  inhibitors	  reduces	  phagocytosis	  of	  S.	  Typhimurium	  	  and	  E.	  coli	  in	  HMDM,	  whilst	  co-­‐treatment	  with	  HDAC	  inhibitors	  does	  not.	  ......................................	  127	  5.2.7.	   Co-­‐treatment	  of	  HMDM	  with	  TSA	  or	  SAHA	  at	  the	  time	  of	  infection	  with	  S.	  Typhimurium	  increases	  mitochondrial	  ROS	  production	  .............................................................	  130	  5.2.8.	   Inhibition	  of	  mitochondrial	  ROS	  production	  rescues	  survival	  of	  S.	  Typhimurium	  in	  HMDM	  co-­‐treated	  with	  TSA	  or	  SAHA.	  .............................................................................................	  132	  5.2.9.	   C5a	  co-­‐treatment	  with	  S.	  Typhimurium	  reduces	  IL-­‐6	  release	  and	  S.	  Typhimurium	  survival	  in	  HMDM.	  ..........................................................................................................	  134	  5.3.10.	   MEK	  inhibition	  rescues	  intracellular	  survival	  of	  S.	  Typhimurium	  in	  HMDM	  with	  C5a	  co-­‐treatment.	  ..........................................................................................................................................	  137	  
5.4.	  Discussion	  .................................................................................................................................	  139	  5.4.1.	   Priming	  versus	  co-­‐treatment	  with	  HDACi	  .........................................................................	  139	  5.4.2.	   HDACi	  increases	  mitochondrial	  ROS	  release	  in	  HMDM	  ...............................................	  140	  5.4.3.	   Crosstalk	  between	  C5aR	  and	  TLR4	  in	  human	  macrophages	  .....................................	  143	  5.4.4.	   MEK	  inhibition	  rescues	  survival	  of	  S.	  Typhimurium	  in	  HMDM	  with	  C5a	  co-­‐treatment	  ..........................................................................................................................................................	  144	  
CHAPTER	  6	  ...............................................................................................................................	  146	  
Final	  Discussion	  .....................................................................................................................	  146	  
6.1.	  Thesis	  overview	  ......................................................................................................................	  147	  
6.2.	  Human-­‐specific	  novel	  TLR4-­‐regulated	  genes	  ...............................................................	  148	  6.2.1.	   Potential	  roles	  of	  novel	  TLR4-­‐regulated	  genes	  	  in	  human	  	  macrophage	  function.	   148	  6.2.2.	   Species-­‐specific	  regulation	  of	  RNF144B.	  ............................................................................	  151	  6.2.3.	   The	  role	  of	  RNF144B	  in	  inflammasome	  activation	  and	  p21WAFI	  as	  a	  potential	  binding	  partner.	  .............................................................................................................................................	  153	  6.2.4.	   Potential	  mechanisms	  for	  RNF144B	  regulation	  of	  IL-­‐1β.	  ...........................................	  155	  6.2.4.1.	  RNF144B	  regulation	  of	  IL-­‐1β	  through	  p21WAF1.	  ...........................................................................	  155	  6.2.4.2.	  RNF144B	  regulation	  of	  IL-­‐1β	  through	  HIF1α	  or	  cellular	  stress.	  ...........................................	  156	  
	   xvi	  	  
6.3.	  Role	  of	  HDACi	  and	  GPCRs	  in	  human	  macrophage	  antimicrobial	  and	  
inflammatory	  pathways	  ...............................................................................................................	  161	  6.3.1.	   The	  role	  of	  HDACi	  in	  promoting	  mitochondrial	  ROS	  in	  HMDM	  ................................	  161	  6.3.2.	   The	  effect	  of	  crosstalk	  between	  hC5a	  and	  TLR4	  signalling	  in	  regulating	  HMDM	  antimicrobial	  activity	  ..................................................................................................................................	  163	  
6.4.	  Conclusions	  ..............................................................................................................................	  165	  
CHAPTER	  7	  ...............................................................................................................................	  166	  
References	  ...............................................................................................................................	  166	  
APPENDIXES	  ............................................................................................................................	  222	  
Appendix	  1	  -­‐	  Supplementary	  Figures	  ......................................................................................	  223	  
Appendix	  2	  -­‐	  Standard	  Solutions	  ..............................................................................................	  229	  
Appendix	  3	  -­‐	  Review	  Publication	  ..............................................................................................	  230	  
Appendix	  4	  -­‐	  Research	  Publication	  ..........................................................................................	  239	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
	   xvii	  	  
List	  of	  Figures	  	  Figure	  1.1:	  Mechanisms	  for	  differences	  in	  TLR	  repertoire	  or	  function	  between	  human	  and	  mouse	  and	  possible	  consequences.	  ...........................................................................................	  26	  Figure	  1.2:	  Mechanisms	  for	  differences	  in	  NLR	  repertoire	  or	  function	  between	  human	  and	  mouse	  and	  possible	  consequences.	  ...........................................................................................	  28	  Figure	   3.1:	   Representative	   profiles	   of	   LPS-­‐regulated	   expression	   of	   “human-­‐specific”	  TLR4	  target	  genes	  in	  human	  versus	  mouse	  macrophages	  from	  MacGate.	  .......................	  67	  Figure	   3.2:	   qPCR	   analysis	   of	   LPS-­‐regulated	   expression	   of	   “human-­‐specific”	   TLR4	  target	  genes	  in	  human	  versus	  mouse	  macrophages.	  ..................................................................	  69	  Figure	   3.3:	   siRNA-­‐mediated	   knockdown	   of	   RNF144B,	   SLC41A2,	   NKG7	   and	   G0S2	   in	  primary	  human	  macrophages.	  .............................................................................................................	  72	  Figure	  3.4:	  Knockdown	  of	  RNF144B,	  SLC41A2,	  NKG7	  or	  G0S2,	  followed	  by	  E.	  coli	  or	  S.	  Typhimurium,	  infection	  does	  not	  impact	  viability	  of	  primary	  human	  macrophages.	  .	  73	  Figure	   3.5:	   Knockdown	   of	   RNF144B,	   SLC41A2,	   NKG7	   or	   G0S2	   does	   not	   impact	  intracellular	  survival	  of	  E.	  coli	  or	  S.	  Typhimurium	  within	  HMDM.	  ......................................	  74	  Figure	   3.6:	   Knockdown	   of	   RNF144B,	   SLC41A2,	   NKG7	   or	   G0S2	   does	   not	   impact	  inducible	  IL-­‐6	  secretion	  from	  HMDM.	  ..............................................................................................	  76	  Figure	   3.7:	   Knockdown	   of	   RNF144B,	   SLC41A2,	   NKG7	   or	   G0S2	   does	   not	   impact	  inducible	  TNFα	  secretion	  from	  HMDM.	  ...........................................................................................	  77	  Figure	   3.8:	   Knockdown	   of	   RNF144B,	   SLC41A2,	   NKG7	   or	   G0S2	   does	   not	   impact	  inducible	  CCL20	  secretion	  from	  HMDM.	  .........................................................................................	  78	  Figure	   3.9:	   Knockdown	   of	   RNF144B	   modestly	   increases	   LPS-­‐	   and	   E.	   coli-­‐inducible	  CXCL13	  secretion	  from	  HMDM.	  ...........................................................................................................	  79	  Figure	   3.10:	   Knockdown	   of	   RNF144B	   reduces	   IL-­‐1β	   secretion	   following	   NLRP3	  inflammasome	  activation	  in	  HMDM.	  .................................................................................................	  81	  
	   xviii	  	  
Figure	   3.11:	   Knockdown	   of	   RNF144B	   may	   attenuate	   pyroptosis	   following	   NLRP3	  inflammasome	  activation	  in	  HMDM.	  .................................................................................................	  82	  Figure	  3.12:	  qPCR	  analysis	  of	  RNF144B	  expression	  in	  PMA-­‐differentiated	  THP-­‐1	  cells	  in	  response	  to	  LPS	  and	  S.	  Typhimurium.	  .........................................................................................	  84	  Figure	   3.13:	   Knockdown	   of	   RNF144B	   reduces	   IL-­‐1β	   secretion	   following	   NLRP3	  inflammasome	  activation	  in	  PMA-­‐differentiated	  THP-­‐1	  cells.	  ...............................................	  86	  Figure	   3.14:	   Knockdown	   of	   RNF144B	   may	   attenuate	   pyroptosis	   following	   NLRP3	  inflammasome	  activation	  in	  PMA-­‐differentiated	  THP-­‐1	  cells.	  ...............................................	  87	  Figure	   4.1:	   Schematic	   diagram	   showing	   domain	   structure	   of	   the	   human	   RNF144B	  protein.	  ...........................................................................................................................................................	  95	  Figure	   4.2:	   Gene	   silencing	   of	   RNF144B	   with	   4	   different	   siRNAs	   attenuates	   IL-­‐1β	  release	  from	  PMA-­‐differentiated	  THP-­‐1	  cells.	  ...............................................................................	  98	  Figure	   4.3:	   Knockdown	   of	   RNF144B	   reduces	   IL-­‐1β	   secretion	   following	   NLRP3	   and	  NLRC4	  inflammasome	  activation	  in	  HMDM.	  ...............................................................................	  100	  Figure	  4.4:	  Treatment	  of	  primary	  human	  or	  mouse	  macrophages	  with	  a	  proteasome	  inhibitor	  inhibits	  NLRP3-­‐triggered	  IL-­‐1β	  release.	  ...................................................................	  102	  Figure	  4.5:	  Knockdown	  of	  RNF144B	  reduces	  pro-­‐IL-­‐1β	  protein	  expression	  in	  HMDM.	  .........................................................................................................................................................................	  104	  Figure	  4.6:	  Effect	  of	  knockdown	  of	  RNF144B	  on	  gene	  expression	  in	  HMDM.	  ..............	  106	  Figure	  4.7:	   Effect	   of	   the	  proteasome	   inhibitor	  MG132	  on	  p21	  protein	   expression	   in	  primary	  human	  versus	  mouse	  macrophages.	  ............................................................................	  108	  Figure	   4.8:	   Knockdown	   of	   RNF144B	   does	   not	   affect	   p21WAF1	   mRNA	   expression	   in	  primary	  human	  macrophages.	  ..........................................................................................................	  109	  Figure	   4.9:	   RNF144B	   knock-­‐down	   does	   not	   affect	   LPS-­‐inducible	   p21WAF1	   protein	  expression	  in	  primary	  human	  macrophages.	  .............................................................................	  110	  
Figure	   5.1:	   Priming	   with	   IFNγ	   reduces	   intracellular	   survival	   of	   E.	   coli	   in	   human	  macrophages.	  ............................................................................................................................................	  120	  
	   xix	  	  
Figure	   5.2:	   Priming	   with	   SAHA	   reduces	   intracellular	   survival	   of	   E.	   coli	   and	   S.	  Typhimurium	  in	  primary	  human	  macrophages.	  .......................................................................	  122	  Figure	  5.3:	  SAHA	  treatment	  does	  not	  impair	  S.	  Typhimurium	  growth.	  ..........................	  123	  Figure	   5.4:	   Co-­‐treatment	   of	   primary	   human	   macrophages	   with	   SAHA	   reduces	  intracellular	  survival	  of	  S.	  Typhimurium	  and	  E.	  coli.	  ..............................................................	  125	  Figure	  5.5:	  Levels	  of	  acetylated	  histone	  H3	  protein	   in	  primary	  human	  macrophages	  after	  treatment	  with	  TSA	  or	  SAHA	  is	  comparable.	  ...................................................................	  127	  Figure	  5.6:	  Priming,	  but	  not	  co-­‐treatment,	  of	  primary	  human	  macrophages	  with	  HDAC	  inhibitors	  impairs	  phagocytosis	  of	  E.	  coli.	  ...................................................................................	  128	  Figure	  5.7:	  Co-­‐treatment	  of	  primary	  human	  macrophages	  with	  TSA	  and	  SAHA	  reduces	  intracellular	  survival	  of	  S.	  Typhimurium	  and	  E.	  coli.	  ..............................................................	  129	  Figure	  5.8:	  Co-­‐treatment	  of	  HMDM	  with	  either	  TSA	  or	  SAHA	  at	  the	  time	  of	   infection	  with	  S.	  Typhimurium	  enhances	  mitochondrial	  ROS	  generation.	  .......................................	  131	  Figure	   5.9:	   Inhibition	   of	   mitochondrial	   ROS	   generation	   prevents	   HDACi	   from	  promoting	  clearance	  of	  S.	  Typhimurium	  from	  HMDM.	  ..........................................................	  133	  Figure	   5.10:	   Treatment	   of	   HMDM	   with	   C5a	   at	   the	   time	   of	   infection	   with	   S.	  Typhimurium	  reduces	  IL-­‐6	  secretion	  from	  primary	  human	  macrophages.	  .................	  135	  Figure	   5.11:	   Treatment	   of	   HMDM	   with	   C5a	   at	   the	   time	   of	   infection	   with	   S.	  Typhimurium	  reduces	  intracellular	  bacterial	  survival.	  .........................................................	  135	  Figure	  5.12:	  C5a	  treatment	  does	  not	  impact	  primary	  human	  macrophage	  cell	  viability	  or	  growth	  of	  S.	  Typhimurium.	  ...........................................................................................................	  136	  Figure	   5.13:	   An	   inhibitor	   of	   the	   ERK	   pathway	   prevents	   C5a-­‐mediated	   clearance	   of	  intracellular	  S.	  Typhimurium	  by	  primary	  human	  macrophages.	  .......................................	  138	  Figure	   6.1:	   Diagram	   summarising	   RNF144B	   regulation	   in	   human	   and	   mouse	  macrophages	  and	  potential	  mechanisms	  for	  IL-­‐1β	  regulation.	  ..........................................	  157	  Figure	  6.2:	  Human	  macrophage	  antimicrobial	  pathways	  promoted	  by	  HDACi	  and	  C5a.	  .........................................................................................................................................................................	  161	  
	   xx	  	  
Supplementary	  Figure	  1:	  RNF144B	  mRNA	   is	  LPS-­‐inducible	   in	  both	  GM-­‐CSF-­‐	  and	  M-­‐CSF-­‐derived	  HMDM.	  ...............................................................................................................................	  223	  Supplementary	  Figure	  2:	  qPCR	  analysis	  of	  LPS-­‐,	  Poly(I:C)-­‐	  and	   imiquimod-­‐regulated	  mRNA	  expression	  of	  RNF144B	  in	  primary	  human	  macrophages.	  ....................................	  224	  Supplementary	   Figure	   3:	   Protein	   expression	   of	   a	   potential	   alternative	   isoform	   of	  RNF144B.	  ...................................................................................................................................................	  225	  Supplementary	   Figure	   4:	   The	   promoter	   region	   of	   human	   and	   mouse	   RNF144B	   is	  conserved,	  but	  has	  distinct	  regulatory	  elements.	  .....................................................................	  226	  Supplementary	   Figure	   5:	   Alignment	   of	   the	   amino	   acid	   sequence	   of	   RNF144B	   and	  HHARI	  and	  the	  predicted	  structure	  of	  RNF144B.	  .....................................................................	  227	  
	  
	   	  
	   xxi	  	  










	   	  
	   xxii	  	  
List	  of	  Abbreviations	  	  AP-­‐1	   	   Activator	  protein-­‐1	  ASC	   	   Apoptosis-­‐associated	   speck-­‐like	   protein	   containing	   a	   caspase-­‐recruitment	  domain	  ATP	   	   Adenosine	  triphosphate	  BMM	   	   Bone	  marrow-­‐derived	  macrophage	  bp	   	   Base	  pair	  C5a	   	   Complement	  component	  5a	  CCL	   	   Chemokine	  (C-­‐C	  motif)	  ligand	  CCR	   	   Chemokine	  (C-­‐C	  motif)	  receptor	  CD	   	   Cell	  differentiation	  antigen	  CDK	   	   Cyclin-­‐dependent	  kinase	  cDNA	   	   Complementary	  DNA	  cfu	   	   Colony	  forming	  units	  cIAP	   	   Cellular	  inhibitor	  of	  apoptosis	  proteins	  CSF-­‐1	   	   Macrophage	  colony	  stimulating	  factor	  CXCL	   	   C-­‐X-­‐C	  motif	  chemokine	  DAMP	   	   Danger	  associated	  molecular	  pattern	  DC	   	   Dendritic	  cell	  ERK	   	   Extracellular	  signal-­‐regulated	  kinase	  G-­‐CSF	   	   Granulocyte	  colony	  stimulating	  factor	  GM-­‐CSF	   Granulocyte/macrophage	  colony	  stimulating	  factor	  HECT	   	   homology	  to	  E6AP	  C	  terminus	  	  	  HHARI	  	   human	  homolog	  of	  Ariadne	  HMDM	  	   Human	  monocyte-­‐derived	  macrophage	  HMGB1	   High-­‐mobility	  group	  box	  1	  protein	  HOIL-­‐IL	   Heme-­‐oxidised	  IRP2	  ligase-­‐1	  HOIP	   	   HOIL-­‐IL-­‐interaction	  protein	  IBR	   	   conserved	  in-­‐between-­‐RING	  IDO	   	   Indoleamine	  2,3-­‐dioxygenase	  IL	   	   Interleukin	  iNOS	   	   Inducible	  nitric	  oxide	  synthase	  IRAK	   	   IL-­‐1R	  associated	  kinases	  
	   xxiii	  	  
IRF	   	   Interferon	  regulatory	  factor	  LDH	   	   Lactate	  dehydrogenase	  LPS	   	   Lipopolysaccharide	  LRR	   	   Leucine-­‐rich	  region	  LUBAC	  	   Linear	  ubiquitin	  chain	  assembly	  complex	  MAPK	   	   Mitogen-­‐activated	  protein	  kinase	  MEK	   	   Mitogen-­‐activated	  protein/extracellular	  signal-­‐regulated	  kinase	  kinase	  MHC	   	   Major	  histocompatibility	  complex	  mitoROS	   Mitochondrial	  ROS	  MMP	   	   Mitochondrial	  membrane	  potential	  MOI	   	   Multiplicity	  of	  infection	   	  MyD88	   Myeloid	  differentiation	  factor	  88	  NADPH	   Nicotinamide	  adenine	  dinucleotide	  phosphate	  NAIP	   	   NLRC	  subfamily	  member	  Apoptosis	  Inhibitory	  Protein	  NFκB	   	   Nuclear	  factor	  kappa-­‐light-­‐chain-­‐enhancer	  of	  activated	  B	  cells	  NLR	   	   Nucleotide-­‐binding	  oligomerization	  domain-­‐like	  receptor	  PAMP	   	   Pathogen-­‐associated	  molecular	  pattern	  PMA	   	   Phorbol	  12-­‐myristate	  13-­‐acetate	  PRR	   	   Pathogen	  recognition	  receptor	  PyHIN	  	   Pyrin	  and	  HIN	  domain-­‐containing	  protein	  RA	   	   Rheumatoid	  arthritis	  RING	   	   really	  interesting	  new	  gene	  RNS	   	   Reactive	  nitrogen	  species	  ROS	   	   Reactive	  oxygen	  species	  SAHA	   	   Suberoylanilide	  hydroxamic	  acid	  STAT	   	   Signal	  transducer	  and	  activator	  of	  transcription	  TEPM	   	   Thioglycollate-­‐elicited	  peritoneal	  macrophage	  Th1	   	   Type	  1	  helper	  T	  cell	  Th17	   	   Type	  17	  helper	  T	  cell	  Th2	  	   	   Type	  2	  helper	  T	  cell	  TIR	   	   Toll-­‐IL-­‐1	  resistance	  TLR	   	   Toll-­‐like	  receptor	  TSA	   	   Trichostatin	  A	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1.1. Macrophages	  and	  the	  Innate	  Immune	  System	  The	   immune	   system	   consists	   of	   a	   complex	   system	   of	   biological	   structures	   and	  processes	   which	   function	   to	   protect	   the	   host	   against	   infectious	   diseases,	   tissue	  damage	   and	   dysregulated	   homeostasis.	   The	   first	   layers	   of	   protection	   are	   physical	  barriers	  such	  as	  the	  skin,	  mucous	  membranes	  and	  secretions	  that	  coat	  these	  surfaces.	  Once	   barrier	   defence	   is	   breached,	   the	   second	   line	   of	   defence	   involving	   the	   innate	  immune	   system	   is	   activated.	   This	   arm	   of	   immunity	   is	   rapidly	   activated	   upon	  recognition	   of	   specific	   danger	   signals,	   leading	   to	   initiation	   of	   antimicrobial	   and	  inflammatory	   responses.	   Innate	   immune	  mediators	   include	   soluble	   factors	   such	   as	  complement,	  as	  well	  as	  phagocytic	  leukocytes	  such	  as	  neutrophils,	  macrophages	  and	  dendritic	  cells	  that	  are	  present	  at	  and/or	  migrate	  to	  the	  site	  of	  infection.	  These	  cells	  engulf	   and	   eliminate	   pathogens,	   secrete	   soluble	   mediators	   (e.g.	   cytokines,	  chemokines)	   and	   present	   antigens	   to	   T	   cells	   to	   recruit	   the	   third	   and	   last	   line	   of	  defense	   –	   the	   adaptive	   immune	   system.	   Adaptive	   immunity	   differs	   from	   innate	  immunity	   in	   that	   it	   is	   able	   to	   generate	   antigen-­‐specific	   and	   memory	   immune	  responses	  to	  enable	  effective	  host	  defence.	  Adaptive	  immunity	  is	  intimately	  linked	  to	  innate	   immunity;	   the	   innate	   immune	   activation	   is	   required	   for	   the	   development	   of	  adaptive	   immunity,	   and	   antigen-­‐specific	   immune	   responses	   often	   activate	   innate	  immune	   cells	   to	   elicit	   optimal	   antimicrobial	   responses.	   Hence,	   the	   innate	   immune	  system	  has	  a	  central	  role	   in	   immune	  responses	  and	  effective	  host	  defence.	  Amongst	  the	  cellular	  mediators	  of	  the	  innate	  immune	  system,	  macrophages	  play	  a	  critical	  role	  in	  regulating	  immune	  responses	  by	  clearing	  infectious	  pathogens	  as	  well	  as	  initiating	  and	   resolving	   inflammation	   in	   response	   to	   endogenous	   danger	   signals	   and	   threats	  from	  invading	  microbes.	  	  	  
1.1.1.	   Monocyte/Macrophage	  Differentiation	  Differentiation	   of	   haematopoietic	   stem	   cells	   (HSC)	   within	   bone	   marrow	   into	  monocytes	   requires	   several	   growth	   factors	   and	   cytokines.	   These	   include	   growth	  factors	   such	   as	   stem	   cell	   factor	   (SCF),	   macrophage	   colony	   stimulating	   factor	   (M-­‐CSF/CSF-­‐1),	  granulocyte	  colony	  stimulating	  factor	  (G-­‐CSF),	  granulocyte/macrophage	  colony	   stimulating	   factor	   (GM-­‐CSF)	   and	   multi-­‐CSF	   (IL-­‐3)	   (Barreda	   et	   al.,	   2004;	  Fairbairn	  et	  al.,	  2011).	  The	  CSF-­‐1	  receptor	  is	  indispensable	  for	  development	  of	  most	  tissue	   macrophages,	   osteoclasts,	   Langerhans	   cells	   and	   Paneth	   cells	   (Stanley	   and	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Chitu,	  2014).	  GM-­‐CSF	  and	  IL-­‐3	  are	  required	  during	  early	  expansion	  and	  maturation	  of	  haematopoietic	   progenitors,	   while	   M-­‐CSF	   and	   G-­‐CSF	   play	   roles	   in	   proliferation,	  differentiation,	   and	   survival	   of	   macrophages,	   neutrophils	   and	   their	   precursors	  (Barreda	   et	   al.,	   2004).	   IL-­‐34	   was	   also	   recently	   discovered	   as	   a	   growth	   factor	   that	  signals	  through	  the	  CSF-­‐1	  receptor	  and	  is	  specifically	  required	  for	  differentiation	  and	  maintenance	  of	  microglia	  and	  Langerhans	  cells	  (Liu	  et	  al.,	  2012;	  Wang	  and	  Colonna,	  2014;	  Wei	  et	  al.,	  2010).	  	  Human	   monocytes	   are	   typically	   classified	   into	   three	   main	   subsets	   based	   on	  expression	  of	   the	  CD14	   (endotoxin	  co-­‐receptor)	  and	  CD16	   (FcγIII	   receptor)	   surface	  markers.	   These	   subsets	   are	   the	   classical	   inflammatory	   or	   phagocytic	   monocytes	  (CD14++CD16-­‐),	   intermediate	   or	   inflammatory	   monocytes	   (CD14++CD16+)	   and	   non-­‐classical	   or	   patrolling	   anti-­‐inflammatory	   monocytes	   (CD14+CD16++)	   (Ziegler-­‐Heitbrock	   et	   al.,	   2010).	   In	   human	   monocyte	   differentiation,	   it	   is	   thought	   that	  CD14++CD16-­‐	   classical	   monocytes	   depart	   the	   bone	   marrow	   and	   sequentially	  differentiate	  into	  CD14++CD16+	  intermediate	  monocytes	  and	  finally	  into	  CD14+CD16++	  anti-­‐inflammatory	  monocytes	  in	  peripheral	  blood	  (Zawada,	  2012).	  	  	  In	  mice,	  a	  different	   set	  of	   cell-­‐surface	  markers	  are	  used	   for	  parallel	   classification	  of	  monocytes.	  These	  subsets	  and	  their	  human	  monocyte	  counterparts	  are	  classified	  as	  follows:	  Ly6Chigh	  (both	  CD14++CD16-­‐	  and	  CD14++CD16+	  subsets	  classified	  together	  as	  CD14high)	  and	  Ly6Clow	  (CD14+CD16++	  or	  CD16+)	  (Ginhoux	  and	  Jung,	  2014;	  Yang	  et	  al.,	  2014).	   In	   terms	   of	   function,	   murine	   monocytes	   are	   classed	   as	   phagocytic	   or	   pro-­‐inflammatory	  (Ly6Chigh)	  and	  patrolling	  or	  involved	  in	  tissue	  repair	  (Ly6Clow)(Yang	  et	  al.,	   2014),	   and	   are	   thought	   to	   differentiate	   from	   Ly6Chigh	   to	   Ly6Clow	   cells	   in	   the	  circulation	  (Varol	  et	  al.,	  2007;	  Yona	  et	  al.,	  2013).	  However,	   there	   is	  also	  speculation	  that	  Ly6Clow	  monocytes	   and	   their	  human	   counterparts	   (CD16+	  monocytes)	   function	  as	   terminally	   differentiated	   luminal	   blood-­‐resident	   macrophages	   rather	   than	   true	  monocytes,	   due	   to	   their	   primary	   functions	   in	   surveying	   endothelial	   integrity,	   and	  their	   long	   steady-­‐state	   half-­‐life	   of	   2	   days	   (in	   comparison	   to	   20	   hours	   for	   Ly6Chigh	  monocytes)	  (Auffray	  et	  al.,	  2007;	  Carlin	  et	  al.,	  2013;	  Yona,	  2013).	  Ly6Clow	  cells	  have	  also	   been	   shown	   to	   respond	   to	   local	   danger	   signals	   by	   recruiting	   neutrophils	   and	  triggering	   focal	  endothelial	  necrosis,	   then	  subsequently	  phagocytosing	   the	  resultant	  cellular	   debris	   (Auffray	   et	   al.,	   2007;	   Carlin	   et	   al.,	   2013).	   In	   contrast,	   Ly6Chigh	   and	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CD14+	   monocytes	   are	   accepted	   as	   true	   classical	   monocytes	   that	   respond	   to	  inflammation	   and	   are	   precursors	   of	   peripheral	   mononuclear	   phagocytes	   (Ziegler-­‐Heitbrock	  and	  Hofer,	  2013).	  	  	  The	   description	   of	   the	   mononuclear	   phagocyte	   system	   (MPS)	   in	   terms	   of	   the	  homeostatic	   maintenance	   of	   tissue-­‐resident	   macrophages	   through	   constant	  recruitment	  and	  differentiation	  of	  blood	  monocytes	  (van	  Furth	  and	  Cohn,	  1968)	  was	  widely	   accepted	   for	   decades.	   However,	   recent	   parabiotic	   experiments	   involving	  shared	   blood	   circulation	   between	   wild-­‐type	   mice	   and	   CCR2-­‐deficient	   mice	   that	  possess	   monocytes	   incapable	   of	   exiting	   bone	   marrow	   (Serbina	   and	   Pamer,	   2006),	  have	  challenged	   this	  view.	  These	  studies	  revealed	   that,	  while	  circulating	  monocytes	  predominantly	  originated	  from	  the	  wild-­‐type	  mouse,	  tissue	  macrophage	  populations	  remained	   chimeric	   within	   the	   two	   mice.	   This	   and	   other	   studies	   indicate	   that	  peripheral	   tissue	   macrophage	   populations	   are	   not	   solely	   reliant	   on	   monocyte	  replenishment	   (Hashimoto	   et	   al.,	   2013;	   Yona,	   2013).	   Rather,	   it	   has	   recently	   been	  discovered	   that	   tissue-­‐resident	   macrophages	   in	   adults	   can	   be	   derived	   from	  embryonic	  progenitors	  in	  the	  embryonic	  yolk	  sac	  and	  fetal	  liver	  that	  seed	  developing	  tissues	   before	   birth	   and	   persist	   by	   self-­‐renewal	   throughout	   life	   (Ginhoux	   and	   Jung,	  2014).	  Upon	  pathogen	   invasion,	   inflammation	  or	   tissue	   injury,	   these	  tissue-­‐resident	  macrophages	   proliferate	   and	   also	   recruit	   Ly6Chigh/CD14high	   blood	   monocytes	   to	  differentiate	   into	   tissue-­‐resident	   macrophages	   and	   dendritic	   cells	   for	   immune	  responses	  in	  inflamed	  tissue	  (Gomez	  Perdiguero	  and	  Geissmann,	  2013;	  Jenkins	  et	  al.,	  2011;	   Sieweke	   and	   Allen,	   2013).	   However,	   there	   are	   some	   organs	   in	   adults	   that	  contain	   populations	   of	   highly	   specialised	   macrophages	   that	   do	   rely	   on	   monocyte	  maintenance,	   such	   as	   the	   intestine,	   skin,	   spleen,	   uterus,	   and	   possibly	   the	   heart	   (A-­‐Gonzalez	   et	   al.,	   2013;	   Ginhoux	   and	   Jung,	   2014;	   Tamoutounour	   et	   al.,	   2013;	  Tamoutounour	   et	   al.,	   2012).	   This	   is	   very	  much	   an	   emerging	   research	   area	   that	   has	  been	  studied	  mainly	   in	  the	  context	  of	  homeostasis.	   Indeed,	   the	  contribution	  of	  HSC-­‐derived	  monocytes	  versus	  embryonic-­‐derived	  macrophages	  to	  the	  macrophage	  pool	  in	   specific	   tissues	   is	   likely	   to	   be	   greatly	   influenced	   by	   the	   past	   and	   present	  inflammatory	  microenvironment,	   which	  may	  well	   skew	   tissue-­‐residue	  macrophage	  populations	  towards	  being	  monocyte-­‐derived.	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1.1.2.	   GM-­‐CSF-­‐	  and	  M-­‐CSF-­‐differentiated	  macrophages	  Macrophages	   are	   pleiotropic	   cells	   that	   can	   exist	   in	   a	   multitude	   of	   phenotypes,	  depending	   on	   the	   environment	   they	   have	   been	   differentiated	   in	   or	   are	   exposed	   to	  upon	  differentiation.	  Different	  macrophage	  phenotypes	  were	  originally	  defined	  based	  on	   their	   activation/polarised	   status	   as	   M1/classically-­‐activated	   macrophages	   with	  roles	  in	  inflammation	  and	  host	  defence	  and	  M2/alternatively-­‐activated	  macrophages	  with	   roles	   in	   wound	   healing	   and	   tissue	   repair	   (Mills,	   2012;	   Mills	   et	   al.,	   2000).	  Macrophages	   differentiated	   with	   GM-­‐CSF	   or	   M-­‐CSF	   may	   be	   activated	   or	   polarised	  towards	  M1	   and	  M2	   phenotypes,	   and	   so	   are	   sometimes	   referred	   to	   as	  M1	   and	  M2	  macrophages	   (Jaguin	   et	   al.,	   2013).	   In	   vitro	   polarisation	   of	   monocytes	   into	   pro-­‐inflammatory	   M1-­‐polarised	   macrophages	   is	   conducted	   either	   by	   differentiating	  monocytes	  in	  the	  presence	  of	  GM-­‐CSF,	  or	  by	  stimulation	  of	  mature	  macrophages	  with	  microbial	   products	   and/or	   the	   inflammatory	   cytokines	   TNFα	   or	   IFNγ.	   The	   TNFα	  cytokine	   is	   produced	   by	   CD4+	  T	   cells,	   natural	   killer	   (NK)	   cells	   and	  neutrophils,	   but	  mainly	  by	  activated	  macrophages,	  and	  acts	  as	  a	  modulator	  of	  immune	  cells	  to	  induce	  inflammation	   and	   apoptotic	   cell	   death,	   and	   to	   inhibit	   viral	   replication	   and	  tumorigenesis	   (Aggarwal	   et	   al.,	   2011).	   IFNγ	   is	   predominantly	   produced	   by	   NK,	  natural	   killer	   T	   (NKT)	   cells,	   CD4+	   and	   CD8+	   T	   cells	   and	   functions	   to	   activate	  macrophages,	   induce	   major	   histocompatibility	   (MHC)	   II	   molecule	   expression	   and	  directly	   inhibit	   viral	   replication	   (Schoenborn,	   2007).	   An	  M2-­‐like	   phenotype	   can	   be	  generated	  by	  differentiating	  monocytes	  with	   the	  M-­‐CSF	  growth	   factor,	   triggering	  of	  Fcγ	   and	   Toll-­‐like	   receptors	   (TLR),	   immune	   complexes,	   and	   anti-­‐inflammatory	  signalling	  involving	  the	  anti-­‐inflammatory	  cytokine	  IL-­‐10,	  transforming	  growth	  factor	  β	   (TGF-­‐β),	   which	   controls	   proliferation	   and	   cellular	   differentiation,	   and	  glucocorticoids,	  which	  are	  steroid	  hormones	  that	  reduce	  inflammation	  (El-­‐Behi	  et	  al.,	  2011;	  Gordon,	  2003).	  M2	  polarisation	  in	  vitro	  is	  also	  promoted	  by	  Type	  2	  helper	  T	  cell	  (Th2)-­‐related	   cytokines	   such	   as	   IL-­‐4	   and	   IL-­‐13,	   which	   promote	   B	   and	   T	   cell	  proliferation,	  MHC	  Class	   II	  expression	  and	  anti-­‐inflammatory	  and	  allergic	  responses	  (Gordon,	  2003).	  	  GM-­‐CSF	   and	   M-­‐CSF-­‐derived	   macrophages	   have	   distinct	   gene-­‐expression	   profiles,	  phenotypes	  and	   functions	   (Hashimoto	  et	   al.,	   1999;	  Lacey	  et	   al.,	   2012;	  Martinez	  and	  Gordon,	  2014).	  GM-­‐CSF	  macrophages	  efficiently	  produce	  inflammatory	  cytokines	  IL-­‐
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1β,	  TNFα,	  IL-­‐6	  and	  IL-­‐12/-­‐23	  and	  participate	  in	  Type	  1	  helper	  T	  cell	  (Th1)	  responses	  that	  promote	  macrophage	  killing	  and	  proliferation	  of	  cytotoxic	  CD8+	  T	  cells	  (Gordon	  and	  Taylor,	  2005).	  On	  the	  other	  hand,	  M-­‐CSF-­‐derived	  macrophages	  take	  part	  in	  Th2	  responses	   and	   are	   involved	   in	   allergy,	   parasite	   clearance,	   immunoregulation,	  dampening	  of	  inflammation,	  tissue	  remodelling,	  angiogenesis	  and	  tumour	  promotion	  (Sica	  and	  Mantovani,	  2012).	  Metabolism	  in	  the	  two	  different	  macrophage	  populations	  is	  also	  distinct.	  GM-­‐CSF	  macrophages	  utilise	  arginine	  to	  produce	  nitric	  oxide	  (NO)	  for	  antimicrobial	  functions	  and	  inhibition	  of	  cell	  proliferation	  (MacMicking	  et	  al.,	  1997).	  In	   contrast,	   M-­‐CSF	   macrophages	   utilise	   conversion	   of	   arginine	   to	   ornithine	   and	  polyamine	   to	   promote	   cell	   repair	   and	   proliferation,	   collagen	   synthesis	   and	   tissue	  remodelling	   (MacMicking	  et	   al.,	   1997;	  Mills	   et	   al.,	   2000).	   Polyamine	  production	  has	  also	  been	   reported	   to	  drive	  M-­‐CSF	  polarisation	   (Van	  den	  Bossche	  et	   al.,	   2012),	   and	  the	   healing/growth	   promoting	   M-­‐CSF	   phenotype	   is	   typical	   of	   tissue-­‐resident	  macrophages	   (Murray	  and	  Wynn,	  2011).	  GM-­‐CSF	  and	  M-­‐CSF	  macrophages	  also	  have	  distinct	  chemokine	  production	  profiles	  (Mantovani	  et	  al.,	  2004),	  and	  iron	  and	  glucose	  metabolism	  (Biswas	  and	  Mantovani,	  2012;	  Rodriguez-­‐Prados	  et	  al.,	  2010).	  	  Although	  various	  growth	  factors,	  cytokines	  and	  stimuli	  may	  polarise	  macrophages	  in	  
vitro	  towards	  an	  M1	  or	  M2	  phenotype,	  these	  simple	  classifications	  do	  not	  truly	  reflect	  the	  diversity	  and	  plasticity	  of	  macrophage	  phenotypes,	  nor	  do	  they	  fully	  recapitulate	  the	   spectrum	   of	   macrophage	   functions	   in	   vivo	   where	   more	   than	   one	   macrophage	  population	   can	   share	   similar	   characteristics	   (Mantovani	   et	   al.,	   2002;	   Mosser	   and	  Edwards,	   2008;	   Sica	   and	   Mantovani,	   2012).	   Indeed,	   a	   recent	   study	   showed	   that	  macrophage	  activation	  occurs	  in	  a	  spectrum	  of	  states	  that	  is	  characterised	  by	  distinct	  transcriptional	   signatures	   (Xue	   et	   al.,	   2014).	   In	   this	   study,	   GM-­‐CSF-­‐	   and	   M-­‐CSF-­‐derived	   human	   alveolar	   macrophages	   from	   smokers	   and	   patients	   with	   chronic	  obstructive	   pulmonary	   disease	   (COPD)	   were	   stimulated	   with	   diverse	   stimuli	  including	  pattern	  recognition	  receptor	   (PRR)	   ligands,	  cytokines	  and	  metabolic	  cues,	  and	   subjected	   to	   functional	   assessments,	   gene	   expression	   profiling	   and	  bioinformatics	  analysis	  to	  link	  the	  transcriptomic	  responses	  of	  the	  macrophages	  with	  biological	   processes	   and	   macrophage	   phenotypes.	   The	   authors	   proposed	   that	  macrophage	   activation	   states	   may	   be	   broadened	   beyond	   the	   M1/M2	   classification	  system	   to	  at	   least	  9	  distinct	   activation	  programs,	  based	  on	   the	  activation	  of	   central	  transcriptional	   regulators	   associated	   with	   an	   activated	   macrophage	   phenotype	   or	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stimuli.	  For	  example,	  signal	  transducer	  and	  activators	  of	  transcription	  1	  (STAT1)	  was	  identified	   as	   a	   core	   transcriptional	   regulator	   in	   GM-­‐CSF-­‐derived	   macrophages	  stimulated	  with	   IFNγ,	   STAT6	   for	  M-­‐CSF-­‐derived	  macrophages	   stimulated	  with	   IL-­‐4	  and	   STAT4	   in	   macrophages	   with	   chronic	   inflammation-­‐associated	   stimuli.	   Thus,	  macrophage	   classification	   may	   be	   re-­‐evaluated	   and	   expanded	   based	   on	   their	  responses	   and	   activation	   profiles	   in	   host-­‐defense,	   wound	   healing,	   and	   immune	  regulation	   (Fleming	   and	   Mosser,	   2011;	   Manjili	   et	   al.,	   2014;	   Mosser	   and	   Edwards,	  2008;	  Xue	  et	  al.;	  Xue	  et	  al.,	  2014).	  
	  
In	   vivo,	   tissue-­‐resident	   macrophages	   recognise	   sterile	   and	   non-­‐sterile	   stimuli	   and	  respond	  accordingly	  to	  recruit	  other	  immune	  cells,	  facilitate	  or	  resolve	  inflammation	  by	   wound	   healing	   and	   tissue	   repair,	   or	   by	   unleashing	   a	   suite	   of	   antimicrobial	  mechanisms	   for	   destruction	   of	   infectious	   microorganisms.	   However,	   excessive	   or	  dysregulated	   macrophage	   function	   can	   lead	   to	   development	   of	   acute	   and	   chronic	  inflammation-­‐related	  pathologies.	   For	   example,	   in	   septic	   shock,	   acute	   inflammatory	  responses	  mediated	  by	  macrophages	  results	  in	  excessive	  influx	  of	  inflammatory	  cells	  resulting	   in	   hypotension,	   hypoxia	   and	   in	   extreme	   cases,	  multiple	   organ	   failure	   and	  death	   (Castellheim	   et	   al.,	   2009).	   Chronic	   inflammatory	   diseases,	   including	  autoimmune	  diseases	  such	  as	  rheumatoid	  arthritis	  (RA),	  metabolic	  diseases	  such	  as	  diabetes	  and	  atherosclerosis,	  and	  diseases	  due	   to	  environmental	  conditions	  such	  as	  asthma	  and	  COPD,	  are	  caused	  by	  excessive	  inflammation,	  tissue	  damage	  and	  scarring	  due	  to	  repeated	  attempts	  for	  tissue	  repair	  (Libby,	  2007;	  Nathan	  and	  Ding,	  2010)	  and	  are	   strongly	   linked	   to	   macrophage	   function	   (Murray	   and	   Wynn,	   2011).	   Hence,	  appropriate	   activation	   of	   macrophages	   for	   immune	   responses	   and	   host	   defence	   is	  critical.	   Further	   details	   on	   microbial	   recognition	   and	   macrophage	   antimicrobial	  pathways	  are	  detailed	  below.	  	  	  
1.1.3.	   Microbial	  Recognition	  Systems	  Cells	  of	  the	  innate	  immune	  system	  employ	  a	  range	  of	  PRRs	  to	  recognize	  endogenous	  danger-­‐associated	  molecular	   patterns	   (DAMPs)	   and	   conserved	   pathogen-­‐associated	  molecular	  patterns	  (PAMPs),	  which	  are	  present	  on	  the	  cell	  surface	  of	  intact	  microbes	  or	  are	  released	  into	  the	  extracellular	  milieu	  upon	  microbial	  degradation.	  Activation	  of	  PRRs	   results	   in	   the	   relaying	   of	   specific	   intracellular	   signals	   to	   trigger	   antimicrobial	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mechanisms,	   inflammation	  and	  recruitment	  of	   immune	  cells.	  The	  several	   families	  of	  PRRs	   include	   the	   Toll-­‐like	   receptors	   (TLRs),	   nucleotide-­‐binding	   oligomerization	  domain-­‐like	   receptors	   (NLRs),	   retinoic	   acid-­‐inducible	   gene	   I	   (RIG-­‐I)-­‐like	   receptors	  (RLRs),	   C-­‐type	   lectin	   receptors	   (CLRs)	   and	   the	   pyrin	   and	   HIN	   domain-­‐containing	  protein	  (PyHIN)	  family	  (Goubau	  et	  al.,	  2010;	  Kumagai	  and	  Akira,	  2010;	  Schattgen	  and	  Fitzgerald,	  2011).	  TLRs	  and	  CLRs	  are	  transmembrane	  proteins	  located	  on	  the	  plasma	  membrane	   and	   endosomal	  membranes	  where	   they	  detect	   PAMPs	   and	  DAMPs	   from	  the	   extracellular	  milieu,	  while	  RLRs,	  NLRs	   and	  PyHIN	   receptors	  primarily	   reside	   in	  the	  cytosol	  (Takeuchi	  and	  Akira,	  2010).	  	  
1.1.3.1. Toll-­‐like	  receptors	  TLRs	   are	   evolutionary	   conserved	   PRRs	   that	   are	   predominantly	   expressed	   by	  monocytes,	  macrophages	  and	  neutrophils.	  Stimulation	  of	   individual	  TLRs	  by	  PAMPs	  activates	  overlapping	  but	  distinct	  signalling	  pathways	  that	  mediate	  antimicrobial	  and	  inflammatory	   responses	   for	  host	  defence.	  All	  TLRs	  contain	  an	  extracellular	   leucine-­‐rich	  region	  (LRR),	  a	  transmembrane	  region,	  and	  a	  cytoplasmic	  tail	  with	  a	  conserved	  ‘Toll-­‐IL-­‐1	  resistance’	  (TIR)	  domain.	  	  The	  LRR	  region	  of	  TLRs	  is	  diverse	  between	  TLRs	  and	  is	  involved	  in	  microbial	  recognition,	  thus	  conveying	  each	  TLR	  with	  specificity	  for	  distinct	  classes	  of	  pathogen.	  In	  contrast,	  the	  TIR	  domain	  shares	  significant	  homology	  with	  members	  of	  the	  interleukin-­‐1	  receptor	  (IL-­‐1R)	  superfamily	  and	  mediates	  signal	  transduction.	  To	  date,	  ten	  human	  TLRs	  (TLR1-­‐10)	  and	  twelve	  murine	  TLRs	  (TLR1-­‐9,	  TLR11-­‐13)	   have	   been	   discovered.	   Each	   member	   detects	   distinct	   ligands	   such	   as	  lipopolysaccharide	   (LPS),	   lipopeptides	   and	   nucleic	   acid	   (see	   Table	   1.1	   for	   ligand	  specificity	  for	  each	  TLR).	  	  




TLR1/2	   triacyl	  lipopeptides	   bacteria	  (mainly	  Gram-­‐negative)	   MyD88/Mal	   (Takeuchi	   et	   al.,	  2002)	  triacyl	  lipopeptides	   mycoplasma	  
TLR2	   lipoteichoic	  acid	  (LTA)	   Gram-­‐positive	  bacteria	   MyD88/Mal	   (LaRue	  et	  al.,	  2013;	  Takeuchi	   et	   al.,	  2002)	  lipoarabinomannan	  (LAM)	   mycobacterium	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Heat	  shock	  protein	  (HSP)	  70	   host	  cells	  Phospholipomannans	  and	  glucuronoxyl	  mannans;	  zymosan	  	   fungi	  tGPI-­‐mutin	   parasites	  Haemagglutinin	  and	  structural	  proteins	   viruses	  TLR3	   double-­‐stranded	  RNA	   viruses	   TRIF	   (Alexopoulou	  et	  al.,	  2001)	  poly(I:C)	   synthetic	  ligand	  
TLR4	  
lipopolysaccharide	  (LPS)	   Gram-­‐negative	  bacteria	  
MyD88/Mal/	  	  TRIF/TRAM	  
(Hoshino	   et	   al.,	  1999;	   LaRue	   et	   al.,	  2013;	   Poltorak	   et	  al.,	  1998)	  
HSP	  60	  and	  70	   bacteria	  and	  host	  cells	  Fibronectin	   host	  cells	  
Taxol	   plant	  alkaloid	  used	  in	  anti-­‐cancer	  therapy	  fusion	  (F)	  protein	  	   respiratory	  syncytial	  virus	  HMGB1	   dying	  or	  injured	  host	  cells	  
TLR5	   flagellin	   flagellated	  bacteria	   MyD88/Mal/	  	  TRIF	  
(Choi	   et	   al.,	   2010;	  Choi	   et	   al.,	   2013;	  Hayashi	   et	   al.,	  2001)	  TLR2/6	   diacyl	  lipopeptides	   mycoplasma	   MyD88/Mal	   (Takeuchi	   et	   al.,	  2001)	  
TLR7	   Single-­‐stranded	  RNA	   viruses	   MyD88	   (Heil	   et	   al.,	   2004;	  Lund	  et	  al.,	  2004)	  Imidazoquinolines	   synthetic	  anti-­‐viral	  compounds	  
TLR8	   single-­‐stranded	  RNA	   viruses	   MyD88	   (Heil	  et	  al.,	  2004)	  Imidazoquinolines	   synthetic	  anti-­‐viral	  compounds	  TLR9	   unmethylated	  CpG	  DNA	   bacteria	  and	  mycobacteria	   MyD88	   (Bauer	  et	  al.,	  2001;	  Hemmi	   et	   al.,	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CpG	  oligodeoxynucleotides	  (ODNs)	   synthetic	  ligand	  
2000;	   LaRue	   et	   al.,	  2013;	   Takeshita	   et	  al.,	  2001)	  haemozoin	   Plasmodium	  
falciparum	  Self-­‐DNA/LL37;	  self	  RNA/LL37;	  self	  DNA/HMGB1	   host	  cell	  
TLR2/10†	   triacyl	  lipopeptides	   Gram-­‐negative	  bacteria	   MyD88	   (Guan	   et	   al.,	   2010;	  Hasan	   et	   al.,	   2005;	  Regan	  et	  al.,	  2013)	  
TLR11‡	   flagellin	   Gram-­‐negative	  bacteria	  	   MyD88	   (Broz	  and	  Monack,	  2013;	   Zhang	   et	   al.,	  2004a)	  
	  	  TLR11‡/	  TLR12‡	  	  
Profilin	  	   apicomplexan	  parasites	  	   MyD88	  
(Andrade	   et	   al.,	  2013;	  Koblansky	  et	  al.,	   2013;	   Lauw	   et	  al.,	   2005;	   Raetz	   et	  al.,	   2013;	  Yarovinsky	   et	   al.,	  2005b;	   Zhang	   et	  al.,	  2004c)	  
TLR13‡	   Gram-­‐positive	  bacterial	  ssRNA	  (23S	  rRNA)	   Gram-­‐positive	  bacteria	   MyD88	  
(Hidmark	   et	   al.,	  2012;	   Oldenburg	  et	  al.,	  2012)	  	  
Table	   1.1:	   TLRs,	   examples	   of	   TLR	   ligands	   and	   TLR	   adapters	   used	   in	   TLR	  
signalling	  pathways.	  	  †	   Functional	   form	   in	   humans,	   pseudogene	   in	   mice.	   ‡	   Functional	   form	   in	   mice,	  pseudogene	  in	  humans.	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1.1.3.2. TLR	  signalling	  Activation	   of	   TLRs	   upon	   binding	   of	   PAMPs	   to	   the	   LRR	   region	   causes	  homodimerisation	   (e.g.	   TLR4)	   or	   heterodimerisation	   of	   TLRs	   (e.g.	   TLR1/TLR2)	   to	  form	  TLR	  complexes.	  Recognition	  and	  binding	  of	  TLR	  complexes	   to	   their	  respective	  ligands	   is	   assisted	   by	   a	   number	   of	   accessory	   molecules	   that	   perform	   various	  functions.	   These	   include	   enabling	   ligand	  detection	  by	  TLRs	   (e.g.	  MD2	  binds	   ligands	  and	  is	  then	  detected	  by	  TLR4	  (Brodsky	  and	  Medzhitov,	  2007)),	  control	  of	  trafficking	  and	  distribution	  of	  TLRs	  (e.g.	  Unc93B	  is	  required	  for	  delivery	  of	  TLR7	  and	  TLR9	  from	  the	  ER	  to	  endolysosomes	  (Kim	  et	  al.,	  2008)),	  assisting	  TLR	  protein	  maturation	  in	  the	  ER	  (e.g.	  gp96	  associates	  with	  TLRs	   in	   the	  ER	  and	   is	  a	  chaperone	   for	  protein	   folding	  (Yang	   et	   al.,	   2007)),	   and	   direct	   interaction	   with	   TLR	   ligands	   to	   modulate	   TLR	  activation	   (e.g.	   CD14	   binds	   TLRs	   and	   their	   ligands	   and	   is	   implicated	   in	   multiple	  functions	  such	  as	  chaperoning	  ligands	  to	  TLRs	  (Lee	  et	  al.,	  2006)	  and	  amplifying	  TLR	  responses	  (Finberg	  and	  Kurt-­‐Jones,	  2006))(Akashi-­‐Takamura	  and	  Miyake,	  2008).	  	  	  Activated	   TLR	   complexes	   then	   associate	   with	   specific	   adaptor	   proteins,	   which	  activate	   downstream	   IL-­‐1R-­‐associated	   kinases	   (IRAKs)	   to	   trigger	   downstream	  signalling	   cascades	   leading	   to	   activation	   of	   transcription	   factors	   such	   as	   nuclear	  factor	   kappa-­‐light-­‐chain-­‐enhancer	   of	   activated	   B	   cells	   (NFκB),	   activator	   protein	   1	  (AP-­‐1),	   and	  members	   of	   the	   interferon	   (IFN)-­‐regulatory	   factor	   (IRF)	   family.	   These	  adaptor	   proteins	   are	   myeloid	   differentiation	   primary	   response	   gene	   88	   (MyD88),	  MyD88-­‐adaptor-­‐like	   (MAL),	   TIR-­‐domain-­‐containing	   adaptor	   protein	   inducing	   IFNβ	  (TRIF),	   TRIF-­‐related	   adaptor	   molecular	   (TRAM),	   and	   sterile	   α-­‐and	   armadillo-­‐motif	  containing	  protein	   (SARM).	  The	   two	  major	  TLR	  signalling	  pathways	   that	  have	  been	  defined	   are	   the	   MyD88-­‐dependent	   and	   the	   MyD88-­‐independent	   pathways.	   In	   the	  MyD88-­‐dependent	   pathway,	  MyD88	   is	   a	   key	   adaptor	   for	   all	   TLRs	   except	   TLR3	   and	  some	  TLR4	   responses,	   but	   requires	  MAL	   as	   a	   bridging	   adaptor	   for	  TLR2	   and	  TLR4	  signalling	   (Fitzgerald	  et	  al.,	  2001;	  Horng	  et	  al.,	  2002;	  Horng	  et	  al.,	  2001;	  Kagan	  and	  Medzhitov,	  2006;	  Yamamoto	  et	  al.,	  2002).	  In	  the	  MyD88-­‐independent	  pathway,	  TRIF	  mediates	   TLR3	   signalling	   (Fitzgerald	   et	   al.,	   2003)	   and	   also	   enables	   TLR4-­‐mediated	  IFN	   induction	  with	   the	   aid	   of	   the	   bridging	   adaptor	   TRAM	   (Rowe	   et	   al.,	   2006).	   The	  most	   recently	   discovered	   adaptor,	   SARM	   is	   reported	   to	   be	   a	   negative	   regulator	   of	  NFκB	   and	   IRF	   activation	   by	   blocking	  TRIF-­‐dependent	   signalling	   (Carty	   et	   al.,	   2006;	  O'Neill	  and	  Bowie,	  2007).	  Recently,	   it	  has	  also	  been	  reported	   that	  MyD88	   is	  able	   to	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recruit	  and	  complex	  with	  IRAK-­‐4	  and	  IRAK-­‐2	  via	   its	  death	  domains	  (DD),	  which	  are	  revealed	  upon	  MyD88	  binding	  to	  the	  TIR	  domains	  of	  a	  receptor	  or	  bridging	  adaptor,	  to	  form	  an	  oligomeric	  signalling	  complex	  termed	  the	  Myddosome	  (Bryant	  et	  al.,	  2015;	  Gay	   et	   al.,	   2011).	   It	   has	   been	   shown	   that	   TRIF-­‐based	   signalling	   complexes	   are	   also	  formed	  (Funami	  et	  al.,	  2008)	  however	  the	  structure	  of	  these,	  and	  the	  involvement	  of	  the	   bridging	   adaptors,	   MAL	   and	   TRAM	   have	   yet	   to	   be	   elucidated.	   The	   MyD88-­‐dependent	   pathway	   is	   important	   in	   LPS-­‐mediated	   B	   cell	   proliferation	   and	   cytokine	  secretion,	  and	  early	  NFκB	  translocation	  and	  mitogen-­‐activated	  protein	  (MAP)	  kinase	  (MAPK)	   activation	   (Akira	   &	   Takeda	   2004a).	   On	   the	   other	   hand,	   the	   MyD88-­‐independent	   pathway	   is	   essential	   for	   a	   second	   wave	   of	   delayed	   NFκΒ	   and	   MAPK	  activation	   and	   mediates	   dendritic	   cell	   maturation,	   phosphorylation	   of	   interferon	  (IFN)-­‐regulatory	   factor	   (IRF)-­‐3,	   and	   IFN-­‐β-­‐	   and	   STAT-­‐1-­‐dependent	   gene	   expression	  (Akira	  and	  Takeda,	  2004;	  Kaisho	  et	  al.,	  2001;	  Kraatz	  et	  al.,	  1998)	  	  Stimulation	   of	   the	   different	   TLRs	   and	   subsequent	   signalling	   through	   the	   MyD88-­‐dependent	   and	   MyD88-­‐independent	   pathways	   is	   not	   only	   strictly	   controlled	   by	  receptor-­‐ligand	  specificity	  but	  also	  by	  the	  spatial	  organisation	  of	  receptors	  (Akashi-­‐Takamura	  and	  Miyake,	  2008;	  Barton	  and	  Kagan,	  2009).	  Cell	   surface	  TLRs	   (TLR1/2,	  TLR2/6,	  TLR4,	  TLR5)	  recognise	  microbial	  membrane	  components	  while	  endosomal	  TLRs	  (TLR3,	  TLR7,	  TLR8,	  and	  TLR9)	  recognise	  microbial	  nucleic	  acids	  (Beutler	  et	  al.,	  2006;	   Takeda	   and	   Akira,	   2004)	   (see	   Table	   1.1).	   The	   occurrence	   of	   receptor	  segregation	  is	  seen	  as	  a	  strategy	  for	  the	  immune	  system	  to	  avoid	  self-­‐reactivity	  such	  as	   the	   recognition	   of	   host	   nucleic	   acids	   by	   TLRs	   that	   normally	   detect	   viral	   nucleic	  acids	   (Marshak-­‐Rothstein,	   2006).	   This	   is	   supported	   by	   studies	   on	  mice	   and	   human	  patients	   that	   show	   the	   contribution	   of	   nucleic	   acid-­‐sensing	   TLRs	   to	   autoimmune	  disorders	   such	   as	   systemic	   lupus	   erythematosus	   (SLE)	   (Christensen	   et	   al.,	   2005;	  Subramanian	   et	   al.,	   2006).	   However,	   receptor	   translocation	   from	   cell	   surface	   to	  endosomal	   compartments	   does	   occur	   and	   involves	   a	   sequential	   shift	   in	   signalling	  pathway	   activation.	   In	   TLR4	   signalling,	   receptor	   stimulation	   by	   LPS	   at	   the	   plasma	  membrane	   mediates	   MAL	   recruitment	   of	   MyD88,	   triggering	   downstream	   pro-­‐inflammatory	   signal	   transduction	   (Akashi	   et	   al.,	   2003).	   LPS	   binding	   also	   results	   in	  internalisation	  of	  TLR4	  into	  endolysosomes,	  resulting	  in	  dissociation	  of	  MyD88/MAL	  interaction	  and	  promotion	  of	  TRIF/TRAM	  signalling	  (Husebye	  et	  al.,	  2006;	  Kagan	  et	  al.,	   2008).	   Thus,	   TLR	   signalling	   involves	   a	   complex	   interplay	   of	   ligand-­‐specific	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receptor	   activation,	   receptor	   localisation,	   and	   signalling	   via	   MyD88-­‐dependent	   or	  independent	  pathways,	  enabling	  a	  customised	  cellular	  response	  matched	  to	  the	  type	  of	  danger	  that	  is	  encountered.	  	  	  
1.1.3.3. Downstream	  consequences	  of	  TLR	  signalling	  TLR	   signalling	   through	   the	   MyD88-­‐dependent	   or	   MyD88–independent	   pathways	  results	   in	  a	  wide	  variety	  of	  responses,	   including	  regulation	  of	   inflammation,	  antigen	  presentation	   and	   antimicrobial	   responses.	   In	   the	   advent	   of	   an	   infection,	   cell	   death	  may	  also	  be	  induced	  in	  order	  to	  limit	  replication	  of	  intracellular	  pathogens	  within	  an	  infected	  cell,	   and	   to	  alert	  neighbouring	   leukocytes	  of	   infection.	  This	   thesis	  explored	  the	   concept	   that	   novel	   TLR-­‐inducible	   genes	   may	   contribute	   to	   macrophage	  antimicrobial	   responses.	   Consequently,	   more	   in	   depth	   descriptions	   of	   specific	  macrophage	  antimicrobial	  mechanisms	  are	  detailed	  below.	  	  	  
1.1.4. Macrophage	  antimicrobial	  responses	  Once	   a	   macrophage	   recognizes	   a	   pathogen	   through	   opsonic	   or	   non-­‐opsonic	  phagocytic	  receptors	  (Aderem	  and	  Underhill,	  1999),	  it	  engulfs	  it	  within	  a	  phagosome	  that	   matures	   to	   become	   increasingly	   acidic	   and	   microbicidal	   through	   fusion	   with	  endosomes	   and	   lysosomes,	   resulting	   in	   the	   formation	   of	   a	   phagolysosome	   within	  which	   the	  pathogen	   is	  killed.	  Upon	  phagocytosis,	   release	  of	  cellular	  reactive	  oxygen	  species	   (ROS),	   antimicrobial	   peptides,	   and	   lysosomal	   enzymes	   are	   triggered	   as	  immediate	   antimicrobial	   responses.	   PRR	   signalling	   is	   triggered	   concomitantly	  with	  microbial	   uptake	   and	   is	   able	   to	   prime	   components	   of	   the	   immediate	   antimicrobial	  response	   to	   prepare	   cells	   for	   subsequent	   pathogen	   encounters.	   PRR	   signalling	   also	  induces	   the	   expression	   of	   a	   suite	   of	   genes	   that	   contributes	   to	   a	   second	   wave	   of	  responses	   aimed	   at	   microbial	   destruction.	   This	   second	   wave	   of	   antimicrobial	  mechanisms,	  which	  require	   induction	  by	  PRRs,	   include	  generation	  of	  mitochondrial	  ROS	   (mitoROS),	   release	   of	   reactive	   nitrogen	   species	   (RNS),	   nutrient	   deprivation,	  autophagy,	   and	   cell	   death.	   	   Further	   details	   of	   immediate	   and	   PRR-­‐inducible	  antimicrobial	  mechanisms	  are	  discussed	  below.	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1.1.4.1. Lysosomal	  enzymes	  and	  antimicrobial	  peptides	  Lysosomal	   enzymes	   consists	   of	   approximately	   50	   different	   acid	   hydrolases	   that	  degrade	  proteins,	  carbohydrates,	  nucleic	  acids	  and	  lipids	  (Cooper,	  2000;	  Lübke	  et	  al.,	  2009).	  These	  acid	  hydrolases	  are	  delivered	  from	  the	  Golgi	  apparatus	  into	  lysosomes	  and	  are	  active	  at	  an	  acidic	  pH	  of	  approximately	  pH	  5.0,	  but	  are	  not	  active	  at	  a	  neutral	  pH	  (Cooper,	  2000).	  Upon	  pathogen	  engulfment,	   lysosomes	  fuse	  with	  phagosomes	  to	  form	  phagolysosomes,	  enabling	  delivery	  of	  lysosomal	  enzymes	  to	  facilitate	  immediate	  microbial	   killing.	   Lysosomal	   enzymes	   also	   facilitate	   antigen	   presentation	   to	   enable	  recruitment	   of	   adaptive	   immunity.	   For	   example,	   MHC	   class	   II	   molecules	   require	  cathepsin	  S-­‐mediated	  proteolytic	  degradation	  of	  the	  invariant	  chain-­‐derived	  peptide	  (CLIP)	  from	  the	  antigen-­‐binding	  groove	  to	  enable	  binding	  of	  an	  antigenic	  peptide	  to	  the	   MHC	   class	   II	   molecule	   (Bird	   et	   al.,	   2009;	   Jensen	   et	   al.,	   1999).	   In	   addition	   to	  facilitating	  pathogen	  destruction,	  lysosomal	  acid	  hydrolases	  regulate	  many	  biological	  activities,	  such	  as	  autophagy,	  extracellular	  matrix	  remodelling,	  chemotaxis,	  cytokine	  induction,	  signal	  processing,	  cell	  homeostasis,	  and	  triggering	  of	  apoptosis	  in	  infected	  cells	  (Bird	  et	  al.,	  2009).	  	  Antimicrobial	   peptides	   consist	   of	   defensins	   and	   cathelicidins.	   These	   small	   peptides	  bind	   to	   negatively-­‐charged	  microbial	   surfaces	   to	   form	   a	  multimeric	   ion-­‐permeable	  channel	   that	  mediates	  membrane	   permeabilisation	   and	   subsequent	   death	   of	   Gram-­‐positive	   and	   Gram-­‐negative	   bacteria	   (Lehrer	   and	   Ganz,	   2002;	   Lehrer	   et	   al.,	   1993;	  Zanetti	   and	   Gennaro,	   1995).	   Defensins	   are	   small	   cationic	   proteins	   that	   possess	   6	  conserved	  cysteines	  which	  form	  3	  disulphide	  bridges,	  are	  stored	  within	  azurophils	  or	  primary	  granules,	  and	  can	  be	  subdivided	  into	  α,	  β	  and	  θ	  subgroups	  (Lehrer	  and	  Ganz,	  2002).	   Humans	   possess	   11	   α-­‐defensins	   (6	   functional,	   5	   pseudogenes)	   and	   >30	   β-­‐defensins	   (Li	   et	   al.,	   2014a).	   In	   comparison	   to	   α-­‐defensins,	   β-­‐defensins	   are	   longer,	  have	  different	  cysteine	  pairings,	  a	  less	  anionic	  propiece,	  are	  encoded	  by	  2	  instead	  of	  3	  exons,	   and	   have	   more	   lysines	   than	   arginines	   (Ganz,	   2003).	   θ-­‐defensins	   are	   cyclic	  peptides	  that	  evolved	  from	  α-­‐defensins	  and	  are	  expressed	  in	  old	  world	  monkeys	  such	  as	  the	  rhesus	  macaque	  and	  the	  olive	  baboon,	  but	  not	  in	  humans	  and	  other	  primates	  (Cheng	   et	   al.,	   2014).	   Interestingly,	   artificial	   activation	   of	   a	   human	   θ-­‐defensin	  pseudogene	  produced	   the	  θ-­‐defensin,	   retrocyclin,	  which	  prevented	  cellular	  entry	  of	  viruses	  such	  as	  HIV,	  herpes	  simplex	  virus	  and	  influenza	  A	  (Lehrer	  et	  al.,	  2012;	  Munk	  et	  al.,	  2003;	  Venkataraman	  et	  al.,	  2009).	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  Cathelicidins	   are	   the	  major	   antimicrobial	   peptides	  produced	  by	  macrophages.	  They	  are	   stored	   in	   secondary	   granules	   and	   are	   normally	   present	   in	   an	   unprocessed	   or	  partially	   cleaved	   form	   (Zanetti,	   2005).	   Upon	   phagocytosis,	   pro-­‐cathelicidin	   is	  immediately	   processed	   into	   active	   cathelicidin	   and	   released	   into	   the	   phagosome	  (Zaiou	  and	  Gallo,	  2002).	  The	  only	  human	  cathelicidin,	  LL-­‐37,	  is	  cleaved	  proteolytically	  from	   CAP18	   protein	   (Agerberth	   et	   al.,	   1995;	   De	   Smet	   and	   Contreras,	   2005).	   LL-­‐37	  mRNA	  and	  protein	  expression	  is	  also	  upregulated	  by	  TLR1/2	  agonism	  via	  a	  Vitamin	  D-­‐dependent	   pathway	   in	   human	   macrophages,	   and	   is	   crucial	   for	   killing	   M.	  
tuberculosis	   (Liu	   et	   al.,	   2007d).	   Human	   β-­‐defensins	   are	   also	   effective	   against	   M.	  
tuberculosis	  (Miyakawa	  et	  al.,	  1996)	  and	  human	  β-­‐defensin-­‐2	  was	  similarly	  shown	  to	  be	  upregulated	  by	  TLR2	  and	  TLR4	  signalling	   (Lee	  et	  al.,	   2014;	  Tsutsumi-­‐Ishii	   et	   al.,	  2000;	   Vora	   et	   al.,	   2004;	   Zaiou	   and	   Gallo,	   2002).	   The	   upregulation	   of	   LL-­‐37	   and	   β-­‐defensins	  illustrates	  how	  TLR	  signalling	  is	  also	  able	  to	  prime	  immediate	  antimicrobial	  responses.	  	  
1.1.4.2. Reactive	  oxygen	  species	  ROS	   are	   produced	   as	   normal	   by-­‐products	   of	   cellular	   metabolism	   and	   are	   usually	  inactivated	   by	   catalase	   and	   superoxide	   dismutase.	   However,	   in	   host	   defence,	   ROS	  production	   occurs	   within	   30	   minutes	   of	   phagocytosis	   via	   a	   process	   known	   as	   the	  respiratory	   burst	   (Gantt	   et	   al.,	   2001).	   ROS	   elicits	   antimicrobial	   effects	   by	   directly	  damaging	  and	  destroying	  pathogens,	  as	  well	  as	   indirectly	   through	   induction	  of	  host	  defence	   genes,	   ion	   transport	   (Reeves	   et	   al.,	   2002)	   and	   apoptosis	   (Hampton	   and	  Orrenius,	   1997).	   The	  major	   cellular	   source	   of	  ROS	   is	   through	   a	  multimeric	   enzyme	  complex,	   the	   nicotinamide	   adenine	   dinucleotide	   phosphate	   (NADPH)	   oxidase	  complex,	   which	   is	   found	   on	   cell	   membranes,	   mitochondria,	   peroxisomes	   and	   the	  endoplasmic	   reticulum.	   NADPH	   oxidase	   is	   made	   up	   of	   two	   membrane-­‐bound	  elements	   (gp91phox	   and	   p22phox,	   which	   form	   cytochrome	   b558),	   three	   cytosolic	  components	   (p67phox,	   p47phox	   and	   p40phox),	   and	   either	   the	   Rac1	   (predominant	  isoform	  in	  primary	  human	  monocytes)	  or	  Rac2	  (predominant	  isoform	  in	  neutrophils)	  G	  protein	  (Babior,	  2004;	  Zhao	  et	  al.,	  2003).	  Activation	  of	  NADPH	  oxidase	  involves	  the	  migration	  of	   the	   cytosolic	   components	   to	   the	  organelle	  membranes	   for	  assembly	  of	  the	   complete	   oxidase	   complex.	   NADPH	   oxidases	   reduce	   free	   oxygen	   to	   superoxide	  anion	  (O2-­‐),	  a	  precursor	  radical	  with	  limited	  antimicrobial	  activity	  that	  is	  used	  for	  the	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production	  of	  other	  ROS	  such	  as	  hydrogen	  peroxide	  (H2O2)	  via	  superoxide	  dismutase,	  perchlorite	   ion	   (ClO-­‐)	   via	   myeloperoxidase,	   and	   the	   hydroxyl	   radical	   (OH-­‐)	   from	  hydrogen	  peroxide	  in	  the	  presence	  of	  certain	  heavy	  metal	  ions	  such	  as	  copper	  (Cu+)	  or	   iron	   (Fe2+)	   (Babior,	   1999;	   Castro	   and	   Freeman,	   2001).	   Rapid	   production	   of	   ROS	  during	   the	   respiratory	  burst	   is	   enabled	   through	   constitutive	   gp91phox	   expression	   in	  myeloid	   cells	   (Suzuki	   et	   al.,	   1998;	   Voo	   and	   Skalnik,	   1999).	   Macrophages	   can	   be	  further	   primed	   for	   ROS	   production	   by	   IFNγ	   and	   LPS-­‐mediated	   upregulation	   of	  gp91phox	   gene	   expression	   (Cassatella	   et	   al.,	   1990;	   VanderVen	   et	   al.,	   2009).	   ROS	   can	  also	   be	   produced	   later	   during	   infection	   through	   recruitment	   of	   mitochondria	   to	  macrophage	   phagosomes.	   This	   process	   is	   triggered	   by	   signalling	   through	   the	   cell	  surface	   TLRs,	   TLR1,	   2	   and	   4,	   and	   involves	   the	   translocation	   of	   evolutionarily	  conserved	   signalling	   intermediate	   in	   Toll	   pathways	   (ECSIT)	   and	   the	   E3	   ubiquitin	  ligase	   TRAF6,	   to	   the	   mitochondria	   periphery	   for	   enhanced	   mitochondrial	   ROS	  (mitoROS)	  and	  cellular	  ROS	  generation	  (West	  et	  al.,	  2011).	  	  	  
1.1.4.3. Reactive	  nitrogen	  species	  In	   addition	   to	   ROS,	   RNS	   are	   another	   free	   radical	   species	   that	   are	   important	   as	  antimicrobial	  mediators	  in	  macrophages.	  Nitric	  oxide	  (NO)	  is	  formed	  by	  oxidation	  of	  the	   amino	   acid	   L-­‐arginine	   to	   citrulline	   and	   NO	   by	   constitutive	   and	   inducible	   nitric	  oxide	   synthases	   (iNOS)	   (Stuehr,	   1999).	   In	   contrast	   to	   the	   immediate	   generation	   of	  cellular	  ROS	  upon	  phaocytocic	  uptake,	  transcriptional	  activation	  of	  iNOS	  is	  triggered	  by	   agonists	   of	   PRRs	   (Stuehr	   and	   Marletta,	   1985),	   as	   well	   as	   by	   pro-­‐inflammatory	  cytokines	   (IFNs,	   IL-­‐1β	   and	   TNF-­‐α)	   via	   the	   MAPK	   and	   NFκB	   and	   Janus-­‐activated	  kinase–signal	  transducer	  and	  activator	  of	  transcription–interferon	  regulatory	  factor	  1	  (JAK-­‐STAT-­‐IRF1)	  pathways.	  Enzymatic	  activity	  of	  iNOS	  is	  also	  controlled	  by	  substrate	  and	  co-­‐factor	  availability	  (El-­‐Gayar	  et	  al.,	  2003;	  Schoedon	  et	  al.,	  1993).	  Formation	  of	  NO	   occurs	   on	   the	   cytoplasmic	   side	   of	   phagosomes,	   but	   it	   diffuses	   across	   the	  membrane	  to	  encounter	  intraphagosomal	  targets	  and	  ROS	  (Webb	  et	  al.,	  2001).	  Upon	  encountering	  ROS,	  NO	  undergoes	   spontaneous	   or	   catalytic	   conversion	   to	   form	  RNS	  such	   as	   peroxynitrite	   (ONOO-­‐),	   nitrogen	   dioxide	   (NO2),	   dinitrogen	   trioxide	   (N2O3),	  dinitrosyl	   iron	   complexes,	   nitrosothiols	   and	   nitroxyl	   (HNO)	   (Fang,	   2004).	   RNS	   and	  ROS	   inflict	   oxidative	   damage	   upon	   microbial	   targets	   such	   as	   thiols,	   metal	   centres,	  protein	   tyrosine	   residues,	   nucleic	   acids	   and	   lipids,	   thus	   resulting	   in	   inactivation	   of	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proteins	  and	  other	  macromolecules,	   in	  addition	  to	  causing	  DNA	  damage	  (Flannagan	  et	  al.,	  2009).	  	  
1.1.4.4.	   Nutrient	  deprivation	  In	  addition	  to	  direct	  microbial	  killing,	   immune	  cells	  utilize	  a	  number	  of	  pathways	  to	  sequester	   nutrients,	   such	   as	   metal	   ions	   and	   amino	   acids	   to	   slow	   or	   halt	   bacterial	  growth.	   For	   example,	   lactoferrin	   is	   a	   glycoprotein	   that	  binds	   iron,	   thus	  making	   this	  essential	  element	  unavailable	  to	  bacteria	  for	  growth	  (Masson	  et	  al.,	  1969).	  Similarly,	  some	  ion	  transporters	  such	  as	  the	  divalent	  metal	  ion	  transporter	  natural	  resistance-­‐associated	   macrophage	   protein	   1	   (NRAMP1,	   also	   known	   as	   SLC11A1)	   removes	  cations	   such	   as	   Fe2+	   and	  Mn2+	   from	   the	  phagosome	   (Cellier	   et	   al.,	   2007).	   Fe2+	   is	   an	  important	   co-­‐factor	   of	   microbial	   enzymes,	   and	   Mn2+	   is	   utilized	   as	   a	   co-­‐factor	   for	  superoxide	   dismutase	   (Flannagan	   et	   al.,	   2009).	   Amino	   acid	   starvation	   is	   also	  employed,	  as	  exemplified	  by	  IFNγ-­‐	  and	  TLR-­‐stimulated	  deprivation	  of	  tryptophan	  by	  the	   enzyme	   indoleamine	   2,3-­‐dioxygenase	   (IDO)	   (Furset	   et	   al.,	   2008;	   Pfefferkorn,	  1984;	   Schroder	   et	   al.,	   2012a;	   Yoshida	   et	   al.,	   1981).	   IDO	   degrades	   tryptophan	   to	  kynurenine	   and	  N-­‐formylkynurenine,	   thus	   starving	   and	   suppressing	   the	   growth	   of	  some	   intracellular	   pathogens	   including	   Toxoplasma	   gondii,	   Rickettsia	   conorii,	   and	  group	   B	   streptococci	   (Feng	   and	  Walker,	   2000;	  MacKenzie	   et	   al.,	   1998;	   Pfefferkorn,	  1984).	  	  	  
1.1.4.5.	   Autophagy	  Autophagy	   typically	   maintains	   cell	   homeostasis	   by	   recycling	   nutrients	   and	  degradation	  of	  damaged	  or	  aged	  membranes	  and	  cytoplasmic	  organelles.	  However,	  in	  innate	  immunity,	  autophagy	  also	  functions	  as	  a	  defence	  pathway	  against	  intracellular	  invasion	   of	   bacteria	   and	   viruses.	   Autophagosomal-­‐mediated	   killing	   of	   microbes	  occurs	  with	   intra-­‐phagosomal	   bacteria	   such	   as	  M.	  tuberculosis	  (Deretic	   et	   al.,	   2009;	  Gutierrez	  et	  al.,	  2004),	  bacteria	  that	  escape	  from	  the	  phagosome	  into	  the	  cytosol	  such	  as	  Shigella	   (Ogawa	  et	  al.,	  2005),	  as	  well	  as	  extracellular	  pathogens	  such	  as	  Group	  A	  
Streptococci	  that	  invade	  host	  cells	  as	  part	  of	  their	  virulence	  strategy	  (Nakagawa	  et	  al.,	  2004).	   This	   process	   involves	   the	   formation	   of	   an	   autophagosome	   that	   captures	  intracellular	   components	   and	   processes	   them	   into	   an	   autolysosome,	   which	   has	   a	  distinct	   environment	   from	   the	   standard	   phagolysosome.	   This	   is	   emphasised	   by	  studies	   showing	   that	  mycobacteria	   can	   survive	   in	   phagolysosomes	   (Armstrong	   and	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Hart,	  1975),	  but	  are	  efficiently	  cleared	  in	  autolysosomes	  (Biswas	  et	  al.,	  2008;	  Lammas	  et	   al.,	   1997;	   Xu	   et	   al.,	   2007b).	   Studies	   focused	   on	   determining	   microbicidal	  components	   within	   the	   autolysosome	   reported	   that	   cytosolic	   ubiquitin	   or	  ubiquitinated	   protein	   aggregates	   undergo	   proteolysis	   and	   fragment	   as	   the	  autophagosome	   matures	   into	   an	   autolysosome	   and	   are	   then	   delivered	   to	   M.	  
tuberculosis,	  somehow	  enhancing	  microbial	  killing	  (Alonso	  et	  al.,	  2007;	  Kieffer	  et	  al.,	  2003).	   Other	   cytoplasmic	   proteins	   such	   as	   ubiquicidin	   (ribosomal	   protein	   S30,	  homologous	  to	  ubiquitin),	  and	  ribosomal	  polypeptides	  S19	  and	  L30	  are	  also	  reported	  to	   have	   antimicrobial	   activity	   (Howell	   et	   al.,	   2003)	   and	   may	   contribute	   to	   the	  microbicidal	   environment	   within	   autolysosomes.	   The	   autophagy	   pathway	   is	  upregulated	   by	   agonists	   of	   TLR3,	   TLR4,	   TLR7	   and	   possibly	   TLR9	   (Delgado	   et	   al.,	  2008;	  Sanjuan	  et	  al.,	  2007;	  Xu	  et	  al.,	  2013;	  Xu	  et	  al.,	  2007b),	  and	  also	  by	  TNFα	  via	  a	  ROS-­‐dependent	  mechanism	  (Djavaheri-­‐Mergny	  et	  al.,	  2006).	  	  
1.1.4.6.	   Cell	  death	  	  	  Cell	  death	  can	  occur	  in	  the	  form	  of	  apoptosis,	  necrosis,	  pyroptosis	  and	  pyronecrosis.	  Apoptosis	  is	  usually	  considered	  as	  a	  silent	  or	  non-­‐inflammatory	  form	  of	  programmed	  cell	  death,	  with	  its	  effects	  being	  limited	  to	  the	  dying	  cell.	  Morphological	  features	  that	  distinguish	  apoptosis	  are	  plasma	  membrane	  blebbing,	   recycling	  of	   cellular	   contents	  and	   chromatin	   condensation.	   Apoptosis	   is	   mediated	   by	   intrinsic	   and	   extrinsic	  caspase-­‐dependent	   pathways.	   The	   intrinsic	   pathway	   involves	   cytochrome	   c	   release	  from	  mitochondria,	  which	  induces	  formation	  of	  the	  apoptosome	  complex	  made	  up	  of	  cytochrome	   c,	   apoptotic	   protease	   activating	   factor	   1	   (APAF1),	   and	   deoxyadenosine	  triphosphate	  (dATP).	  The	  apoptosome	  complex	  recruits	  and	  activates	  pro-­‐caspase-­‐9,	  leading	  to	  activation	  of	  effector	  caspases-­‐3,	  -­‐6	  and	  -­‐7	  and	  triggering	  of	  apoptosis	  (Zou	  et	   al.,	   1997).	   The	   extrinsic	   pathway	   involves	   ligand	   binding	   to	   cell-­‐death	   receptors	  that	   trigger	   intracellular	   signalling	   resulting	   in	   the	   cleavage	   of	   effector	   caspases	  (Zimmermann	   et	   al.,	   2001).	   These	   caspases	   act	   on	  proteins	   and	   cellular	   structures,	  ultimately	  causing	  the	  destruction	  and	  death	  of	  the	  cell	  (Nicholson,	  1999).	  Necrosis,	  pyroptosis	  and	  pyronecrosis	  are	  inflammatory	  forms	  of	  cell	  death	  that	  affect	  the	  local	  environment	   by	   exposing	   intracellular	   pathogens,	   thus	   allowing	   recruitment	   of	  leukocytes.	  These	  forms	  of	  cell	  death	  involve	  loss	  of	  plasma	  membrane	  integrity	  but	  do	   not	   involve	   chromatin	   condensation	   (Ting	   et	   al.,	   2008).	   Necrotic	   macrophages	  release	   pro-­‐inflammatory	   cytokines	   such	   as	   TNFα	   and	   IL-­‐1	   (Chen	   et	   al.,	   2007;	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Dinarello,	   1996),	   as	   well	   as	   alarmins	   such	   as	   high-­‐mobility	   group	   protein	   B1	  (HMGB1)	   (Lotze	   and	   Tracey,	   2005).	   The	   latter	   activates	   the	   receptor	   for	   advanced	  glycan	  end-­‐products	  and	  TLRs	  to	  drive	  inflammation	  (Park	  et	  al.,	  2004).	  The	  process	  of	  pyroptosis	  lies	  downstream	  of	  inflammatory	  caspase	  activation,	  and	  is	  triggered	  by	  a	  subset	  of	  PRRs	  that	  are	  able	  to	  form	  inflammasomes	  (below).	  	  	  
1.2. Inflammasomes	  Another	  mechanism	  used	  by	  the	  host	   for	   inflammatory	  cell	  death	  and	  antimicrobial	  responses	   involves	  activation	  of	   inflammasomes,	  cytosolic	  signalling	  complexes	  that	  lie	   downstream	   of	   certain	   members	   of	   the	   NLR	   and	   PyHIN	   families	   of	   PRR	   (see	  
Section	   1.1.3),	   NLRs	   typically	   contain	   an	   LRR	   domain	   for	   ligand	   sensing,	   a	  nucleotide-­‐binding	  domain,	  and	  either	  a	  caspase-­‐activation	  and	  recruitment	  domain	  (CARD)	  or	  a	  PYRIN	  domain	  that	  enables	  interactions	  with	  other	  proteins	  containing	  PYRIN	   domains	   (Schroder	   and	   Tschopp,	   2010).	   PyHIN	   receptors	   contain	   a	   PYRIN	  domain	  as	  well	  as	  a	  DNA-­‐binding	  HIN-­‐200	  domain	  (Schattgen	  and	  Fitzgerald,	  2011).	  In	   response	   to	   ligand	   detection,	   some	   NLRs	   and	   PyHIN	   receptors	   assemble	   into	  inflammasomes,	   which	   are	   cytosolic	   signalling	   platforms	   that	   activate	   pro-­‐inflammatory	   caspases	   such	   as	   caspase-­‐1.	   Inflammasomes	   enable	   autocatalytic	  conversion	  of	  pro-­‐caspase-­‐1	  into	  its	  catalytically	  active	  form,	  caspase-­‐1,	  which	  in	  turn	  cleaves	  pro-­‐IL-­‐1β	  and	  pro-­‐IL-­‐18	  into	  their	  mature	  forms	  of	  IL-­‐1β	  and	  IL-­‐18.	  These	  are	  then	  released	  from	  cells	  to	  mediate	  inflammation.	  Caspase-­‐1	  activation	  also	  initiates	  an	  inflammatory	  cell	  death	  pathway	  called	  pyroptosis	  (Schroder	  and	  Tschopp,	  2010).	  NLRP3,	  NLRP1,	  NLRC4,	  NLRP6	  and	  AIM2	   (Nlrp3,	  Nlrp1b,	  Nlrc4,	  Nlrp6	  and	  Aim2	   in	  mouse)	   are	   all	   capable	   of	   forming	   inflammasomes	   (Schroder	   and	   Tschopp,	   2010;	  Vanaja	   et	   al.,	   2015).	   Other	   NLRs	   (NLRP2,	   NLRP7,	   NLRP12)	   and	   PyHIN	   receptors	  (IFI16)	   have	   been	   reported	   to	   assemble	   into	   inflammasomes	   (Lamkanfi	   and	   Dixit,	  2014),	  but	   their	   association	  with	   caspase-­‐1	  activation	  has	  yet	   to	  be	  determined.	  As	  most	   studies	   on	   inflammasomes	   have	   been	   conducted	   using	   the	  mouse	  model,	   the	  studies	   described	   below	   will	   mainly	   focus	   on	   inflammasome	   responses	   in	   this	  species.	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1.2.1.	   Inflammasome	  activation	  Inflammasomes	   assemble	   in	   response	   to	   a	   variety	   of	   endogenous	   and	   exogenous	  danger	   signals.	  For	  example,	  different	  PAMPs,	  DAMPs,	  pore-­‐forming	   toxins,	   crystals	  and	   UV	   radiation	   can	   all	   trigger	   Nlrp3	   inflammasome	   activation.	   It	   is	   thought	   that	  Nlrp3	   does	   not	   directly	   detect	   such	   diverse	   stimuli,	   rather	   these	   stimuli	   are	   more	  likely	  to	  affect	  a	  host-­‐derived	  factor	  or	  event	  that	  is	  monitored	  by	  Nlrp3.	  Events	  that	  are	  thought	  to	  trigger	  Nlrp3	  activation	  downstream	  of	  these	  stimuli	  include	  K+	  efflux	  and/or	   release	   of	   lysosomal	   cathepsins,	   recruitment	   of	   Nlrp3	   to	   the	  mitochondrial	  outer	   membrane	   and	   production	   of	   ROS	   or	   oxidised	   mitochondrial	   DNA	   and	  cardiolipin.	  However	  these	  effects	  do	  not	  occur	  with	  all	  Nlrp3-­‐activating	  agents	  and	  a	  single	   unifying	   stimuli	   or	   event	   has	   yet	   to	   be	   found	   (Lamkanfi	   and	   Dixit,	   2014).	  Nlrp1b	   detects	  Bacillus	  antracis	   lethal	   toxin	  within	   the	   cytosol	   (Terra	   et	   al.,	   2010),	  while	   the	   Nlrc4	   inflammasome,	   in	   collaboration	   with	   NLRC	   subfamily	   member	  apoptosis	  inhibitory	  proteins	  (Naip)	  co-­‐receptors,	  detects	  flagellin	  and	  components	  of	  the	  type	  III	  (T3SS)	  or	  IV	  (T4SS)	  secretion	  systems	  (Kofoed	  and	  Vance,	  2011).	  Naip5	  and	  Naip6	  sense	   flagellin	   from	  bacteria	   such	  as	  S.	  Typhimurium	  and	  L.	  pneumophila	  while	  Naip1	   detects	   T3SS	   needles	   such	   as	   from	  Shigella	   flexneri,	   and	  Naip2	   detects	  rod	   proteins	   such	   as	   PrgJ	   from	   S.	   Typhimurium	   and	   BsaK	   from	   Burkholderia	  
thailandensis	   (Lage	  et	  al.,	  2014).	  The	  human	  genome	  encodes	  only	  1	  NAIP;	   this	  acts	  similarly	   to	   Naip1	   for	   detection	   of	   T3SS	   needle	   proteins,	   such	   as	   CprI	   from	  
Chromobacterium	  violacium,	   (Yang	  et	   al.,	   2013;	  Zhao	  et	   al.,	   2011).	  The	  activator	   for	  NLRP6	   has	   yet	   to	   be	   identified,	   however	   the	   NLRP6	   inflammasome	   was	   recently	  discovered	   to	   sustain	   intestinal	   homeostasis	   by	   IL-­‐18-­‐dependent	   regulation	   of	  intestinal	   microbiota	   (Vanaja	   et	   al.,	   2015).	   Finally,	   the	   Aim2	   inflammasome	   is	  activated	   by	   cytoplasmic	   dsDNA	   from	  DNA	  viruses	   such	   as	  mouse	   cytomegalovirus	  and	   vaccinia	   virus,	   and	   from	   cytosolic	   bacteria	   such	   as	   Francisella	   tularensis	   and	  
Listeria	  monocytogenes	  (Fernandes-­‐Alnemri	  et	  al.,	  2010;	  Vanaja	  et	  al.,	  2015).	  	  The	  mechanism	  of	   inflammasome	  activation	  has	  been	  extensively	   studied	  using	   the	  Nlrp3	   inflammasome	   as	   a	  model,	   and	   is	   widely	   considered	   to	   occur	   by	   a	   two-­‐step	  process.	  The	   first	   step	   involves	   a	  priming	   signal	   delivered	  by	  TLR	  agonists,	   TNF	  or	  other	   pro-­‐inflammatory	   stimuli	   that	   upregulate	   expression	   of	   inflammasome	  components,	   such	  as	  pro-­‐IL-­‐1β	  and	  Nlrp3,	   through	  NFκB	  signalling	   (Bauernfeind	  et	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al.,	   2009).	   However,	   the	   need	   for	   upregulation	   of	   inflammasome	   components	   as	   a	  priming	  mechanism	  has	  been	  debated,	  as	  even	  acute	  TLR	  stimulation	  was	  sufficient	  to	  prime	  inflammasome	  activation,	  and	  this	  effect	  was	  apparent	  before	  Nlrp3	  or	  Aim2	  protein	  upregulation	  (Juliana	  et	  al.,	  2012;	  Lin	  et	  al.,	  2014;	  Schroder	  et	  al.,	  2012p).	  This	  is	   further	   demonstrated	   in	   another	   study	   that	   showed	   that	   stimulation	   of	   TLR	  signalling	   in	   the	   presence	   of	   transcriptional	   inhibitors	   did	   not	   affect	   caspase-­‐1	  activation	  and	   therefore	   inflammasome	  activation	  (Fernandes-­‐Alnemri	  et	  al.,	  2013).	  In	  addition,	   the	  authors	   reported	  a	  need	   for	   IRAK1	   for	   rapid	  NLRP3	   inflammasome	  activation	   and	   possible	   association	   of	   IRAK1	   with	   NLRP3,	   suggesting	   that	   NLRP3	  might	   require	   or	   be	   modulated	   by	   IRAK1	   kinase	   activity.	   The	   second	   step	   of	  inflammasome	  activation	  is	  referred	  to	  as	  inflammasome	  triggering.	  Specific	  agonists	  such	   as	   ATP	   or	   the	   pore-­‐forming	   toxin,	   nigericin,	   trigger	   clustering	   of	   Nlrp3,	   thus	  enabling	   the	   PYRIN	   domain	   of	   Nlrp3	   to	   recruit	   apoptosis-­‐associated	   speck-­‐like	  protein	   containing	   a	   caspase-­‐recruitment	   domain	   (ASC),	   via	   homotypic	   PYRIN	  domain	   interactions.	   ASC,	   in	   turn,	   recruits	   caspase-­‐1	   to	   enable	   processing	   and	  subsequent	   release	   of	   mature	   IL-­‐1β	   and	   IL-­‐18,	   as	   well	   as	   initiation	   of	   pyroptosis	  (Lamkanfi	  and	  Dixit,	  2012).	  Release	  of	  IL-­‐1β	  acts	  to	  promote	  Th1	  and	  Th17	  responses	  and	   humoral	   immunity.	   Cleavage	   of	   pro-­‐IL-­‐18,	  which	   is	   constitutively	   expressed	   in	  macrophages,	   results	   in	   active	   IL-­‐18	   that	  mediates	   IL-­‐17	   production	   by	   Th17	   cells	  and	  that	  skews	  T	  cells	  towards	  either	  a	  Th1	  or	  Th2	  phenotype	  in	  concert	  with	  other	  cytokines	   (Dinarello	   2009).	   Pyroptosis	   results	   in	   the	   release	   of	   inflammatory	  cytokines	  and	  antigens	  from	  the	  cell	  along	  with	  DAMPs	  such	  as	  IL-­‐1α	  and	  HMGB1	  that	  may	   act	   as	   adjuvants	   to	   recruit	   the	   adaptive	   immune	   system	   (Lamkanfi	   and	   Dixit,	  2014).	  Each	  inflammasome	  complex	  consumes	  ATP	  and	  is	  thought	  to	  form	  a	  double-­‐ringed	   wheel	   structure	   with	   7-­‐	   or	   8-­‐fold	   symmetry	   similar	   to	   the	   structure	   of	   the	  apoptosome	  (Lechtenberg	  et	  al.,	  2014).	  	  In	   addition	   to	   canonical	   inflammasome	  activation	   involving	   activation	  of	   caspase-­‐1,	  non-­‐canonical	  inflammasome	  activation	  can	  also	  occur	  through	  activation	  of	  caspase-­‐11.	  Caspase-­‐11	  senses	  cytosolic	  acylated	  LPS	  with	  a	   lipid	  A	  structure	  and	   therefore	  responds	   to	   Gram-­‐negative	   bacteria	   independently	   of	   TLR4	   (Hagar	   et	   al.,	   2013;	  Kayagaki	  et	  al.,	  2013;	  Lupfer	  et	  al.,	  2014;	  Yang	  et	  al.,	  2015).	  Expression	  of	  caspase-­‐11	  is	  regulated	  by	  ROS	  (Lupfer	  et	  al.,	  2014)	  and	  caspase-­‐11	  is	  able	  to	  self-­‐oligomerise	  to	  form	   an	   inflammasome	   independently	   of	   caspase-­‐1	   activation	   (Vanaja	   et	   al.,	   2015;	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Yang	  et	  al.,	  2015).	  Caspase-­‐11	  is	  required	  for	  macrophages	  to	  secrete	  IL-­‐1β	  and	  IL-­‐18	  in	  response	  to	  infection	  with	  bacteria	  such	  as	  Escherichia	  coli,	  Citrobacter	  rodentium,	  and	  Vibrio	  cholerae,	  however	  caspase-­‐11	  is	  unable	  to	  mediate	  release	  of	  IL-­‐1β	  and	  IL-­‐18	   by	   itself.	   Instead,	   caspase-­‐11	   activation	   signals	   canonical	   NLRP3	   inflammasome	  activation	  to	  activate	  caspase-­‐1	  and	  thereby	  induce	  IL-­‐β	  and	  IL-­‐18	  secretion	  (Vanaja	  et	  al.,	  2015).	  In	  contrast,	  pyroptosis	  in	  response	  to	  these	  bacteria	  relies	  on	  caspase-­‐11	  but	  not	  caspase-­‐1.	  This	  was	  illustrated	  through	  the	  use	  of	  mouse	  models	  of	  endotoxic	  shock,	   where	   caspase-­‐11	   deficient	   mice	   were	   protected,	   while	   caspase-­‐1-­‐deficient	  mice	  were	   not	   (Kayagaki	   et	   al.,	   2011;	  Wang	   et	   al.,	   1998).	   It	   has	   also	   recently	   been	  shown	  that	  human	  caspase-­‐4	  and	  -­‐5	  are	  able	  to	  substitute	  for	  caspase-­‐11	  for	  cytosolic	  LPS	   sensing	   and	   pyroptosis	   induction	   and	   vice	   versa	   in	   human	   cells	   (Yang	   et	   al.,	  2015).	  Thus,	  caspases-­‐4	  and	  -­‐5	  function	  as	  human	  counterparts	  of	  caspase-­‐11	  (Vanaja	  et	  al.,	  2015).	  	  	  
1.2.2. Role	  of	  ubiquitination	  in	  inflammasome	  activation	  	  	  	  Although	   exact	   post-­‐translational	  mechanisms	   involved	   in	   inflammasome	   assembly	  are	   still	   poorly	   defined,	   several	   recent	   studies	   have	   implicated	   ubiquitin	  modifications	   in	   this	   process,	   particularly	   for	   the	   NLRP3	   inflammasome.	   The	  most	  commonly	  studied	  forms	  of	  ubiquitination	  are	  K48-­‐linked	  ubiquitin	  chains	  (ubiquitin	  linked	  by	  the	  48th	  lysine)	  and	  typically	  function	  to	  promote	  proteasomal	  degradation,	  and	  K63-­‐linked	  (linked	  by	  the	  63rd	  lysine)	  ubiquitin	  that	  support	  assembly	  of	  protein	  complexes	   and	   downstream	   signalling	   in	   the	   context	   of	   endocytic	   trafficking,	  inflammation,	  translation	  and	  DNA	  repair	  (Zinngrebe	  et	  al.,	  2014).	  	  In	  its	  resting	  state,	  NLRP3	  is	  ubiquitinated	  with	  both	  K48-­‐	  and	  K63-­‐linked	  ubiquitin	  chains	   (Py	   et	   al.,	   2013).	   Removal	   of	   these	   ubiquitin	   chains	   is	   required	   to	   allow	  interactions	   with	   ASC	   and	   pro-­‐caspase-­‐1,	   and	   thus	   assembly	   of	   the	   inflammasome	  (Lopez-­‐Castejon	  et	  al.,	  2013).	  Deubiquitination	  of	  NLRP3	  is	  suggested	  to	  occur	  by	  a	  2-­‐step	  deubiquitination	  mechanism.	  The	   first	   step	   is	   initiated	  by	  TLR4	   signalling	   and	  proposed	   to	   require	   mitoROS,	   but	   occurs	   rapidly	   and	   therefore	   independently	   of	  NFκB	  signalling.	  The	  second	  step	  involves	  ATP-­‐triggered	  deubiquitination	  and	  is	  not	  dependent	  on	  mitoROS.	  BRCC3	  was	  identified	  as	  one	  NLRP3	  deubiquitinase	  (Py	  et	  al.,	  2013),	  however	  others	  are	  likely	  to	  be	  involved.	  In	  addition,	  linear	  ubiquitination	  of	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ASC	  by	  the	  linear	  ubiquitin	  chain	  assembly	  complex	  (LUBAC),	  which	  is	  composed	  of	  SHANK-­‐associated	   RH	   domain	   interactor	   (SHARPIN),	   heme-­‐oxidised	   IRP2	   ligase-­‐1	  (HOIL-­‐IL)	   and	   HOIL-­‐IL-­‐interaction	   protein	   (HOIP)	   (Rodgers	   et	   al.,	   2014;	   Tokunaga	  and	   Iwai,	   2012),	  was	   also	   shown	   to	   be	   required	   for	   ASC-­‐dependent	   inflammasome	  assembly	   and	   activation	   (Rodgers	   et	   al.,	   2014).	   Proximal	   events	   in	   inflammasome	  activation	   are	   also	   affected	   by	   ubiquitination.	   For	   example,	   cellular	   inhibitor	   of	  apoptosis	  proteins	   (cIAPs),	   cIAP1	  and	  cIAP2,	   interact	  with	   the	  adaptor	  protein	  TNF	  receptor	   associated	   factor	   2	   (TRAF2),	   that	   mediates	   TNFα-­‐mediated	   activation	   of	  MAPK8/JNK	   and	   NFκB	   activation,	   in	   caspase-­‐1-­‐containing	   complexes	   to	   promote	  K63-­‐linked	  polyubiquitination	  of	  caspase-­‐1	  (Bertrand	  et	  al.,	  2009;	  Labbé	  et	  al.,	  2011).	  Deficiency	   of	   these	   cIAPs	   impaired	   caspase-­‐1	   activation,	   indicating	   that	  polyubiquitination	   of	   caspase-­‐1	   with	   K63-­‐linked	   ubiquitin	   is	   essential.	   This	   was	  suggested	   to	  occur	  by	  mediating	   recruitment	  and	  oligomerisation	  of	   inflammasome	  components	  or	  by	  enhancing	  the	  catalytic	  activity	  of	  caspase-­‐1.	  Finally,	  mouse	  models	  with	  deletion	  of	   the	  deubiquitinase	  tumour	  necrosis	   factor,	  alpha-­‐induced	  protein	  3	  (A20	   or	   Tnfaip3	   in	   mice)	   in	   macrophages	   showed	   increased	   basal	   and	   inducible	  Nlrp3	  and	  pro-­‐IL-­‐1β	  expression	  and	  Nlrp3	   inflammasome	  activation,	   indicating	  that	  A20/Tnfaip3	  may	  function	  as	  a	  negative	  regulator	  of	  Nlrp3	  inflammasome	  activation	  (Vande	  Walle	  et	  al.,	  2014).	   Indeed,	  a	  subsequent	  study	  revealed	  that	  A20	  prevented	  ubiquitination	   of	   pro-­‐IL-­‐1β	   with	   K63-­‐linked	   and	   unanchored	   polyubiquitin,	   which	  was	  required	  to	  promote	  pro-­‐IL-­‐1β	  proteolysis	  by	  caspase-­‐1	  (Duong	  et	  al.,	  2015).	  One	  component	   of	   this	   thesis	   explored	   the	   role	   of	   a	   novel	   ubiquitin	   ligase	   in	   regulating	  inflammasome	  responses	  in	  human	  macrophages.	  	  
1.3.	  Species-­‐Specific	  Immunity	  	  Studies	  of	  immunity	  commonly	  utilise	  mice	  as	  a	  model	  system	  to	  replicate	  molecular	  pathways,	   cellular	   responses	   and	   disease	   processes	   in	   humans.	   Indeed,	   the	  mouse	  model	   has	   proven	   to	   be	   incredibly	   effective	   in	   contributing	   to	   the	   development	   of	  many	  therapeutics,	  for	  example	  anti-­‐TNFα	  and	  anti-­‐IL-­‐6	  for	  RA,	  and	  IL-­‐1	  antagonists	  for	   gout	   and	   type	   II	   diabetes	   (Dinarello,	   2010).	  However,	   not	   all	   therapies	   that	   are	  promising	  in	  mice	  necessarily	  translate	  to	  positive	  outcomes	  in	  human	  clinical	  trials.	  In	  some	  cases,	  trials	  of	  some	  therapies	  have	  actually	  exacerbated	  disease,	  for	  example	  sepsis	   (Table	   1.2).	   Such	   failures	   may	   relate	   to	   deficiencies	   in	   specific	   models	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employed.	   For	   example,	   experimental	   sepsis	   therapies	   that	   are	   effective	   in	   the	   LPS	  shock	  model	  are	  not	  efficacious	  in	  polymicrobial	  sepsis	  models	  that	  more	  effectively	  model	  human	  sepsis	  (Rittirsch	  et	  al.,	  2007;	  Ward,	  2012).	  Another	  contributing	  factor	  is	   likely	   to	  be	   species	  differences	   in	   immune	  pathways.	   In	   this	   regard,	   humans	  and	  mice	  diverged	  from	  a	  common	  ancestor	  70	  to	  80	  million	  years	  ago	  (Waterston	  et	  al.,	  2002),	   and	   genes	   involved	   in	   reproduction,	   perception	   and	   immune	   responses	   are	  particularly	   sensitive	   to	   evolutionary	   change	   (Ellegren,	   2008;	   Heger	   and	   Ponting,	  2007;	   Pizzari	   and	   Birkhead,	   2002).	   Indeed,	   numerous	   phenotypic	   differences	   have	  been	   recorded	   between	   the	   immune	   systems	   of	   humans	   and	   mice	   (Mestas	   and	  Hughes,	  2004),	  particularly	  in	  innate	  immunity	  (Messier-­‐Solek	  et	  al.,	  2010),	  since	  this	  system	   is	   under	   constant	   selection	   pressure	   to	   co-­‐evolve	   with	   rapidly-­‐evolving	  pathogens.	   In	   this	   respect,	   understanding	   species	   differences	   in	   immune	   pathways	  may	  provide	  new	  insights	   into	  pathogen	  control	  mechanisms	  used	  by	  different	  host	  species.	  	  
Therapeutic	  
strategy	  
Outcome	  of	  clinical	  trials	   References	  
TNFα	  blockade	  	   No	  improvement	  or	  dose-­‐dependent	  increase	  in	  mortality,	  though	  some	  trials	  have	  also	  reported	  beneficial	  effects	  in	  seriously	  ill	  septic	  patients	  
(Arndt	   and	   Abraham,	  2001;	   Fisher	   et	   al.,	  1996;	   Rittirsch	   et	   al.,	  2007)	  IL-­‐1	  receptor	  antagonism	  	  
No	  significant	  reduction	  in	  mortality	  in	  two	  phase	  III	  trials,	  although	  a	  slight	  increase	  in	  survival	  rates	  or	  survival	  time	  was	  reported	  in	  patients	  with	  organ	  dysfunction	  and/or	  ≥24%	  risk	  of	  mortality	  
(Fisher	   et	   al.,	   1994;	  Opal	   et	   al.,	   1997;	  Rittirsch	  et	  al.,	  2007)	  
Anti-­‐endotoxin	  	   Numerous	  large	  scale	  trials	  conducted,	  with	  no	  consistent	  therapeutic	  benefit	   (Arndt	   and	   Abraham,	  2001;	   Rittirsch	   et	   al.,	  2007)	  Nitric	  oxide	  synthase	  inhibition	   Increased	  mortality,	  possibly	  due	  to	  cardiovascular	  effects,	  in	  a	  phase	  III	  trial	   (Fortin	  et	  al.,	  2010)	  
Table	  1.2:	  Examples	  of	  therapeutic	  strategies	  effective	  in	  mouse	  sepsis	  models	  
but	  not	  in	  subsequent	  human	  clinical	  studies.	  	  This	  table	  is	  from	  (Ariffin	  and	  Sweet,	  2013).	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One	  mechanism	  by	  which	  species	  differences	  arise	   is	   through	   the	  evolution	  of	  non-­‐orthologous	   genes.	   Divergent	   expression	   or	   function	   of	   paralogous	   genes	   due	   to	  mutations	  may	  ultimately	  result	  in	  a	  non-­‐functional	  pseudogene	  in	  one	  species	  or	  the	  emergence	  of	  an	  entirely	  new	   function	   in	  another,	   thus	   resulting	   in	   species-­‐specific	  gene	  repertoires.	  Differential	  regulation	  or	  function	  of	  strict	  one-­‐to-­‐one	  orthologous	  genes	   can	   also	   occur	   through	   multiple	   mechanisms,	   thus	   leading	   to	   differences	   in	  biological	   roles.	   These	   differences	  may	   arise	   through	  mutations	   in	   gene	   regulatory	  sequences	   that	   alter	   regulation	   of	   gene	   expression,	   or	   through	   amino	   acid	   changes	  that	  affect	   ligand	  specificity	   thereby	  changing	  protein	   function.	  Examples	  of	   species	  differences	  in	  the	  context	  of	  PRRs	  are	  discussed	  below	  and	  are	  illustrated	  in	  Figure	  
1.1	  and	  Figure	  1.2.	  	  
1.3.1.	   Differences	  in	  Pathogen-­‐sensing	  mechanisms	  As	  previously	  mentioned,	  humans	  possess	  ten	  functional	  TLRs	  (TLR	  1-­‐10)	  while	  mice	  have	  12	  (Tlr1-­‐9,	  Tlr11-­‐13)	  (Roach	  et	  al.,	  2005).	  In	  humans,	  TLR10	  is	  a	  functional	  gene,	  while	   in	  mice	   it	   is	  a	  pseudogene,	  and	   the	  reverse	   is	   true	   for	  Tlr11,	  12	  and	  13.	   Since	  TLR2/10	  detects	  triaceylated	  lipopeptides	  similarly	  to	  TLR1/2,	  but	  activates	  distinct	  signalling	   pathways	   (Table	   1.1),	   this	   particular	   difference	   in	   TLR	   repertoire	   likely	  reflects	   a	   species-­‐specific	   difference	   in	   signalling	   and	   gene	   expression	   outputs	  between	   humans	   and	  mice.	   The	   existence	   of	   species-­‐specific	   pathogen	   recognition	  systems	   is	  also	  highlighted	  by	  the	  detection	  of	  E.	  coli	  and	  T.	  gondii	  by	  murine	  Tlr11	  (mTlr11)	   (Yarovinsky	  et	  al.,	  2005a;	  Zhang	  et	  al.,	  2004a),	  and	  of	  vesicular	  stomatitis	  virus	   and	  23S	   rRNA	   from	  Gram-­‐positive	   bacteria	   by	  mTlr13	   (Hidmark	   et	   al.,	   2012;	  Oldenburg	   et	   al.,	   2012).	   Intriguingly,	   mTlr13	   recognises	   a	   specific	   nucleic	   acid	  sequence	  within	  23S	   rRNA.	  Methylation	  of	   this	   sequence	   confers	  not	   only	  bacterial	  resistance	   to	   a	   group	   of	   antibiotics	   including	   erythromycin,	   but	   also	   evasion	   of	  detection	  by	  mTlr13	  (Oldenburg	  et	  al.,	  2012).	  Thus,	  it	  was	  proposed	  that	  widespread	  antibiotic	  resistance	  led	  to	  subversion	  of	  recognition	  by	  TLR13,	  resulting	  in	  its	  lack	  of	  conservation	   in	   humans.	   Even	   for	   PRRs	   that	   share	   one-­‐to-­‐one	   orthologs	   between	  species,	   differences	   in	   cell-­‐specific	   expression	   and/or	   ligand	   specificity	   also	   exist	  between	  human	  and	  mouse.	  For	  example,	  the	  TLR4/MD2	  LPS	  receptor	  complex	  has	  different	  sensitivities	  in	  detecting	  lipid	  IVa	  and	  taxol	  (Rossol	  et	  al.,	  2011).	  Lipid	  IVa	  is	  a	  lipid	  A	  (active	  moiety	  of	  LPS)	  precursor	  that	  has	  only	  4	  acyl	  chains	  instead	  of	  6	  as	  in	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lipid	  A,	  and	  acts	  as	  a	  TLR4	  agonist	  in	  mouse	  and	  a	  TLR4	  antagonist	  in	  human	  due	  to	  its	   difference	   in	   binding	   affinity	  with	   human	   and	  mouse	  MD2	   (Saitoh	   et	   al.,	   2004).	  This	   was	   hypothesised	   to	   lead	   to	   the	   enhanced	   sensitivity	   of	   humans	   to	   LPS	   in	  comparison	  to	  mice.	  Taxol,	  which	   is	  a	  chemical	   isolated	  from	  the	  bark	  of	   the	  Pacific	  yew	   tree	   and	   currently	   in	   use	   for	   cancer	   therapy	   as	  Paclitaxel	   (Zheng	   et	   al.,	   2015),	  mimics	  the	  action	  of	  LPS	  and	  is	  similarly	  agonistic	  in	  mouse	  but	  not	  in	  human	  due	  to	  differential	   recognition	  by	  MD2	  (Kawasaki	  et	   al.,	   2003).	  These	  differences	   illustrate	  how	  TLR	   responses	   can	  be	   as	   a	  whole	   conserved	  between	   species,	   but	   still	   display	  certain	  species-­‐specific	  pathogen	  recognition	  pathways.	  	  
	  
Figure	  1.1:	  Mechanisms	  for	  differences	   in	  TLR	  repertoire	  or	   function	  between	  
human	  and	  mouse	  and	  possible	  consequences.	  Differences	   in	  TLRs	  between	  human	   and	  mouse	  have	   arisen	   through	  differences	   in	  gene	  repertoire	  (e.g.	  loss	  of	  TLR13	  in	  human),	  as	  well	  as	  differences	  in	  the	  functions	  of	   one-­‐to-­‐one	   orthologues	   (e.g.	   differences	   in	   expression,	   ligand	   specificity,	   target	  genes	   and/or	   downstream	   biological	   responses).	   This	   figure	   is	   from	   Ariffin	   and	  Sweet,	  2013.	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In	   the	   NLR	   family,	   humans	   express	   22	  NLR	   genes	  while	   there	   are	   >30	  murine	  Nlr	  (mNlr)	   genes.	   Interestingly,	   the	   divergence	   in	   repertoire	   is	   more	   apparent	   in	  inflammasome-­‐forming	  NLRP	  and	  NLRC	  subfamilies,	  rather	  than	  the	  NOD	  subfamily	  (Schroder	   and	   Tschopp,	   2010).	  Multiple	   paralogs	   of	   the	   human	  NAIP	   gene	   exist	   in	  mouse	  (Kofoed	  and	  Vance,	  2012),	  and	  hNLRP1,	  hNLRP4	  and	  hNLRP9	  also	  share	  one-­‐to-­‐many	  orthology	  relationships	  with	  mouse	  genes	  (Elinav	  et	  al.,	  2011;	  Schroder	  and	  Tschopp,	  2010).	  In	  contrast,	  there	  are	  no	  orthologs	  of	  hNLRP7,	  hNLRP8,	  hNLRP11	  and	  hNLRP13	   in	  mice.	  For	  NLRP8	  and	  NLRP13,	   this	  likely	  reflects	  the	  loss	  of	  these	  genes	  during	  rodent	  evolution,	  since	  orthologs	  are	  present	  across	  other	  mammalian	  species	  (Tian	  et	  al.,	  2009).	  In	  the	  case	  of	  NLRP7	  and	  NLRP11,	  the	  absence	  from	  mouse	  reflects	  primate-­‐specific	  evolution;	  hNLRP7	   is	   thought	  to	  have	  arisen	  from	  duplication	  of	  an	  ancestral	  NLRP2	   gene	  during	  primate	   evolution,	   and	   a	   similar	   scenario	   is	   likely	   for	  hNLRP11,	  which	  is	  related	  to	  hNLRP4	  and	  hNLRP9	  (Tian	  et	  al.,	  2009).	  Although	  some	  of	  the	  most	  widely	  studied	  NLRs,	  for	  example,	  NLRP3,	  NOD1	  and	  NOD2	  show	  one-­‐to-­‐one	   orthology	   relationships	   between	   human	   and	   mouse,	   differences	   in	   activation	  signals	   or	   function	   have	   been	   observed.	   For	   example,	   hNLRP3	   but	   not	   mNlrp3	   is	  activated	  by	  Francisella	  tularensis	   (Atianand	  et	   al.,	   2011),	  whereas	  both	  hAIM2	  and	  mAim2	  are	  able	  to	  sense	  this	  pathogen	  (Atianand	  et	  al.,	  2011;	  Fernandes-­‐Alnemri	  et	  al.,	  2010).	  This	  may	  result	  from	  sequence	  differences	  between	  hNLRP3	  and	  mNlrp3,	  or	  pathways	  regulating	  their	  activation,	  and	  could	  contribute	  to	  species	  differences	  in	  detection	  of	  other	  danger	  signals.	  The	  species-­‐specific	  expansion	  or	  loss	  of	  NLRs	  and	  differences	   in	   ligand	   detection	   demonstrates	   how	   NLRs	   have	   evolved	   to	   allow	   the	  tailoring	  of	  immune	  responses	  within	  each	  species.	  This	  highlights	  the	  importance	  of	  NLRs	  as	  key	  microbial	  and	  danger	  sensors	  for	  immune	  responses	  (Vanaja	  et	  al.,	  2015;	  Vasseur	  et	  al.,	  2012).	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Figure	  1.2:	  Mechanisms	  for	  differences	   in	  NLR	  repertoire	  or	   function	  between	  
human	  and	  mouse	  and	  possible	  consequences.	  	  NLR	  repertoires	   in	  human	  and	  mouse	  have	  diverged	   through	  gain	  or	   loss	  of	   genes,	  and	   through	   diversification	   of	   sensing	   mechanisms	   (e.g.	   use	   of	   multiple	   Naip	   co-­‐receptors	  to	  modulate	  specificity	  of	  Nlrc4	  ligand	  sensing	  in	  mouse).	  Orthologous	  NLR	  genes	   have	   also	   undergone	   functional	   divergence	   leading	   to	   differences	   in	  inflammasome	   priming,	   activation	   and	   regulation	   *number	   of	   Naip	   genes	   varies	  between	  different	  mouse	  strains.	  This	  figure	  is	  from	  (Ariffin	  and	  Sweet,	  2013).	  	  
1.3.2.	   Differences	  in	  PRR-­‐regulated	  gene	  expression	  Given	   that	   many	   PRRs	   initiate	   substantial	   transcriptional	   programs,	   differences	   in	  regulation	  of	  target	  genes	  could	  also	  contribute	  substantially	  to	  species	  differences	  in	  immune	  pathways.	  Indeed,	  there	  are	  well	  known	  examples	  of	  differential	  regulation	  of	   innate	   immune	  PRR	  target	  genes	  resulting	   in	  species	  differences	   in	  antimicrobial	  pathways.	   For	   example,	   Vitamin-­‐D-­‐mediated	   antimicrobial	   activity	   against	   M.	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tuberculosis	  occurs	   in	   a	   TLR2-­‐inducible	  manner	   for	   the	   induction	   of	   cathelicidin	   in	  human	  macrophages	  (Liu	  et	  al.,	  2007c;	  Martineau	  et	  al.,	  2007;	  Yang	  et	  al.,	  2009;	  Yuk	  et	  al.,	  2009).	  However,	  vitamin	  D-­‐inducible	  cathelicidin	  production	  does	  not	  occur	  in	  mouse	   macrophages.	   Instead,	   mouse	   macrophages	   produce	   cathelicidin	   through	  TLR9-­‐mediated	   activation	   of	   extracellular	   signal-­‐regulated	   kinase	   (ERK)	   signalling	  upon	   recognition	   of	   bacterial	   DNA	   (Koon	   et	   al.,	   2011).	   In	  mouse	  macrophages,	   the	  
iNOS	  gene	  is	  robustly	  induced	  by	  IFNγ	  and	  LPS	  to	  enable	  NO-­‐mediated	  host	  defence	  against	   bacterial	   pathogens	   (Bogdan,	   2001;	   Schroder	   et	   al.,	   2004).	   However,	   the	  human	   iNOS	   gene	   is	   not	   regulated	   by	   these	   stimuli	   (Bogdan,	   2001),	   but	   rather	   is	  weakly	  upregulated	  by	  IFNα/β,	  IL-­‐4	  and	  anti-­‐CD23	  in	  human	  macrophages	  (Aubry	  et	  al.,	   1997;	  Diefenbach	   et	   al.,	   1998).	  The	   lack	  of	   conservation	   in	  LPS/IFNγ	   regulation	  was	  revealed	  to	  be	  due	  to	  multiple	  substitutions	  in	  an	  enhancer	  region	  of	  the	  human	  promoter	  (Zhang	  et	  al.,	  1996).	  In	  contrast,	  the	  mouse	  promoter	  elements	  enabled	  LPS	  responsiveness,	   and	   subsequent	   studies	   also	   revealed	   a	   requirement	   for	   the	  transcription	  factors	  STAT1	  and	  IRF-­‐1	  for	  induction	  of	  iNOS	  (Kamijo	  et	  al.,	  1994).	  In	  contrast	  to	  LPS-­‐induction	  of	   iNOS	  in	  mouse	  macrophages,	  production	  of	  IDO	  is	  LPS-­‐inducible	  in	  human	  but	  not	  mouse	  macrophages	  (Roshick	  et	  al.,	  2006;	  Schroder	  et	  al.,	  2012a).	  As	  NO	  inhibits	  IDO	  (Thomas	  et	  al.,	  1994),	  this	  may	  relate	  to	  differential	  iNOS	  induction	  in	  human	  versus	  mouse	  macrophages.	  The	  differential	  use	  of	  IDO	  in	  human	  and	   mouse	   antimicrobial	   responses	   illustrates	   an	   example	   of	   host/pathogen	   co-­‐evolution;	  only	  the	  human-­‐tropic	  strain	  of	  Chlamydia,	  C.	  trachomatis,	  expresses	  genes	  to	  divert	   the	  host	   tryptophan	   starvation	  pathway,	  while	   the	  mouse-­‐tropic	   strain,	  C.	  
muridarum	  does	  not	  (Nelson	  et	  al.,	  2005).	  	  	  The	  above	   studies	  highlight	  how	  regulatory	  mechanisms	  can	  be	  quite	  divergent	   for	  antimicrobial	  pathways	  that	  are	  common	  between	  species.	  More	  recent	  studies	  have	  attempted	   to	   define	   how	   widespread	   innate	   immune	   gene	   regulation	   is	   between	  species.	  One	  study	   looking	  at	  gene	  expression	  profiles	   from	  datasets	  obtained	   from	  burn,	   trauma	   and	   endotoxemia	   patients	   in	   comparison	   to	   mouse	   models	   reported	  that	   correlation	   between	   the	   gene	   expression	   profiles	   in	   humans	   and	   the	  corresponding	  mouse	  models	   is	  very	   low	  and	  close	   to	  random	  (R2	  between	  0.0	  and	  0.1)	   (Seok	  et	   al.,	   2013).	  However,	   a	   separate	   study	   re-­‐evaluating	   the	   same	  datasets	  reported	  high	  correlation	  of	  gene	  expression	  between	  humans	  and	  mice	  (Takao	  and	  Miyakawa,	  2015).	  Among	   the	  differences	   in	  analysis	  employed	  by	   the	   second	  study	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are	   the	   exclusion	   of	   murine	   genes	   not	   significantly	   responsive	   to	   stimuli	   for	  comparison	  against	   orthologous	  human	  genes	   responsive	   to	   stimuli,	   and	   the	  use	  of	  mouse	   datasets	   that	   most	   highly	   matched	   a	   particular	   human	   disorder.	   This	   was	  conducted	  due	   to	   the	   assumption	   that	  mouse	  models	   only	  mimic	   partial	   aspects	   of	  human	   disorders	   and	   inclusion	   of	   non-­‐responsive	  murine	   genes	   would	   reduce	   the	  sensitivity	   of	   the	   analysis	   for	   detection	   of	   shared	   responses	   between	   the	   human	  disorders	  and	  corresponding	  mouse	  models.	  The	  authors	  also	  used	  the	  best-­‐matching	  datasets	  with	   the	   rationale	   that	  mouse	  models	   that	  most	   closely	  match	   the	   human	  condition	   are	   most	   useful	   as	   models	   and	   thus	   for	   comparisons.	   While	   in	   vivo	  comparisons	  between	  humans	  and	  mice	  are	  difficult	  because	  of	  many	  variables	  that	  cannot	   be	   adequately	   controlled	   for,	   a	   study	   comparing	   the	   transcriptional	   profiles	  from	   7	   human	   and	  mouse	   immune	   cell	   groups	   during	   differentiation,	   showed	   that	  global	   transcription	   profiles,	   lineage-­‐specific	   gene	   expression,	   and	   underlying	  regulatory	  mechanisms	  were	  extensively	  conserved	  between	  the	  species	  (Shay	  et	  al.,	  2013).	   Nevertheless,	   divergence	   in	   cis-­‐regulatory	   elements	  was	   observed	   for	   some	  lineage-­‐specific	   genes.	   Similar	   findings	   were	   reported	   in	   a	   prior	   study	   from	   this	  laboratory	   looking	   specifically	   at	   human	   and	   mouse	   macrophage	   transcriptional	  responses	   to	   LPS	   (Schroder	   et	   al.,	   2012a).	   This	   study	   found	   that	   conservation	   of	  orthologous	   TLR4-­‐responsive	   genes	   was	   high	   between	   human	   and	   mouse,	   with	  intracellular	  signalling	  components	  typically	  regulated	  similarly	  between	  the	  species.	  However,	   24%	   of	   orthologous	   genes	   were	   identified	   to	   be	   differentially	   LPS-­‐regulated.	  This	   subset	  of	  divergently	   regulated	  genes	  was	  enriched	  with	  genes	   that	  encode	  for	  cellular	  inputs	  such	  as	  PRRs	  and	  cytokine	  receptors	  (e.g.	  TLR6,	  TLR8	  and	  IL-­‐7Rα),	   outputs	   such	   as	   inflammatory	   cytokines	   and	   chemokines	   (e.g.	   CCL20	   and	  CXCL13),	  feedback	  regulators	  (e.g.	  IRAK3,	  JDP2,	  SOCS1	  and	  ATF3)	  and	  antimicrobial	  effector	  genes	  (e.g.	  iNOS	  and	  IDO).	  Intriguingly,	  divergently	  regulated	  genes	  had	  high	  promoter	  conservation	  between	  species,	  but	  were	  associated	  with	  specific	  promoter	  architectural	   features	   (e.g.	   TATA	   box	   enrichment,	   CpG	   island	   depletion)	   and	   a	  dynamic	   range	   of	   gene	   expression,	   suggesting	   that	   the	   most	   complex	   and	   highly	  conserved	  promoters	  are	  also	  hypersensitive	  to	  selection	  pressure	  and	  evolutionary	  change	   in	   cis-­‐regulatory	   elements.	   Thus,	   divergently	   regulated	   genes	   are	   likely	  involved	   in	   species-­‐specific	   adaptations	  of	   critical	   immune	  pathways	  and	   strategies	  that	  are	  important	  for	  host	  defence.	  In	  view	  of	  this,	  one	  part	  of	  this	  project	  sought	  to	  investigate	   the	   functional	   consequences	   resulting	   from	   interspecies	   divergence	   of	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novel	   LPS-­‐responsive	   genes	   in	   the	   context	   of	   human	   macrophage	   antimicrobial	  responses	  to	  Gram-­‐negative	  bacteria.	  These	  studies	  ultimately	  led	  to	  investigating	  the	  role	  of	  one	  TLR-­‐inducible	  gene	  in	  inflammasome	  responses	  in	  human	  macrophages.	  	  
1.4.	  Immunoregulatory	  effects	  of	  pharmacological	  agents	  Research	  on	   inflammatory	  and	  autoimmune	  diseases	  has	   led	   to	   the	  development	  of	  many	   agents	   that	   control	   inflammatory	   processes.	   Classic	   examples	   include	   the	  treatment	   of	   RA	   and	   inflammatory	   bowel	   disease	   (IBD)	   with	   biological	   agents	  targeting	   TNFα	   and	   IL-­‐6	   (Feldmann,	   2002;	   Nishimoto	   et	   al.,	   2004).	   However	   these	  agents	  have	  been	  reported	  to	  compromise	  host	  defence	  due	  to	  lowered	  immunity.	  For	  example,	   treatment	   of	   RA	   and	   IBD	   patients	   with	   Infliximab,	   a	   humanized	   TNFα	  neutralizing	  antibody,	  leads	  to	  increased	  risk	  of	  serious	  infections	  particularly	  in	  the	  first	  six	  months	  of	  treatment	  (Galloway	  et	  al.,	  2011).	  Anti-­‐TNFα	  therapy	  has	  also	  been	  associated	   with	   increased	   risk	   of	   malignancies	   (Bongartz	   et	   al.,	   2006)	   as	   well	   as	  reactivation	  of	  latent	  tuberculosis	  (Gómez-­‐Reino	  et	  al.,	  2003;	  Keane	  et	  al.,	  2001).	  This	  is	  perhaps	  unsurprising,	  given	  that	  TNFα	  is	  known	  to	  be	  important	  for	  host	  defence	  and	   tumour	   growth	   control.	   The	  occurrence	  of	   such	  unwanted	   side	   effects	   stresses	  the	   need	   to	  monitor	   the	   impact	   of	   novel	   anti-­‐inflammatory	   agents	   on	   host	   defence	  pathways.	  Impaired	  bacterial	  clearance	  by	  macrophages	  could	  reveal	  potential	  risks	  for	   therapeutic	   applications,	   given	   the	   importance	   of	   these	   cells	   in	   host	   defence.	  Conversely,	   if	   these	   responses	   are	   promoted,	   novel	   insights	   into	   macrophage	  antimicrobial	   pathways	   and	   new	   therapeutic	   opportunities	  might	   also	   be	   unveiled.	  Therefore,	   the	   second	   component	   of	   this	   project	   focused	   on	   investigating	   potential	  immunoregulatory	  effects	  of	  novel	  pharmacological	  agents	   that	   target	  host	  proteins	  under	   consideration	   as	   anti-­‐inflammatory	   targets,	   the	   G	   protein-­‐coupled	   receptor	  (GPCR)	  C5aR	  and	  histone	  deacetylases	  (HDACs).	  	  	  
1.4.1.	   Histone	  Deacetylases	  DNA	  inside	  a	  eukaryotic	  cell	   is	  compacted	  into	  chromatin	  fibres	  that	  wrap	  around	  4	  pairs	   of	   histone	   proteins,	   forming	   a	   nucleosome.	   Regulation	   of	   eukaryotic	   gene	  expression	  depends	  on	  the	  accessibility	  of	  the	  DNA	  on	  these	  histone	  proteins.	  Histone	  acetyltransferases	  (HATs)	  acetylate	  lysine	  residues	  on	  core	  histone	  tails,	  relaxing	  the	  coiling	  of	  DNA	  and	  allowing	  initiation	  of	  transcription,	  while	  histone	  deacetylases,	  or	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HDACs,	  reverse	  this	  process	  by	  removing	  acetylation	  on	  lysine	  residues.	  This	  results	  in	   chromatin	   compaction,	   silencing	  of	   gene	   transcription,	   and	  genome	  maintenance	  such	   as	   DNA	   replication	   and	   DNA	   damage	   responses	   and	   repair	   (Bhaskara	   et	   al.,	  2008;	   Conti	   et	   al.,	   2010;	   Frew	   et	   al.,	   2009;	   Haberland	   et	   al.,	   2009).	   There	   are	   18	  human	  HDAC	  enzymes	  that	  are	  classed	  into	  4	  main	  groups	  based	  on	  their	  sequence	  homology	   to	   yeast	  proteins	   (Dokmanovic	   et	   al.,	   2007).	   Class	   I,	   II	   and	   IV	  HDACs	  are	  considered	   classical	   HDACs	   as	   they	   are	   dependent	   on	   Zn2+	   for	   enzymatic	   activity,	  share	  sequence	  similarity,	  and	  are	   inhibited	  by	  compounds	   like	  TSA	  or	  SAHA,	  while	  non-­‐classical	  Class	  III	  HDACs	  consists	  of	  7	  sirtuins	  that	  require	  NAD+	  but	  not	  zinc,	  and	  are	  not	  inhibited	  by	  compounds	  like	  TSA	  or	  SAHA	  (Dokmanovic	  et	  al.,	  2007).	  Class	  II	  HDACs	  may	  also	  be	  divided	  into	  Class	  IIa	  (HDAC4,	  5,	  7,	  9)	  and	  Class	  IIb	  (HDAC6,	  10)	  based	  on	  their	  domain	  organisation	  (Martin	  et	  al.,	  2007).	  Although	  HDACs	  are	  termed	  ‘histone’	  deacetylases,	  they	  are	  also	  able	  to	  act	  on	  many	  non-­‐histone	  proteins	  such	  as	  transcription	  factors,	  cell	  cycle	  proteins	  and	  protein	  kinases,	  and	  are	  thus	  important	  for	  many	  cellular	  functions	  beyond	  epigenetic	  control	  (Choudhary	  et	  al.,	  2009).	  	  	  	  
1.4.1.1.	   HDACi	  as	  anti-­‐cancer	  drugs	  Overexpression	   of	  HDACs	   induces	   epigenetic	   silencing	   of	   tumour	   suppressor	   genes	  and	  the	  development	  of	  many	  cancers.	  Consequently,	  HDAC	  inhibitors	  (HDACi)	  have	  been	   found	   to	   be	   effective	   as	   anti-­‐cancerous	   agents,	   at	   least	   for	   some	   cancers,	   by	  restoring	   the	   expression	   of	   tumour	   suppressor	   genes	   and	   inducing	   cell	  differentiation,	  growth	  arrest	  and	  apoptosis	  (Kim	  et	  al.,	  2000;	  Mai	  et	  al.,	  2005).	  HDACi	  may	   be	   classified	   into	   6	   categories:	   (i)	   hydroxamates	   such	   as	   suberoylanilide	  hydroxamic	   acid	   (SAHA)	   also	   known	   as	   Vorinostat	   or	   Zolinza,	   and	   trichostatin	   A	  (TSA);	  (ii)	  benzamides	  such	  as	  entinostat	  (MS-­‐275);	  (iii)	  short-­‐chain	  fatty	  acids	  such	  as	  valproic	  acid	  (VPA)	  and	  butyric	  acid;	  (iv)	  cyclic	  peptides	  such	  as	  romidepsin	  also	  known	   as	   Istodax,	   and	   depsipeptide;	   (v)	   electrophilic	   ketones	   such	   as	  trifluoromethylketone;	  and	  (vi)	  miscellaneous	  compounds	  such	  as	  MGCD0103	  (Tang	  et	  al.,	  2013).	  They	  may	  also	  be	  classified	  according	  to	  their	  specificity	  for	  HDACs.	  Most	  HDACi,	   for	   example	   SAHA	   and	   TSA,	   are	   broad	   spectrum	   inhibitors,	   while	   others	  exhibit	  some	  selectivity	  for	  individual	  classes	  of	  enzymes.	  For	  example,	  VPA	  inhibits	  class	  I	  and	  IIa	  HDACs,	  MS-­‐275	  and	  romidepsin	  are	  class	  I	  specific,	  and	  Tubastatin	  A	  is	  specific	   for	   HDAC6	   (Haggarty	   et	   al.,	   2003;	   Khan	   and	   La	   Thangue,	   2012).	   However,	  recently	   it	   has	   been	   suggested	   that	   broad-­‐spectrum	   HDACi	   might	   also	   have	   some	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degree	   of	   selectivity	   for	   different	   HDACs	   (Bantscheff	   et	   al.,	   2011;	   Bradner	   et	   al.,	  2010).	   Approximately	   11	   HDACi,	   including	   SAHA	   MS-­‐275,	   VPA	   and	   FK228,	   are	  currently	  in	  use	  clinically	  or	  are	  in	  clinical	  trials	  as	  anti-­‐cancer	  agents	  (Bolden	  et	  al.,	  2006;	   Frew	   et	   al.,	   2009;	  Marsoni	   et	   al.,	   2008;	  West	   and	   Johnstone,	   2014;	   Xu	   et	   al.,	  2007a).	  Of	  note	  are	  SAHA	  and	  romidepsin	  that	  were	  approved	  by	  the	  Food	  and	  Drug	  Administration	   (FDA)	   in	   2006	   for	   the	   treatment	   of	   cutaneous	   T	   cell	   lymphoma	  (Dokmanovic	  et	  al.,	  2007;	  Piekarz	  et	  al.,	  2011)	  and	  VPA,	  which	  was	  approved	  in	  1995	  as	  an	  anticonvulsant	   for	  mania	  (Leo	  and	  Narendran,	  1999).	  Although	  recent	  studies	  report	  that	  treatment	  with	  HDACi	  alone	  shows	  minimal	  or	  no	  effect	  for	  some	  cancers	  in	  human	  clinical	  trials,	  including	  renal	  cell	  cancer,	  ovarian	  carcinoma,	  squamous	  cell	  carcinoma	   and	   peritoneal	   carcinoma,	   the	   use	   of	   HDACi	   in	   combination	   with	   other	  anti-­‐tumour	  agents	  appears	  to	  enhanced	  efficacy	  (Frew	  et	  al.,	  2009;	  Qiu	  et	  al.,	  2013).	  For	  example,	  this	  was	  the	  case	  for	  treatment	  of	  cancer	  cell	  lines	  of	  diverse	  origin	  and	  in	   murine	   embryonic	   fibroblasts	   with	   selective	   class	   I	   HDACi	   targeting	   HDAC3	   in	  concert	  with	  DNA	  damaging	  agents	  (Khabele,	  2014).	  	  	  
1.4.1.2.	   HDACi	  as	  anti-­‐inflammatory	  agents	  Apart	   from	   histone	   proteins,	   HDACi	   also	   affect	   the	   acetylation	   status	   of	   proteins	  involved	   in	   regulation	   of	   gene	   expression,	   apoptosis,	   cell-­‐cycle	   progression,	   redox	  pathways,	  mitotic	  division,	  DNA	  repair,	  cell	  migration	  and	  angiogenesis	  (Tang	  et	  al.,	  2013).	   Thus,	   the	   use	   of	   HDACi	   has	   been	   explored	   in	   diseases	   beyond	   cancer,	  especially	  as	  therapeutic	  agents	  in	  models	  of	  acute	  and	  chronic	  inflammatory	  disease.	  	  Initial	  studies	  showed	  that	  SAHA	  reduced	  LPS-­‐induced	  expression	  of	  TNFα,	  IL-­‐1β,	  IL-­‐6	  and	  IFNγ	  in	  vitro	  and	  in	  vivo	  and	  reduced	  the	  release	  of	  NO	  in	  mouse	  macrophages	  stimulated	   with	   TNFα	   and	   IFNγ	   (Leoni	   et	   al.,	   2002).	   TSA	   had	   a	   similar	   effect	   in	  reducing	   pro-­‐inflammatory	   cytokine	   expression,	  while	   increasing	   expression	   of	   the	  immunosuppressive	   cytokine	   IL-­‐10	   (Han	   and	   Lee,	   2009).	   Subsequently,	   it	   was	  reported	   that	  TSA	   treatment	   resulted	   in	   inhibition	  of	  up	   to	  60%	  of	  TLR2	  and	  TLR4	  inducible	  genes	  while	  only	  16%	  of	  genes	  were	  potentiated,	  indicating	  that	  HDACi	  are	  immunosuppressive	  (Bode	  and	  Dalpke,	  2011).	  HDACi	   treatment	  was	  reported	  to	  be	  protective	   in	   mouse	   models	   of	   septic	   shock	   (Ciarlo	   et	   al.,	   2013),	   systemic	   lupus	  erythomatosus	   (SLE)	   (Reilly	   et	   al.,	   2011)	   and	   colitis	   (Bode	   and	   Dalpke,	   2011).	  Therapeutic	  HDACi	   treatment	   in	  mouse	  models	  of	  RA	  was	  also	  effective	   in	  multiple	  ways,	  by	  blocking	  pro-­‐inflammatory	  cytokine	  production	  (Lin	  et	  al.,	  2007),	  induction	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of	  macrophage	  apoptosis	   (Grabiec	  et	  al.,	  2010),	  upregulation	  of	   cell	   cycle	   inhibitors	  (Chung,	   2003),	   and	   blocking	   cartilage	   (Young	   et	   al.,	   2005)	   and	   bone	   resorption	  (Cantley	  et	  al.,	  2012;	  Joosten	  et	  al.,	  2011).	  HDACi	  were	  similarly	  therapeutic	  in	  mouse	  models	   of	   asthma	   (Choi	   et	   al.,	   2005),	   IBD	   (Glauben	   and	   Siegmund,	   2011)	   and	   SLE	  (Reilly	  et	  al.,	  2011),	  and	  a	  recent	  clinical	  trial	  assessing	  safety	  in	  human	  patients	  with	  juvenile	   idiopathic	  arthritis	  (JIA)	  also	  reported	  beneficial	  effects	   in	  reducing	  disease	  symptoms	  (Vojinovic	  and	  Damjanov,	  2011).	  The	  mechanisms	  by	  which	  HDACi	  inhibit	  inflammatory	   responses	   are	   not	   fully	   elucidated,	   however	   many	   potential	  mechanisms	  have	  been	  described.	  For	  example,	   treatment	  of	  murine	  dendritic	   cells	  and	  human	  and	  mouse	  macrophages	  with	  TSA	  or	  SAHA	  inhibited	  recruitment	  of	  IRF1	  to	  target	  promoters,	  and	  this	  was	  associated	  with	  reduced	  TLR-­‐inducible	  expression	  of	   IL-­‐12p40	   and	   co-­‐stimulatory	  molecules.	   (Bode	   et	   al.,	   2007).	   TSA	   treatment	   also	  reduced	   nuclear	   retention	   of	   NFκB	   after	   stimulation	   of	   IL-­‐1β	   and	   promoted	   IL-­‐6	  mRNA	  decay	  in	  RA	  fibroblast-­‐like	  synoviocytes	  (Grabiec	  et	  al.,	  2012).	  TSA	  treatment	  was	   also	   shown	   to	   increase	   Mi-­‐2β	   transcription	   and	   enhance	   the	   DNA-­‐binding	  activity	   of	   the	   Mi-­‐2/NuRF	   complex,	   which	   acts	   as	   a	   transcriptional	   repressor	   of	  cytokine	   production	   in	   macrophages,	   suggesting	   another	   avenue	   for	   pro-­‐inflammatory	  cytokine	  inhibition,	  besides	  modulation	  of	  NFκB	  transcriptional	  activity	  (Bode	   and	   Dalpke,	   2011;	   Roger	   et	   al.,	   2011).	   Finally,	   HDAC	   activity	   is	   required	   for	  stability	   and/or	   transcriptional	   activity	   of	   a	   key	   pro-­‐inflammatory	   transcription	  factor,	   hypoxia-­‐inducible	   factor	   1α	   (HIF1α)	   (Shakespear	   et	   al.,	   2011).	   Thus,	   HDACi	  affects	  many	  pathways	  involved	  in	  regulation	  of	  pro-­‐inflammatory	  cytokine	  secretion.	  	  	  
1.4.1.3.	   HDACi	  and	  effects	  on	  host	  defence	  As	   the	   cytokines	   induced	   during	   inflammation	   often	   play	   important	   roles	   in	   host	  defence,	  it	  is	  a	  distinct	  possibility	  that	  HDACi	  would,	  in	  dampening	  inflammation,	  also	  compromise	   host	   defence.	   Indeed,	   a	   genome-­‐wide	   microarray	   analysis	   of	   gene	  expression	   profiles	   from	   murine	   macrophages	   and	   dendritic	   cells	   stimulated	   with	  TLR	  agonists	  revealed	   that	  TSA	  treatment	   impaired	  up	   to	  60%	  of	  genes	   induced	  by	  TLR2	   or	   TLR4,	   including	   PRRs,	   cytokines,	   chemokines,	   costimulatory	   molecules,	  transcription	   regulators	   and	   kinases,	   while	   only	   16%	   of	   genes	   were	   upregulated	  (Roger	  et	  al.,	  2011).	  In	  in	  vivo	  mouse	  models,	  although	  HDACi	  protected	  against	  lethal	  toxic	   shock	   induced	   by	   PAM3CSK4	   (TLR1/2	   agonist)	   and	   sepsis	   induced	   by	   caecal	  ligation	  and	  puncture	  (CLP),	  they	  exacerbated	  bacterial	  and	  fungal	  infections	  (Roger	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et	   al.,	   2011).	   Another	   study	   also	   reported	   that	   TSA	   and	   VPA	   treatment	   reduced	  expression	  of	  phagocytic	   receptors,	  NADPH	  oxidase	   subunits	   and	   iNOS,	   resulting	   in	  impaired	  phagocytosis,	  ROS	  and	  NO	  production	  and	  subsequently	  reduced	  ability	  to	  clear	  E.	   coli	  and	   S.	  aureus	   infection	   in	  mouse	  macrophages	   (Mombelli	   et	   al.,	   2011).	  HDACi	  also	  impaired	  production	  of	  Th1	  and	  Th17-­‐inducing	  cytokines,	  IL-­‐12	  and	  IL-­‐23	  and	   Th1-­‐attracting	   chemokines,	   CXCL9,	   CXCL10	   and	   CXCL11	   in	   human	   monocyte-­‐derived	  DC	  with	  LPS	  and	  IFNγ	  stimulation	  and	  in	  mouse	  models	  with	  LPS	  and	  soluble	  tachyzoite	   (motile	   form	   of	   an	   apicomplexan	   parasite)	   antigen	   (STAg)	   injection	  (Bosisio	   et	   al.,	   2008),	   suggesting	   that	   HDACi	   may	   compromise	   T-­‐cell	   mediated	  antigen-­‐specific	   responses.	   Another	   study	   also	   reported	   that	   HDACi	   treatment	  downregulated	   IL-­‐12	   and	   TNFα	   while	   skewing	   mouse	   bone	   marrow-­‐derived	  macrophages	   (BMM)	   and	   RAW264.7	   macrophages	   against	   Th1	   and	   towards	   Th2	  responses	   by	   promotion	   of	   IL-­‐10	   and	   downregulation	   of	   co-­‐stimulatory	   molecules	  (Wu	  et	  al.,	  2012).	  In	  addition	  to	  direct	  immunosuppressive	  effects	  of	  HDACi,	  patients	  treated	   with	   HDACi	   commonly	   experience	   thrombocytopenia	   (Ciarlo	   et	   al.,	   2013;	  Glaser,	  2007;	  Ma	  et	  al.,	  2009;	  O'Connor	  et	  al.,	  2006).	  Interestingly,	  treatment	  with	  the	  HDACi,	  butyrate,	  propionate	  and	  TSA,	  is	  reported	  to	  induce	  release	  of	  cathelicidin	  LL-­‐37	   in	   gastrointestinal	   cells,	   with	   induction	   dependent	   on	   mitogen-­‐activated	  protein/extracellular	  signal-­‐regulated	  kinase	  kinase	   (MEK)/ERK	  pathway	  activation	  (Schauber	   et	   al.,	   2004),	   suggesting	   that	   HDACi	   may	   boost	   certain	   antimicrobial	  mechanisms	   while	   dampening	   others.	   Thus,	   the	   continuing	   and	   expanded	   use	   of	  HDACi	  for	  therapeutic	  applications	  would	  benefit	  from	  a	  greater	  understanding	  of	  the	  effects	  of	  these	  agents	  on	  host	  defence	  pathways.	  Indeed,	  short-­‐term	  treatment	  with	  HDACi	  has	  been	  used	  clinically	   to	  reactivate	   latent	  HIV-­‐1	   in	  primary	  resting	  human	  CD4+	  T	   cells	   (Shan	  et	   al.,	   2014)	   and	   in	  2D10	   latency	   cell	   line	  models	   (Barton	  et	   al.,	  2014)	   as	   a	   strategy	   to	   enable	   clearance	   of	   viral	   reservoirs.	   Moreover,	   an	  understanding	   of	   specific	   HDACs	   involved	   in	   inflammatory	   processes,	   and	   the	  development	  of	  more	  selective	  HDACi	  may	  ultimately	  reduce	  the	  side	  effects	  that	  are	  associated	  with	  currently	  employed	  HDACi.	  Previous	  studies	  on	   the	  effect	  of	  HDACi	  on	   immune	   responses	   have	   primarily	   utilized	   mouse	   models	   or	   mouse	   cells,	   and	  effects	  on	  host	  defence	  pathways	  in	  humans	  have	  not	  been	  widely	  investigated.	  	  Thus,	  research	   conducted	   for	   this	   thesis	   focused	   on	   the	   immunomodulatory	   effects	   of	  HDACi	   in	   regards	   to	   their	   impact	  on	  human	  macrophage	  antimicrobial	  mechanisms	  against	  intracellular	  bacteria.	  
Introduction	  
	   36	  	  
	  
1.4.2.	  G	  protein-­‐Coupled	  Receptors	  The	  G	  protein-­‐coupled	   receptor	   (GPCR)	   family,	  which	   consists	  of	  >800	  members,	   is	  the	   largest	   family	   of	   cell-­‐surface	   proteins	   (Ritter	   and	   Hall,	   2009).	   Indeed,	   GPCRs	  account	   for	   >2%	   of	   the	   total	   genes	   encoded	   in	   the	   human	   genome	   (Dorsam	   and	  Gutkind,	   2007).	   These	   receptors	   are	   involved	   in	   signal	   transmission	   and	   their	  dysfunction	   contributes	   to	   many	   commonly	   occurring	   human	   diseases.	   The	  therapeutic	  potential	  of	  GPCRs	  as	  drug	  targets	  is	  underscored	  by	  the	  fact	  that	  they	  are	  direct	  or	  indirect	  targets	  of	  30-­‐50%	  of	  all	  current	  therapeutic	  agents	  (Garland,	  2013).	  Current	   research	   on	   the	   functions	   of	   GPCRs	   in	   inflammation	   suggests	   promising	  avenues	   for	   therapeutic	   development	   of	  modulators	   of	   several	   GPCRs,	   for	   example	  the	   receptors	   for	   the	   complement	   products	   C5a	   (C5aR)	   and	  C3a	   (C3aR),	   as	  well	   as	  proteinase-­‐activated	   receptor-­‐2	   (PAR2).	   For	   example,	   PAR2	   antagonists	   have	  demonstrated	  efficacy	   in	  mouse	  models	  of	  arthritis	  (Ferrell	  et	  al.,	  2003;	  Kelso	  et	  al.,	  2006),	  inflammatory	  airway	  disease	  (Schmidlin	  et	  al.,	  2002),	  IBD	  (Cenac	  et	  al.,	  2002),	  multiple	   sclerosis	   and	  autoimmune	  encephalomyelitis	   (Noorbakhsh	  et	   al.,	   2006),	   as	  well	   as	   artherothrombosis	   (Angiolillo	   et	   al.,	   2010).	   C5aR	   is	   also	   an	   attractive	  candidate	  target	  for	  many	  inflammatory	  diseases,	  and	  will	  be	  discussed	  in	  more	  detail	  below.	  	  
1.4.2.1.	   GPCR	  structure,	  activation	  and	  regulation	  GPCRs	  respond	  to	  diverse	  stimuli	  and	  possess	  a	  characteristic	  seven-­‐transmembrane	  core	  of	  helices	   (Pierce	  et	   al.,	   2002).	  GPCR	  activation	  by	  agonists	   such	  as	  hormones,	  neurotransmitters	   or	   sensory	   stimuli,	   results	   in	   the	   revelation	   of	   intracellular	   sites	  that	  bind	  a	  G	  protein	  hetero-­‐trimer	  consisting	  of	  α,	  β	  and	  γ	  subunits	  (Gilman,	  1987).	  This	  triggers	  the	  exchange	  of	  Gα-­‐bound	  GDP	  for	  GTP,	  and	  the	  dissociation	  of	  the	  Gβγ	  subunits	   from	  the	  Gα	  subunit.	   	  The	  Gα	  and	  Gβγ	  subunits	   then	  mediate	  downstream	  effector	   functions.	   There	   are	  multiple	   subtypes	   of	   GTP	   subunits,	   including	  Gαs,	   Gαi,	  Gα12/13	  and	  Gαq,	  which	  bind	  and	  regulate	  different	  effectors	  such	  as	  adenylyl	  cyclase,	  RhoGEF	   and	   phospholipase	   Cβ	   (PLCβ)	   (Ross	   and	   Wilkie,	   2000).	   These	   effectors	  modulate	   downstream	   pathways	   either	   directly	   or	   by	   generating	   secondary	  messengers	   (cyclic	   AMP,	   diacylglycerol	   (DAG),	   and	   inositol-­‐1,4,5-­‐triphosphate)	   that	  in	   turn	  modulate	   further	  downstream	  effectors	  such	  as	  protein	  kinase	  A	   (PKA)	  and	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protein	  kinase	  C	  (PKC)	  (Luttrell,	  2005).	  Thus,	  different	  combinations	  of	  Gα	  and	  Gβγ	  subunits	  allow	  for	  specific	  initiation	  and	  regulation	  of	  cellular	  responses	  to	  different	  stimuli	   (Ross	   and	   Wilkie,	   2000).	   Termination	   of	   GPCR	   signalling	   occurs	   by	   GPCR	  internalisation,	   and	   by	   coordinated	   intracellular	   responses	   involving	   secondary	  messenger	   kinases,	   GPCR	   kinases,	   arrestins	   and	   regulator	   of	   G	   protein	   signalling	  proteins	  (Patel	  et	  al.,	  2013).	  Secondary	  messenger	  kinases	  and	  GRKs	  phosphorylate	  the	  GPCRs,	   targeting	  them	  for	   internalisation	  and	   lysosomal	  degradation	  (Ferguson,	  2001)	   through	   recruitment	   of	   clathrin-­‐interacting	   arrestins	   (Hanyaloglu	   and	   von	  Zastrow,	   2008;	   Moore	   et	   al.,	   2007;	   Premont	   and	   Gainetdinov,	   2007;	   Reiter	   and	  Lefkowitz,	   2006).	   This	   allows	   for	   receptor	   desensitization	   and	   regulation	   of	   GPCR	  signalling.	   Arrestin	   recruitment	   to	   activated	   GPCRs	   also	   initiates	   arrestin-­‐mediated	  signalling	  pathways	  such	  as	   the	  activation	  of	   the	  MAPK/ERK	  pathway.	  Endocytosed	  GPCRs	  are	  trafficked	  to	  lysosomes	  for	  degradation,	  or	  to	  recycling	  endosomes	  where	  receptor	   dephosphorylation	   can	   enable	   recycling	   of	   the	   receptor	   back	   to	   the	   cell	  surface	   (Ritter	   and	   Hall,	   2009).	   GPCR	   signalling	   may	   also	   be	   controlled	   by	   RGS	  proteins	  that	  do	  not	  interact	  with	  the	  GPCR,	  but	  instead	  contribute	  to	  termination	  of	  signalling	  by	  enhancing	  the	  intrinsic	  GTPase	  activity	  of	  the	  Gα	  subunit	  in	  hydrolysing	  GTP	   to	   GDP,	   enabling	   the	   heterotrimer	   of	   Gαβγ	   subunits	   to	   reform,	   and	   thereby	  promoting	   inactive	  G-­‐protein	   formation	   (Patel	  et	  al.,	  2013).	  Thus,	   the	   fate	  of	  GPCRs	  depends	  on	  ligand-­‐dependent	  selectivity	  that	  specifically	  promotes	  either	  G	  protein-­‐mediated	   signalling	   pathways	   and/or	   desensitisation	   or	   termination	   of	   GPCR	  signalling	  (Urban	  et	  al.,	  2007).	  	  	  
1.4.2.2.	   GPCR	  and	  TLR	  signalling	  crosstalk	  Modulation	   of	   macrophage	   inflammatory	   and	   antimicrobial	   pathways	   is	   not	   only	  achieved	   through	   the	   recognition	  of	  PAMPs	  by	  PRRs,	  but	  also	   through	  activation	  of	  GPCRs	  expressed	  by	   these	   cells.	   Indeed,	  numerous	  GPCRs	  are	   capable	  of	   regulating	  macrophage	  cytokine	  production,	  ROS	  generation,	  migration	  and	  adherence	  (Lattin	  et	  al.,	  2007).	  These	  include	  a	  number	  of	  chemokine	  receptors	  (Sun	  and	  Ye,	  2012),	  C5aR	  (Mollnes	   et	   al.	   2012),	   the	   PAR	   family	   (Johansson	   et	   al.	   2005),	   the	   endothelial	  differentiation	   gene	   (EDG)	   family	   (Hornuss	   et	   al.	   2001),	   the	   endothelin	   receptors	  (Battistini	  et	  al.	  1996),	  and	  the	   formyl	  peptide	  receptor	  (FPR)	   family	  (Sullivan	  et	  al.	  1987).	   As	   TLRs	   and	   GPCRs	   can	   both	   regulate	   inflammatory	   and	   antimicrobial	  pathways	   in	  macrophages,	   it	   is	   likely	   that	   crosstalk	   occurs	   between	   these	   receptor	  
Introduction	  
	   38	  	  
families.	   Indeed,	   this	  has	  been	  observed	  to	  occur	   in	   the	  case	  of	  multiple	  GPCRs.	  For	  example,	   co-­‐operative	   interaction	  between	  PAR2	  and	  TLR4	   in	  LPS-­‐stimulated	  NFκB	  signalling	  results	   in	  synergistic	  ERK1/2	  phosphorylation	  and	   induction	  of	  cytokines	  such	  as	  IL-­‐6	  and	  IL-­‐8	  (Bosisio	  et	  al.,	  2008;	  Rallabhandi	  et	  al.,	  2008).	  	  	  
1.4.2.3.	   C5aR	  and	  host	  defence	  The	  complement	  system	  consists	  of	  locally	  or	  systemically	  produced	  plasma	  proteins	  that	  regulate	  immune	  and	  inflammatory	  responses.	  Complement	  proteins	  are	  present	  in	   the	   circulation	   in	   an	   inactive	   form	   and	   can	   be	   activated	   through	   the	   “classical	  pathway”	   (e.g.	   formation	   of	   antigen-­‐antibody	   complexes),	   the	   “lectin	   pathway”	  (interaction	   of	   a	   pattern	   recognition	   molecule	   e.g.	   mannose	   binding	   lectin,	   with	  microbial	   surface	   carbohydrates)	   or	   by	   an	   “alternative	   pathway”	   (mediated	   by	   e.g.	  endotoxins,	   complex	  polysaccharides	   or	   IgA)	   (Ricklin	   et	   al.,	   2010).	   These	  pathways	  converge	   on	   activation	   of	   C3	   convertases	   leading	   to	   the	   generation	   of	   a	   range	   of	  complement	   products.	   These	   include	   anaphylatoxins	   such	   as	   C3a	   and	   C5a	   that	   are	  involved	  in	   inflammatory	  cell	  recruitment	  and	  activation,	  products	  such	  as	  C3b	  that	  act	  as	  opsonins	  to	  enhance	  phagocytosis,	  and	  the	  membrane	  attack	  complex	  (MAC	  or	  C5b-­‐9)	  that	  mediates	  direct	  lysis	  of	  targeted	  pathogens	  (Ricklin	  et	  al.,	  2010).	  	  	  During	   complement	   activation,	   complement	   component	   C5	   is	   cleaved	   by	   C5	  convertase	   into	   C5a	   and	   C5b	   fragments.	   In	   addition	   to	   forming	   C5b-­‐9	   (Muller-­‐Eberhard,	  1985),	  C5b	  can	  also	  form	  a	  terminal	  complement	  complex	  with	  C8	  (C5b-­‐8).	  Both	   C5b-­‐9	   and	   C5b-­‐8	   can	   activate	   phospholipase	   A2	   resulting	   in	   release	   of	  arachidonic	  acid	  and	  synthesis	  of	  prostaglandin	  E2	  by	  synovial	  cells	  and	  macrophages	  (Nicholson-­‐Weller	   and	  Halperin,	   1993;	  Niculescu	   and	  Rus,	   2001;	   von	  Kempis	   et	   al.,	  1989).	   C5a	   binding	   to	   its	   receptor,	   C5aR,	   co-­‐regulates	   antibody-­‐mediated	  phagocytosis	  and	  activates	  downstream	  signalling	  pathways	  resulting	  in	  recruitment	  of	   immune	   cells	   and	   modulation	   of	   inflammation	   and	   other	   immune	   pathways	  (Ricklin	  et	  al.,	  2010).	  C5a	  is	  also	  able	  to	  bind	  a	  G-­‐protein-­‐independent	  receptor,	  C5L2,	  whose	  function	  is	  not	  fully	  determined	  (Bamberg	  et	  al.,	  2010;	  Rittirsch	  et	  al.,	  2008).	  Both	   C5aR	   and	   C5L2	   recognise	   C5a	   and,	   more	   weakly,	   its	   degradation	   product,	  C5adesArg.	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Activation	   of	   the	   complement	   receptor	   C5aR	   is	   reported	   to	   synergistically	   enhance	  TLR-­‐mediated	   induction	   of	   TNFα,	   IL-­‐1β	   and	   IL-­‐6	   both	   in	   vitro	   and	   in	   vivo	   mouse	  models	   through	   crosstalk	  with	  TLR2,	   TLR4	   and	  TLR9	  by	   converging	   at	   the	   level	   of	  MAPKs,	  specifically	  ERK1/2	  and	  JNK	  (Ricklin	  et	  al.,	  2010;	  Zhang	  et	  al.,	  2007).	  Direct	  association	   of	   C5aR	   and	   TLR2	   was	   also	   shown	   by	   confocal	   microscopy	   and	  fluorescent	   resonance	   energy	   transfer	   (FRET)	   studies	   in	   activated	   macrophages	  (Wang	   et	   al.,	   2010b).	   In	   addition,	   the	   contribution	   of	   complement	   during	   TLR	  crosstalk	  was	   investigated	   using	   human	  whole	   blood	   incubated	  with	  E.	   coli.	   In	   the	  study,	   samples	  were	   treated	  with	   anti-­‐CR3	   and/or	   anti-­‐CD14	   antibodies,	   C5aR	   and	  C3aR	  antagonists	  and	  antibodies	  to	  block	  FcγRs,	  CD16,	  CD32	  and	  CD64.	  The	  authors	  reported	   that	   E.	   coli-­‐induced	   release	   of	   ROS,	   opsonisation	   and	   phagocytosis	   was	  crucially	  dependent	  on	  C5aR,	  but	  cytokine	  release	   (TNFα,	   IL-­‐6,	   IL-­‐8	  and	   IL-­‐10)	  was	  CD14-­‐	   and	  not	   C5aR-­‐dependent,	   as	   release	   of	   these	   cytokines	  were	   abrogated	  with	  anti-­‐CD14	  antibodies	  but	  not	  with	  C5aR	  antagonists	  (Lappegård	  et	  al.,	  2009;	  Mollnes	  et	  al.,	  2012).	  Thus,	  it	  was	  proposed	  that	  TLR-­‐C5aR	  crosstalk	  may	  rely	  on	  CD14,	  which	  participates	   in	   TLR3,	   TLR4,	   and	   TLR2/6	   signalling	   (Akashi-­‐Takamura	   and	   Miyake,	  2008),	   or	   through	   extracellular	   interactions	   of	   CD14	   with	   complement	   receptors	  (Ricklin	   et	   al.,	   2010).	   Intriguingly,	   in	   mouse	   models	   of	   CLP-­‐induced	   sepsis	   with	  antibody-­‐mediated	  blockade	  of	  C5a	  receptors	  and	  knockout	  mice,	  blockade	  of	  either	  C5aR	  or	  C5L2	  improved	  survival	  and	  reduced	  inflammation	  in	  mid-­‐grade	  sepsis	  (30-­‐40%	   survival)	   (Rittirsch	   et	   al.,	   2008).	   Notably,	   HMGB1	   release	   in	   septic	   mice,	   and	  with	  in	  vitro	  LPS	  stimulation	  of	  macrophages,	  was	  dependent	  on	  C5L2	  but	  not	  C5aR.	  In	  addition,	  only	  combined	  blockade	  of	  C5aR	  and	  C5L2	  was	  protective	  against	  high-­‐grade	  CLP-­‐induced	  sepsis	  (100%	  fatality).	  Thus,	  the	  authors	  suggested	  that	  C5L2	  is	  a	  functional	   receptor	   that	  may	   contribute	   synergistically	  with	  C5aR	   to	  mediate	   lethal	  inflammation	   in	   sepsis	   and	   also	   crosstalk	   with	   TLR4	   for	   induction	   of	   HMGB1.	  However,	  the	  role	  of	  C5L2	  remains	  controversial	  as	  it	  has	  also	  been	  described	  to	  have	  an	   anti-­‐inflammatory	   role	   by	   either	   1)	   acting	   as	   a	   decoy	   receptor	   through	   binding	  active	  complement	   fragments	   to	  prevent	  C5aR	  activation,	  or	  2)	  by	  complexing	  with	  C5aR	   following	   its	   activation	   by	   C5a,	   leading	   to	   phosphorylation	   of	   both	   receptors	  that	   allows	   β-­‐arrestin	   binding,	   which	   ultimately	   leads	   to	   internalisation	   of	   both	  receptors	   in	   an	   early/recycling	   endosome	   and	   inhibition	   of	   C5aR-­‐mediated	   MAPK	  signalling	  	  (Li	  et	  al.,	  2013).	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GPCR-­‐TLR	   receptor	   crosstalk	   can	   be	   manipulated	   by	   pathogens	   to	   enhance	   their	  survival.	   An	   example	   of	   this	   is	   the	   Gram-­‐negative	   periodontal	   pathogen,	  
Porphyromonas	  gingivalis,	  which	  is	  implicated	  in	  atherosclerosis	  and	  RA	  (Lundberg	  et	  al.,	  2010;	  Pihlstrom	  et	  al.,	  2005),	  to	  enhance	  its	  survival.	  Specifically,	  it	  induces	  TLR2	  crosstalk	   with	   2	   GPCR	   receptors,	   C5aR	   and	   CXCR4,	   leading	   to	   impairment	   of	   iNOS	  production	  by	  increasing	  cAMP-­‐dependent	  protein	  kinase	  A	  signalling,	  as	  well	  as	  by	  suppression	  of	  IRF1,	  which	  induces	  IL-­‐12	  that	  in	  turn	  induces	  IFNγ	  for	  production	  of	  iNOS	   (Hajishengallis	   et	   al.,	   2013;	  Hajishengallis	   et	   al.,	   2008;	  Wang	  et	   al.,	   2010b).	   In	  contrast,	  pro-­‐inflammatory	  cytokines,	  IL-­‐1β,	  IL-­‐6,	  IL-­‐17	  and	  TNFα	  are	  upregulated	  by	  
P.	  gingivalis-­‐induced	  GPCR-­‐TLR2	  crosstalk.	  This	  was	  proposed	  to	  reflect	  the	  evolution	  of	  P.	  gingivalis	  to	  suppress	  host-­‐antimicrobial	  activity	  through	  iNOS,	  while	  benefiting	  from	  inflammatory	  responses	  that	  cause	  tissue	  damage.	  Preventative	  and	  therapeutic	  administration	   of	   a	   C5aR	   antagonist	   (C5aRA;	   PMX-­‐53)	   resulted	   in	   inhibition	   of	   P.	  
gingivalis-­‐induced	  bone	  loss	  and	  reduced	  release	  of	  TNFα,	  IL-­‐1β	  and	  IL-­‐17	  (Abe	  et	  al.,	  2012).	  Blocking	  the	  C5aR	  also	  reduced	  pathology	  in	  multiple	  animal	  disease	  models	  including	  those	  for	  asthma	  (Staab	  et	  al.,	  2014),	  hyperoxic	  lung	  injury	  (Xu	  et	  al.,	  2014),	  dermatitis	   (Dang	   et	   al.,	   2015),	   hypertension	   (Iyer	   et	   al.,	   2011;	   Zhang	   et	   al.,	   2014),	  intracerebral	  haemorrhage	  (Li	  et	  al.,	  2014b),	  and	  neurodegenerative	  diseases	  such	  as	  Alzheimer’s	  disease	  (Fonseca	  et	  al.,	  2009)	  and	  Huntington’s	  disease	  (Woodruff	  et	  al.,	  2006).	   In	   most	   cases,	   these	   effects	   are	   associated	   with	   attenuated	   production	   of	  inflammatory	  mediators	  and	  reducing	   tissue	   injury.	  Thus,	   studying	   the	  mechanisms	  of	   GPCR-­‐TLR	   crosstalk	   provides	   an	   opportunity	   to	   understand	   more	   about	   TLR	  signalling	  pathways,	  mechanisms	  of	   infectious	  and	   inflammatory	  disease	  processes,	  and	  possible	  contraindications	  of	  GPCR	  modulators	  as	  anti-­‐inflammatory	  agents.	  	  
1.5.	  Scope	  of	  thesis	  and	  Aims	  Species-­‐specific	   immune	   responses	   are	   of	   particular	   interest	   in	   the	   context	   of	   host	  defence.	  For	  example,	  studies	  on	  human-­‐specific	  innate	  immune	  responses	  may	  lead	  to	   the	   discovery	   of	   novel	   genes	   and	   pathways	   that	   impact	   human	   macrophage	  antimicrobial	   responses.	   Therefore,	   this	   project	   functionally	   investigated	   novel	  human-­‐specific	  TLR4	  target	  genes	  previously	   identified	   to	  be	  divergently	  expressed	  between	  primary	  human	  and	  mouse	  macrophages	  (Schroder	  et	  al.,	  2012a)	  for	  roles	  in	  macrophage	   antimicrobial	   responses.	   Secondly,	   pharmacological	   agents	   with	   anti-­‐
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inflammatory	  properties	  have	  the	  potential	  to	  also	  compromise	  host	  defence.	  Prior	  to	  undertaking	   the	   studies	   in	   this	   thesis,	   the	  majority	   of	   studies	   examining	   effects	   of	  HDACi	   and	   C5aR	   modulators	   on	   macrophage	   functions	   were	   conducted	   using	   the	  mouse	  model.	  Consequently,	  effects	  on	  human	  macrophage	  antimicrobial	   responses	  were	   much	   less	   understood,	   if	   at	   all.	   Therefore,	   investigation	   of	   the	   impact	   of	  pharmacological	  modulators	   of	  HDACs	   and	   C5aR	   on	   host	   defence	  was	   predicted	   to	  identify	   limitations,	   and	   potentially	   new	   applications,	   for	   such	   compounds.	   These	  agents	  may	  also	  provide	  useful	  probes	  to	  interrogate	  specific	  signalling	  mechanisms	  controlling	  macrophage	  antimicrobial	  responses.	  As	  such,	  the	  aims	  of	  this	  thesis	  were	  as	  follows:	  	  
Aim	   1:	   To	   study	   the	   role	   of	   novel	   human-­‐specific	   TLR4	   target	   genes	   in	   human	  macrophage	  antimicrobial	  and	  inflammatory	  responses.	  	  Aim	  2:	  To	  investigate	  effects	  of	  pharmacological	  modulators	  of	  HDACs	  and	  C5aR	  on	  human	  macrophage	  antimicrobial	  responses.	  	  The	  first	  aim	  was	  addressed	  in	  Chapters	  3	  and	  4	  by	  conducting	  expression	  analysis	  of	  selected	  novel	  human-­‐specific	  TLR4	  target	  genes	  to	  validate	  previous	  microarray	  expression	  profiling	  (Schroder	  et	  al.,	  2012a).	  Subsequently,	  target	  gene	  function	  was	  investigating	  by	  perturbation	  of	  gene	  function	  through	  gene	  knockdown,	  followed	  by	  pathogen	  challenge	  to	  assay	  effects	  on	  macrophage	  survival,	  bacterial	  clearance	  and	  cytokine	   production.	   The	   results	   of	   these	   investigations	   are	   detailed	   in	  Chapter	   3,	  while	  more	  detailed	   functional	  analysis	  of	  one	  selected	  gene	   for	  which	  a	  phenotype	  was	  observed	  (RNF144B)	  was	  undertaken	  in	  Chapter	  4.	  The	  second	  aim	  of	  the	  thesis	  was	  addressed	   in	  Chapter	  5,	  which	  details	   the	  effects	  of	  HDAC	  inhibitors	  and	  C5aR	  modulators	   on	   bacterial	   clearance	   by	   human	   macrophages,	   and	   the	   partial	  characterisation	  of	  mechanisms	  likely	  to	  be	  responsible	  for	  these	  effects.	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2.1.	  Reagents	  
2.1.1.	   General	  reagents	  Phorbol	  12-­‐myristate	  13-­‐acetate	  (PMA)	  (Sigma-­‐Aldrich)	  was	  solubilised	   in	  dimethyl	  sulfoxide	  (DMSO)	  at	  a	  concentration	  of	  10	  μg/mL,	  stored	  at	  -­‐80˚C	  and	  diluted	  in	  tissue	  culture	   medium	   to	   be	   used	   at	   final	   concentration	   of	   30	   ng/mL.	   Ampicillin	   (Life	  Technologies)	   was	   stored	   at	   -­‐20˚C	   and	   was	   used	   at	   100	   μg/mL	   for	   selection	   of	  bacteria	   containing	   plasmids	   encoding	   ampicillin	   resistance	   following	  transformation.	  The	  proteasome	  inhibitor	  MG132	  (Z-­‐Leu-­‐Leu-­‐Leu-­‐al)	  (Sigma-­‐Aldrich)	  was	  solubilised	  in	  DMSO	  at	  a	  concentration	  of	  10	  mg/mL,	  stored	  at	  -­‐20˚C	  and	  used	  at	  a	  final	  concentration	  of	  10-­‐30	  μg/mL.	  The	  MEK1/2	  inhibitor,	  U0126	  monoethanolate	  (Sigma	  Aldrich)	  was	  solubilised	  in	  DMSO	  at	  a	  stock	  concentration	  of	  2.5	  mM,	  stored	  at	  -­‐20˚C	   and	   used	   at	   1	   μM.	   Nigericin	   (Sigma	   Aldrich)	   was	   resuspended	   to	   10	   mM	   in	  ethanol,	  stored	  at	  4˚C	  with	  protection	  from	  light	  and	  used	  at	  a	  working	  concentration	  of	  10	  μM.	  ATP	  (Sigma	  Aldrich)	  was	  resuspended	  to	  1	  mM	  in	  water	  followed	  by	  snap	  freezing	  using	  dry	  ice,	  then	  stored	  at	  -­‐20˚C	  before	  use	  at	  5	  mM	  concentration.	  Possible	  endotoxin	   contamination	   of	   reagents	   was	   not	   routinely	   assessed,	   however	   tissue-­‐culture	  grade	  plastic	  and	  reagents	  manufactured	  to	  be	  endotoxin-­‐free	  were	  used	  for	  all	  cell	  culture	  experiments.	  	  	  
2.1.2	  	   TLR	  agonists	  and	  recombinant	  cytokines	  The	   synthetic	   TLR3	   agonist,	   dsRNA	   analogue	   polyinosinic-­‐polycytidylic	   acid	   (Poly	  (I:C))	   (Invivogen)	  was	   solubilised	   in	   sterile	  water	   at	   1	  mg/mL,	   stored	   at	   -­‐20˚C	   and	  used	   at	   a	   final	   concentration	   of	   30	   μg/mL.	   Chromatographically-­‐purified	  lipopolysaccharide	   (LPS)	   from	   Salmonella	   enterica	   serotype	   Minnesota	   (Sigma	  Aldrich)	  was	  prepared	  in	  culture	  medium	  at	  10	  μg/mL,	  stored	  at	  -­‐20˚C	  and	  used	  at	  a	  final	   concentration	   of	   10-­‐100	   ng/mL	   as	   a	   TLR4	   agonist.	   Imiquimod	   (R837)	  (Invivogen),	   an	   imidazoquinoline	   amine	   analogue	   to	   guanosine,	   was	   solubilised	   in	  sterile	  water	  at	  1	  mg/mL,	  stored	  at	   -­‐20˚C	  and	  used	  at	  20	  μg/mL	  to	  stimulate	  TLR7.	  Recombinant	   human	   CSF-­‐1	   (Chiron)	   was	   resuspended	   in	   tissue	   culture	   media	   at	  1x108	  U/mL	  and	  stored	  at	  -­‐20˚C,	  then	  working	  stocks	  of	  1x106	  U/mL	  were	  prepared	  in	  tissue	  culture	  media	  and	  stored	  at	  4˚C,	  to	  be	  used	  at	  a	  final	  concentration	  of	  1x104	  U/mL.	  Recombinant	  human	  GM-­‐CSF	  (Abacus	  ALS)	  was	  resuspended	  in	  tissue	  culture	  media	   at	   100	   μg/mL	   and	   stored	   at	   -­‐80˚C,	   then	   working	   stocks	   of	   10	   μg/mL	   were	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made	  in	  tissue	  culture	  media	  and	  stored	  at	  4˚C,	  to	  be	  used	  at	  a	  final	  concentration	  of	  10	  ng/mL.	  Human	  recombinant	  IFNγ	  (R&D	  Systems)	  was	  stored	  at	  a	  concentration	  of	  2.5	  μg/mL	  at	  -­‐20˚C	  and	  diluted	  in	  tissue	  culture	  media	  to	  a	  final	  concentration	  of	  2.5	  ng/mL.	  	  
2.1.3	  	   HDAC	  inhibitors	  TSA	  purified	  from	  Streptomyces	  sp.	  (Sigma	  Aldrich)	  was	  dissolved	  in	  100%	  ethanol	  (EtOH)	  stored	  at	  4˚C,	  and	  diluted	  in	  media	  to	  be	  used	  at	  the	  indicated	  concentrations.	  SAHA	   (Richon	   et	   al.,	   2000)	   was	   synthesised	   in-­‐house	   in	   Professor	   David	   Fairlie’s	  Group	   (Institute	   for	  Molecular	  Bioscience,	  The	  University	  of	  Queensland),	  dissolved	  in	  DMSO,	  stored	  at	  -­‐20˚C,	  and	  diluted	  in	  tissue	  culture	  media	  to	  be	  used	  10	  μM.	  	  
2.1.4.	   GPCR	  agonists/antagonists	  Human	  C5a	  (initially	  received	  as	  a	  kind	  gift	  from	  the	  Fairlie	  Group,	  then	  subsequently	  purchased	  from	  Sino	  Biological)	  was	  diluted	  to	  50	  μM	  in	  sterile	  PBS,	  stored	  at	  -­‐80˚C,	  and	   diluted	   in	   tissue	   culture	  media	   to	   be	   used	   at	   30	   nM.	   All	   C5a	   batches	   used	   for	  experiments	  were	   tested	   for	   contaminating	   endotoxin	   using	   RAW264.7	   ELAM	   cells	  and	  flow	  cytometry	  (see	  Section	  2.2.13).	  The	  C5aR	  antagonist	  3D53	  (also	  licensed	  as	  PMX-­‐53)	  (Seow	  et	  al.,	  2013)	  was	  synthesised	  in	  the	  Fairlie	  Group,	  diluted	  to	  10	  mM	  in	  DMSO,	  stored	  at	  -­‐20˚C	  and	  used	  at	  a	  final	  concentration	  of	  1	  μM.	  	  
2.1.5.	   Oligonucleotides	  Oligonucleotides	  used	  for	  qPCR	  (Table	  2.1)	  were	  purchased	  from	  Geneworks	  or	  from	  Sigma	   Aldrich.	   Primers	   for	   qPCR	   were	   designed	   using	   NCBI	   primer	   blast	  (http://www.ncbi.nlm.nih.gov/tools/primer-­‐blast/)	   and	   Primer	   3	  (http://bioinfo.ut.ee/primer3-­‐0.4.0/)	   (Rozen	   and	   Skaletsky,	   2000).	  Where	   possible,	  primers	   were	   designed	   to	   span	   exon-­‐exon	   junctions	   to	   avoid	   amplification	   of	   any	  contaminating	  genomic	  DNA.	  MacVector	  software	  was	  used	  to	  predict	  and	  minimize	  any	   oligonucleotide	   secondary	   structure	   for	   qPCR	   primers.	   For	   each	   primer	   pair,	  quality	   controls	   for	   qPCR	   products	  were	   performed	   by	   analysis	   of	   the	   dissociation	  curve	  of	  each	  qPCR	  reaction.	  	  
Materials	  and	  Methods	  
	   45	  	  
	  
 





RNF144B	   F:	  GAGCACCGAGCCCTCTTTGGGA	  R:	  GAGCGCAGCCTTCATTGCGT	   94	  
qPCR	  primers	  for	  human	  gene	  
TMEM140	  	   F:	  CAACCAACCCTGATTTCCTGCTTCT	  R:	  TCTGCCGGGGGACAGAAAGGA	   79	  
NKG7	   F:	  TCAGGCTACATCCACGTGAC	  R:	  GACAGGACCAGGAAGCTCAC	   83	  
BATF3	   F:	  AGGCTGACAAGCTCCATGAGGAAT	  R:	  TCCCGATCTCTCTCCGCAGCA	   72	  
G0S2	   F:	  CTGACTCCGCTGGGAGAGTG	  R:	  TCCTTTGGTGGATGCTTGTGG	   109	  
HPRT	   F:	  TCAGGCAGTATAATCCAAAGATGGT	  R:	  AGTCTGGCTTATATCCAACACTTCG	   84	  
Rnf144b	   F:	  TGCCAGAGCATGGGGCTCTCT	  R:	  CATCTGGGCGCAGCCTTCGT	   104	  
qPCR	  primers	  for	  mouse	  gene	  
Tmem140	   F:	  ATCGACTCCCCAGACAGACGCT	  R:	  TTGCAGGGAGACAAAAACCAACGC	   87	  
Nkg7	   F:	  TGGCTTTTTCTGCAGCTCTCTCC	  R:	  GTCTGGCTCCATCTCATACTGGTGT	   70	  
Batf3	   F:	  TTTCGAAGCTGAAGGAGGAG	  	  	  	  	  R:	  CGAAGCTGCACAAAGTTCAT	   103	  
G0s2	   F:	  GTGCTCGGCCTAGTTGAGAC	  R:	  GACTGCTGTTCACACGCTTC	   107	  
Hprt	   F:	  GTTGGATACAGGCCAGACTTTGTTG	  R:	  GAGGGTAGGCTGGCCTATAGGCT	   352	  
Table	  2.1:	  List	  of	  qPCR	  primers	  used.	  	  	  	  	  	  
Materials	  and	  Methods	  
	   46	  	  
2.1.6.	   Antibodies	  Antibodies	  used	  in	  these	  studies	  are	  listed	  in	  Table	  2.2.	  










Mouse	  monoclonal	  anti-­‐human/mouse	  IL-­‐1β	  (pro	  and	  cleaved	  form)	  
WB	   1:1000	   17,	  31	   Cell	  Signalling	  (#12242)	  
IL-­‐1β	   Rabbit	  polyclonal	  anti-­‐human	  IL-­‐1β	  (cleaved	  form)	   WB	   1:1000	   17	  
Cell	  Signalling	  (#2021)	  
Caspase-­‐1	  
Rabbit	  monoclonal	  anti-­‐human/monkey	  caspase-­‐1	  (pro	  and	  cleaved	  form)	  
WB	   1:1000	   20,	  48	   Cell	  Signalling	  (#3866)	  
Caspase-­‐1	  
Rabbit	  monoclonal	  anti-­‐human/monkey	  caspase-­‐1	  (cleaved	  form)	  
WB	   1:1000	   20,	  22	   Cell	  Signalling	  (#4199)	  
NLRP3	   Rabbit	  monoclonal	  anti-­‐human	  NLRP3	   WB	   1:1000	   85,	  110	  
Cell	  Signalling	  (#13158)	  
RNF144B	   Mouse	  monoclonal	  anti-­‐human	  RNF144B	   WB	   1:1000	   34	  
Abcam	  (ab110458)	  
ASC	   Rabbit	  polyclonal	  anti-­‐human	  ASC	   WB	   1:1000	   24	   Santa	  Cruz	  Biotech	  	  (sc-­‐30153)	  Acetylated	   Rabbit	  anti-­‐acetyl	   WB	   1:1000	   17	   Millipore	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histone	  H3	   histone	  H3	  (Lys9)	   (06-­‐599)	  
GAPDH	   Rabbit	  anti-­‐GAPDH	   WB	   1:2500	   37	   Trevigen	  
	  IL-­‐6	  
	  Rat	  anti-­‐human	  IL-­‐6	   ELISA	   1:250	   n/a	  
BD	  Pharmingen	  (#554543)	  
TNFα	  
C:	  Rabbit	  anti	  human	  TNFα	  D:	  Rabbit	  anti	  human	  TNFα	   ELISA	  
C:	  1	  μg/mL	  D:	  0.5	  μg/mL	   n/a	   PeproTech	  (PT900K25)	  
CCL20	  
C:	  Mouse	  anti	  human	  CCL20	  D:	  Goat	  anti-­‐human	  CCL20	   ELISA	  
C:	  2	  μg/mL	  D:	  25	  ng/mL	   n/a	   Bio-­‐scientific	  (DY360)	  
CXCL13	  
C:	  Mouse	  anti	  human	  CXCL13	  D:	  Goat	  anti-­‐human	  CXCL13	   ELISA	  
C:	  2	  μg/mL	  D:	  200	  ng/mL	   n/a	   Bio-­‐scientific	  (DY801)	  
IL-­‐1β	  
C:	  Mouse	  anti	  human	  IL-­‐1β	  D:	  Goat	  anti-­‐human	  IL-­‐1β	   ELISA	  
C:	  4	  μg/mL	  D:	  200	  ng/mL	   n/a	   Bio-­‐scientific	  (DY201)	  
Secondary	  antibodies	  
Rabbit-­‐IgG	   Goat	  anti-­‐rabbit	  IgG	  HRP	   WB	   1:4000	   n/a	   Cell	  Signalling	  (#7074)	  
Mouse-­‐IgG	   Horse	  anti-­‐mouse	  IgG-­‐HRP	   WB	   1:4000	   n/a	   Cell	  Signalling	  (#7076)	  
IL-­‐6	   Biotin	  rat	  anti-­‐human	  IL-­‐6	   ELISA	   1:250	   n/a	   BD	  Pharmingen	  #554546	  
Table	  2.2:	  List	  of	  antibodies	  used.	  	  WB	  =	  western	   blotting;	   ELISA	   =	   enzyme-­‐linked	   immunosorbent	   assay;	   C	   =	   capture	  antibody;	  D	  =	  detection	  antibody.	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2.1.7.	   siRNAs	  siRNA	   used	   for	   gene	   knockdown	   studies	   (Table	   2.3)	   were	   purchased	   from	   Life	  Technologies	   or	   from	   GE	   Dharmacon	   (Thermo	   Scientific).	   Specificity	   of	   siRNAs	  (possible	   off-­‐target	   effects)	   was	   examined	   using	   NCBI	   standard	   nucleotide	   blast	  (http://blast.ncbi.nlm.nih.gov/Blast.cgi).	  
Target	  gene	  of	  siRNA	   Details	  and	  Sequence/s	  (5’-­‐3’)	   Company	  RNF144B	   siGENOME	  SMARTpool	  siRNA:	  D-­‐025119-­‐01:	  CAGCUUGCCUGAAACAGUA	  D-­‐025119-­‐02:	  AAGCUGAGAUUGCCUGUUU	  D-­‐025119-­‐03:	  GUAGAGACAGUCAGCCUAU	  D-­‐025119-­‐04:	  GGGUUUAUAUCGAACGCAA	  
GE	  Dharmacon	  
SLC41A2	   siGENOME	  SMARTpool	  siRNA:	  D-­‐007321-­‐01:	  GAAAGGACCCGGAUAGUUU	  D-­‐007321-­‐02:	  GGUCAUACUUCUUUAACUA	  D-­‐007321-­‐03:	  CAAUAAUGGGCACGCAUCA	  D-­‐007321-­‐04:	  GCUUAUUGGAGAUCGAGAU	  NKG7	   siGENOME	  SMARTpool	  siRNA:	  D-­‐016047-­‐01:	  GAGCACCGAUUUCUGGUUU	  D-­‐016047-­‐02:	  GGUCUCAGCUAUCCUCUUG	  D-­‐016047-­‐03:	  CAUUAUGGCUGUUCUGUGG	  D-­‐016047-­‐04:	  CAUCAUAUCAGGCUACAUC	  G0S2	   siGENOME	  SMARTpool	  siRNA:	  D-­‐015771-­‐01:	  GCGACAGGCUCUCCAGAAG	  D-­‐015771-­‐02:	  GCAAGCAGCAGGACACGGU	  D-­‐015771-­‐03:	  GUGCUCGGCCUGAUGGAGA	  	  D-­‐015771-­‐04:	  UGGUGAAGCUGUACGUGCU	  NLRP3	   #10620310	  B04	  and	  B05	  CCAAGAUUGAGAUCAAUGU[dt][dt]	  AGAUUGAUCUCAAUCUUGG[dt][dt]	   Invitrogen	  (Life	  Technologies)	  NLRP1	   #10620318-­‐240157	  E03	  CAGCCAGGGUGGAGCUGCAUCACAU	  AUGUGAUGCAGCUCCACCCUGGCUG	  
Table	  2.3:	  List	  of	  siRNAs	  used.	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2.2.	  Methods	  
2.2.1.	   Cell	  lines	  and	  culture	  conditions	  
RAW264.7	  and	  RAW264.7	  ELAM	  RAW264.7	   is	   a	   mouse	   macrophage-­‐like	   cell	   line,	   originally	   derived	   from	   a	   murine	  tumour	  transformed	  by	  Abelson	  Leukaemia	  virus	  (Raschke	  et	  al.,	  1978).	  This	  cell	  line	  was	   obtained	   from	   the	   American	   Type	   Culture	   Collection	   (ATCC).	   RAW264.7	   cells	  possess	  macrophage-­‐like	  characteristics	  such	  as	  phagocytosis,	  and	  responsiveness	  to	  stimulation	  with	  PAMPs.	  RAW264.7	  ELAM	   cells	   are	  RAW264.7	   cells	   that	   are	   stably	  transfected	   with	   the	   NFκB-­‐dependent	   endothelial	   leucocyte	   adhesion	   molecule	  (ELAM)	   promoter,	   which	   drives	   expression	   of	   green	   fluorescent	   protein	   (GFP)	  (Stacey	   et	   al.,	   2003).	   Cells	  were	   cultured	   in	   complete	  media	   (Table	   2.4)	   on	   square	  sterilin	   bacteriological	   plastic	   plates	   (Thermo	   Scientific)	   and	  were	   sub-­‐cultured	   by	  first	  detaching	  cells	  by	  syringing	  with	  an	  18-­‐gauge	  blunt	  end	  needle	  attached	  to	  a	  5	  mL	  syringe,	  washing	  cells	  twice	  by	  pelleting	  cells	  at	  500	  g	  for	  5	  minutes,	  then	  seeding	  an	  aliquot	  at	  appropriate	  density	  onto	  plates.	  	  
	  
Human	  Embryonic	  Kidney	  (HEK)	  293T	  	  The	  HEK293T	  cell	  line	  was	  obtained	  from	  Dr.	  Kate	  Schroder	  (Institute	  for	  Molecular	  Bioscience,	   The	   University	   of	   Queensland).	   HEK293T	   cells	   are	   HEK293	   cells	   stably	  expressing	  the	  SV40	  large	  T	  antigen,	  resulting	  in	  enhanced	  transfection	  efficiency	  and	  SV40	  promoter-­‐dependent	  gene	  expression.	  Cells	  were	  grown	  in	  tissue	  culture	  flasks	  (Thermo	   scientific	   NUNC)	   and	   sub-­‐cultured	   by	   first	   rinsing	   cells	   with	   PBS,	   then	  harvesting	   cells	   by	   incubation	   with	   0.25%	   Trypsin-­‐EDTA	   (Life	   Technologies),	  followed	  by	  neutralisation	  with	  complete	  media.	  Cells	  were	  washed	  twice	  by	  pelleting	  at	  500	  g	  for	  5	  minutes,	  and	  then	  an	  aliquot	  was	  seeded	  into	  tissue	  culture	  flasks.	  	  
	  
THP-­‐1	  	  THP-­‐1	  cells	  are	  a	  human	  monocytic	   cell	   line,	  originally	  derived	   from	  the	  peripheral	  blood	  of	  a	  patient	  with	  acute	  monocytic	  leukemia	  (Tsuchiya	  et	  al.,	  1980).	  Cells	  were	  obtained	   from	   ATCC	   and	   maintained	   in	   tissue	   culture	   flasks	   or	   plates	   (Thermo	  scientific	  NUNC)	  in	  complete	  media	  (Table	  2.4).	  Cells	  were	  sub-­‐cultured	  by	  pipetting	  into	   a	   homogeneous	   suspension,	   washing	   twice	   by	   pelleting	   cells	   at	   500	   g	   for	   5	  minutes,	   then	   seeding	   an	   aliquot	   into	   a	   new	   flask	   or	   plate.	   THP-­‐1	   cells	   were	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differentiated	  into	  macrophage-­‐like	  cells	  by	  seeding	  cells	  into	  tissue	  culture	  wells	  and	  treating	   with	   30	   ng/mL	   PMA	   (Sigma	   Aldrich)	   for	   48	   h.	   Cells	   were	   rested	   for	   4	   h	  following	  differentiation	   in	   complete	  media	  without	  PMA	  before	   commencement	  of	  experimentation.	  	  	  
2.2.2.	   Primary	  cells	  
Bone	  marrow-­‐derived	  macrophages	  (BMM)	  All	   experiments	  using	  mice	  were	  approved	  by	   the	  University	  of	  Queensland	  animal	  ethics	   committee.	   Bone	   marrow	   cells	   were	   harvested	   from	   femurs	   and	   tibias	   of	  specific	   pathogen-­‐free	   male	   C57Bl/6	   mice	   from	   6	   to	   8	   weeks	   of	   age.	   Briefly,	   mice	  were	  euthanized	  by	  performing	  cervical	  dislocation	  or	  administering	  carbon	  dioxide	  at	   a	   rate	   of	   20%	   chamber	   volume	   per	  minute,	   after	  which	   femurs	   and	   tibias	  were	  removed.	  Surrounding	  muscle	  tissue	  was	  removed	  using	  70%	  ethanol.	  Under	  sterile	  conditions,	  the	  bone	  cavity	  was	  flushed	  with	  complete	  media	  using	  a	  27-­‐gauge	  needle	  attached	   to	   a	   5	   mL	   syringe.	   Pooled	   bone	   marrow	   was	   cultured	   on	   square	   sterilin	  bacteriological	   plastic	   plates	   (Thermo	   Scientific)	   in	   complete	   media	   (Table	   2.4)	  containing	  recombinant	  human	  CSF-­‐1	  (10,000	  U/mL)	  at	  a	  density	  of	  approximately	  1	  bone	  per	  3-­‐4	  plates	  for	  6	  days.	  Differentiating	  BMM	  were	  given	  fresh	  CSF-­‐1	  on	  day	  5	  and	  were	  replated	  on	   tissue	  culture	  plates	  on	  day	  6	  with	   fresh	  media	  and	  CSF-­‐1,	  at	  the	   required	   density	   for	   experimental	   purposes.	   To	   store	   BMM,	   equivalent	   bone	  marrow	  from	  1	  bone	  per	  vial	  was	  frozen	  according	  to	  the	  protocol	  in	  Section	  2.2.3.	  	  
 
Thioglycollate-­‐elicited	  peritoneal	  macrophages	  (TEPM)	  TEPM	   cells	   were	   generated	   by	   injecting	   1	  mL	   of	   10%	   thioglycollate	   broth	   (Becton	  Dickinson)	   into	  the	  peritoneal	  cavity	  of	  6	  to	  8	  week	  old	  C57Bl/6	  mice.	  After	  5	  days,	  mice	  were	  euthanized	  and	  peritoneal	  lavages	  were	  performed	  using	  sterile	  PBS.	  Cells	  obtained	  from	  lavages	  were	  washed	  in	  PBS	  and	  red	  blood	  cells	  were	  lysed	  using	  red	  blood	  cell	   lysis	  buffer	  (Sigma	  Aldrich).	  The	  remaining	  white	  blood	  cells	  were	  plated	  on	  square	  sterilin	  bacteriological	  plastic	  plates	  (Thermo	  Scientific)	  at	  approximately	  1x107	   cells	   per	   plate	   in	   complete	   media	   (Table	   2.4).	   The	   next	   day,	   cells	   were	  harvested	  and	  plated	  according	  to	  experimental	  requirements.	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Human	  monocyte-­‐derived	  macrophages	  (HMDM)	  All	  experiments	  involving	  the	  use	  of	  human	  blood	  were	  approved	  by	  the	  University	  of	  Queensland	   medical	   research	   ethics	   committee.	   HMDM	   were	   differentiated	   from	  monocytes	   isolated	   from	  buffy	   coats	  obtained	   from	   the	  Australian	  Red	  Cross	  Blood	  Service.	   In	   brief,	   buffy	   coats	   were	   diluted	   in	   sterile	   PBS,	   then	   layered	   onto	   Ficoll-­‐Paque	  Plus	  (GE	  Healthcare	  Life	  Sciences)	  and	  centrifuged	  at	  400	  g	  for	  30	  minutes	  for	  density	   gradient	   separation.	   White	   blood	   cells	   were	   harvested	   using	   a	   pipette,	  washed	   in	  sterile	  PBS,	   then	   incubated	  with	  MACS	  CD14	  microbeads	   for	  40	  minutes.	  After	  washing	  cells,	  CD14+	  monocytes	  were	  isolated	  by	  positive	  selection	  using	  CD14+	  beads	   and	   MACS®	   manual	   cell	   separation	   LS	   columns,	   according	   to	   the	  manufacturer’s	  protocol	  (Miltenyi	  Biotech).	  Isolated	  cells	  were	  washed,	  counted	  and	  plated	  at	  15x106	  per	  10cm2	  	  round	  tissue	  culture	  plastic	  plates	  (Thermo	  Scientific)	  in	  10	  mL	   complete	   media	   containing	   either	   1x104	  U/mL	   CSF-­‐1	   or	   10	   ng/mL	   GM-­‐CSF	  (Table	   2.4)	   for	  6	  days.	  Purity	  of	  monocyte	  preparations	  was	   routinely	  assessed	  by	  staining	   with	   an	   anti-­‐CD14	   antibody	   conjugated	   to	   PE	   and	   analysing	   by	   flow	  cytometry.	   	   A	   purity	   of	   >90%	   was	   considered	   to	   be	   sufficient	   for	   further	  experimentation.	  On	  the	  6th	  day	  after	  isolation,	  cells	  were	  harvested	  with	  a	  blunt	  edge	  18-­‐gauge	  needle	  and	  5	  mL	  syringe	  and	  replated	  with	  1x104	  U/mL	  CSF-­‐1	  or	  10	  ng/mL	  GM-­‐CSF	   for	  experimentation	  on	  day	  7.	  Throughout	   the	  experimental	  process,	  CSF-­‐1	  or	  GM-­‐CSF	  was	  maintained	  in	  the	  media.	  	  	  
2.2.3.	   Storage	  of	  cell	  lines	  and	  primary	  cells	  Cell	  lines	  (RAW264.7,	  HEK293T	  and	  THP-­‐1	  cells)	  were	  stored	  by	  freezing	  aliquots	  of	  approximately	   2.5x106	   cells	   in	   freezing	   media,	   which	   consisted	   of	   50%	   FBS,	   40%	  complete	  media	  and	  10%	  DMSO.	  Vials	  of	  cells	  were	  placed	  in	  isopropanol-­‐containing	  cryo-­‐freezing	   containers	   and	   transferred	   to	   -­‐80˚C	   freezers	   overnight	   for	   slow	  freezing,	  before	  transfer	  to	  liquid	  nitrogen.	  For	  recovery	  of	  stored	  cells,	  aliquots	  were	  thawed	   at	   37˚C,	   washed	   twice	   by	   pelleting	   cells	   at	   500	   g	   for	   5	   minutes	   and	  resuspending	   in	   complete	   media	   to	   remove	   DMSO,	   before	   plating	   in	   appropriate	  media.	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Cell	  Type	   Complete	  Media	  Specifications	  
RAW264.7	  and	  RAW264.7	  ELAM	  
RPMI	  1640	  containing:	  5%	  Heat	  inactivated	  Foetal	  Bovine	  Serum	  (FBS)	  (Invitrogen)	  50	  U/mL	  Penicillin	  (Life	  Technologies)	  50	  μg/mL	  Streptomycin	  (Life	  Technologies)	  2	   mM	   L-­‐	   glutamine	   (GlutaMAX,	   Life	  Technologies)	  
HEK293T	  
DMEM	  containing:	  10%	  Heat	  inactivated	  FBS	  (Invitrogen)	  50	  Units/mL	  Penicillin	  (Life	  Technologies)	  50	  μg/mL	  Streptomycin	  (Life	  Technologies)	  2	   mM	   L-­‐	   glutamine	   (GlutaMAX,	   Life	  Technologies)	  
THP-­‐1	  
RPMI	  1640	  containing:	  10%	  Heat	  inactivated	  FBS	  (Invitrogen)	  50	  U/mL	  Penicillin	  (Life	  Technologies)	  50	  μg/mL	  Streptomycin	  (Life	  Technologies)	  2	  mM	  L-­‐	  glutamine	  (GlutaMAX,	  Life	  Technologies)	  1	  mM	  Sodium	  pyruvate	  (Life	  Technologies)	  10	  mM	  Hepes	  buffer	  (Life	  Technologies)	  50	  μM	  β-­‐mercaptoethanol	  (Sigma-­‐Aldrich)	  
BMM	  	  
RPMI	  1640	  containing:	  10%	  Heat	  inactivated	  FBS	  (Invitrogen)	  50	  U/mL	  Penicillin	  (Life	  Technologies)	  50	  μg/mL	  Streptomycin	  (Life	  Technologies)	  2	  mM	  L-­‐	  glutamine	  (GlutaMAX,	  Life	  technologies)	  1x104	  U/mL	  CSF-­‐1	  (Chiron)	  
TEPM	   RPMI	  1640	  containing:	  10%	  Heat	  inactivated	  FBS	  (Invitrogen)	  50	  U/mL	  Penicillin	  (Life	  Technologies)	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50	  μg/mL	  Streptomycin	  (Life	  Technologies)	  2	  mM	  L-­‐	  glutamine	  (GlutaMAX,	  Life	  technologies)	  
HMDM	  
Iscove’s	  Modified	  Dulbecco’s	  Medium	  (IMDM)	  
containing:	  10%	  Heat	  inactivated	  	  FBS	  (Invitrogen)	  50	  units/mL	  Penicillin	  (Life	  technologies)	  50	  μg/mL	  Streptomycin	  (Life	  technologies)	  Either	  1x104	  U/mL	  CSF-­‐1	   (Chiron)	  or	  10	  ng/mL	  GM-­‐CSF	  (Peprotech)	  
Table	  2.4:	  Complete	  media	  specifications	  for	  different	  cell	  types.	  	  
2.2.4.	   Bacterial	  culture	  
Salmonella	   enterica	   serovar	   Typhimurium	   strain	   SLI	   344	   and	  Escherichia	  coli	  
strain	  MG1655	  	  
S.	  Typhimurium	  strain	  SLI	  344	  (Hoiseth	  and	  Stocker,	  1981)	  and	  E.	  coli	  strain	  MG1655	  (Blattner	  et	  al.,	  1997)	  (obtained	  from	  Dr.	  Makrina	  Totsika	  from	  the	  Schembri	  Group,	  School	  of	  Chemistry	   and	  Molecular	  Biosciences,	  The	  University	  of	  Queensland)	  was	  stored	   in	  LB	  broth	  with	  50%	  sterile	  glycerol	  at	   -­‐80˚C.	  Bacteria	   from	  glycerol	   stocks	  were	   plated	   on	   LB	   agar	   plates	   and	   incubated	   overnight	   at	   37˚C,	   2	   days	   before	  experimentation.	  The	  next	  day,	  an	  isolated	  colony	  was	  picked	  and	  cultured	  in	  10	  mL	  LB	  broth	  at	  37˚C	  overnight	  for	  14-­‐16	  h.	  Overnight	  cultures	  were	  washed	  twice	  in	  PBS	  and	   resuspended	   in	   PBS.	   Optical	   density	   at	   600	   nm	   was	   measured	   by	  spectrophotometry,	   and	   cell	   density	   for	   S.	   Typhimurium	   was	   calculated	   using	   1	  AU600nm	   =	   8.5x108	  colony	   forming	   units	   (cfu)/mL,	  while	   cell	   density	   for	  E.	   coli	  was	  calculated	  using	  1	  AU600nm	  =	  1x109	  cfu/mL.	  The	  appropriate	  multiplicity	  of	  infection	  (MOI)	  was	  then	  calculated	  using	  the	  density	  obtained.	  	  
2.2.5.	   Bacterial	  growth	  assays	  The	   effect	   of	   compounds	   (HDAC	   inhibitors	   and	   GPCR	   ligands)	   was	   assessed	   on	   S.	  Typhimurium	   and	   E.	   coli	   growth	   in	   HMDM	   complete	   cell	   media	   by	  spectrophotometric	  analysis	  of	  optical	  density	  at	  600	  nm.	  S.	  Typhimurium	  and	  E.	  coli	  were	   cultured	   overnight	   in	   LB	   broth	   in	   a	   shaking	   incubator	   at	   37˚C.	   Bacteria	  were	  washed	  twice	  in	  sterile	  PBS,	  and	  resuspended	  in	  media	  for	  mammalian	  cell	  culture.	  1	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AU	  of	  bacteria,	  as	  determined	  by	  spectrophotometry,	  was	  resuspended	  in	  a	  total	  of	  10	  mL	   of	   cell	   culture	   media	   and	   cultured	   in	   a	   shaking	   incubator	   at	   37˚C.	   Bacterial	  growth,	   as	   determined	   by	   optical	   density,	  was	  measured	   every	   10	  minutes	   for	   the	  first	  hour,	  then	  every	  20	  minutes	  for	  the	  second	  hour	  and	  finally	  every	  half	  hour	  until	  7	  h	  post-­‐inoculation,	  by	  which	  time	  bacterial	  growth	  had	  plateaued.	  	  
2.2.6.	   Bacterial	  infection	  assays	  Bacterial	   infection	   assays	   were	   conducted	   in	   human	   and	   mouse	   macrophages	   to	  assess	   intracellular	   survival	   using	   gentamicin	   exclusion	   assays.	   In	   brief,	   primary	  human	   and	   mouse	   macrophages	   were	   harvested	   at	   day	   6	   to	   8	   following	  differentiation	   and	   plated	   out	   in	   24	   well	   plates	   at	   a	   density	   of	   2x105	   or	   4x105	  cells/well	   (as	   per	   experimental	   requirements)	   in	   1	   mL	   P/S-­‐free	   media	   containing	  CSF-­‐1	  or	  GM-­‐CSF.	  Cells	  were	  infected	  on	  the	  following	  day.	  THP-­‐1	  cells	  were	  plated	  at	  the	   required	  density	   and	  were	  differentiated	   into	  macrophage-­‐like	   cells	  by	   treating	  with	  PMA	  for	  48	  h,	  after	  which	  media	  was	  replaced	  with	  fresh	  media	  without	  PMA	  for	  4	  h.	  At	  this	  point,	  cells	  were	  infected	  with	  bacteria	  at	  an	  appropriate	  MOI	  (MOI	  10	  for	  10	   bacteria	   per	   cell,	   MOI	   100	   for	   100	   bacteria	   per	   cell),	   and	   1	   h	   later,	   cells	   were	  washed	   three	   times	   with	   200	   μg/mL	   gentamicin	   resuspended	   in	   P/S-­‐free	   media	  (gentamedia)	   then	   incubated	   for	   1	   h	   in	   200	  μg/mL	   gentamedia	   to	   enable	   killing	   of	  extracellular	  bacteria	  (gentamicin	  exclusion).	  Cells	  were	  then	  washed	  thrice	  with	  20	  μg/mL	  gentamedia	  and	  incubated	  in	  20	  μg/mL	  gentamedia	  supplemented	  with	  either	  CSF-­‐1	   (BMM/HMDM)	   or	   GM-­‐CSF	   (HMDM)	   until	   the	   appropriate	   time-­‐point.	   In	  situations	   where	   cells	   were	   being	   treated	   with	   specific	   pharmacological	   reagents,	  those	  reagents	  were	  re-­‐added	  to	  the	  20	  μg/mL	  gentamedia	  following	  the	  third	  wash	  and	   left	  on	  cells	   throughout	   incubation.	   If	  required,	  supernatants	  were	  harvested	  at	  the	  appropriate	   timepoint	  by	   first	   spinning	   the	   cell	   culture	  plate	   containing	  cells	   at	  500	  g	  for	  ~5	  minutes,	  then	  pipetting	  up	  supernatant	  to	  carefully	  avoid	  collecting	  cells.	  Adherent	   cells	   were	   then	  washed	   twice	  with	   P/S	   free	  media	   and	   lysed	  with	   1	  mL	  0.01%	   Triton-­‐X100	   in	   sterile	   PBS.	   Lysates	   were	   serially	   diluted	   and	   cultured	  overnight	  at	  37˚C	   for	  ~9	  h	  on	  antibiotic-­‐free	  LB	  agar	  plates.	  Bacterial	  colonies	   from	  lysates	  were	  counted	  and	  used	  to	  assess	  intracellular	  bacterial	  loads.	  The	  actual	  MOI	  used	  in	  infection	  assays	  was	  also	  calculated	  by	  plating	  out	  inoculum	  on	  LB	  agar	  plates	  immediately	  after	  carrying	  out	  infection	  assays.	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2.2.7.	   Macrophage	  viability	  assays	   	  	  
MTT	  assays	  Macrophage	  survival	  after	   specific	   treatments	  was	  estimated	  by	  MTT	  assays,	  which	  measure	  mitochondrial	  activity	  and	  thus	  provide	  an	  indirect	  measure	  of	  cell	  viability.	  Although	  this	  assay	  does	  not	  discriminate	  between	  effects	  on	  cell	  viability	  and	  effects	  on	  mitochondrial	  activity,	  it	  was	  primarily	  used	  to	  show	  that	  specific	  treatments	  had	  no	  gross	  effects	  on	  cell	  functions.	  Moreover,	  LDH	  assays	  (described	  below)	  were	  also	  used	  to	  assess	  potential	  cytotoxic	  effects	  of	  specific	  treatments.	  For	  MTT	  assays,	  cells	  were	  incubated	  for	  3	  h	  at	  37˚C	  in	  1	  mg/mL	  MTT	  reagent	  ((3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyltetrazolium	   bromide)	   (Sigma	   Aldrich)	   diluted	   in	   complete	   media.	  Media	  was	  then	  discarded	  and	  cells	  were	  solubilized	  in	  100	  μl	  of	  100%	  isopropanol	  and	  incubation	  on	  a	  rotator	  for	  ~	  1-­‐2	  h.	  Absorbance	  was	  measured	  at	  570	  nm	  using	  a	  Powerwave	  XS	  plate	  reader.	  	  
LDH	  assays	  Lactate	  dehydrogenase	  (LDH)	  is	  a	  metabolic	  enzyme	  that	  is	  released	  from	  dying	  cells,	  and	  thus	  LDH	  release	  assays	  are	  commonly	  used	  as	  a	  read-­‐out	  of	  cell	  death.	  Using	  the	  LDH	  Activity	  Assay	  kit	  (Sigma	  Aldrich),	  LDH	  release	  is	  quantified	  through	  its	  activity	  in	  reducing	  NAD	  to	  NADH.	  NADH	  then	  reduces	  a	  tetrazolium	  salt	  into	  a	  red	  formazan	  product	   that	   is	  detectable	  by	  a	   colorimetric	   assay,	  with	   this	   read-­‐out	  being	  directly	  proportional	   to	   the	   amount	   of	   LDH	   released	   into	   the	   medium.	   Supernatants	   were	  tested	   for	   LDH	   release	   by	   mixing	   20	   μL	   of	   supernatant/lysate	   with	   40	   μL	   of	   the	  master	  reaction	  in	  replicates	  in	  a	  96	  well	  plate,	  following	  the	  manufacturer’s	  protocol.	  Complete	   media	   was	   used	   as	   a	   control	   for	   the	   background	   signal.	   Untreated	   cells	  were	  lysed	  by	  the	  addition	  of	  1	  μL	  of	  10%	  Triton-­‐X100	  into	  1	  mL	  media	  to	  achieve	  a	  final	   concentration	  of	   0.01%	  Triton-­‐X100,	   following	  by	  pipetting	   to	   enable	   efficient	  cell	   lysis.	   These	   cell	   lysates	   were	   used	   as	   control	   for	   measuring	   total	   LDH.	   The	  mixture	   was	   incubated	   at	   room	   temperature	   in	   the	   dark	   for	   approximately	   40	  minutes,	   before	   absorbance	   was	   measured	   at	   450	   nm	   using	   a	   Powerwave	   XS	  Spectrophotometer.	   LDH	   release	   was	   quantified	   by	   subtracting	   background,	   then	  normalising	   absorbance	   from	   cell	   supernatants	   over	   cell	   lysates	   to	   obtain	   %LDH	  release	  over	  total	  LDH.	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2.2.8.	   siRNA-­‐mediated	  gene	  knockdown	  
HMDM	  HMDM	  at	  day	  6-­‐8	  were	  harvested	  and	  washed	  twice	  in	  media	  before	  resuspension	  in	  complete	  media	  at	  2.5x106	  cells/300	  μL.	  1M	  Hepes	  (tissue	  culture	  grade)	  was	  added	  per	   mL	   of	   cells.	   300	   μL	   cell	   suspensions	   were	   transferred	   to	   0.4	   cm	   sterile	  electroporation	   cuvettes,	   and	  mixed	  with	   siRNA	   to	   achieve	   a	   final	   concentration	   of	  0.25	  μM	   (Table	   2.3).	   Cells	  were	   electroporated	   at	   240	  V,	   1000	  μF	   and	  ∞Ω	  using	   a	  Biorad	   electroporator,	   after	   which	   cells	   were	   rested	   for	   5	   minutes	   for	   recovery.	   2	  replicates	  were	  performed	  for	  each	  experimental	  condition	  and	  were	  pooled,	  washed	  twice,	  counted,	   then	  plated	  out	   for	  experiments.	  24	  h	   later,	  media	  was	  changed	  and	  experimentation	  was	  commenced.	  	  
THP-­‐1	  cells	  THP-­‐1	   cells	   were	   differentiated	   into	   macrophages	   for	   48	   h,	   then	   harvested.	  Electroporation	  with	  siRNA	  was	  conducted	  as	  described	  above	  for	  HMDM.	  Following	  that,	  cells	  were	  plated	  for	  experimental	  purposes,	  differentiated	  for	  another	  24	  h	  with	  30	  ng/mL	  PMA,	  after	  which	  media	  was	  replaced	  with	  fresh	  PMA-­‐free	  complete	  media	  for	  4	  h.	  At	  this	  point,	  experimentation	  was	  commenced.	  	  	  
2.2.9.	   Quantification	  of	  mRNA	  expression	  
RNA	  purification	  RNA	  was	  harvested	  from	  cells	  using	  the	  Qiagen	  RNeasy	  Mini	  Kit	  (Qiagen)	  or	  Direct-­‐zolTM	  RNA	  MiniPrep	  Kit	   (Zymo	  Research)	   according	   to	  manufacturer’s	   instructions.	  RNA	  was	  quantified	  using	  an	  ND	  1000	  nanodrop	  spectrophotometer	   (Biolab)	  using	  Beer’s	  Law	  and	  the	  assumption	  that	  1	  AU	  =	  40	  µg/mL	  RNA.	  RNA	  purity	  was	  assessed	  by	  determining	  the	  A260/280	  ratio,	  with	  a	  ratio	  of	  1.8-­‐2.0	  considered	  as	  acceptable	  for	  subsequent	  analysis.	  
	  
cDNA	  synthesis	  for	  qPCR	  cDNA	  was	   synthesised	   from	  500	  ng	  of	   extracted	  RNA.	  Contaminating	  genomic	  DNA	  was	   removed	   from	   RNA	   by	   conducting	   off-­‐column	   DNA	   digestion	   using	   a	   kit	   from	  Invitrogen.	  Briefly,	  1	  μL	  of	  amplification	  grade	  100	  U	  DNase	  I	  and	  1	  μL	  10x	  DNase	  I	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Reaction	  Buffer	  was	  added	  to	  500	  ng	  RNA,	  after	  which	  the	  mixture	  was	  incubated	  at	  25˚C	   for	   15	   minutes.	   Reactions	   were	   terminated	   by	   incubation	   with	   1	   μL	   25	   mM	  EDTA	  (pH	  8.0)	  at	  65˚C	  for	  10	  minutes.	  cDNA	  was	  synthesised	  by	  incubating	  with	  1	  μL	  of	  500	  ng	  oligo	  dT	  primer	  (Geneworks)	  and	  1	  μl	  10	  μM	  dNTPs	  in	  a	  19	  μL	  reaction	  at	  70˚C	  for	  10	  minutes,	  then	  chilling	  on	  ice.	  Following	  that,	  4	  μL	  of	  First	  Strand	  Buffer,	  1	  μL	  of	  0.1	  M	  DTT,	  0.2	  μL	  of	  Superscript	  III	  Reverse	  Transcriptase	  (Life	  Technologies)	  was	   added	   and	   the	   reaction	   was	   made	   up	   to	   25	   μL	   with	   RNase-­‐free	   water.	   The	  reaction	  was	  placed	   in	  a	   thermal	  cycler	  and	   incubated	  at	  50˚C	   for	  50	  minutes,	   then	  70˚C	  for	  15	  minutes.	  A	  negative	  control	  was	  included	  using	  pooled	  RNA	  and	  with	  the	  same	   conditions,	   except	   without	   the	   addition	   of	   Superscript	   III	   (-­‐RT).	   Synthesised	  cDNA	   was	   diluted	   10	   times	   in	   RNase-­‐free	   water	   and	   stored	   at	   -­‐20˚C,	   before	  subsequent	  use	  for	  qPCR.	  	  	  
Quantitative	  real-­‐time	  PCR	  (qPCR)	  	  qPCR	  was	  performed	  by	  preparing	  a	  10	  μL	  reaction	  mix	  containing	  5	  μL	  SYBR	  Green	  PCR	  Master	  Mix	  (Applied	  	  Biosystems),	  2	  μL	  of	  forward	  and	  reverse	  qPCR	  primers	  at	  2	  μM	  concentration	  (Table	  2.2),	  1	  μL	  of	  RNase-­‐free	  water,	  and	  2	  μL	  of	  1	  in	  10	  diluted	  cDNA.	   All	   samples	  were	   run	   in	   triplicate	   in	   a	   384-­‐well	   plate	   (Invitrogen).	   The	   –RT	  sample,	  and	  a	  no-­‐template	  control	  using	  water	  instead	  of	  cDNA	  template	  were	  run	  as	  negative	  controls	  in	  all	  experiments.	  Relative	  mRNA	  levels	  for	  individual	  genes	  were	  determined	   using	   the	   ΔCt	   method,	   with	   hypoxanthine-­‐guanine	  phosphoribosyltransferase	   (HPRT)	   used	   as	   the	   reference	   gene.	   To	   do	   so,	   the	  following	  equation,	  recommended	  by	  Applied	  Biosystems,	  was	  used:	  
 gene/hprt	  =	  2-­‐ΔCt;	  where	  ΔCt	  =	  geneCt	  –	  hprtCt	  (the	  difference	  in	  cycle	  thresholds)	  	  	  	  	  	  SD	  =	  2-­‐ΔCt	  -­‐	  2-­‐x;	  where	  x	  =	  ΔCt	  +	  SQRT	  (SDgene2	  +	  SDhprt2)	  	  
2.2.10.	  Enzyme-­‐linked	  immunosorbent	  assays	  Levels	   of	   IL-­‐6,	   TNFα,	   CCL20,	   CXCL13	   and	   IL-­‐1β	   cytokines	   were	   quantified	   by	  performing	   enzyme-­‐linked	   immunosorbent	   assays	   (ELISA)	   on	   supernatants	  harvested	   at	   the	   indicated	   timepoints.	   Plates	   were	   centrifuged	   at	   ~500	   g	   for	   5	  minutes	   to	  pellet	   cells	  before	   supernatants	  were	  harvested	   for	  ELISA.	  Protocols	   for	  detection	  of	  each	  cytokine	  by	  ELISA	  are	  detailed	  below.	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ELISAs	  IL-­‐6	  ELISAs	  were	  conducted	  using	  paired	  antibodies	  from	  BD	  Bioscience	  (Table	  2.2).	  96	  well	  maxisorp	  plates	  (Thermo	  Scientific)	  were	  coated	  with	  capture	  antibody	  (50	  μL/well)	  diluted	  in	  0.1	  M	  NaHCO3	  then	  incubated	  overnight	  at	  4˚C.	  On	  the	  following	  day,	  plates	  were	  washed	  twice	  with	  PBST	  (PBS/0.05%	  Tween-­‐20),	  then	  blocked	  with	  200	  μL	  blocking	  buffer	  (10%	  FCS/PBS)	   for	  at	   least	  1	  h	  at	  37˚C.	  Plates	  were	  washed	  twice	  with	  PBST	  then	  50	  μL	  of	  sample	  or	  cytokine	  standards	  were	  added	  and	  plates	  were	   incubated	   overnight	   at	   4˚C.	   The	   next	   day,	   plates	   were	   washed	   5	   times	   and	  detection	  antibody	  was	  added	  (50	  μL/well	  diluted	  in	  10%	  FCS/PBS).	  Plates	  were	  then	  incubated	  for	  2	  h	  at	  room	  temperature,	  washed	  6	  times	  with	  PBST,	  then	  extra-­‐avidin	  peroxidase	  (Sigma	  Aldrich)	  diluted	  1:1000	  in	  10%	  FCS/PBS	  was	  added	  (50	  μL/well)	  and	   plates	   were	   incubated	   at	   room	   temperature	   for	   30	  minutes.	   Plates	   were	   then	  washed	  6	  times	  with	  PBST,	  after	  which	  100	  µL/well	  TMB	  substrate	  (Sigma	  Aldrich)	  was	  added	  and	  plates	  were	  incubated	  at	  room	  temperature	  in	  the	  dark.	  Once	  colour	  had	   developed	   in	   positive	   wells,	   reactions	  were	   stopped	   by	   adding	   2	  M	   H2SO4	  (50	  μL/well).	  Absorbance	  was	  read	  at	  450	  nm	  using	  a	  Powerwave	  XS	  Spectrophotometer	  and	  sample	  concentrations	  were	  extrapolated	  using	  a	  quadratic	  curve	  generated	  from	  the	   absorbance	   values	   obtained	   from	   the	   standards.	   ELISA	   to	   detect	   TNFα,	   CCL20,	  CXCL13	   and	   IL-­‐1β	   cytokines	   were	   conducted	   according	   to	   the	   manufacturer’s	  protocols	  using	  the	  kits	  and	  antibodies	  as	  detailed	  in	  Table	  2.2.	  	  
2.2.11.	  Inflammasome	  activation	  assays	  To	  assess	   inflammasome	  activation,	  HMDM	  or	  PMA-­‐differentiated	  THP-­‐1	  cells	  were	  plated	  out	  the	  day	  prior	  to	  the	  experiment	  at	  2x105	  cells	  per	  well	  in	  1	  mL	  of	  complete	  media.	  The	  next	  day,	  cells	  were	  treated	  with	  100	  ng/mL	  LPS	  for	  4	  h	  then	  triggered	  for	  3	   h	   with	   various	   inflammasome-­‐activating	   stimuli.	   For	   NLRP3	   inflammasome	  activation,	   10	   μM	   nigericin	   or	   5	   mM	   ATP	   was	   added	   to	   the	   media.	   For	   NLRC4	  inflammasome	   activation,	  S.	  Typhimurium	  was	   grown	  overnight,	   then	   an	   aliquot	   of	  the	  overnight	  culture	  was	  diluted	  1/40	  and	  grown	  for	  ~3	  h	  to	  ensure	  bacteria	  were	  in	  logarithmic	   growth	   phase.	   Concentration	   of	   log	   phase	   S.	   Typhimurium	   was	  determined	  using	  1	  AU600nm	  =	  1x109	  cfu/mL	  and	  infection	  was	  conducted	  as	  detailed	  in	  Section	  2.2.5.	  Following	  infection,	  plates	  containing	  cells	  were	  centrifuged	  at	  700	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g	   for	   10	   minutes.	   Gentamicin	   exclusion	   was	   conducted	   by	   adding	   50	   μg/mL	  gentamicin	   at	   30	  minutes	   post-­‐infection.	   Cells	   were	   incubated	   for	   a	   total	   of	   3	   h	   of	  infection.	  Plates	  were	   then	  centrifuged	  at	  700	  g	   for	  10	  minutes,	  prior	   to	  harvesting	  cell	  culture	  supernatants.	  	  
2.2.12.	  Western	  Blotting	  
Preparation	  of	  cell	  lysates	  Cells	  were	  rinsed	  with	  PBS,	  then	  lysed	  in	  RIPA	  buffer	  (Table	  2.5),	  supplemented	  with	  1	   x	  protease	   inhibitors	   (Roche	  Life	   Science)	   and	  1	   x	  phosphatase	   inhibitors	   (Table	  
2.5).	  Lysates	  were	  harvested	  by	  scraping	  with	  a	  cell	  scraper,	   then	  homogenising	  by	  syringing	   with	   a	   21-­‐gauge	   needle	   and	   a	   1	   mL	   syringe,	   after	   which	   samples	   were	  stored	   at	   -­‐20˚C.	   Protein	   concentrations	   were	   determined	   by	   BCA	   assay	   (Pierce),	  according	  to	  the	  manufacturer’s	  instructions.	  	  	  
Immunoblotting	  Approximately	   5-­‐10	   μg	   of	   protein	  were	   diluted	   in	   4X	  NuPAGE®	   LDS	   Sample	  Buffer	  and	  10X	  NuPAGE®	  Sample	  Reducing	  Agent,	  boiled	  at	  100˚C	  for	  10	  minutes,	  then	  used	  for	   immunoblotting.	   Samples	  were	   loaded	   onto	   pre-­‐cast	   4-­‐20%	  gradient	   SDS-­‐PAGE	  gels	   (Bio-­‐Rad)	  or	  pre-­‐cast	  4-­‐12%	  Bis-­‐Tris	  NuPAGE	  gels	   (Invitrogen),	   and	   separated	  by	  electrophoresis.	  Gels	  were	  then	  transferred	  onto	  nitrocellulose	  membranes	  (Bio-­‐Rad)	  using	  a	  semi-­‐dry	  transfer	  method,	  after	  which	  membranes	  were	  blocked	  for	  30	  minutes	   to	   1	   h	   at	   room	   temperature,	   or	   overnight	   at	   4˚C,	   in	   blocking	   buffer	   (5%	  BSA/Tris-­‐buffered	  saline	  containing	  0.05%	  v/v	  Tween-­‐20	  (TBST)).	  Membranes	  were	  probed	   using	   antibodies	   detailed	   in	   Table	   2.2	   by	   incubation	   overnight	   at	   4˚C	   for	  primary	   antibodies	   or	   2	   h	   at	   4˚C	   for	   secondary	   antibodies.	   Membranes	   were	  developed	   using	   ECL	   reagent	   (Amersham	   ECL	   Plus,	   GE	   Healthcare),	   followed	   by	  exposure	  to	  X-­‐ray	  film	  (Fuji	  Film),	  according	  to	  the	  manufacturer’s	  protocol.	  	  
Reprobing	  blots	  Following	   development	   of	   blots,	   nitrocellulose	   membranes	   were	   coated	   with	   30%	  H202	  and	  incubated	  at	  37˚C	  for	  40	  minutes	  to	  inactivate	  HRP.	  Blots	  were	  then	  washed	  thrice	  in	  TBST	  and	  blocked	  with	  5%	  BSA/TBST	  for	  30	  minutes	  at	  room	  temperature,	  or	  4˚C	  overnight,	  before	   incubation	  with	  a	  different	  primary	  antibody	  as	  previously	  
Materials	  and	  Methods	  
	   60	  	  
described.	  Where	  possible,	   primary	   antibodies	  were	   alternated	   in	   order	   to	   prevent	  subsequent	  probing	  with	  antibodies	  raised	  in	  the	  same	  species.	  	  	  
Quantification	  of	  immunoblots	  	  To	   quantify	   relative	   protein	   levels,	   blots	   were	   imaged	   using	   the	   ChemiDocTM	  MP	  System.	   Volume	   intensity,	   adjusted	   for	   background,	   was	   measured	   using	   BioRad	  ImageLab	   software	   for	   the	   desired	   protein	   bands	   and	  was	   normalised	   against	   the	  adjusted	   volume	   intensity	   of	   GAPDH	   or	   ASC	   protein,	   obtained	   after	   reprobing	   the	  same	  blot.	  	  	  
2.2.13.	  Flow	  Cytometry	  
RAW-­‐ELAM	  assays	  as	  a	  read-­‐out	  for	  NFκB	  activation	  RAW264.7	   ELAM	   cells	  were	   plated	   in	   complete	  media	   (Table	   2.4)	   at	   a	   density	   of	  1x106	  cells/well	  in	  1	  mL	  complete	  media	  in	  6	  well	  plates,	  and	  were	  grown	  overnight.	  On	  the	  following	  day,	  cells	  were	  treated	  with	  10	  ng/mL	  LPS,	  with	  or	  without	  either	  30	  nM	  C5a	  and	  1	  μM	  3D53	  or	  both,	  or	  were	  left	  untreated,	  for	  6	  h.	  Cells	  were	  then	  washed	  with	  PBS	  and	  harvested	   in	  LIFT	  buffer	  by	   syringing	  with	  a	  blunt	   edge	  18-­‐gauge	  needle	  and	  5	  mL	  syringe,	  then	  filtered	  into	  a	  FACs	  tube	  (Corning)	  with	  a	  35	  μM	  strainer	   cap	   in	   order	   to	   prevent	   cell	   clumping.	   FACs	   analysis	   was	   conducted	   by	  measuring	  GFP	  mean	   fluorescence	   intensity	  using	  a	  FACS	  Canto	   II	  Flow	  Cytometer	  (BD	  Bioscience).	  Data	  was	  analysed	  using	  FlowJo	  7.6.5	  software	  (Tree	  Star).	  	  	  
Quantification	  of	  phagocytosis	  HMDM	  were	  plated	  overnight	  at	  5x105	  cells/well	  in	  a	  6	  well	  plate	  in	  500	  μL	  complete	  media.	  The	  next	  day	  Cytochalasin	  D	  (Life	  Technologies)	  was	  added	  at	  10	  μM	  per	  well	  as	   a	   positive	   control	   for	   phagocytosis	   inhibition	   and	   cells	   were	   incubated	   for	   30	  minutes	  at	  37˚C.	  Alternatively,	  cells	  were	  treated	  as	  indicated	  in	  specific	  figures.	  Cells	  were	   then	   treated	   with	   100	   μg	   pHrodo	   Green	   E.	   coli	   BioParticles®	   Conjugate	  (Invitrogen)	   for	   1.5	   h.	   Cells	   were	   harvested	   as	   previously	   described	   and	   FACS	  analysis	  of	  GFP	  median	  fluorescence	  intensity	  was	  conducted.	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Quantification	  of	  mitochondrial	  ROS	  HMDM	  were	  plated	  overnight	  at	  4x105	  cells/well	  in	  a	  24	  well	  plate	  in	  1	  mL	  P/S-­‐free	  media.	  On	  the	  following	  day,	  cells	  were	  treated	  with	  HDACi	  at	  the	  same	  time	  as	  they	  were	  infected	  with	  S.	  Typhimurium	  at	  MOI	  100,	  as	  described	  in	  Section	  2.2.5.	  HDACi	  was	  re-­‐added	  to	  the	  media	  following	  the	  second	  gentamicin	  exclusion	  wash.	  After	  6	  h	   of	   infection,	   cells	   were	   washed	   twice	   with	   PBS	   and	   5	   μM	   MitoSOXTM	   Red	  Mitochondrial	  Superoxide	  Indicator	  (Life	  Technologies)	  was	  added	  in	  1	  mL	  of	  LIFT	  buffer.	  Cells	  were	   incubated	  for	  10	  minutes	  at	  37˚C.	  Cells	  were	  then	  harvested	  and	  FACs	   analysis	   was	   conducted	   as	   previously	   described	   by	   measuring	   median	  fluorescence	  intensity	  at	  excitation	  wavelength	  of	  510	  nm	  and	  emission	  at	  580	  nm.	  Comparison	  of	   fluorescence	   from	  live	  cells	  versus	  dead	  cells	  as	  stained	  by	  SYTOX®	  Blue	  Dead	  Cell	  Stain	  (Life	  Technologies)	  was	  also	  conducted	   for	  some	  experiments	  by	   staining	   cells	   with	   1	   μM	   SYTOX®	   Blue	   nucleic	   acid	   stain	   (Excitation/Emission	  wavelength	  of	  444	  nm/480	  nm)	  immediately	  prior	  to	  FACS	  analysis,	  then	  comparing	  median	   fluorescence	   at	   580	   nm	   with	   or	   without	   exclusion	   of	   cells	   stained	   with	  SYTOX®	  Blue.	  	  
2.2.14.	  Statistical	  analysis	  Statistical	   analysis	   was	   performed	   using	   Prism	   6	   software	   (Graphpad)	   for	   data	  combined	   from	   3	   or	   more	   independent	   experiments,	   with	   error	   bars	   indicating	  standard	  error	  of	  the	  mean.	  For	  data	  sets	  with	  at	  least	  3	  variables,	  a	  one-­‐way	  ANOVA	  analysis	  was	  performed,	   followed	  by	  Dunnett’s	  multiple	   comparison	   test.	  Data	  with	  confidence	   values	   of	   95%	   and	   beyond	   (p<0.05)	   were	   considered	   statistically	  significant.	   To	   compare	   two	   data	   points,	   significance	   was	   calculated	   using	   a	   two-­‐tailed	  unpaired	  t-­‐test	  using	  data	  combined	  from	  3	  or	  more	  independent	  experiments,	  In	   some	   figures,	   data	   is	   shown	   from	   representative	   experiments,	   and	   statistical	  analysis	   was	   not	   performed	   on	   these	   data.	   In	   these	   cases,	   error	   bars	   for	  representative	   experiments	   indicate	   range	   to	   provide	   an	   indication	   of	   variance	  between	  replicates	  within	  individual	  experiments.	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3.1.	  	   Introduction	  As	   discussed	   in	   Chapter	   1,	   species	   differences	   in	   innate	   immunity	   have	   been	  observed	  with	  PRR	  gene	  repertoires	  and	  PRR-­‐regulated	  gene	  expression.	  Therefore,	  studying	   innate	   immune	   responses	   uniquely	   regulated	   in	   human	   macrophages	   in	  comparison	  to	  mouse	  macrophages	  can	  provide	  insights	  into	  human-­‐specific	  immune	  mechanisms	   that	   are	  not	  present	  or	   activated	   in	  mice,	  which	  are	   a	   commonly	  used	  model	  organism	  for	  immunological	  research.	  It	  was	  hypothesised	  that	  genes	  that	  are	  specifically	   TLR4-­‐regulated	   in	   human	   macrophages	   may	   be	   important	   for	   human	  macrophage	   antimicrobial	   and	   inflammatory	   responses	   against	   Gram-­‐negative	  bacterial	  pathogens.	  A	  previous	  expression	  profiling	  study	  from	  this	  laboratory,	  using	  a	  custom	  microarray	  to	  compare	  LPS-­‐regulated	  gene	  expression	  in	  human	  and	  mouse	  primary	  macrophages,	   found	  that	   the	  broad	  majority	  of	  TLR4-­‐regulated	  genes	  were	  similarly	  regulated	  between	  the	  species.	  However,	  approximately	  24%	  of	  orthologues	  showed	  divergent	  regulation	  (Schroder	  et	  al.,	  2012a).	  	  	  The	   aim	   of	   this	   chapter	   was	   to	   select	   candidate	   LPS-­‐regulated	   genes	   that	   were	  identified	   in	   the	   expression	   profiling	   study	   to	   be	   divergently	   regulated	   in	   human	  versus	  mouse	  macrophages,	  validate	  the	  expression	  of	  those	  genes,	  and	  then	  conduct	  screening	  for	  potential	  roles	  in	  macrophage	  antimicrobial	  or	  inflammatory	  functions	  through	   functional	   analysis.	   Candidate	   genes	   were	   knocked	   down	   in	   macrophages	  and	   effects	   on	   intracellular	   survival	   of	   S.	   Typhimurium	   and	   E.	   coli,	   inflammatory	  cytokine	   secretion	   and	   inflammasome	  activation	  were	   analysed	   to	   select	   individual	  genes	  for	  further	  study	  to	  determine	  the	  mechanisms	  involved.	  	  Candidate	  genes	  were	  chosen	  based	  on	  “human-­‐specific”	  regulation	  by	  LPS	  as	  well	  as	  for	  novelty	  and	  biological	  function	  of	  the	  genes	  in	  the	  context	  of	  immunity	  (if	  known).	  These	  genes	  were	  also	  analysed	  with	  Ingenuity	  Pathway	  Analysis	  for	  association	  with	  immune	   pathways,	   and	   autoimmune	   and	   inflammatory	   disease	   conditions.	   Among	  the	   genes	   chosen	   were	   those	   encoding	   ion	   transporters	   (SLC41A2),	   novel	  transmembrane	   proteins	   (TMEM140	   and	   NKG7),	   and	   potential	   signalling	   or	  transcriptional	   regulators	   (RNF144B,	   BATF3	   and	   G0S2).	   Ion	   transporters	   were	  considered	   as	   ion	   flux	   has	   been	   increasingly	   linked	   to	   macrophage	   antimicrobial	  pathways.	   For	   example,	   regulated	   copper	   trafficking	   contributes	   to	   macrophage	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killing	  of	  E.	  coli	  and	  S.	  Typhimurium	  (Achard	  et	  al.,	  2012;	  Stafford	  et	  al.,	  2013;	  White	  et	   al.,	   2009).	  The	   transmembrane	  protein,	  NKG7	   is	   present	   in	   cytotoxic	   granules	  of	  natural	   killer	   cells	   and	  T	   cells	   (Medley	   et	   al.,	   1996b).	   It	   contains	   4	   transmembrane	  domains,	  as	  does	  the	  novel	  transmembrane	  protein	  encoded	  by	  TMEM140.	  Therefore	  these	  genes	  were	  of	  interest	  as	  they	  contain	  a	  common	  structure,	  suggesting	  that	  they	  may	  participate	  in	  a	  common	  pathway.	  The	  genes	  RNF144B,	  BATF3	  and	  G0S2	  had	  not	  been	   linked	  to	  TLR	  responses	  or	  antimicrobial	  responses	   in	  macrophages	  and	  were	  selected	   based	   on	   novelty	   and	   potential	   functions	   as	   signalling	   or	   transcriptional	  regulators.	  G0S2	   and	  RNF144B	  were	  also	  selected	  because	  of	   links	   to	  mitochondrial	  function,	   which	   has	   been	   of	   increasing	   interest	   in	   the	   context	   of	   macrophage	  antimicrobial	   pathways	   (Benard	   et	   al.,	   2010;	  Welch	   et	   al.,	   2009;	  West	   et	   al.,	   2011;	  Wiese	  et	  al.,	  2012).	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Table	   3.1:	   Candidate	   LPS-­‐regulated	   genes	   chosen	   for	   expression	   analysis	   and	  





Rationale	  for	  selection	   References	  RNF144B	  (PIR2/IBDC2/	  p53RFP)	   E3	  ubiquitin	  ligase	  
Potential	  role	  in	  signalling,	  links	  to	  mitochondria	  and	  apoptosis	  
(Benard	  et	  al.,	  2010;	  Ng	  et	  al.,	  2003)	  
SLC41A2	  	  
Plasma	  membrane	  magnesium	  transporter	   Magnesium	  transporter	  
(Goytain	  and	  Quamme,	  2005)	  
TMEM140	   Transmembrane	  proteins	  
NKG7	  linked	  to	  cytotoxic	  granules	  in	  NK	  and	  T	  cells,	  and	  both	  genes	  have	  related	  structures	  
(Ota	  et	  al.,	  2004;	  Scherer	  et	  al.,	  2003)	  NKG7	  (GMP-­‐17/p15-­‐TIA-­‐1/GIG-­‐1	  	  (G-­‐CSF-­‐induced	  Gene	  1)	  Protein	  
(Turman	  et	  al.,	  1993)	  
BATF3/Jun	  dimerization	  protein	  1	  (JUNDM1)/JDP1/	  p21-­‐kDa	  small	  nuclear	  factor	  isolated	  from	  T-­‐cells	  p21	  (SNFT)	  
Basic	  leucine	  zipper	  transcription	  factor	  
Negative	  regulator	  of	  AP-­‐1	  mediated	  transcription	  by	  heterodimerising	  with	  c-­‐jun	  and	  binding	  to	  DNA-­‐response	  elements;	  a	  role	  in	  CD8α+	  dendritic	  cell	  mediated	  cross-­‐presentation	  
(Bower	  et	  al.,	  2004;	  Bower	  et	  al.,	  2002;	  Hildner	  et	  al.,	  2008;	  Iacobelli	  et	  al.,	  2000)	  
G0/G1	  switch	  2	  (G0S2)	   G0/G1	  switch	  regulatory	  protein	  2	  
Cell	  cycle	  regulator,	  retinoic	  acid	  and	  peroxisome-­‐proliferator-­‐activated	  receptor	  (PPAR)-­‐target	  gene;	  encodes	  a	  TNFα-­‐inducible	  pro-­‐apoptotic	  mitochondrial	  protein	  
(Kitareewan	  et	  al.,	  2008;	  Welch	  et	  al.,	  2009;	  Zandbergen	  et	  al.,	  2005)	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3.2.	  	   Results	  
3.2.1	  	   Species-­‐specific	   regulation	   of	   LPS	   target	   genes	   in	   human	   versus	   mouse	  
macrophages.	  The	   previously	   conducted	   expression	   profiling	   study	   (Schroder	   et	   al.,	   2012a)	  revealed	   differential	   LPS-­‐regulated	   expression	   of	   the	   candidate	   genes	   in	   human	  versus	   mouse	   macrophages	   (Figure	   3.1,	   http://www.macgate.qfab.org).	   Thus,	   gene	  expression	  of	  selected	  novel	  TLR4	  target	  genes	  was	  evaluated	  using	  primary	  HMDM,	  primary	   C57Bl/6	   mouse	   BMM	   and	   primary	   C57Bl/6	   TEPM.	   BMM	   and	   TEPM	   are	  distinct	  mouse	  macrophage	  populations	  with	  observable	  differences	  in	  LPS-­‐regulated	  gene	   expression	   (Lattin	   et	   al.,	   2008).	   Therefore	   genes	   were	   determined	   to	   be	  divergently	   regulated	   if	   LPS-­‐induced	   expression	   was	   divergent	   in	   human	  macrophages	   compared	   to	   both	   mouse	   macrophage	   populations,	   to	   ensure	   that	  differences	   were	   more	   likely	   to	   reflect	   true	   species	   differences	   (Schroder	   et	   al.,	  2012a).	  However,	  there	  was	  still	  a	  possibility	  that	  differential	  expression	  of	  the	  genes	  related	   to	   cell	   type-­‐specific	   differences,	   rather	   than	   species	   differences.	   Thus,	  expression	   analysis	   was	   expanded	   to	   compare	   LPS-­‐regulated	   gene	   expression	   in	  HMDM	  versus	  six	  distinct	  mouse	  macrophage	  populations	  (BMM	  from	  C57Bl/6	  and	  BALBc	   mice,	   TEPMs	   from	   C57Bl/6	   mice,	   BMM	   from	   C57Bl/6	   mice	   with	   overnight	  IFNγ	   priming,	   splenocytes,	   and	   the	   mouse	   macrophage	   cell	   line	   RAW264.7).	   The	  analysis	  was	  conducted	  with	  five	  of	  the	  candidate	  genes	  (RNF144B,	  TMEM140,	  NKG7,	  
BATF3	   and	  G0S2)	   (Figure	   3.2).	  Differential	  expression	  of	  SLC41A2	   across	   these	  cell	  populations	  was	  previously	  validated	  by	  Dr.	  Nilesh	  Bokil	  (Sweet	  Group,	  Institute	  for	  Molecular	   Bioscience,	   University	   of	   Queensland),	   and	   so	   was	   not	   included	   in	   the	  initial	  expression	  analysis	  undertaken	  here.	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Figure	   3.1:	   Representative	   profiles	   of	   LPS-­‐regulated	   expression	   of	   “human-­‐
specific”	   TLR4	   target	   genes	   in	   human	   versus	   mouse	   macrophages	   from	  
MacGate.	  	  Relative	   expression	   of	   human	   and	   mouse	   genes,	   (A)	   RNF144B,	   (B)	   TMEM140,	   (C)	  
NKG7,	  (D)	  BATF3	  and	  (E)	  G0S2,	  was	  determined	  by	  custom	  microarray	  in	  response	  to	  LPS	  over	   the	   indicated	   time	   course	   in	  HMDM	  and	   two	  primary	  mouse	  macrophage	  populations	   (BMM	   and	   TEPM	   from	   C57Bl/6	   mice).	   Data	   (mean+SEM)	   shows	   fold	  change	   relative	   to	   unstimulated	   controls	   and	   is	   combined	   from	   3-­‐4	   independent	  experiments.	   These	   data,	   extracted	   from	   the	  MacGate	   database,	   are	   derived	   from	   a	  previously	  published	  dataset	  (Schroder	  et	  al.,	  2012a).	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Figure	  3.2:	  qPCR	  analysis	  of	  LPS-­‐regulated	  expression	  of	  “human-­‐specific”	  TLR4	  
target	  genes	  in	  human	  versus	  mouse	  macrophages.	  	  Relative	  mRNA	   levels	   of	   human	  and	  mouse	   genes,	   (A)	  RNF144B,	   (B)	  TMEM140,	   (C)	  
NKG7,	  (D)	  BATF3	  and	  (E)	  G0S2,	  was	  determined	  by	  qPCR	  for	  the	  indicated	  number	  of	  biological	   replicate	   experiments	   across	   HMDM	   and	   various	  mouse	   cell	   populations	  (BMM	   from	   C57Bl/6	   mice,	   TEPM	   from	   C57Bl/6	   mice,	   mixed	   splenocytes,	   IFNγ-­‐primed	  BMM,	  BMM	   from	  BALB/c	  mice	   and	  RAW264.7	   cells).	  mRNA	   levels	   for	   each	  gene	  were	  analysed	  following	  treatment	  with	  10	  ng/mL	  LPS	  over	  the	  indicated	  time	  course.	  Data	  (mean+SEM)	  shows	  fold	  change	  relative	  to	  unstimulated	  controls	  and	  is	  combined	  from	  3-­‐5	   independent	  experiments	  (except	   for	  BALB/c	  RNA,	  where	  n	  =	  2	  and	  error	  bars	  indicate	  range).	  *P≤0.05;	  **P≤0.01;	  by	  one-­‐way	  Kruskal-­‐Wallis	  ANOVA	  followed	  by	  Bonferroni-­‐Dunn’s	  Multiple	  Comparison	  test.	  N.D	  indicates	  not	  detected.	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The	  five	  candidate	  genes	  showed	  robust	  up-­‐regulation	  in	  response	  to	  LPS	  in	  HMDM	  (Figure	   3.2),	  with	  broadly	  similar	  expression	  profiles	  as	   found	   through	   the	  custom	  microarray	  (Figure	  3.1).	  RNF144B,	  NKG7,	  and	  G0S2	  were	  not	  regulated	  or	  modestly	  regulated	   by	   LPS	   in	   all	   mouse	   macrophage	   populations	   examined.	   BATF3	   was	  upregulated	   in	   BALB/c	   BMM	   at	   24	   h	   in	   response	   to	   LPS,	   however	   showed	   low	  expression	   in	   all	   other	   mouse	   macrophage	   populations.	   TMEM140	   was	   down-­‐regulated	  at	  2	  h	  post	  LPS	  followed	  by	  modest	  up-­‐regulation	  in	  all	  mouse	  macrophage	  populations,	  except	  for	  IFNγ	  primed	  C57Bl/6	  BMM,	  which	  had	  almost	  equivalent	  up-­‐regulation	  of	  TMEM140	  as	   compared	   to	  HMDM.	  Although	   certain	   genes	   (NKG7	   and	  
G0S2)	  were	  not	  detectable	  in	  BMM,	  the	  efficacy	  of	  all	  gene	  primers	  was	  confirmed	  by	  performing	   qPCR	   on	  mixed	   human	   or	  mixed	  mouse	   cell	   populations	   alongside	   the	  analysis	   as	   positive	   controls.	   Hence,	   the	   analysis	   revealed	   that	   all	   genes	   were	  divergently	   regulated	   in	   HMDM	   versus	   TEPM	   and	   BMM,	   consistent	   with	   the	  microarray	   data.	   RNF144B,	   NKG7,	   and	   G0S2	   were	   not	   regulated	   in	   any	   mouse	  macrophage	  populations	  examined,	  suggesting	  that	  these	  particular	  genes	  were	  most	  likely	   to	   represent	  genes	  displaying	   true	  human	  versus	  mouse	  differences	   in	  TLR4-­‐regulated	  expression.	  	  	  Subsequently,	  functional	  analysis	  focused	  on	  the	  above	  three	  genes	  that	  showed	  most	  divergent	  regulation	  between	  human	  and	  mouse	  macrophages	  (RNF144B,	  NKG7	  and	  
G0S2).	   Genes	  were	   also	   selected	   for	   further	   analysis	   based	   on	   diversity	   of	   function	  (RNF144B	  and	  G0S2	  for	  potential	  roles	  in	  signalling	  and	  cell	  cycle	  regulation,	  NKG7	  as	  a	  novel	  transmembrane	  protein).	  SLC41A2	  was	  also	  included	  as	  a	  representative	  of	  an	  ion	   transport	   gene	   that	   was	   divergently	   regulated	   between	   human	   and	   mouse	  macrophages.	  	  
3.2.2.	  	   siRNA-­‐mediated	  knockdown	  of	  selected	  TLR4	  target	  genes	  does	  not	  impact	  
intracellular	   survival	   of	   E.	   coli	   or	   S.	   Typhimurium	   in	   primary	   human	  
macrophages	  The	   human-­‐specific	   expression	   of	   candidate	   novel	   genes	   in	   response	   to	   LPS	   as	  described	   above,	   suggested	   potentially	   important	   roles	   in	   human	   macrophage	  responses	   to	   Gram-­‐negative	   pathogens.	   Therefore	   the	   genes	   chosen	   for	   functional	  analysis,	   RNF144B,	   SLC41A2,	   NKG7	   and	   G0S2	   were	   analysed	   by	   conducting	   siRNA-­‐
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mediated	  gene	  knockdown	  in	  HMDM,	  followed	  by	  infection	  assays	  with	  E.	  coli	  and	  S.	  Typhimurium	   to	   examine	   intracellular	   survival.	   Experiments	   were	   conducted	   in	  HMDM	  as	  Dr.	  Nilesh	  Bokil	  had	  previously	  established	  the	  method	  of	  gene	  knockdown	  in	  HMDM	  using	  electroporation	  with	  siRNA.	  As	  primary	  human	  macrophages,	  HMDM	  are	   also	   functionally	   more	   relevant	   and	   representative	   of	   human	   macrophage	  responses	   in	   comparison	   to	   cell	   lines	   such	   as	   THP-­‐1,	   which	   are	   an	   immortalised	  monocytic	  cell	  line	  derived	  from	  an	  acute	  monocytic	  leukemia	  patient	  (Tsuchiya	  et	  al.,	  1980)	  and	  require	  stimulation	  with	  PMA	  for	  differentiation	  into	  macrophages.	  	  	  Initial	   experiments	   to	   optimise	   gene	   knockdown	   and	   subsequent	   infection	   assays	  were	   performed	   by	   varying	   the	   concentration	   of	   siRNA,	   time	   of	   infection	   following	  gene	  knockdown,	  and	  multiplicity	  of	  infection	  (MOI),	  or	  number	  of	  bacteria	  per	  cell,	  to	   allow	   for	   reliable	   assessment	   of	   bacterial	   loads.	   From	   these	   analyses,	  electroporation	  with	  0.25	  μM	  of	  pooled	  siRNA	  was	   found	  to	  be	  sufficient	   to	  achieve	  efficient	   knockdown	   of	  mRNA	   expression	   at	   basal	   and	   LPS-­‐inducible	   levels	   for	   the	  four	   genes	   (Figure	   3.3).	   Within	   the	   same	   experiments	   that	   had	   confirmed	   gene	  knockdown,	  HMDM	  were	  rested	  for	  6	  h	  following	  electroporation,	  then	  treated	  with	  10	  ng/mL	  LPS,	  or	  infected	  with	  either	  E.	  coli	  or	  S.	  Typhimurium	  at	  an	  MOI	  100	  for	  16	  h.	   This	   acute	   timepoint	   of	   6	   h	   post-­‐transfection	  with	   siRNAs	  was	   chosen	   to	   ensure	  that	   siRNAs	   would	   still	   be	   present	   at	   sufficient	   levels	   to	   suppress	   LPS-­‐inducible	  mRNA	   expression	   of	   target	   genes.	   The	   effect	   of	   gene	   knockdown	   on	   viability	   of	  bacterially-­‐infected	  HMDM	  was	  first	  assessed	  by	  examining	  LDH	  release	  into	  culture	  supernatants.	   This	   was	   because	   if	   cell	   viability	   was	   altered,	   then	   data	   would	   be	  difficult	   to	   interpret.	  By	  quantifying	  LDH	  levels	   in	   lysates	  of	  HMDM	  from	  within	  the	  same	   experiment,	   LDH	   release	   into	   culture	   supernatants	   was	   determined	   as	   a	  percentage.	   No	   negative	   impact	   on	   cell	   viability	   of	   infected	   HMDM	   was	   observed	  following	  gene	  knockdown	  (Figure	  3.4).	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Figure	  3.3:	   siRNA-­‐mediated	  knockdown	  of	  RNF144B,	  SLC41A2,	  NKG7	   and	  G0S2	  
in	  primary	  human	  macrophages.	  	  HMDM	  were	  electroporated	  with	  no	  siRNA,	  or	  with	  pooled	  siRNAs	  for	  (A)	  RNF144B,	  
(B)	  SLC41A2,	  (C),	  NKG7	  or	  (D)	  G0S2	  at	  a	  concentration	  of	  0.25	  µM.	  Cells	  were	  allowed	  to	  recover	  for	  6	  h,	  then	  treated	  with	  or	  without	  100	  ng/mL	  LPS	  for	  16	  h,	  after	  which	  time	   RNA	  was	   prepared	   and	   relative	  mRNA	   expression	   of	   the	   indicated	   genes	  was	  quantified	   by	   qPCR.	   Data	   (mean+SEM)	   shows	   fold	   change	   relative	   to	   unstimulated	  controls,	  combined	  from	  3	  independent	  experiments.	  *P≤0.05;	  **P≤0.01;	  by	  one-­‐way	  ANOVA	  followed	  by	  Dunnett’s	  Multiple	  Comparison	  test.	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Figure	  3.4:	  Knockdown	  of	  RNF144B,	  SLC41A2,	  NKG7	  or	  G0S2,	  followed	  by	  E.	  coli	  
or	   S.	   Typhimurium,	   infection	   does	   not	   impact	   viability	   of	   primary	   human	  
macrophages.	  	  HMDM	  were	  electroporated	  with	  no	  siRNA,	  or	  with	  pooled	  siRNAs	  for	  the	  indicated	  genes,	   as	   per	   Figure	   3.3.	   After	   6	   h,	   cells	   were	   infected	   with	   (A)	   E.	   coli	   or	   (B)	   S.	  Typhimurium	  at	  MOI	  100,	  for	  16	  h.	  Cell	  death	  was	  assessed	  using	  LDH	  release	  assays	  of	   collected	   culture	   supernatants.	   Data	   (mean+SEM)	   are	   combined	   from	   3	  independent	  experiments.	  	  	  Intracellular	  survival	  of	  E.	  coli	  and	  S.	  Typhimurium	  was	  analysed	  at	  2	  and	  16	  h	  post-­‐infection	  by	  plating	  cell	  lysates	  and	  counting	  colony-­‐forming	  units	  (cfu)	  per	  millilitre	  (cfu/mL).	  Survival	  was	  assayed	  at	  2	  h	  post-­‐infection	  to	  determine	  the	  impact	  of	  gene	  knockdown	   on	   bacterial	   uptake	   and/or	   acute	   antimicrobial	   responses,	   and	   at	   16	   h	  post-­‐infection	   to	   examine	   effects	   on	   inducible	  macrophage	   antimicrobial	   functions.	  Intracellular	   survival	   of	   both	   E.	   coli	   and	   S.	   Typhimurium	   was	   reduced	   at	   16	   h	   in	  comparison	   to	   2	   h	   post-­‐infection	   in	   cells	  without	   gene	   knockdown,	   consistent	  with	  activation	  of	  macrophage	  antimicrobial	  responses	  to	  combat	  infection.	  In	  accordance	  with	   the	   ability	   of	   S.	   Typhimurium	   to	   subvert	   host	   antimicrobial	   mechanisms,	  intracellular	  survival	  of	  S.	  Typhimurium	  at	  16	  h	  post-­‐infection	  was	  higher	  than	  E.	  coli,	  which	   was	   more	   effectively	   cleared	   within	   HMDM.	   However,	   no	   difference	   in	  intracellular	  pathogen	  survival	  was	  seen	  at	  either	  2	  h	  or	  16	  h	  post-­‐infection	  in	  cells	  transfected	  with	  pooled	  siRNAs	  against	  the	  four	  genes	  examined,	  as	  compared	  to	  cells	  transfected	  with	  no	   siRNA	   (Figure	   3.5).	   These	   findings	   suggest	   that	   knockdown	  of	  the	   novel	   candidate	   genes	   had	   no	   effect	   on	   bacterial	   uptake	   and/or	   macrophage	  antimicrobial	  responses.	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Figure	   3.5:	   Knockdown	   of	  RNF144B,	   SLC41A2,	  NKG7	   or	  G0S2	   does	   not	   impact	  
intracellular	  survival	  of	  E.	  coli	  or	  S.	  Typhimurium	  within	  HMDM.	  	  HMDM	   cells	   were	   transfected	   with	   no	   siRNA,	   or	   with	   pooled	   siRNAs	   against	   each	  gene	   as	   labelled.	   Infection	  with	   (A)	   E.	   coli	  or	   (B)	   S.	  Typhimurium	   at	  MOI	   100	  was	  performed	  6	  h	  following	  siRNA	  transfection,	  and	  intracellular	  survival	  was	  assayed	  at	  2	   and	   16	   h	   post-­‐infection.	   Data	   (mean+SEM)	   are	   combined	   from	   3	   independent	  experiments,	  and	  are	  presented	  as	  fold	  change	  relative	  to	  the	  no	  siRNA	  control	  at	  2	  h.	  
(C)	  and	  (D)	  Representative	  experiments	  showing	  intracellular	  survival	  of	  E.	  coli	  (C)	  and	   S	   Typhimurium	   (D)	   as	   cfu/mL.	   Data	   (mean+range)	   show	   technical	   replicates	  from	  1	  experiment.	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3.2.3.	  	   Effect	   of	   siRNA-­‐mediated	   gene	   knockdown	   on	   cytokine	   and	   chemokine	  
release	  from	  primary	  human	  macrophages.	  To	  determine	  whether	  gene	  knockdown	  of	  the	  four	  candidate	  genes	  had	  an	  effect	  on	  inflammatory	   pathways,	   cytokine	   and	   chemokine	   levels	   were	   assessed	   using	  supernatants	   obtained	   from	   the	   experiments	   described	   above.	   Supernatants	   were	  collected	   at	   16	   h	   post-­‐treatment	  with	   LPS	   or	   post-­‐infection	  with	   either	  E.	  coli	   or	  S.	  Typhimurium	   and	   analysed	   by	   ELISA	   for	   levels	   of	   the	   cytokines	   IL-­‐6	   and	   TNFα,	   as	  well	  as	  the	  chemokines	  CCL20	  and	  CXCL13	  (Figure	  3.6	  to	  Figure	  3.9).	  IL-­‐6	  and	  TNFα	  cytokines	   were	   chosen	   as	   representatives	   of	   classical	   pro-­‐inflammatory	   cytokines	  released	  from	  macrophages,	  whilst	  the	  CCL20	  and	  CXCL13	  chemokines	  were	  chosen	  as	   these	   chemokines	   are	   LPS-­‐inducible	   in	   human	   macrophages	   but	   not	   in	   mouse	  macrophages	  (Schroder	  et	  al.,	  2012a).	  	  	  As	   expected,	   treatment	  with	   LPS	   or	   bacterial	   infection	   promoted	   secretion	   of	   IL-­‐6,	  TNFα,	   CCL20	   and	  CXCL13	   in	   comparison	   to	   unstimulated	   cells.	  Higher	   induction	  of	  cytokine	  and	  chemokine	  secretion	  was	  also	  observed	  when	  cell	  were	  infected	  with	  E.	  
coli,	   as	   compared	   to	   S.	  Typhimurium.	  However,	   siRNA-­‐mediated	   knockdown	   of	   the	  four	  genes	  had	  no	  consistent	  effect	  on	  inducible	  IL-­‐6,	  TNFα	  and	  CCL20	  secretion	  from	  HMDM.	   Knockdown	   of	   RNF144B	   modestly	   increased	   secreted	   CXCL13	   levels	   in	  HMDM	  treated	  with	  LPS	  or	  infected	  with	  E.	  coli	  (Figure	  3.9).	  This	  effect	  was	  observed	  in	   all	   three	   experiments	   conducted,	   however	   the	   effect	   was	   not	   statistically	  significant.	  This	  may	  relate	  to	  donor-­‐to-­‐donor	  variation	  in	  the	  magnitude	  of	  the	  effect	  on	  CXCL13	  secretion.	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Figure	   3.6:	   Knockdown	   of	  RNF144B,	   SLC41A2,	  NKG7	   or	  G0S2	   does	   not	   impact	  
inducible	  IL-­‐6	  secretion	  from	  HMDM.	  	  HMDM	  were	  transfected	  with	  no	  siRNA,	  or	  with	  pooled	  siRNAs	  against	  each	  gene	  as	  labelled.	   Treatment	   with	   100	   ng/mL	   LPS	   (A,	   C)	   or	   infection	   with	   E.	   coli	   or	   S.	  Typhimurium	   at	  MOI	   100	   (B,	   D)	  was	   performed	   6	   h	   following	   siRNA	   transfection.	  Supernatants	   were	   harvested	   16	   h	   post-­‐treatment	   or	   –infection,	   and	   IL-­‐6	  concentrations	   were	   determined	   by	   ELISA.	   (A)	   and	   (B)	   Data	   (mean+SEM)	   are	  combined	  from	  3	  independent	  experiments,	  and	  are	  presented	  as	  fold	  change	  relative	  to	  the	  no	  siRNA	  control	   for	  LPS	  treatment	  (A)	  or	   the	  no	  siRNA	  control	   for	   infection	  with	  S.	  Typhimurium	  (B).	  (C)	  and	  (D)	  Representative	  experiments	  showing	  secreted	  IL-­‐6	   levels	   in	   ng/mL,	   following	   LPS	   treatment	   or	   bacterial	   infection.	   Data	  (mean+range)	   show	   technical	   replicates	   from	   1	   experiment.	   N.D	   indicates	   not	  detected.	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Figure	   3.7:	   Knockdown	   of	  RNF144B,	   SLC41A2,	  NKG7	   or	  G0S2	   does	   not	   impact	  
inducible	  TNFα	  secretion	  from	  HMDM.	  	  HMDM	  were	  transfected	  with	  no	  siRNA,	  or	  with	  pooled	  siRNAs	  against	  each	  gene	  as	  labelled.	   Treatment	   with	   100	   ng/mL	   LPS	   (A,	   C)	   or	   infection	   with	   E.	   coli	   or	   S.	  Typhimurium	   at	  MOI	   100	   (B,	   D)	  was	   performed	   6	   h	   following	   siRNA	   transfection.	  Supernatants	   were	   harvested	   16	   h	   post-­‐treatment	   or	   –infection,	   and	   TNFα	  concentrations	   were	   determined	   by	   ELISA.	   (A)	   and	   (B)	   Data	   (mean+SEM)	   are	  combined	  from	  3	  independent	  experiments,	  and	  are	  presented	  as	  fold	  change	  relative	  to	  no	  siRNA	  control	  for	  LPS	  treatment	  (A)	  or	  the	  no	  siRNA	  control	  for	  infection	  with	  S.	  Typhimurium	  (B).	  (C)	  and	  (D)	  Representative	  experiments	  showing	  secreted	  TNFα	  levels	   in	  ng/mL,	   following	  LPS	   treatment	  or	  bacterial	   infection.	  Data	   (mean+range)	  show	  technical	  replicates	  from	  1	  experiment.	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Figure	   3.8:	   Knockdown	   of	  RNF144B,	   SLC41A2,	  NKG7	   or	  G0S2	   does	   not	   impact	  
inducible	  CCL20	  secretion	  from	  HMDM.	  	  HMDM	  were	  transfected	  with	  no	  siRNA,	  or	  with	  pooled	  siRNAs	  against	  each	  gene	  as	  labelled.	   Treatment	   with	   100	   ng/mL	   LPS	   (A,	   C)	   or	   infection	   with	   E.	   coli	   or	   S.	  Typhimurium	   at	  MOI	   100	   (B,	   D)	  was	   performed	   6	   h	   following	   siRNA	   transfection.	  Supernatants	   were	   harvested	   16	   h	   post-­‐treatment	   or	   –infection,	   and	   CCL20	  concentrations	   were	   determined	   by	   ELISA.	   (A)	   and	   (B)	   Data	   (mean+SEM)	   are	  combined	  from	  3	  independent	  experiments,	  and	  are	  presented	  as	  fold	  change	  relative	  to	  no	  siRNA	  control	  for	  LPS	  treatment	  (A)	  or	  the	  no	  siRNA	  control	  for	  infection	  with	  S.	  Typhimurium	  (B).	  (C)	  and	  (D)	  Representative	  experiments	  showing	  secreted	  CCL20	  levels	   in	  ng/mL,	   following	  LPS	   treatment	  or	  bacterial	   infection.	  Data	   (mean+range)	  show	  technical	  replicates	  from	  1	  experiment.	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Figure	   3.9:	   Knockdown	   of	   RNF144B	   modestly	   increases	   LPS-­‐	   and	   E.	   coli-­‐
inducible	  CXCL13	  secretion	  from	  HMDM.	  HMDM	  were	  transfected	  with	  no	  siRNA,	  or	  with	  pooled	  siRNAs	  against	  each	  gene	  as	  labelled.	   Treatment	   with	   100	   ng/mL	   LPS	   (A,	   C)	   or	   infection	   with	   E.	   coli	   or	   S.	  Typhimurium	   at	  MOI	   100	   (B,	   D)	  was	   performed	   6	   h	   following	   siRNA	   transfection.	  Supernatants	   were	   harvested	   16	   h	   post-­‐treatment	   or	   –infection,	   and	   CXCL13	  concentrations	   were	   determined	   by	   ELISA.	   (A)	   and	   (B)	   Data	   (mean+SEM)	   are	  combined	  from	  3	  independent	  experiments,	  and	  are	  presented	  as	  fold	  change	  relative	  to	  no	  siRNA	  control	  for	  LPS	  treatment	  (A)	  or	  the	  no	  siRNA	  control	  for	  infection	  with	  S.	  Typhimurium	  (B).	  (C)	  and	  (D)	  Representative	  experiments	  showing	  secreted	  CXCL13	  levels	   in	  ng/mL,	   following	  LPS	   treatment	  or	  bacterial	   infection.	  Data	   (mean+range)	  show	  technical	  replicates	  from	  1	  experiment.	  N.D	  indicates	  not	  detected.	  	  	  	  	  	  	  
Human	  versus	  mouse	  differences	  in	  TLR4-­‐regulated	  gene	  expression	  
	   80	  	  
3.2.4.	  	   Silencing	   of	   RNF144B	   expression	   attenuates	   NLRP3-­‐mediated	  
inflammasome	  responses	  in	  human	  primary	  macrophages.	  As	   inflammasome	   responses	   are	   an	   important	   component	   of	   antimicrobial	   activity,	  potential	   roles	   for	   the	   four	   candidate	   genes	   in	   inflammasome	   activation	  were	   next	  investigated.	   Stimulation	   of	   the	   NLRP3	   inflammasome	   was	   chosen	   for	   preliminary	  assays	   on	   effects	   of	   gene	   knockdown	   on	   inflammasome	   responses	   since	   it	   is	   a	  commonly	  studied	  inflammasome	  with	  well-­‐established	  readouts	  for	  activation,	  such	  as	  secretion	  of	  IL-­‐1β	  and	  activation	  of	  pyroptosis.	  Gene	  knockdown	  was	  conducted	  in	  HMDM	  as	  described	  previously.	   In	  addition	  to	  the	   four	  candidate	  genes,	  NLRP3	  was	  knocked	  down	  as	  a	  positive	  control	  for	  attenuation	  of	  inflammasome	  activation.	  24	  h	  post-­‐electroporation	   with	   siRNA,	   HMDM	  were	   primed	   with	   10	   ng/mL	   LPS	   for	   4	   h	  then	   treated	   with	   10	   μM	   nigericin	   for	   3	   h	   to	   activate	   the	   NLRP3	   inflammasome.	  Supernatants	  were	  collected	  for	  analysis	  of	  IL-­‐1β	  cytokine	  secretion	  as	  an	  indication	  of	   NLRP3	   inflammasome	   activation.	   Levels	   of	   IL-­‐6	   and	   TNFα	   cytokines	   were	   also	  analysed	  as	  positive	  controls	  for	  HMDM	  responses	  towards	  LPS	  priming.	  LDH	  assays	  were	  conducted	  with	  collected	  supernatants	  to	  analyse	  effect	  of	  gene	  knockdown	  on	  activation	  of	  pyroptosis	  downstream	  of	  NLRP3	  inflammasome	  activation.	  	  Gene	   knockdown	   of	   RNF144B	   was	   found	   to	   significantly	   reduce	   IL-­‐1β	   cytokine	  release	   in	   HMDM,	  while	   knockdown	   of	   SLC41A2,	  NKG7	   and	  G0S2	   had	   no	   effect.	   As	  expected,	   NLRP3	   knockdown	   also	   significantly	   reduced	   IL-­‐1β	   cytokine	   release	  (Figure	   3.10).	   There	  was	  no	   effect	   of	   gene	   knockdown	  on	   levels	   of	   IL-­‐6	   and	  TNFα	  cytokine	  secretion,	  supporting	  results	  described	  above	  that	  show	  that	  knockdown	  of	  these	   genes	   do	   not	   affect	   LPS	   responses	   in	   HMDM.	   As	   expected,	   NLRP3	   gene	  knockdown	  reduced	  pyroptosis	  as	  seen	  by	  LDH	  release	  (Figure	  3.11).	  Knockdown	  of	  
RNF144B	  also	  resulted	   in	  a	  slight	  (but	  not	  statistically	  significant)	  reduction	   in	  LDH	  release	   indicating	   that	  RNF144B	  knockdown	  may	  attenuate	  pyroptosis	  downstream	  of	  NLRP3	  inflammasome	  activation.	  However,	  electroporation	  of	  cells	  was	  observed	  to	  interfere	  with	  LDH	  release	  assays	  (low	  LDH	  levels,	  as	  compared	  to	  untransfected	  cells),	  thus	  compromising	  interpretation	  of	  these	  assays	  of	  pyroptotic	  cell	  death.	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Figure	  3.10:	  Knockdown	  of	  RNF144B	   reduces	   IL-­‐1β	  secretion	   following	  NLRP3	  
inflammasome	  activation	  in	  HMDM.	  	  HMDM	  were	  transfected	  with	  no	  siRNA,	  or	  with	  pooled	  siRNAs	  against	  each	  gene	  as	  labelled.	  24	  h	   following	  siRNA	   transfection,	   cells	  were	  primed	  with	  100	  ng/mL	  LPS	  for	   4	   h,	   then	   treated	   with	   10	   μM	   nigericin	   for	   3	   h	   to	   activate	   the	   NLRP3	  inflammasome.	  Supernatants	  were	  harvested	  and	  analysed	  for	  levels	  of	  secreted	  (A)	  IL-­‐1β,	   (B)	   TNFα	   and	   (C)	   IL-­‐6	   by	   ELISA.	   Data	   (mean+SEM)	   are	   combined	   from	   4	  independent	   experiments,	   and	   are	   presented	   as	   fold	   change	   relative	   to	   no	   siRNA	  control	  in	  cells	  treated	  with	  LPS	  and	  nigericin.	  *P≤0.05;	  **P≤0.01;	  by	  one-­‐way	  ANOVA	  followed	  by	  Dunnett’s	  Multiple	  Comparison	  test.	  N.D	  indicates	  not	  detected.	  	  	  
	  
Human	  versus	  mouse	  differences	  in	  TLR4-­‐regulated	  gene	  expression	  
	   82	  	  
	  
Figure	  3.11:	  Knockdown	  of	  RNF144B	  may	  attenuate	  pyroptosis	  following	  NLRP3	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3.2.5.	  	   LPS	   and	   S.	   Typhimurium-­‐regulated	   expression	   of	   RNF144B	   in	   PMA-­‐
differentiated	  THP-­‐1	  cells	  	  Given	   that	   RNF144B	   knockdown	   was	   affecting	   NLRP3	   inflammasome	   activation	   in	  HMDM,	   the	   analysis	  was	   expanded	   to	   look	   at	   the	   role	   of	  RNF144B	   in	   other	   human	  macrophage	   cell	   types	   to	   confirm	   that	   this	  was	  not	   a	   cell	   type-­‐specific	   effect.	   Thus,	  similar	   assays	   as	   described	   above	   were	   repeated	   using	   PMA-­‐differentiated	   THP-­‐1	  macrophages.	  	  qPCR	  analysis	  was	  first	  performed	  to	  examine	  LPS-­‐regulated	  expression	  of	  RNF144B	  in	  THP-­‐1	  cells.	  Monocytic	  THP-­‐1	  cells	  were	  differentiated	  into	  macrophages	  by	  48	  h	  treatment	  with	  30	  ng/mL	  PMA,	  rested	  for	  4	  h	  in	  PMA-­‐free	  media,	  then	  treated	  with	  10	  ng/mL	  LPS.	  Confirming	  the	  results	  obtained	  with	  HMDM,	  RNF144B	  was	  similarly	  upregulated	  by	  LPS	  in	  PMA-­‐differentiated	  THP-­‐1	  macrophages	  (Figure	  3.12A).	  PMA-­‐differentiated	   THP-­‐1	   cells	   were	   also	   infected	   with	   S.	   Typhimurium	   at	   MOI	   10	   to	  confirm	  that	  RNF144B	  expression	  was	  upregulated	  by	  whole	  Gram-­‐negative	  bacterial	  pathogens,	  which	  can	  present	  a	  diverse	  array	  of	  PAMPs.	  Again,	  RNF144B	  expression	  was	  upregulated	  upon	   infection	  with	  S.	  Typhimurium,	  with	  higher	   fold	   induction	  of	  expression	  from	  2	  to	  24	  h	  post	  infection	  in	  comparison	  to	  treatment	  with	  LPS	  (Figure	  
3.12B).	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Figure	  3.12:	  qPCR	  analysis	  of	  RNF144B	  expression	  in	  PMA-­‐differentiated	  THP-­‐1	  
cells	  in	  response	  to	  LPS	  and	  S.	  Typhimurium.	  THP-­‐1	  monocytic	  cells	  were	  differentiated	  into	  macrophages	  with	  30	  ng/mL	  PMA	  for	  48	  h	  then	  rested	  for	  4	  h	  in	  PMA-­‐free	  media.	  RNF144B	  mRNA	  expression	  was	  analysed	  following	  treatment	  with	  (A)	  10	  ng/mL	  LPS	  or	  infection	  with	  (B)	  S.	  Typhimurium	  at	  MOI	  10	  for	  the	  indicated	  time	  course.	  Data	  (mean+SEM)	  shows	  fold	  change	  relative	  to	  unstimulated	   controls	   combined	   from	   (A)	   3	   or	   (B)	   4	   independent	   experiments.	  *P≤0.05,	   **P≤0.01;	   by	   one-­‐way	  ANOVA	   followed	   by	  Dunnett’s	  Multiple	   Comparison	  test.	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3.2.6.	  	   Silencing	   of	   RNF144B	   expression	   attenuates	   NLRP3-­‐mediated	  
inflammasome	  responses	  in	  PMA-­‐differentiated	  THP-­‐1	  macrophages.	  Stimulation	  of	   the	  NLRP3	   inflammasome	  following	  gene	  knockdown	  was	  conducted	  in	   PMA-­‐differentiated	   THP-­‐1	  macrophages,	   using	   similar	  methodology	   to	   that	   used	  for	   HMDM,	   to	   determine	   whether	   RNF144B	   knockdown	   also	   affected	   NLRP3	  inflammasome	   activation	   in	   these	   cells.	   As	   observed	   with	   HMDM,	   RNF144B	   and	  
NLRP3	  knockdown	  in	  PMA-­‐differentiated	  THP-­‐1	  macrophages	  resulted	  in	  reduced	  IL-­‐1β	  cytokine	   levels,	  whereas	  knock-­‐down	  of	  SLC41A2,	  NKG7	  or	  G0S2	  had	  no	  obvious	  effect.	   The	   effect	   was	   specific,	   since	   TNFα	   cytokine	   release	   was	   unaffected	   by	  
RNF144B	  or	  NLRP3	  silencing	  (Figure	  3.13).	  In	  these	  experiments,	  the	  effect	  of	  NLRP3	  knockdown	   was	   more	   pronounced	   than	   was	   observed	   for	   RNF144B	   knockdown.	  Again,	  NLRP3-­‐stimulated	  cells	  showed	  a	  trend	  for	  reduced	  pyroptosis	  upon	  RNF144B	  or	  NLRP3	  knockdown,	  however	  as	  mentioned	  earlier,	  pyroptotic	  death	  as	  analysed	  by	  LDH	   release	  was	   compromised	   by	   electroporation,	   with	   low	   LDH	   release	   obtained	  (Figure	  3.14).	  	  	  Thus,	  RNF144B	  knockdown	  attenuated	  NLRP3-­‐mediated	  IL-­‐1β	  release	  in	  both	  HMDM	  and	   PMA-­‐differentiated	   THP-­‐1	   macrophages.	   These	   data	   therefore	   suggest	   that	  
RNF144B	  has	  a	  role	  in	  regulation	  of	  inflammasome	  responses	  in	  human	  macrophages.	  Subsequent	   study	   to	   address	   the	   mechanism(s)	   by	   which	   RNF144B	   regulates	  inflammasome	  responses	  was	  pursued	  in	  Chapter	  4.	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Figure	  3.13:	  Knockdown	  of	  RNF144B	  reduces	  IL-­‐1β	  secretion	  following	  NLRP3	  
inflammasome	  activation	  in	  PMA-­‐differentiated	  THP-­‐1	  cells.	  	  THP-­‐1	  monocytic	  cells	  were	  differentiated	  into	  macrophages	  with	  30	  ng/mL	  PMA	  for	  48	  h.	  Cells	  were	  transfected	  with	  no	  siRNA,	  or	  with	  pooled	  siRNAs	  against	  each	  gene	  as	  labelled,	  differentiated	  with	  30	  ng/mL	  PMA	  for	  another	  24	  h,	  then	  rested	  in	  PMA-­‐free	  media	  for	  4	  h.	  THP-­‐1	  macrophages	  were	  primed	  with	  100	  ng/mL	  LPS	  for	  4	  h	  then	  treated	   with	   10	   μM	   nigericin	   for	   3	   h	   to	   activate	   the	   NLRP3	   inflammasome.	  Supernatants	  were	  harvested	  and	  analysed	   for	   levels	  of	   secreted	  (A)	   IL-­‐1β	  and	  (B)	  TNFα	  by	   ELISA.	  Data	   (mean+SEM)	   are	   combined	   from	  3	   independent	   experiments,	  and	   are	   presented	   as	   fold	   change	   relative	   to	   the	   no	   siRNA	   control	   for	   cells	   treated	  with	  LPS	  plus	  nigericin.	  (C-­‐D)	  Representative	  experiments	  showing	  levels	  of	  (C)	   IL-­‐1β	   and	   (D)	   TNFα	   in	   ng/mL.	   Data	   (mean+range)	   show	   technical	   replicates	   from	   1	  experiment.	   **P≤0.01;	   by	   one-­‐way	   ANOVA	   followed	   by	   Dunnett’s	   Multiple	  Comparison	  test.	  N.D	  indicates	  not	  detected.	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Figure	   3.14:	   Knockdown	   of	   RNF144B	   may	   attenuate	   pyroptosis	   following	  
NLRP3	  inflammasome	  activation	  in	  PMA-­‐differentiated	  THP-­‐1	  cells.	  	  THP-­‐1	  monocytic	  cells	  were	  differentiated	  into	  macrophages	  with	  30	  ng/mL	  PMA	  for	  48	  h.	  Cells	  were	  transfected	  with	  no	  siRNA,	  or	  with	  pooled	  siRNA	  at	  a	  concentration	  of	   0.25	   µM	   against	   each	   gene	   as	   labelled,	   differentiated	   with	   30	   ng/mL	   PMA	   for	  another	   24	   h,	   then	   rested	   in	   PMA-­‐free	   media	   for	   4	   h.	   THP-­‐1	   macrophages	   were	  primed	  with	   100	   ng/mL	   LPS	   for	   4	   h	   then	   treated	  with	   10	   μM	   nigericin	   for	   3	   h	   to	  activate	   the	   NLRP3	   inflammasome.	   Supernatants	   were	   harvested	   and	   analysed	   for	  LDH	  release	  (calculated	  as	  a	  percentage	  of	  total	  cellular	  LDH).	  Data	  (mean+SEM)	  are	  combined	  from	  3	  independent	  experiments,	  and	  are	  presented	  as	  fold	  change	  relative	  to	  the	  no	  siRNA	  control	  for	  cells	  treated	  with	  LPS	  plus	  nigericin.	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3.3	  Discussion	  
3.3.1.	  	   Divergent	   regulation	   of	   TLR4	   target	   genes	   in	   human	   versus	   mouse	  
macrophages	  populations.	  qPCR	   analysis	   of	   LPS-­‐induced	   expression	   of	   the	   five	   selected	   candidate	   genes	  (RNF144B,	   TMEM140,	   NKG7,	   BATF3	   and	   G0S2)	   matched	   the	   expression	   patterns	  obtained	  from	  the	  initial	  expression	  profiling	  study	  conducted	  by	  custom	  microarray	  (Schroder	   et	   al.,	   2012a).	   The	   analysis	   was	   expanded	   to	   include	   a	   panel	   of	   diverse	  mouse	  macrophage	   cell	   types	   to	   ensure	   differences	   in	   gene	   expression	  most	   likely	  reflected	   true	   species	   differences,	   rather	   than	   cell	   type	   heterogeneity.	   Three	   of	   the	  five	  candidate	  genes	  (RNF144B,	  NKG7	  and	  G0S2)	  showed	  dramatically	  selective	  LPS-­‐induced	   up-­‐regulation	   in	   human	   but	   not	   mouse	   macrophages,	   suggesting	   that	   the	  observed	  differences	   in	   regulation	  were	   indeed	   likely	   to	   reflect	   species	   differences.	  The	  other	  candidate	  genes,	  BATF3	  and	  TMEM140,	  were	  regulated	  in	  both	  human	  and	  mouse	   macrophages,	   but	   with	   different	   timing	   in	   regulation	   and	   only	   in	   selected	  mouse	   macrophage	   populations.	   This	   suggests	   that	   species-­‐	   and/or	   cell	   type-­‐dependent	   differences	   may	   account	   for	   the	   differential	   regulation	   of	   these	   genes.	  
SLC41A2,	   which	   was	   also	   selected	   for	   functional	   analysis,	   behaved	   like	   RNF144B,	  
NKG7	   and	   G0S2	   in	   being	   regulated	   only	   in	   human	   macrophages	   (Dr.	   Nilesh	   Bokil,	  unpublished).	  Thus,	  4	  of	  the	  6	  selected	  genes	  that	  were	  LPS-­‐regulated	  in	  HMDM	  were	  not	  significantly	  regulated	  in	  any	  of	  the	  mouse	  macrophage	  populations	  examined.	  	  The	  data	  presented	   for	   validation	  of	   human-­‐specific	   LPS-­‐regulated	   gene	   expression	  focused	   only	   on	   HMDM	   as	   cells	   representative	   of	   human	   macrophages.	   However,	  follow	  up	  studies	  in	  PMA-­‐differentiated	  THP-­‐1	  macrophages	  confirmed	  that	  RNF144B	  was	   also	   LPS-­‐regulated	   in	   these	   cells,	   and	   this	   gene	  was	   also	   LPS-­‐inducible	   in	   GM-­‐CSF-­‐differentiated	  human	  macrophages	  (see	  Appendix	  1,	  Supplementary	  Figure	  1	  and	  Chapter	   6,	   Section	   6.2.3).	  However,	   some	  preliminary	  analyses	   indicated	   that	  not	  all	  of	  the	  genes	  examined	  were	  consistently	  LPS-­‐regulated	  in	  PMA-­‐differentiated	  THP-­‐1	  cells.	  This	  may	  be	  explained	  by	  the	  fact	  that	  THP-­‐1	  cells	  are	  an	  immortalised	  monocytic	  cell	  line	  with	  potential	  genetic	  abnormalities.	  Interestingly,	  further	  studies	  on	  RNF144B	  revealed	  that	  it	  is	  not	  only	  inducible	  by	  LPS	  but	  also	  inducible	  to	  a	  lesser	  extent	   by	   Poly	   (I:C)	   and	   imiquimod	   in	   HMDM	   (see	   Appendix	   1,	   Supplementary	  
Figure	  2).	  This	  is	  discussed	  further	  in	  Chapter	  6,	  Section	  6.2.2.	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3.3.2.	  	   Gene	   silencing	   screen	   fails	   to	   identify	   regulators	   of	   macrophage	  
antimicrobial	  responses.	  The	  initial	  hypothesis	  relating	  to	  the	  genes	  examined	  was	  that	  they	  would	  have	  some	  role	  in	  macrophage	  antimicrobial	  responses.	  E.	  coli	  and	  S.	  Typhimurium	  were	  chosen	  as	  microorganisms	   to	   investigate	   this	   hypothesis,	   as	   the	   particular	   strain	   of	  E.	   coli	  used	   (MG1655)	   is	   a	   non-­‐pathogenic	   K12	   strain	   that	   is	   effectively	   cleared	   by	  macrophages,	   while	   S.	   Typhimurium	   is	   a	   ‘professional’	   pathogen	   with	   evasion	  mechanisms	   to	   aid	   its	   survival	   within	   macrophages.	   Thus,	   use	   of	   both	   bacterial	  species	   might	   have	   provided	   insights	   regarding	   enhancement	   or	   subversion	   of	  antimicrobial	  responses.	  	  	  Although	  a	  system	  for	  efficient	  siRNA-­‐mediated	  knockdown	  of	  basal	  and	  LPS-­‐induced	  expression	  of	  individual	  genes	  was	  established,	  no	  effect	  on	  intracellular	  survival	  of	  S.	  Typhimurium	   and	   E.	   coli	   in	   HMDM	  was	   observed	   upon	   silencing	   individual	   genes.	  This	   suggests	   that	   the	   selected	   candidate	   genes	   were	   not	   involved	   in	   macrophage	  antimicrobial	   functions	   against	   either	   of	   the	   bacterial	   species	   examined.	  Nevertheless,	   since	   infection	   assays	   were	   conducted	   only	   6	   h	   following	   gene	  knockdown	  and	  intracellular	  survival	  was	  analysed	  at	  a	  maximum	  of	  16	  h	  following	  infection,	  it	  is	  possible	  that	  more	  time	  may	  be	  required	  following	  gene	  knockdown	  for	  an	  observable	  effect	  on	  bacterial	  survival.	   It	  would	  have	  been	  highly	  desirable	  to	  be	  able	   to	   examine	   protein	   levels	   to	   confirm	   that	   knockdown	   of	   mRNA	   resulted	   in	  reduced	   protein	   at	   specific	   time	   points	   post-­‐transfection,	   prior	   to	   performing	   the	  described	  functional	  assays.	  However,	  because	  the	  majority	  of	  genes	  examined	  were	  novel,	   reliable	  antibodies	  against	   the	  encoded	  proteins	  were	  generally	  not	  available	  at	   the	   time	   these	   studies	   were	   commenced.	   While	   an	   antibody	   for	   RNF144B	   was	  obtained	  and	  used	  for	  further	  experiments	  detailed	  in	  Chapter	  4,	  this	  antibody	  was	  observed	   to	   detect	   an	   additional	   protein	   band	   in	   LPS-­‐stimulated	   HMDM	   that	   may	  represent	   non-­‐specific	   protein	   detection,	   or	   a	   potential	   alternative	   isoform	   of	  RNF144B	   (see	   Appendix	   1,	   Supplementary	   Figure	   3	   and	   Chapter	   6,	   Section	  
6.2.4.2).	  Thus,	  in	  the	  future,	  these	  approaches	  could	  be	  revisited	  using	  more	  reliable	  and	   specific	   antibodies	   to	   determine	   conditions	   for	   optimal	   knockdown	   of	   protein	  expression,	   prior	   to	   examining	   potential	   roles	   in	   antimicrobial	   pathways.	   Another	  point	  to	  note	  is	  that	  only	  two	  species	  of	  Gram-­‐negative	  bacteria	  were	  examined,	  and	  it	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is	   possible	   that	   these	   genes	   have	   roles	   in	   responses	   to	   other	   bacterial	   pathogens	  and/or	   other	   classes	   of	   microorganism	   (e.g.	   viruses,	   fungi,	   parasites).	   This	   also	  warrants	  further	  investigation	  in	  the	  future.	  	  Secretion	  of	  the	  cytokines	  IL-­‐6	  and	  TNFα	  and	  the	  chemokines	  CCL20	  and	  CXCL13	  was	  highest	  from	  cells	  infected	  with	  E.	  coli,	  as	  compared	  to	  S.	  Typhimurium.	  Since	  E.	  coli	  is	  not	   able	   to	   evade	   antimicrobial	  mechanisms	   as	   effectively	   as	   S.	   Typhimurium,	   this	  might	  be	  an	  explanation	   for	   the	  higher	  cytokine	  and	  chemokine	  secretion	  observed	  upon	  infection	  of	  HMDM	  with	  E.	  coli.	  However,	  inducible	  secretion	  of	  IL-­‐6,	  TNFα	  and	  CCL20	  was	   not	   obviously	   affected	   by	   silencing	   of	   any	   of	   the	   genes	   examined.	   This	  suggests	  that	  these	  genes	  have	  no	  roles	  in	  regulating	  expression	  of	  these	  cytokines,	  or	  that	  mRNA	  expression,	  but	  not	  protein	  expression,	  was	  effectively	  reduced	  by	  siRNA	  knockdown.	   However,	   a	   consistent,	   albeit	   not	   statistically	   significant,	   increase	   in	  CXCL13	  secretion	  upon	  RNF144B	  knockdown	  suggests	   that	  expression	  of	  RNF144B	  protein	  was	  at	  least	  effectively	  reduced.	  CXCL13	  is	  known	  to	  be	  produced	  by	  myeloid	  and	  plasmacytoid	  dendritic	  cells,	  stromal	  cells	  in	  secondary	  lymphoid	  tissue	  follicles	  and	  primed	  follicular	  B	  helper	  T	  cells	  (Carlsen	  et	  al.,	  2004;	  Vinuesa	  et	  al.,	  2005),	  and	  to	  act	  as	  a	  chemoattractant	  to	  recruit	  B	   lymphocytes	  to	  secondary	   lymphoid	  tissues	  (Legler	  et	  al.,	  1998).	  Deficiency	  of	  CXCL13	  or	   its	  receptor,	  CXCR5,	   in	  mice	  results	   in	  defective	   follicles	   including	   abnormal	   segregation	   of	   T	   and	   B	   lymphocytes,	   and	  reduced	   peripheral	   lymph	   nodes	   and	   Peyer’s	   patches,	   and	   aberrant	   CXCL13	  expression	   contributes	   to	   chronic	   inflammatory	   disease	   associated	   with	   human	  lymphoid	   neogenesis.	   There	   are	   currently	   no	   direct	   links	   between	   RNF144B	  expression	   and/or	   function	   and	   the	   CXCL13	   chemokine,	   however	   IL-­‐1β	   has	   been	  shown	  to	  induce	  production	  of	  CXCL13	  in	  bone	  marrow	  stromal	  cells	  and	  osteoblasts	  from	  osteoarthritis	  and	  post-­‐traumatic	  patients	   (Lisignoli	  et	  al.,	  2004).	  Thus,	   it	  may	  be	  that	  RNF144B-­‐mediated	  inhibition	  of	  CXCL13	  production	  is	  somehow	  linked	  to	  its	  role	  in	  regulation	  of	  IL-­‐1β.	  	  
3.3.3.	  	   RNF144B	  regulates	  IL-­‐1β	  release	  from	  human	  macrophages.	  Functional	   analysis	   of	   the	   4	   selected	   candidate	   genes	   in	   regulating	   inflammasome	  responses	   was	   performed	   by	   conducting	   siRNA-­‐mediated	   gene	   knockdown,	   then	  treating	  HMDM	   to	   stimulate	  NLRP3	   inflammasome	   activation.	   Release	   of	   IL-­‐1β	   and	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LDH	   was	   used	   as	   readouts	   for	   NLRP3	   inflammasome-­‐mediated	   pro-­‐inflammatory	  cytokine	   secretion	   and	   initiation	   of	   pyroptosis.	   Knockdown	   of	   SLC41A2,	   NKG7	   and	  
G0S2	   showed	   no	   effect,	   however	   RNF144B	   knockdown	   resulted	   in	   reduced	   IL-­‐1β	  secretion	  and	  a	  trend	  for	  reduced	  LDH	  release	  in	  both	  HMDM	  and	  PMA-­‐differentiated	  THP-­‐1	   macrophages.	   RNF144B	   knockdown	   had	   no	   effect	   on	   IL-­‐6	   and	   TNFα	   levels	  indicating	  that	  gene	  knockdown	  was	  not	  globally	  affecting	  the	  LPS	  response.	  Hence,	  there	   was	   some	   degree	   of	   specificity	   in	   regulation	   of	   inflammatory	   responses	   by	  
RNF144B.	  The	  reduction	  in	  LDH	  release	  suggested	  a	  role	  in	  pyroptosis,	  however	  the	  effect	   was	   quite	   variable	   between	   biological	   replicates,	   and	   much	   less	   LDH	   was	  released	   from	   cells	   that	   had	   previously	   been	   electroporated.	   Thus,	   this	   method	   of	  assaying	   cell	   death	   was	   not	   well	   suited	   for	   the	   siRNA	   screening	   studies	   that	   were	  performed.	  Alternative	  approaches	  that	  could	  be	  considered	  in	  the	  future	  include	  cell	  viability	  assays	  (e.g.	  MTT	  assays)	  and	  propridium	  iodide	  staining	  to	  assess	  membrane	  integrity.	   Nevertheless,	   results	   from	   this	   chapter	   suggest	   a	   role	   for	   RNF144B	   in	  regulation	  of	  inflammasome	  responses.	  	  Prior	  to	  the	  studies	  described	  here,	  this	  gene	  has	  not	  previously	  been	  investigated	  in	  the	  context	  of	  inflammasome	  biology.	  Hence,	  the	   next	   chapter	   focused	   on	   assessing	   mechanisms	   by	   which	   RNF144B	   regulates	  inflammasome	  responses	  in	  human	  macrophages.	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4.1.	   Introduction	  The	  RNF144	  family	  is	  conserved	  across	  higher	  eukaryotes.	  The	  family	  consists	  of	  the	  E3	   ubiquitin	   ligases,	   RNF144A	   (UIP4)	   and	   RNF144B,	   which	   have	   71%	   amino	   acid	  homology	  (Ho	  et	  al.,	  2014;	  Huang	  et	  al.,	  2006).	  Human	  RNF144B	  has	  88%	  amino	  acid	  similarity	  with	   its	  murine	  ortholog	   (Benard	  et	  al.,	  2010).	  RNF144B	   is	  encoded	  by	  8	  exons,	  the	  first	  of	  which	  is	  non-­‐coding,	  and	  is	  expressed	  in	  many	  human	  tissues,	  most	  highly	   in	   skeletal	   muscle,	   prostate	   and	   peripheral	   blood	   leukocytes	   (Huang	   et	   al.,	  2006).	  RNF144B	  is	  reported	  to	  be	  inducible	  by	  several	  members	  of	  the	  p53	  family	  of	  transcription	   factors,	   p53,	   p63	   and	   p73,	   though	   some	   studies	   disagree	   on	   its	  induction	   by	   the	   tumour	   suppressor,	   p53	   (Ho	   et	   al.,	   2014;	   Huang	   et	   al.,	   2006;	  Nakamura	   et	   al.,	   2006;	   Ng	   et	   al.,	   2003).	   Despite	   differences	   in	   the	   LPS-­‐regulated	  expression	  of	  RNF144B	  between	  human	  and	  mouse	  (see	  Chapter	  3),	  both	  genes	  are	  controlled	  by	  highly	  conserved,	  TATA-­‐containing	  promoters,	  although	  there	  are	  some	  differences	   in	   predicted	   transcription	   factor	   binding	   sites	   between	   the	   promoters	  (see	  Appendix	  1,	  Supplementary	  Figure	  4	  and	  Chapter	  6,	  Section	  6.2.2).	  RNF144B	  protein	  has	  been	  detected	  in	  the	  cytoplasm,	  plasma	  membrane,	  Golgi	  apparatus	  and	  mitochondria	  of	  different	  cell	   types	  under	  different	  conditions	   (Benard	  et	  al.,	  2010;	  Ng	  et	  al.,	  2003).	  	  	  E3	  ubiquitin	  ligases	  function	  to	  transfer	  ubiquitin	  from	  E2	  ubiquitin	  ligases	  to	  target	  proteins.	  There	  are	  more	  than	  600	  E3	  ubiquitin	  ligases	  but	  fewer	  than	  40	  E2	  ligases	  estimated	  to	  be	  encoded	  by	  the	  mammalian	  genome,	  underlining	  the	  specificity	  of	  E3	  ligases	  for	  substrate	  selection	  (Li	  et	  al.,	  2008).	  These	  ligases	  are	  implicated	  in	  many	  pathophysiological	  conditions,	  making	  them	  attractive	  therapeutic	  targets.	  There	  are	  three	   families	   of	   E3	   ligases,	   the	   really	   interesting	   new	   gene	   (RING)	   family,	   which	  consists	   of	   ligases	   that	   directly	   catalyse	   ubiquitin	   transfer	   from	   an	   E2	   ligase	   to	   its	  substrate	   by	   simultaneously	   binding	   both,	   and	   the	   homology	   to	   E6AP	   C	   terminus	  	  (HECT)	  and	  RING-­‐between-­‐RING	  (RBR)	   families,	  which	  contain	   ligases	   that	   transfer	  ubiquitin	  in	  a	  two-­‐step	  reaction	  by	  first	  conjugating	  ubiquitin	  from	  an	  E2	  ligase	  onto	  an	  active	  site	  cysteine	  on	  the	  E3	  ligase,	  then	  transferring	  the	  ubiquitin	  to	  a	  substrate	  (Huibregtse	   et	   al.,	   1995;	   Wenzel	   and	   Klevit,	   2012).	   Substrates	   of	   ubiquitination	  receive	  either	  mono-­‐ubiquitin	  at	  one	  or	  more	  sites;	  or	  poly-­‐ubiquitin	  which	  are	  either	  chains	   of	   ubiquitin	   that	   are	   named	   according	   to	   the	   lysine	   residue	   through	   which	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ubiquitins	   are	   linked	   such	   as	   K48-­‐	   and	   K63-­‐linked	   ubiquitin,	   or	   linear	   ubiquitin	  chains	  where	  the	  carboxyl	  terminus	  of	  one	  ubiquitin	  and	  the	  amino	  terminus	  of	  the	  next	  are	  linked.	  	  The	  E3	  ubiquitin	  ligase	  encoded	  by	  RNF144B	  is	  a	  member	  of	  the	  RING-­‐between-­‐RING	  (RBR)	   family	   of	   E3	   ligases	   that	   are	   characterised	   by	   a	   canonical	   C3HC4-­‐type	   RING	  domain	   (RING1),	   followed	   by	   two	   conserved	   Cys/His-­‐rich	   Zn2+-­‐binding	   domains,	   a	  conserved	   in-­‐between-­‐RING	   (IBR)	   and	  a	   second	  RING	   (RING2)	  domain	   (Aguilera	   et	  al.,	   2000;	  Wenzel	   et	   al.,	   2011).	  RBR	  E3	   ligases	  unexpectedly	  have	   characteristics	   of	  both	  RING	  and	  HECT	  family	  members,	  while	  possessing	   their	  own	  distinct	  methods	  for	   ubiquitination	   and	   autoregulation	   of	   activity	   (Berndsen	   and	  Wolberger,	   2014).	  Members	  of	  the	  RBR-­‐family	  include	  Parkin,	  an	  E3	  ligase	  frequently	  mutated	  in	  early-­‐onset	  Parkinson’s	  disease	   (Dawson	  and	  Dawson,	  2010),	  human	  homolog	  of	  ariadne	  (HHARI),	  and	  HOIP,	  an	  RBR	  protein	  that	  assembles	  linear	  ubiquitin	  chains	  as	  part	  of	  the	  LUBAC	  (Kirisako	  et	  al.,	  2006).	  Parkin	  and	  HHARI	  recruit	  ubiquitin-­‐conjugated	  E2	  ligases	  through	  a	  cysteine	  on	  the	  RING1	  domain,	  while	  binding	  ubiquitin	  on	  a	  cysteine	  on	   the	   RING2	   domain	   before	   transferring	   it	   onto	   a	   substrate	   lysine,	   thus	   requiring	  conformational	  rearrangement	  to	  bring	  both	  RING1	  and	  RING2	  domains	  into	  contact	  (Duda	   et	   al.,	   2013;	  Wenzel	   et	   al.,	   2011).	   Although	   possessing	   distinct	   domains	   and	  linkers,	   the	  structures	  of	  both	  Parkin	  and	  HHARI	  portray	  auto-­‐inhibitory	  forms	  that	  require	  significant	  conformational	  change	  for	  catalysis	  of	  ubiquitin	  transfer,	  possibly	  through	  phosphorylation	  or	  post-­‐translational	  modifications.	   This	   suggests	   that	   the	  structure	   of	   these	   proteins	   are	   very	   important	   for	   regulation	   of	   their	   function,	   and	  that	   RNF144B	   protein	  may	   also	   possess	   an	   auto-­‐inhibitory	   form	   (see	  Appendix	   1,	  
Supplementary	  Figure	  5	  and	  Chapter	  6,	  Section	  6.2.3).	  HOIP	  also	  demonstrates	  an	  auto-­‐inhibitory	  form	  that	   is	  relieved	  upon	  binding	  to	  HOIL-­‐IL	  and	  SHARPIN	  to	  form	  the	  LUBAC	  multi-­‐protein	  RBR	  ligase	  (Smit	  et	  al.,	  2012;	  Smit	  et	  al.,	  2013;	  Stieglitz	  et	  al.,	  2012;	  Stieglitz	  et	  al.,	  2013).	  	  	  
Role	  of	  RNF144B	  in	  inflammasome	  responses	  in	  human	  macrophages	  
	   95	  	  
	  	  
Figure	   4.1:	   Schematic	   diagram	   showing	   domain	   structure	   of	   the	   human	  
RNF144B	  protein.	  Human	  RNF144B	  has	  2	  really	  interesting	  new	  gene	  (RING)	  domains,	  an	  in-­‐between-­‐RING	  (IBR)	  domain,	  and	  a	  transmembrane	  (TM)	  domain	  as	  well	  as	  a	  predicted	  Golgi	  transport	  motif	  and	  a	  predicted	  caspase	  cleavage	  site.	  Domains	  are	  shown	  as	  boxes	  and	  arrows	  indicate	  predicted	  motifs.	  	  In	  addition	  to	   the	  RING	  and	  IBR	  domains	   typical	  of	  RBR	  family	  members,	  RNF144B	  has	  a	  highly	  conserved	  hydrophobic	  C-­‐terminal	  transmembrane	  domain,	  a	  predicted	  caspase-­‐1	  cleavage	  site	  (PeptideCutter-­‐ExPaSy),	  and	  a	  Golgi	  transport	  motif	  in	  the	  N-­‐terminal	   region	   (PSORT	   II)	   (Ng	   et	   al.,	   2003)	   (Figure	   4.1).	   Existing	   literature	   on	  RNF144B	   reports	   it	   as	   an	   E3	   ubiquitin	   ligase	   that	   accepts	   K48-­‐linked	   ubiquitin	   to	  target	  proteins	  for	  proteasomal	  degradation	  (Benard	  et	  al.,	  2010;	  Conforti	  et	  al.,	  2013;	  Huang	  et	  al.,	  2006;	  Sayan	  et	  al.,	  2010;	  Taebunpakul	  et	  al.,	  2012).	  There	  is	  currently	  no	  knowledge	  on	  whether	  RNF144B	  accepts	  K63-­‐linked	  ubiquitin,	  which	  are	  associated	  with	   regulation	   of	   endocytic	   trafficking,	   inflammation,	   translation	   and	   DNA	   repair.	  Both	  members	   of	   the	   RNF144	   family,	   RNF144A	   and	   RNF144B	   are	   able	   to	   interact	  with	  the	  E2	  ubiquitin	  ligases,	  UbcH7	  and	  UbcH8	  (Huang	  et	  al.,	  2006;	  Martinez-­‐Noel	  et	  al.,	  2001).	  Unlike	  RNF144A,	  RNF144B	  does	  not	  target	  DNA-­‐dependent	  protein	  kinase	  holoenzymes	   (DNA-­‐PKcs)	   (Ho	   et	   al.,	   2014).	   Instead,	   RNF144B	   has	   been	   associated	  with	   both	   induction	   and	   negative	   regulation	   of	   apoptosis	   downstream	   of	   p53	  signalling,	   and	   through	   regulation	   of	   p21	   (also	   known	   as	   wild-­‐type	   p53-­‐activated	  fragment	  1	  (WAF1)	  or	  cdk-­‐interacting	  protein	  (Cip1))	  (p21WAF1)	  (Ng	  et	  al.,	  2003),	  p73	  (Sayan	  et	  al.,	  2010;	  Taebunpakul	  et	  al.,	  2012)	  and	  Bax	  (Benard	  et	  al.,	  2010).	  	  p53-­‐dependent	   cell	   death	   was	   reportedly	   induced	   in	   HEK293T	   cells	   with	  overexpression	  of	  RNF144B.	  This	  effect	  required	  the	  C-­‐terminal	  portion	  of	  RNF144B	  but	  not	  its	  less-­‐conserved	  RING-­‐IBR-­‐RING	  domain,	  and	  therefore	  E3	  ubiquitin	  ligase	  activity	  (Huang	  et	  al.,	  2006).	  Interestingly,	  transfection	  of	  RNF144B	  was	  observed	  to	  induce	  cell	  death	  as	  seen	  by	  β-­‐Galactosidase	  detection	  assays	  and	  DNA	  fragmentation,	  even	   in	   the	   presence	   of	   caspase	   inhibitors,	   crmA	   and	   z-­‐vad-­‐fmk,	   both	   of	   which	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successfully	   inhibited	   receptor	   interacting	   protein	   (RIP)-­‐induced	   cell	   death.	   This	  suggests	   that	   in	   these	   studies,	   RNF144B-­‐induced	   death	   was	   caspase-­‐independent	  (Huang	  et	  al.,	  2006).	  RNF144B	  was	  also	  shown	  to	  be	  unable	  to	  interact	  with	  p53	  or	  affect	  its	  stability	  during	  induction	  of	  cell	  death	  (Huang	  et	  al.,	  2006;	  Ng	  et	  al.,	  2003).	  p21WAF1	  is	  an	  inhibitor	  of	  cyclin-­‐dependent	  kinase,	  and	  a	  well-­‐known	  p53	  mediator	  in	  cell-­‐cycle	  arrest	  at	  G1	  phase	  (Harper	  et	  al.,	  1993).	  RNF144B-­‐mediated	  ubiquitination	  of	   p21WAF1	   protein	   is	   hypothesised	   to	   be	   involved	   in	   releasing	   cells	   from	   cell-­‐cycle	  arrest	  and	  induction	  of	  apoptosis	  (Huang	  et	  al.,	  2006;	  Nakamura	  et	  al.,	  2006;	  Ng	  et	  al.,	  2003).	   RNF144B	   has	   also	   been	   shown	   to	   regulate	   keratinocyte	   differentiation	   by	  ubiquitinating	   p21WAF1	   and	   p63,	   targeting	   them	   for	   proteasomal	   degradation	   to	  permit	  keratinocyte	  differentiation	  (Conforti	  et	  al.,	  2013).	  RNF144B	  is	  also	  reported	  to	   control	   p73	   function	   to	   permit	   apoptosis,	   via	   modulation	   of	   the	   ratio	   of	   p73	  isoforms.	   RNF144B	   selectively	   promotes	   proteasomal	   degradation	   of	   the	   N-­‐terminally	   truncated	   isoform	   of	   p73	   (ΔNp73).	   This	   allows	   for	   stabilisation	   of	   the	  transcriptionally	   active	   isoform	   (TAp73)	   that	   promotes	   apoptosis	   through	   p53	  upregulated	   modulator	   of	   apoptosis	   (PUMA),	   which	   induces	   Bax	   mitochondrial	  translocation	   and	   cytochrome	   c	   release	   (Melino	   et	   al.,	   2004;	   Sayan	   et	   al.,	   2010;	  Taebunpakul	  et	  al.,	  2012).	  	  	  Bax,	   a	   pro-­‐apoptotic	   protein	   from	   the	   Bcl-­‐2	   family,	   exists	   within	   the	   cytosol	   in	   an	  inactive	   form.	   However,	   upon	   induction	   of	   apoptosis,	   the	   amino-­‐terminus	   of	   Bax	  undergoes	  a	  conformational	  change,	  and	  active	  Bax	  (6A7-­‐Bax)	  is	  inserted	  within	  the	  mitochondrial	   membrane.	   These	   two	   forms	   of	   Bax	   are	   distinguishable	   by	   two	  different	   monoclonal	   antibodies,	   5B7	   and	   6A7.	   The	   reported	   role	   of	   RNF144B	   in	  controlling	  apoptosis	  involves	  ubiquitination	  of	  6A7-­‐Bax.	  In	  unstimulated	  cells,	  YFP-­‐	  and	  MYC-­‐tagged	  RNF144B	  was	  shown	  to	   localise	   in	   the	  cytosol	  of	  HeLa	  cells	  with	  a	  small	  portion	  of	  protein	  showing	  diffuse	  or	  vesicle-­‐like	  distribution	  that	  was	  partially	  associated	   with	   mitochondria.	   However	   in	   about	   1%	   of	   unstimulated	   cells,	   tagged	  RNF144B	   was	   highly	   enriched	   in	   mitochondria	   and	   co-­‐localised	   with	   the	   outer	  mitochondrial	   membrane	   stain,	   TOM20.	   These	   cells	   were	   found	   to	   possess	  fragmented	  mitochondria,	  which	  is	  associated	  with	  change	  of	  mitochondrial	  function,	  such	   as	   membrane	   depolarisation,	   increased	   production	   of	   ROS,	   and	   autophagic	  degradation	   of	   mitochondria,	   suggesting	   that	   RNF144B	   accumulation	   might	   be	  associated	  with	  mitochondrial	  dynamics	  such	  as	  with	  Parkin,	  and	  the	  small	  ubiquitin-­‐
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like	  modifier	  (SUMO)	  protease,	  SenP5	  (Narendra	  et	  al.,	  2008;	  Zunino	  et	  al.,	  2007).	  In	  cells	  treated	  with	  actinomycin	  D	  or	  staurosporine	  to	  initiate	  apoptotic	  pathways,	  but	  also	  with	  caspase	  inhibitors	  to	  block	  cell	  death	  to	  enable	  cell	  imaging,	  RNF144B	  was	  demonstrated	   to	   redistribute	   from	   the	   cytosol	   to	   accumulate	   in	   mitochondrial	  domains.	   Translocation	   of	   RNF144B	   to	   the	   mitochondria	   was	   dependent	   on	  simultaneous	  mitochondrial	   localisation	  of	  6A7-­‐Bax,	   initiation	  of	  apoptosis	  and	  also	  on	   the	   expression	   levels	   of	   B-­‐cell	   lymphoma-­‐extra	   large	   (Bcl-­‐xL),	   an	   anti-­‐apoptotic	  protein	  that	  prevents	  outer	  mitochondrial	  membrane	  permeabilisation	  and	  release	  of	  cytochrome	   c.	   RNF144B	   translocation	   was	   also	   reliant	   on	   its	   predicted	   C-­‐terminal	  transmembrane	   domain,	   but	   partially	   dependent	   on	   its	   ubiquitin	   ligase	   activity,	   as	  RING	  domain	  mutants	  showed	  only	  partial	  mitochondrial	  localisation.	  RNF144B	  was	  determined	   to	   co-­‐localise	   or	   be	   adjacently	   localised	   within	   sub-­‐mitochondrial	  structures	  with	  6A7-­‐Bax,	  and	  was	  shown	  to	  physically	  interact	  with	  6A7-­‐Bax,	  but	  not	  inactive	  Bax,	   leading	  to	  its	  degradation	  within	  the	  mitochondria.	  This	  was	  proposed	  to	  be	  a	  regulatory	  mechanism	  within	  healthy	  cells	  to	  prevent	  accumulation	  of	  active	  Bax	  and	  spontaneous	  apoptosis	  (Benard	  et	  al.,	  2010).	  	  	  Aside	  from	  its	  role	  in	  regulation	  of	  cell	  death,	  very	  little	  is	  known	  about	  the	  function	  of	  RNF144B,	  particularly	   in	  the	  context	  of	   innate	   immunity.	   In	  the	  previous	  chapter	  (Chapter	   3),	   RNF144B	   knockdown	   in	   HMDM	   and	   PMA-­‐differentiated	   THP-­‐1	  macrophages	  impaired	  IL-­‐1β	  secretion	  and	  showed	  a	  trend	  for	  reduced	  pyroptosis	  in	  response	   to	  NLRP3	   activation.	   This	   suggests	   that	   RNF144B	  may	   play	   an	   important	  role	  in	  regulation	  of	  inflammasomes.	  The	  work	  undertaken	  in	  this	  chapter	  focused	  on	  validating	   the	   role	   of	   RNF144B	   in	   regulating	   inflammasome	   responses,	   as	   well	   as	  investigating	  the	  mechanisms	  by	  which	  it	  does	  so.	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4.2	  Results	  
4.2.1.	  	   Silencing	   of	   RNF144B	   expression	   with	   multiple	   siRNAs	   inhibits	   IL-­‐1β	  
secretion	  from	  THP-­‐1	  cells.	  As	   the	   experiments	   described	   in	   Chapter	   3	   utilised	   pooled	   siRNA	   to	   knockdown	  
RNF144B,	   the	   assay	  was	   repeated	   in	   PMA-­‐differentiated	   THP-­‐1	  macrophages	   using	  four	   individual	   siRNAs.	   These	   experiments	   were	   undertaken	   to	   confirm	   that	   the	  reduction	   in	   secreted	   IL-­‐1β	   was	   consistently	   observed	   upon	   RNF144B	   silencing,	  which	  would	  alleviate	  concerns	  about	  possible	  off-­‐target	  effects	  of	  the	  pooled	  siRNAs.	  
G0S2	  and	  NLRP1	  were	  also	  targeted	  for	  knockdown	  as	  negative	  controls	  for	  effects	  on	  NLRP3	  inflammasome	  activation,	  while	  NLRP3	  gene	  knockdown	  was	  conducted	  as	  a	  positive	   control.	   Knockdown	   of	   RNF144B	   with	   all	   four	   of	   the	   individual	   siRNAs	  resulted	  in	  reduced	  IL-­‐1β	  release	  to	  varying	  levels,	  further	  supporting	  the	  conclusion	  that	  RNF144B	  was	  indeed	  involved	  in	  regulation	  of	  the	  NLRP3	  inflammasome	  (Figure	  
4.2).	  As	  expected,	  no	  effect	  was	  seen	  upon	  G0S2	  and	  NLRP1	  gene	  knockdown,	  while	  
NLRP3	  knockdown	  also	  attenuated	  release	  of	  IL-­‐1β.	  	  
	  
	  
Figure	  4.2:	  Gene	  silencing	  of	  RNF144B	  with	  4	  different	  siRNAs	  attenuates	  IL-­‐1β	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presented	  as	   fold	  change	  relative	   to	   the	  no	  siRNA	  control	   for	  cells	   treated	  with	  LPS	  plus	  nigericin.	  
	  
4.2.2.	  	   Silencing	   of	   RNF144B	   expression	   reduces	   IL-­‐1β	   secretion	   in	   human	  
macrophages	  activated	  via	  the	  NLRP3	  and	  NLRC4	  inflammasomes.	  Although	   RNF144B	   was	   shown	   to	   be	   involved	   in	   NLRP3	   inflammasome	   activation,	  previous	   experiments	   were	   conducted	   with	   only	   nigericin	   to	   stimulate	   the	   NLRP3	  inflammasome.	   To	   ensure	   that	   RNF144B	   was	   involved	   in	   NLRP3	   inflammasome	  activation	  regardless	  of	  stimuli,	  the	  experiment	  was	  repeated	  as	  previously	  described	  with	  5	  mM	  ATP	  as	  another	  stimuli	  for	  NLRP3	  inflammasome	  activation.	  In	  addition,	  it	  was	   of	   interest	   to	   determine	   whether	   RNF144B	   was	   specifically	   affecting	   only	   the	  NLRP3	   inflammasome	   or	   whether	   it	   was	   involved	   in	   activation	   of	   other	  inflammasomes	   as	   well.	   Therefore,	   following	   gene	   knockdown	   and	   LPS	   priming,	  HMDM	   were	   infected	   with	   S.	   Typhimurium	   at	   MOI	   100	   to	   stimulate	   NLRC4	  inflammasome	  activation	   (Franchi	   et	   al.,	   2006;	  Mariathasan	  et	   al.,	   2004)	  within	   the	  same	   experiment.	   As	   before,	   G0S2	   and	  NLRP1	   gene	   knockdown	   was	   conducted	   as	  negative	   control	   and	   NLRP3	   knockdown	   as	   positive	   control.	   IL-­‐1β	   release	   was	  reduced	   upon	   stimulation	   with	   both	   nigericin	   and	   ATP	   treatment	   to	   activate	   the	  NLRP3	   inflammasome,	   as	   well	   as	   with	   S.	   Typhimurium	   infection	   to	   activate	   the	  NLRC4	   inflammasome	   (Figure	   4.3).	   In	   these	   experiments,	   the	   effect	   of	   RNF144B	  knockdown	  was	  not	  statistically	  significant	  for	  the	  sample	  size,	  but	  was	  apparent	  in	  all	  experiments	  performed.	  These	  data	  suggest	  that	  RNF144B	  regulates	  activation	  of	  both	  the	  NLRP3	  and	  NLRC4	  inflammasomes.	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Figure	   4.3:	   Knockdown	   of	   RNF144B	   reduces	   IL-­‐1β	   secretion	   following	  NLRP3	  
and	  NLRC4	  inflammasome	  activation	  in	  HMDM.	  	  HMDM	  were	  transfected	  with	  no	  siRNA	  or	  with	  pooled	  siRNAs	  against	  each	  gene	  as	  labelled.	  24	  h	   following	  siRNA	   transfection,	   cells	  were	  primed	  with	  100	  ng/mL	  LPS	  for	  4	  h	  then	  treated	  with	  10	  μM	  nigericin	  or	  5mM	  ATP	  for	  3	  h	  to	  activate	  the	  NLRP3	  inflammasome,	   or	   with	   S.	   Typhimurium	   at	   MOI	   100	   to	   activate	   the	   NLRC4	  inflammasome.	  Supernatants	  were	  harvested	  and	  analysed	  for	  IL-­‐1β	  levels	  by	  ELISA.	  Data	  (mean+SEM)	  are	  combined	  from	  3	  independent	  experiments,	  and	  are	  presented	  as	  fold	  change	  relative	  to	  the	  no	  siRNA	  control	  in	  cells	  treated	  with	  LPS	  plus	  nigericin.	  **P≤0.01;	   by	   one-­‐way	  ANOVA	   followed	  by	  Dunnett’s	  Multiple	   Comparison	   test.	  N.D	  indicates	  not	  detected.	  	  
	  
4.2.3.	  	   Proteasome	   inhibition	   reduces	   NLRP3-­‐triggered	   IL-­‐1β	   release	   in	   both	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ubiquitin-­‐mediated	  proteasomal	  degradation	  of	   the	   inflammasome	  in	  human	  versus	  mouse	  macrophages.	  	  	  In	   order	   to	   compare	   the	   potential	   role	   of	   proteasomal	   degradation	   of	   an	   unknown	  inflammasome	   inhibitor	   in	   inflammasome	   activation	   in	   human	   and	   mouse	  macrophages,	   HMDM	   and	  BMM	  were	   primed	  with	   LPS	   and	   stimulated	  with	   10	   μM	  nigericin	   for	   NLRP3	   inflammasome	   activation,	   then	   treated	   with	   a	   general	  proteasome	   inhibitor,	   MG132	   (10	   μM),	   15	   minutes	   following	   nigericin	   treatment.	  Supernatants	  were	  collected	  3	  h	  later	  to	  analyse	  levels	  of	  IL-­‐1β	  and	  TNFα.	  Release	  of	  IL-­‐1β	   was	   reduced	   by	   approximately	   50%	   in	   both	   primary	   human	   and	   mouse	  macrophages	   (Figure	   4.4).	   No	   effect	   was	   observed	   on	   TNFα	   with	   inhibition	   of	  proteasomal	   degradation,	   as	   expected	   given	   that	   MG132	   was	   added	   after	  inflammasome	  triggering.	  These	  data	  suggest	  that	  the	  proteasome	  pathway	  positively	  regulates	   IL-­‐1β	   release	   as	   was	   predicted,	   but	   there	   was	   no	   obvious	   difference	   in	  human	   versus	   mouse	   macrophages	   in	   this	   respect,	   at	   least	   as	   assessed	   by	  pharmacological	   inhibition.	   This	   finding	   therefore	   prompted	   investigation	   of	  alternative	  mechanisms	  by	  which	  RNF144B	  might	  regulate	  inflammasome	  responses.	  	  	  
Role	  of	  RNF144B	  in	  inflammasome	  responses	  in	  human	  macrophages	  
	   102	  	  
	  
Figure	   4.4:	   Treatment	   of	   primary	   human	   or	   mouse	   macrophages	   with	   a	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4.2.4.	  	   RNF144B	  knockdown	  reduces	  LPS-­‐induced	  pro-­‐IL-­‐1β	  protein	  expression	  in	  
primary	  human	  macrophages.	  As	   discussed	   in	   Chapter	   1,	   inflammasome	   activation	   is	   a	   two-­‐step	   process	   that	  requires	   priming	   of	   TLR4	   signalling	   to	   promote	   transcription	   of	   inflammasome	  components	  such	  as	  NLRP3	  and	  pro-­‐IL-­‐1β,	  and	  a	  second	  signal	  sensed	  by	  NLRs	  that	  promotes	  oligomerisation	  of	  NLRs,	  ASC	  and	  pro-­‐caspase-­‐1.	  Once	   the	   inflammasome	  scaffold	  is	  assembled,	  autocatalytic	  cleavage	  of	  caspase-­‐1	  occurs,	  resulting	  in	  caspase-­‐1-­‐mediated	  pro-­‐IL-­‐1β	  and	  pro-­‐IL-­‐18	  cleavage	  and	  release	  of	  these	  cytokines	  from	  the	  cell.	  	  To	  determine	  whether	  RNF144B	   knockdown	  was	   affecting	   IL-­‐1β	   cytokine	   secretion	  by	   affecting	   inflammasome	   components	   involved	   in	   acute	   inflammasome	  activation	  such	   as	   cleavage	   of	   pro-­‐caspase-­‐1	   and	   pro-­‐IL-­‐1β,	   cell	   lysates	   and	   supernatants	  obtained	  from	  the	  previous	  experiments	  were	  analysed	  for	  protein	  levels	  by	  Western	  blotting.	   As	   expected,	   stimulation	   of	   HMDM	   with	   LPS	   resulted	   in	   induction	   of	  RNF144B	   and	   pro-­‐IL-­‐1β	   protein	   in	   cell	   lysates,	   while	   siRNA-­‐mediated	   gene	  knockdown	   of	   RNF144B	   reduced	   LPS-­‐induced	   RNF144B	   protein	   (Figure	   4.5A).	  Confirming	  the	  results	  from	  analysis	  of	  IL-­‐1β	  release	  by	  ELISA	  assay,	  levels	  of	  cleaved	  IL-­‐1β	  protein	  were	  decreased	   in	  supernatants	   from	  HMDM	  transfected	  with	  siRNAs	  against	  RNF144B	  and	  NLRP3,	  but	  not	  with	  NLRP1	  or	  G0S2.	  In	  these	  experiments,	  the	  effect	  of	  NLRP3	  knockdown	  on	  IL-­‐1β	  release	  was	  more	  pronounced	  than	  for	  RNF144B	  knockdown.	  In	  contrast	  to	  NLRP3	  silencing,	  RNF144B	  silencing	  did	  not	  affect	  levels	  of	  cleaved	  caspase-­‐1	  in	  supernatants	  or	  cell	  lysates.	  This	  indicates	  that	  proximal	  events	  leading	  to	  the	  autocatalytic	  cleavage	  of	  pro-­‐caspase-­‐1	  were	  not	  affected	  by	  RNF144B	  knockdown.	   However,	   LPS-­‐inducible	   pro-­‐IL-­‐1β	   levels	   were	   reduced	   in	   cell	   lysates	  from	  HMDM	  transfected	  with	  siRNAs	  targeting	  RNF144B	  (either	  in	  cells	  primed	  with	  LPS	  alone	  or	  LPS-­‐primed	  then	  nigericin-­‐stimulated).	  This	  decrease	  in	  pro-­‐IL-­‐1β	  levels	  was	  quantified	  by	  measuring	  the	  intensity	  of	  pro-­‐IL-­‐1β	  protein	  bands	  in	  comparison	  to	  ASC	  protein	  using	  the	  ChemiDoc	  MP	  system	  (Figure	  4.5B).	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Figure	   4.5:	   Knockdown	   of	   RNF144B	   reduces	   pro-­‐IL-­‐1β	   protein	   expression	   in	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4.2.5.	  	   RNF144B	   knockdown	   inhibits	   LPS-­‐induced	   IL-­‐1β	   mRNA	   expression	   in	  
primary	  human	  macrophages.	  Since	  pro-­‐IL-­‐1β	  protein	  levels	  were	  reduced	  with	  RNF144B	  gene	  knockdown	  in	  LPS-­‐treated	   cells,	   RNF144B	   appeared	   to	   be	   regulating	   inflammasome	   activity	   through	  effects	   on	   priming	   of	   inflammasome	   responses,	   rather	   than	   proximal	   activation	  events.	  Therefore,	  in	  order	  to	  investigate	  whether	  RNF144B	  was	  regulating	  pro-­‐IL-­‐1β	  at	   the	   protein	   level	   or	   further	   upstream,	   it	   was	   important	   to	   determine	   whether	  mRNA	  levels	  of	  pro-­‐IL-­‐1β	  were	  reduced	  upon	  RNF144B	  gene	  knockdown.	  	  Thus,	  qPCR	  was	   performed	   on	   RNA	   samples	   from	  HMDM	   in	  which	  RNF144B,	  NLRP3	   or	  NLRP1	  had	  been	  knocked	  down,	   then	   stimulated	  with	  LPS	   for	  4	  h.	   In	   these	  experiments,	   a	  reduction	  in	  secreted	  IL-­‐1β	  was	  also	  confirmed.	  As	  expected,	  RNF144B	  mRNA	  levels	  were	   significantly	   reduced	   upon	   RNF144B	   gene	   knockdown	   (Figure	   4.6A).	   LPS-­‐induced	   IL-­‐1β	   mRNA	   levels	   were	   also	   significantly	   reduced	   in	   HMDM	   in	   which	  
RNF144B	  had	  been	  knocked	  down	  (Figure	  4.6B),	  thereby	  explaining	  the	  reduction	  in	  pro-­‐IL-­‐1β	  protein	  observed	  from	  Western	  blot	  analysis	  that	  was	  previously	  described	  (Figure	  4.5A).	  To	  assess	  whether	  the	  effect	  of	  RNF144B	  knockdown	  was	  specific	  to	  
IL-­‐1β	  mRNA,	  mRNA	   levels	   of	   other	   TLR-­‐regulated	   cytokines	  were	   also	   analysed	   by	  qPCR.	   mRNA	   levels	   of	   IL-­‐10	   and	   IFNγ	   were	   not	   affected	   by	   RNF144B	   knockdown	  (Figure	  4.6C	  and	  D),	  while	  LPS-­‐induced	  IL-­‐23p19	  mRNA	  was	  significantly	  attenuated	  (Figure	  4.6H)	  and	  there	  was	  a	  clear	  trend	  for	  reduced	  LPS-­‐inducible	  expression	  of	  IL-­‐
8,	   IL-­‐12p35	   and	   IL-­‐12p40	   (Figure	   4.6G,	   I	   and	   J).	   There	   was	   no	   obvious	   effect	   on	  expression	  of	   IL-­‐18	  and	  HMGB1	  mRNA	  levels	  (Figure	   4.6E	  and	  F),	  which	  are	  other	  targets	   of	   inflammasome	   activation	   (Lamkanfi	   et	   al.,	   2010;	   Martinon	   et	   al.,	   2002;	  Petrilli	  et	  al.,	  2005).	  Thus,	  RNF144B	  appears	  to	  selectively	  promote	  the	  expression	  of	  a	  sub-­‐set	  of	  TLR4	  target	  genes,	  including	  the	  inflammasome	  target	  pro-­‐IL-­‐1β.	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Figure	  4.6:	  Effect	  of	  knockdown	  of	  RNF144B	  on	  gene	  expression	  in	  HMDM.	  	  HMDM	   were	   transfected	   with	   indicated	   siRNAs	   as	   previously	   described.	   24	   h	  following	   siRNA	   transfection,	   mRNA	   levels	   for	   the	   indicated	   genes	   were	   analysed	  following	   treatment	   with	   100	   ng/mL	   LPS	   for	   4	   h.	   (A-­‐H)	   Data	   (mean+SEM)	   are	  combined	  from	  4	  independent	  experiments	  and	  are	  presented	  as	  fold	  change	  relative	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to	   the	   no	   siRNA	   transfection	   +	   LPS	   control.	   *P≤0.05,	   **P≤0.01;	   by	   one-­‐way	  ANOVA	  followed	  by	  Dunnett’s	  Multiple	  Comparison	  test.	  	  
4.2.6.	  	   p21	   protein	   expression	   is	   more	   tightly	   regulated	   by	   proteasomal	  
degradation	   in	   primary	   human	   macrophages	   as	   compared	   to	   primary	   mouse	  
macrophages.	  	  As	  mentioned	  previously,	  RNF144B	  has	  been	  shown	  to	  ubiquitinate	  p21WAF1	  protein	  for	  regulation	  of	  apoptosis	  and	  keratinocyte	  differentiation	  (Conforti	  et	  al.,	  2013;	  Ng	  et	  al.,	  2003).	  Expression	  of	  RNF144B	  has	  also	  been	  shown	  to	  inversely	  correlate	  with	  p21WAF1	  protein	  expression	  in	  several	  studies	  (Conforti	  et	  al.,	  2013;	  Nakamura	  et	  al.,	  2006;	   Ng	   et	   al.,	   2003).	   Interestingly,	   p21WAF1	   protein	   expression	   has	   been	  demonstrated	   to	   inhibit	   IL-­‐1β	   expression	   in	   both	   human	   and	  mouse	  macrophages	  (Scatizzi	  et	  al.,	  2009;	  Trakala	  et	  al.,	  2009).	  siRNA-­‐mediated	  knockdown	  of	  p21WAF1	  in	  human	   macrophages	   resulted	   in	   increased	   IL-­‐1β	   secretion,	   and	   mice	   deficient	   in	  p21WAF1	   displayed	   increased	   serum	   levels	   of	   IL-­‐1β	   and	   higher	   susceptibility	   to	  endotoxic	  shock	  (Scatizzi	  et	  al.,	  2009;	  Trakala	  et	  al.,	  2009).	  The	  inhibition	  of	  IL-­‐1β	  by	  p21WAF1	   was	   subsequently	   mapped	   to	   the	   cyclin-­‐dependent-­‐kinase	   (CDK)-­‐binding	  domain	  of	  p21WAF1	  (Scatizzi	  et	  al.,	  2009).	  
	  Given	   these	   findings,	   it	   was	   hypothesised	   that	   RNF144B	   was	   regulating	   IL-­‐1β	  expression	   through	   regulation	   of	   p21WAF1	   protein.	   For	   example,	   RNF144B	   may	   be	  required	   for	   ubiquitination	   of	   p21WAF1	   protein	   in	   human	  macrophages,	   causing	   its	  degradation	   by	   the	   proteasome	   and	   preventing	   p21WAF1	   inhibition	   of	   IL-­‐1β	  transcription.	  To	   investigate	   this	  possibility,	  HMDM	  and	  BMM	  were	  treated	  with	  10	  μM	  MG132	  for	  30	  minutes	  prior	  to	  treatment	  with	  100	  ng/mL	  LPS	  over	  a	  time	  course.	  Cell	   lysates	  were	   then	   collected	   and	   probed	   for	   p21WAF1	   protein.	   Levels	   of	   p21WAF1	  protein	   were	   quantified	   using	   the	   ChemiDoc	   MP	   system.	   Expression	   of	   p21WAF1	  protein	   was	   increased	   in	   HMDM	   at	   6	   h	   post-­‐stimulation,	   and	   was	   very	   modestly	  upregulated	   in	   BMM	   at	   earlier	   time	   points	   (~	   2	   fold)	   (Figure	   4.7).	   However,	   a	  striking	   effect	   of	   the	   MG132	   proteosome	   inhibitor	   was	   observed	   in	   HMDM,	   as	  compared	   to	   BMM.	   Proteosome	   inhibition	   caused	   a	   substantial	   upregulation	   of	  p21WAF1	   protein	   expression	   only	   in	   the	   former	   cell	   population.	   This	   suggests	   that	  p21WAF1	  protein	  is	  more	  highly	  regulated	  by	  the	  proteosome	  in	  human	  macrophages,	  as	  compared	  to	  mouse	  macrophages.	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Figure	  4.7:	  Effect	  of	  the	  proteasome	  inhibitor	  MG132	  on	  p21	  protein	  expression	  
in	  primary	  human	  versus	  mouse	  macrophages.	  	  HMDM	   (A)	   and	   BMM	   (B)	   were	   treated	  with	   10	   μM	  MG132	   for	   30	  minutes	   before	  treatment	   with	   100	   ng/mL	   LPS	   over	   the	   indicated	   time	   course.	   Cell	   lysates	   were	  harvested	  and	  analysed	   for	  p21WAF1	   and	  GAPDH	  protein	   levels	  by	  western	  blotting.	  Data	  are	  from	  one	  experiment,	  and	  are	  representative	  of	  3	  independent	  experiments	  for	   BMM	   and	   5	   for	   HMDM.	   (C)	   Relative	   levels	   of	   p21WAF1	   protein	   were	   quantified	  using	   the	   ChemiDoc	   MP	   system.	   Data	   (mean+SEM,	   3-­‐5	   independent	   experiments)	  shows	   levels	   of	   p21WAF1	   protein	  normalised	   to	  GAPDH	   levels,	   and	   are	  presented	   as	  fold	   change	   relative	   to	   unstimulated	   cells.	   *P≤0.05,	   **	   P≤0.01;	   by	   one-­‐way	   ANOVA	  followed	  by	  Dunnett’s	  Multiple	  Comparison	  test.	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4.2.7.	  	   Silencing	   of	   RNF144B	   expression	   does	   not	   affect	   LPS-­‐regulated	   p21WAF1	  
mRNA	  and	  protein	  expression	  in	  primary	  human	  macrophages.	  Since	   p21WAF1	   protein	  was	   highly	   regulated	   by	   proteasomal	   degradation	   in	   human	  macrophages	   but	   not	   in	   mouse	   macrophages,	   it	   was	   hypothesised	   that	   p21WAF1	  protein	  might	  be	  regulated	  by	  RNF144B	  in	  human	  macrophages.	  Therefore,	  the	  effect	  of	  RNF144B	  knockdown	  on	  p21WAF1	  mRNA	  and	  protein	  expression	  in	  HMDM	  was	  next	  analysed.	  RNA	   from	  cell	   lysates	  obtained	   in	  previous	   experiments	   (see	  Figure	   4.6)	  was	   thus	   used	   to	   assess	   constitutive	   and	   LPS-­‐regulated	   p21WAF1	  mRNA	   expression.	  
RNF144B	  knockdown	  did	  not	  impact	  expression	  of	  p21WAF1	  mRNA	  (Figure	  4.8).	  This	  was	  expected	  as	  RNF144B	  is	  hypothesised	  to	  exert	  an	  effect	  through	  ubiquitination	  of	  p21WAF1	   protein,	   rather	   than	   by	   affecting	   p21WAF1	  mRNA	   expression.	   Next,	   p21WAF1	  protein	  levels	  were	  analysed	  in	  HMDM	  in	  which	  RNF144B	  had	  been	  knocked	  down	  to	  determine	   whether	   this	   would	   result	   in	   increased	   p21WAF1	   protein	   expression.	   In	  these	  experiments,	  NLRP1	   knockdown	  was	  used	  as	  a	  negative	  control.	   Surprisingly,	  no	   significant	   difference	   in	   p21WAF1	   protein	   levels	   was	   observed	   after	   RNF144B	  knockdown	  (Figure	  4.9).	  When	  p21WAF1	  protein	  levels	  were	  assessed	  48	  h	  following	  gene	   knockdown	   to	   ensure	   that	   sufficient	   time	   was	   allowed	   for	   degradation	   of	  protein,	  similar	  results	  were	  also	  obtained	  (data	  not	  shown).	  	  
	  
Figure	  4.8:	  Knockdown	  of	  RNF144B	  does	  not	  affect	  p21WAF1	  mRNA	  expression	  in	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Figure	  4.9:	  RNF144B	  knock-­‐down	  does	  not	  affect	  LPS-­‐inducible	  p21WAF1	  protein	  
expression	  in	  primary	  human	  macrophages.	  	  HMDM	  were	  transfected	  with	  no	  siRNA	  or	  with	  siRNAs	  against	  each	  gene	  as	  labelled.	  24	  h	   following	  siRNA	  transfection,	   cells	  were	   treated	  with	  100	  ng/mL	  LPS	  over	   the	  indicated	   time	   course,	   after	   which	   levels	   of	   p21WAF1	   and	   GAPDH	   protein	   were	  analysed	   by	   immunoblotting.	   (A)	   Data	   from	   one	   experiment,	   representative	   of	   3	  independent	   experiments,	   is	   shown.	   (B)	   Relative	   p21WAF1	   protein	   expression	   was	  quantified	   using	   the	   ChemiDoc	   MP	   system.	   Data	   (mean+SEM,	   combined	   from	   3	  independent	  experiments)	  show	  levels	  of	  p21WAF1	  protein	  relative	  to	  GAPDH	  protein	  expression,	   and	   are	   presented	   as	   fold	   change	   relative	   to	   unstimulated	   control	   cells	  transfected	  with	  no	  siRNA.	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4.3.	  Discussion	  
4.3.1.	  	   RNF144B	   regulates	   LPS-­‐inducible	   pro-­‐IL-­‐1β	   expression	   in	   human	  
macrophages.	  Knockdown	  using	  four	  individual	  siRNAs	  targeting	  RNF144B	  resulted	  in	  reduced	  IL-­‐1β	  release,	  confirming	  that	  RNF144B	  was	  regulating	  NLRP3-­‐trigggered	  IL-­‐1β	  release	  in	  HMDM.	  RNF144B	  knockdown	   in	  HMDM	  was	   also	   observed	   to	   reduce	   IL-­‐1β	   levels	  following	   NLRP3	   activation	   by	   multiple	   stimuli	   (nigericin	   and	   ATP)	   and	   NLRC4	  inflammasome	   activation.	   This	   suggested	   that	   RNF144B	   was	   a	   broad	   regulator	   of	  inflammasome	   responses.	   Indeed,	   it	   became	   apparent	   that	   RNF144B	  was	   not	   affecting	  proximal	   events	   of	   inflammasome	   activation	   such	   as	   pro-­‐caspase-­‐1	   and/or	   pro-­‐IL-­‐1β	  cleavage	   or	   release,	   but	   rather	   LPS-­‐inducible	   expression	   of	   pro-­‐IL-­‐1β.	   qPCR	   analysis	   of	  LPS-­‐inducible	  IL-­‐1β	  mRNA	  levels	  revealed	  that	  RNF144B	  knockdown	  was	  affecting	  IL-­‐1β	  mRNA	   induction.	   The	   effect	   of	   RNF144B	   in	   regulating	   LPS	   responses	   was	   relatively	  selective	   in	   that	   it	   did	   not	   have	   pronounced	   effects	   on	   LPS-­‐inducible	   TNFα	  and	   IL-­‐6	  secretion,	  or	  on	  LPS-­‐inducible	  mRNA	  expression	  of	  some	  mediators	  such	  as	  IL-­‐10	  and	  IFNγ.	  However,	  mRNA	   for	  other	  pro-­‐inflammatory	   cytokines	   such	   as	   IL-­‐8,	   IL-­‐23p19,	   IL-­‐12p35,	  and	  IL-­‐12-­‐p40	  were	  also	  downregulated	  by	  RNF144B	  knockdown.	  	  	  The	   IL-­‐12	   cytokine	   is	   made	   up	   of	   IL-­‐12p35	   and	   IL-­‐12p40	   subunits	   and	   is	   largely	  secreted	  by	  dendritic	  cells,	  macrophages	  and	  neutrophils	  (Hamza	  et	  al.,	  2010).	  IL-­‐12	  induces	   IFNγ	  production,	   stimulates	   the	  growth	  and	  differentiation	  of	  naive	  CD4+	  T	  cells	   into	   Th1	   cells	   and	   enhances	   the	   cytotoxic	   activity	   of	   NK	   cells	   (Hamza	   et	   al.,	  2010).	  Thus,	  it	  is	  a	  vital	  cytokine	  for	  host	  responses	  against	  infection.	  The	  IL-­‐12p40	  subunit,	  is	  also	  able	  to	  combine	  with	  a	  unique	  subunit,	  IL-­‐23p19,	  which	  is	  encoded	  on	  a	  separate	  gene,	  to	  make	  up	  the	  IL-­‐23	  cytokine,	  which	  belongs	  to	  the	  IL-­‐12	  cytokine	  family	   (Oppmann	   et	   al.,	   2000).	   IL-­‐23	   is	   primarily	   secreted	   by	   macrophages	   and	  dendritic	  cells	  (Oppmann	  et	  al.,	  2000)	  and	  is	  essential	  for	  differentiation	  of	  Th17	  cells	  (Aggarwal	  et	  al.,	  2003;	  Guo	  et	  al.,	  2012;	  McGeachy	  et	  al.,	  2009)	  and	  maintenance	  of	  Th17	  effector	  function	  (Stockinger	  and	  Veldhoen,	  2007;	  Veldhoen	  et	  al.,	  2006).	  IL-­‐1β	  also	   enhances	   Th17	   cell	   development	   by	   downregulating	   TGF-­‐β-­‐induced	   Foxp3	  expression	  (Ikeda	  et	  al.,	  2014;	  Mills,	  2008).	  Th17	  cells	  are	  the	  main	  producers	  of	  IL-­‐17,	   IL-­‐17F,	   IL-­‐21	   and	   IL-­‐22	   pro-­‐inflammatory	   cytokines	   that	   directly	   cause	   tissue	  injury	   and	   promote	   secretion	   of	   pro-­‐inflammatory	   cytokines	   and	   chemokines	   by	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resident	  cells	  (Turner	  et	  al.,	  2010).	  Thus,	  Th17	  cells	  are	  central	  in	  the	  development	  of	  inflammatory	   and	   autoimmune	  disorders	   (Fouser	   et	   al.,	   2008)	   and	   the	   IL-­‐23/IL-­‐17	  pathway	   is	   now	   recognised	   as	   critical	   for	   pathogenesis	   of	   many	   autoimmune	  disorders	   that	   were	   initially	   attributed	   to	   IL-­‐12	   and	   Th1	   cells	   (Cua	   et	   al.,	   2003;	  Iwakura	   and	   Ishigame,	   2006).	   Several	   studies	   have	   reported	   that	   IL-­‐23p19	  expression	  is	  regulated	  by,	  and	  is	  able	  to	  regulate,	  IL-­‐1β.	  For	  example,	  IL-­‐23p19	  was	  demonstrated	   to	   be	   strongly	   induced	   by	   IL-­‐1β	   downstream	   of	   NFκB	   and	   MAPK-­‐dependent	   AP-­‐1	   signalling	   pathways	   in	   fibroblasts	   and	  mononuclear	   cells	   from	  RA	  patients	  (Liu	  et	  al.,	  2007a;	  Sato	  et	  al.,	  2006)	  and	  to	  promote	  inflammatory	  responses	  by	   stimulating	   IL-­‐8	   and	   IL-­‐6	   production	   (Liu	   et	   al.,	   2007a).	   In	   a	   study	   involving	  administration	   of	   IL-­‐23	   cytokine	   into	   the	   peritoneum	   of	  mice,	   IL-­‐23	  was	   shown	   to	  directly	   activate	  macrophages	   in	  vivo	   to	   express	   IL-­‐1β	   and	  TNFα	  mRNA	   (Cua	   et	   al.,	  2003).	   In	   addition	   to	   promoting	   Th17	   cell	   differentiation	   and	   responses,	   IL-­‐1β	  	  functions	  to	  enhance	  antigen-­‐driven	  CD4+	  and	  CD8+	  T	  cell	  responses	  (Ben-­‐Sasson	  et	  al.,	  2013).	  Thus,	  my	  findings	  suggest	  that	  RNF144B	  has	  a	  role	  in	  modulating	  a	  subset	  of	  TLR4-­‐inducible	  cytokines	  that	  are	  important	  for	  antigen-­‐specific	  T-­‐cell	  responses.	  	  	  
4.3.2.	  	   p21WAF1	  as	  a	  candidate	  target	  of	  RNF144B	  in	  human	  macrophages.	  Cyclin-­‐dependent	  kinase	  (CDK)	  inhibitors	  (CDKI)	  are	  proteins	  that	   inhibit	  CDKs	  and	  promote	  cell	  cycle	  arrest	  when	  upregulated.	  CDKIs	  are	  divided	  into	  two	  groups,	   the	  CIP/KIP	  family	  that	  consists	  of	  p21WAF1,	  p27Kip1	  and	  p57Kip2,	  and	  the	  INK4	  family	  that	  consists	   of	   p15INK4b,	   p16INK4a,	   p18INK4c	   and	   p19INK4d	   (Sherr	   and	   Roberts,	   1995).	  p21WAF1	   is	   a	   p53	   transcriptional	   target	   protein	   that	   is	   involved	   in	   many	   cellular	  processes,	  dependent	  on	  its	  intracellular	  localisation.	  Within	  the	  nucleus,	  it	  functions	  as	   a	  negative	   cell	   cycle	   regulator	   and	   tumour	   suppressor,	  while	   in	   the	   cytoplasm	   it	  regulates	  migration,	  apoptosis	  and	  cell	  proliferation	  (Romanov	  et	  al.,	  2012).	  p21WAF1	  regulates	  cell	  cycle	  progression	  at	  the	  G1	  and	  S	  phase	  by	  binding	  and	  inhibiting	  a	  wide	  variety	   of	   cyclin/CDK	   complexes	   to	   inhibit	   their	   activity	   (Brugarolas	   et	   al.,	   1999).	  p21WAF1	   also	   binds	   to	   proliferating	   cell	   nuclear	   antigen	   (PCNA3)	   to	   block	   DNA	  synthesis	   by	   preventing	   the	   interaction	   between	   PCNA	   and	   DNA	   polymerase	   δ	  (Flores-­‐Rozas	  et	  al.,	  1994;	  Waga	  et	  al.,	  1994).	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Previous	   studies	   reported	   that	   p21WAF1	   protein	   negatively	   regulates	   IL-­‐1β	  transcription	   in	   human	   macrophages	   (Scatizzi	   et	   al.,	   2009)	   and	   that	   RNF144B	  ubiquitinates	   p21WAF1	  leading	   to	   its	   degradation	   by	   the	   proteasome	   (Conforti	   et	   al.,	  2013;	  Ng	   et	   al.,	   2003).	   Analysis	   of	   the	   domains	   responsible	   for	   repression	   of	   IL-­‐1β	  revealed	  that	  the	  CDK	  domain	  (amino	  acids	  46	  to	  65)	  of	  p21WAF1,	  and	  not	  the	  PCNA-­‐	  or	  cyclin-­‐	  binding	  domains	  was	  important	  for	  IL-­‐1β	  suppression	  (Scatizzi	  et	  al.,	  2009),	  although	   the	   exact	   mechanism	   of	   suppression	   is	   not	   known.	   In	   support	   of	   this,	  adenoviral	   gene	   transfer	   of	   either	  p21WAF1	   or	  p16INK4a	   and	   selective	   small	  molecule	  inhibition	  of	  CDK4/6	  (shared	  targets	  of	   	   	  p21WAF1	  and	  p16INK4a)	  were	  reported	  to	  be	  therapeutic	   in	   animal	   models	   of	   RA	   (Nasu	   et	   al.,	   2000;	   Sekine	   et	   al.,	   2008).	   The	  therapeutic	   effect	   of	   forced	   expression	   of	   p21WAF1	   or	   p16INK4a	   was	   attributed	   to	   a	  reduction	  in	  synovial	  fibroblast	  proliferation	  as	  well	  as	  suppression	  of	  IL-­‐1β,	  IL-­‐6	  and	  TNFα	   levels	   independently	   of	   reduced	   synovial	   proliferation	   (Nasu	   et	   al.,	   2000).	   A	  peptide	   mimic	   of	   p21WAF1	   was	   also	   reported	   to	   be	   therapeutic	   for	   murine	   lupus,	  although	  this	  was	   found	  to	  be	  due	  to	  pro-­‐apoptotic	  effects	  and	  reduced	   lymphocyte	  proliferation	  (Goulvestre	  et	  al.,	  2005).	  	  	  The	  literature	  above	  led	  to	  my	  hypothesis	  that	  p21WAF1	  protein	  was	  the	  intermediary	  component	   connecting	   RNF144B	   to	   regulation	   of	   IL-­‐1β	   expression.	   The	   proposed	  mechanism	   was	   that	   RNF144B-­‐mediated	   proteasomal	   degradation	   of	   p21WAF1	   was	  required	   for	   derepression	   of	   IL-­‐1β	   gene	   expression.	   Therefore,	   experiments	   were	  conducted	   to	   examine	   the	   effect	   of	   proteosome	   inhibition	   of	   LPS-­‐regulation	   of	  p21WAF1	   protein	   in	   primary	   human	   and	   mouse	   macrophages.	   These	   experiments	  indeed	   revealed	   that	   the	   proteasome	   had	   more	   substantial	   effects	   in	   regulating	  p21WAF1	   protein	   expression	   in	   human	   macrophages	   than	   in	   mouse	   macrophages.	  However,	   further	   functional	   analysis	   by	   gene	   knock-­‐down	  did	   not	   reveal	   a	   role	   for	  RNF144B	   in	   negatively	   regulating	   p21WAF1	   protein	   expression	   in	   HMDM.	   This	   was	  somewhat	  surprising	  because	  it	  was	  shown	  that	  knockdown	  of	  RNF144B	  by	  S-­‐labeled	  antisense	  oligonucleotides	  did	  result	  in	  increased	  p21WAF1	  protein	  at	  12	  and	  24	  h	  post	  knockdown	   in	  H1299	  cells	   (Ng	  et	  al.,	  2003).	  However,	   it	   should	  be	  noted	   that	  even	  though	  this	  study	  reported	  that	  knockdown	  of	  RNF144B	  increased	  levels	  of	  all	  forms	  of	   p21WAF1	  protein,	   as	   assessed	   by	   2D	   electrophoresis,	   p21WAF1	  protein	   levels	   as	   a	  whole	  were	  reported	  to	  be	  only	  slightly	  affected	  (Ng	  et	  al.,	  2003)	  and	  it	  was	  suggested	  that	   additional	   ubiquitination	  or	  proteolysis	   pathways	  may	   regulate	   the	   stability	   of	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p21WAF1.	   RNF144B	   knockdown	   using	   siRNA	   in	   proliferating	   human	   epithelial	  keratinocytes	   also	   resulted	   in	   accumulation	   of	   p21WAF1	   protein	   from	   3	   days	   post-­‐knockdown,	  with	  most	  evident	  p21WAF1	  protein	  accumulation	  observed	  after	  7	  days,	  in	   synchrony	   with	   the	   timing	   for	   impairment	   of	   cell	   proliferation	   (Conforti	   et	   al.,	  2013).	   RNF144B	   was	   also	   shown	   in	   this	   study	   to	   be	   sensitive	   to	   proteasomal	  degradation	  and	  relatively	  unstable	  with	  ~70%	  of	  RNF144B	  protein	  degraded	  within	  the	   first	   4	   h	   of	   cycloheximide	   inhibition	   of	   protein	   synthesis	   and	   ~90%	   protein	  degraded	   at	   36	   h	   (Conforti	   et	   al.,	   2013).	   Thus,	   it	   was	   suggested	   that	   keratinocytes	  may	   utilise	   auxiliary	   mechanisms	   to	   sustain	   RNF144B	   protein	   throughout	  keratinocyte	   differentiation	   during	   which	   its	   inducing	   factor,	   p63,	   was	  downregulated.	  In	  view	  of	  these	  findings,	  it	  is	  unlikely	  that	  residual	  RNF144B	  protein	  in	   HMDM	   was	   preventing	   p21WAF1	   protein	   accumulation,	   especially	   since	   no	  difference	  in	  p21WAF1	  protein	  was	  observed	  at	  48	  h	  post-­‐knockdown,	  while	  RNF144B	  protein	   was	   reduced	   after	   4	   h	   LPS	   stimulation,	   24	   h	   post-­‐knockdown,	   in	   cells	  electroporated	   with	   siRNA	   targeting	   RNF144B,	   compared	   to	   cells	   electroporated	  without	  siRNA	  	  (Figure	  4.5A).	  	  	  As	  an	  RBR	  ubiquitin	  ligase,	  RNF144B	  may	  also	  require	  a	  protein	  complex	  to	  mediate	  ubiquitination,	  such	  as	  with	  HOIL	  within	  the	  LUBAC	  (see	  Section	  1.2.2	  and	  Section	  
4.1).	  However,	  since	  RNF144B	  knockdown	  resulted	  in	  an	  observable	  reduction	  in	  IL-­‐1β	   mRNA	   even	   without	   concurrent	   effects	   on	   p21WAF1	   protein,	   it	   is	   difficult	   to	  conclude	   whether	   RNF144B	   does	   have	   a	   role	   in	   regulating	   p21WAF1	   protein	  expression	   in	   human	   macrophages,	   based	   on	   the	   findings	   from	   this	   chapter.	   It	   is	  possible	   that	   in	   macrophages,	   RNF144B	   is	   regulating	   only	   a	   particular	   form	   of	  p21WAF1	  protein	  that	  is	  not	  reflected	  by	  antibody	  detection	  of	  p21WAF1	  protein	  levels	  as	  a	  whole.	  It	  is	  also	  possible	  that	  RNF144B	  has	  different	  roles	  in	  regulating	  p21WAFI1	  protein	  expression	  in	  different	  cell	  types	  and/or	  in	  different	  activation	  states,	  and/or	  that	   RNF144B	   regulates	   p21WAF1	   function	   rather	   than	   protein	   expression	   levels	   in	  human	   macrophages.	   Nevertheless,	   p21WAF1	   protein	   appeared	   to	   be	   under	   more	  stringent	   control	   in	   human	   macrophages	   as	   compared	   to	   mouse	   macrophages,	   as	  p21WAF1	  protein	  was	  more	  highly	  induced	  by	  LPS	  and	  more	  sensitive	  to	  proteasomal	  degradation	   in	   unstimulated	  HMDM	  compared	   to	  BMM	   (Figure	   4.7).	   This	   suggests	  that	  it	  has	  an	  important	  role	  in	  immune	  responses,	  perhaps	  in	  control	  of	  apoptosis	  in	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5.1.	  Introduction	  One	   of	   the	   original	   goals	   of	   this	   thesis	  was	   to	   generate	   new	  knowledge	   in	   our	  understanding	  of	  direct	  antimicrobial	  pathways	  utilized	  by	  human	  macrophages.	  The	   genetic	   approach	   employed	   in	   Chapter	   3	   identified	   effects	   on	  inflammasome	  responses,	  which	  were	  pursued	  at	  a	  mechanistic	  level	  in	  Chapter	  
4.	  However,	  Chapter	  3	  did	  not	  yield	  phenotypic	  effects	  for	  the	  selected	  genes	  on	  bacterial	   clearance	   by	   human	   macrophages.	   I	   therefore	   employed	   a	  pharmacological	  approach,	  as	  a	  complementary	  strategy,	  to	  identify	  mechanisms	  involved	   in	   regulating	   human	   macrophage	   antimicrobial	   pathways.	  Pharmacological	   compounds	   found	   to	   promote	   antimicrobial	   activities	   could	  provide	   new	   opportunities	   for	   therapeutic	   exploitation,	   while	   compromised	  antimicrobial	   responses	   would	   identify	   potential	   limitations	   for	   therapeutic	  applications.	   This	   chapter	   describes	   the	   findings	   from	   the	   screening	   of	   several	  compounds,	   focusing	   on	   those	   that	   showed	   promise	   for	   modulating	   human	  macrophage	   antimicrobial	   responses,	   and	   the	   mechanisms	   by	   which	   these	  compounds	  exert	  such	  effects.	  	  Among	  the	  compounds	  chosen	  for	  investigation	  were	  HDACi	  that	  are	  currently	  in	  clinical	  use	  as	  anti-­‐cancer	  agents,	  or	  in	  development	  as	  potential	  therapeutics	  for	  inflammatory	  diseases	  (Dokmanovic	  et	  al.,	  2007;	  Kang	  et	  al.,	  2012;	  Shakespear	  et	  al.,	   2011;	  Vigushin	  et	   al.,	   2001).	  As	  mentioned	   in	  Chapter	   1,	  HDACi	  have	  been	  demonstrated	   to	  suppress	   inflammatory	  responses	   (Halili	   et	  al.,	  2009),	  but	  are	  also	   implicated	   in	   compromised	  host	  defence.	   For	   example,	  TSA	  was	   shown	   to	  interfere	   with	   innate	   immune	   responses	   by	   impairing	   production	   of	   ROS	   and	  iNOS	   and	   decreasing	   the	   expression	   of	   phagocytic	   and	   Toll-­‐like	   receptors	   in	  response	  to	  intracellular	  Gram-­‐positive	  and	  Gram-­‐negative	  pathogens	  (Mombelli	  et	  al.,	  2011;	  Roger	  et	  al.,	  2011).	  However,	   these	  findings	  were	  based	  on	  studies	  conducted	  in	  mice	  or	  in	  mouse	  macrophages,	  and	  the	  effects	  of	  HDACi	  on	  human	  macrophages	  antimicrobial	   responses	  had	  not	  yet	  been	  analysed.	  Therefore,	   in	  this	   chapter,	   the	   broad	   spectrum	  HDACi,	   TSA	   and	   SAHA,	  were	   investigated	   for	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effects	   on	   human	   macrophage	   antimicrobial	   responses	   against	   E.	   coli	   and	   S.	  Typhimurium.	  	  	  In	  addition	   to	  HDACi,	  GPCRs	  were	   considered	  as	   relevant	  agents	   to	   investigate	  for	  effects	  on	  human	  macrophage	  antimicrobial	  pathways,	  since	  many	  GPCRs	  are	  involved	   in	   regulation	   of	  macrophage	   functions	   (Lattin	   et	   al.,	   2007)	   and	   GPCR	  and	   TLR	   crosstalk	   impacts	  many	   inflammatory	   and	   antimicrobial	   pathways	   in	  macrophages	   (Hajishengallis	   and	   Lambris,	   2010;	   Hajishengallis	   and	   Lambris,	  2011).	   In	   particular,	   studies	   on	   C5aR	   report	   that	   crosstalk	   between	   C5aR	   and	  TLR4	   modulates	   secretion	   of	   pro-­‐inflammatory	   cytokines	   (Bosmann	   et	   al.,	  2011a;	  Bosmann	   et	   al.,	   2011b;	  Hawlisch	   et	   al.,	   2005;	  Okazaki	   et	   al.,	   2011)	   and	  that	   crosstalk	   between	   C5aR	   and	   TLRs	   is	   exploited	   by	   pathogens	   such	   as	   S.	  
aureus	  and	  P.	  gingivalis	  to	  subvert	  antimicrobial	  responses	  (Postma	  et	  al.,	  2004;	  Wang	  et	  al.,	  2010b).	  There	  is	  also	  considerable	  interest	  in	  C5aR	  as	  a	  therapeutic	  target	  in	  inflammatory	  diseases	  (Abe	  et	  al.,	  2012;	  Dang	  et	  al.,	  2015;	  Fonseca	  et	  al.,	  2009;	  Iyer	  et	  al.,	  2011;	  Li	  et	  al.,	  2014b;	  Staab	  et	  al.,	  2014;	  Woodruff	  et	  al.,	  2006;	  Xu	   et	   al.,	   2014;	   Zhang	   et	   al.,	   2014).	   However,	   the	   majority	   of	   studies	   on	   the	  mechanism	  of	  C5aR	  crosstalk	  with	  TLR4	  utilised	  mouse	  rather	  than	  human	  cells	  (Cavaillon	   et	   al.,	   1990;	  Hajishengallis	   and	   Lambris,	   2010).	   As	   a	   previous	   study	  reported	   divergence	   in	   transcriptional	   responses	   of	   TLR4-­‐regulated	   genes	   in	  human	   and	  mouse	  macrophages	   (Schroder	   et	   al.,	   2012a),	   it	  was	   imperative	   to	  conduct	   investigations	   on	   GPCRs	   in	   human	   macrophages	   as	   	   well.	   Thus,	  modulators	   of	   the	   C5aR	   and	   other	   GPCRs	   were	   tested	   for	   effects	   on	   human	  macrophage	   antimicrobial	   pathways	   upon	   co-­‐infection	   with	   E.	   coli	   and	   S.	  Typhimurium.	  Among	  the	  GPCR	  ligands	  screened,	  the	  complement	  product	  C5a	  was	   found	   to	   influence	   pro-­‐inflammatory	   cytokine	   production	   and	   bacterial	  clearance	  by	  human	  macrophages.	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5.2.	  Results	  
5.2.1.	   IFNγ	   priming	   effectively	   reduces	   E.	   coli	   intracellular	   survival	   in	  
human	  macrophages	  Prior	   to	   conducting	   experiments	   to	   test	   various	   pharmacological	   compounds,	  experiments	  were	  conducted	  using	  IFNγ,	  a	  soluble	  cytokine	  belonging	  to	  the	  type	  II	   class	   of	   interferons	   (Gray	   and	   Goeddel,	   1982),	   so	   as	   to	   establish	   a	   positive	  control	   for	   these	   studies.	   IFNγ	   has	   a	   well-­‐established	   role	   in	   promoting	  macrophage	  antimicrobial	   responses	   (Schroder	  et	  al.,	  2004).	  The	  effect	  of	   IFNγ	  on	  the	  capacity	  of	  human	  macrophages	  to	  clear	  intracellular	  E.	  coli	  was	  examined	  by	   conducting	   initial	   experiments	   using	   PMA-­‐differentiated	   THP-­‐1	   cells.	   PMA-­‐differentiated	  THP-­‐1	   cells	  were	  primed	  with	   5	   ng/mL	  of	   human	   IFNγ	   for	   24	  h	  followed	  by	  infection	  with	  E.	  coli	  at	  a	  MOI	  of	  10	  and	  100.	  Intracellular	  survival	  of	  
E.	  coli	  was	  assayed	  at	  2,	  8	  and	  24	  h	  post-­‐infection.	  IFNγ	  priming	  reduced	  E.	  coli	  survival	   by	   approximately	   50%	   at	   8	   and	   24	   h	   post-­‐infection	   (Figure	   5.1A).	  Similar	  experiments	  were	  performed	  in	  HMDM	  cells.	  In	  these	  cells,	  IFNγ	  had	  an	  even	   more	   substantial	   antimicrobial	   effect,	   with	   significant	   reduction	   of	  intracellular	  survival	  of	  E.	  coli	  in	  IFNγ	  pre-­‐treated	  versus	  untreated	  cells	  at	  2	  and	  8	   h	   post-­‐infection,	  while	   survival	   of	  E.	  coli	   at	   24	   h	   untreated	   and	   IFNγ	   treated	  HMDM	  was	  minimal	   (Figure	   5.1B).	   HMDM	   viability	   was	   not	   affected	   by	   IFNγ	  treatment	   as	   assayed	  by	  MTT	  assay	   (Figure	   5.1C),	   thus	   implying	   that	   reduced	  bacterial	   loads	  reflected	  enhanced	  killing	  capacity	  of	  the	  HMDM.	  These	  findings	  suggested	  that	  HMDM	  provided	  a	  more	  sensitive	  system	  than	  PMA-­‐differentiated	  THP-­‐1	  macrophages	  to	  monitor	  agents	  that	  modulate	  macrophage	  antimicrobial	  pathways.	  Thus,	  subsequent	  experiments	  utilised	  HMDM.	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Figure	   5.1:	   Priming	   with	   IFNγ 	   reduces	   intracellular	   survival	   of	   E.	   coli	   in	  




Pharmacological	  modulation	  of	  human	  macrophage	  antimicrobial	  responses	  
	  	  	  
121	  
5.2.2.	   Priming	  with	  SAHA	  reduces	  S.	  Typhimurium	   intracellular	   survival	   in	  
M-­‐CSF-­‐derived	  HMDM.	  	  Having	  established	  the	  above	  system	  for	  monitoring	  modulation	  of	  macrophage	  antimicrobial	   pathways,	   initial	   experiments	   to	   investigate	   the	   effect	   of	   HDACi	  treatment	   were	   conducted	   using	   SAHA.	   In	   initial	   experiments,	   HMDM	   were	  primed	  with	  10	  μM	  SAHA	  or	  5	  ng/mL	  IFNγ	  (as	  a	  positive	  control)	  overnight	  for	  18	  h.	  Cells	  were	   then	   infected	  with	  E.	  coli	  or	  S.	  Typhimurium	  at	  MOI	  100.	  As	  a	  professional	  intracellular	  pathogen,	  S.	  Typhimurium	  survival	  within	  HMDM	  at	  24	  h	  post-­‐infection	  is	  higher	  than	  E.	  coli.	  This	  pathogen	  was	  thus	  incorporated	  as	  the	  primary	  screen	  to	  allow	  for	  more	  accurate	  analysis	  of	  antimicrobial	  effects	  that	  might	  only	  be	  apparent	  at	   later	  time	  points.	   Intracellular	  survival	  was	  assessed	  at	  2	  and	  24	  h	  post-­‐infection,	  and	  cell	  viability	  was	  also	  examined	  by	  LDH	  release	  assays,	   using	   supernatants	   collected	   at	   24	   h	   post-­‐infection.	   As	   expected,	   IFNγ	  priming	  reduced	  survival	  of	  both	  E.	  coli	  and	  S.	  Typhimurium	  in	  HMDM	  at	  2	  h	  and	  24	  h	  post-­‐infection.	  Interestingly,	  priming	  with	  SAHA	  also	  reduced	  survival	  of	  E.	  
coli	   and	  S.	  Typhimurium,	  with	  a	   similar	   effect	  observed	   to	   that	   seen	  with	   IFNγ	  priming	   	   (Figure	   5.2A	   and	  B).	   This	  was	   not	   due	   to	  HDACi-­‐induced	   cell	   death,	  since	  SAHA	  at	  the	  concentration	  used	  did	  not	  increase	  LDH	  release	  from	  HMDM	  (Figure	  5.2C).	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Figure	  5.2:	  Priming	  with	  SAHA	  reduces	  intracellular	  survival	  of	  E.	  coli	  and	  S.	  
Typhimurium	  in	  primary	  human	  macrophages.	  	  HMDM	  were	  primed	  with	  10	  μM	  SAHA	  or	  5	  ng/mL	  IFNγ	   for	  18	  h	   then	   infected	  with	  E.	  coli	  or	  S.	  Typhimurium	  at	  MOI	  100.	  Intracellular	  survival	  was	  assessed	  at	  2	   and	   24	   h	   post-­‐infection.	   (A)	   Intracellular	   survival	   of	   E.	   coli	   at	   24	   h	   post-­‐infection.	  Data	  (mean+range)	  shows	  technical	  replicates	  from	  1	  experiment,	  and	  are	  representative	  of	  3	  independent	  experiments.	   (B)	  Intracellular	  survival	  of	  S.	  Typhimurium	  at	  2	  and	  24	  h	  post-­‐infection	  Data	  (mean+SEM)	  are	  combined	  from	  3	   independent	   experiments,	   and	   are	   presented	   as	   fold	   change	   relative	   to	  untreated	   controls.	   ***P<0.001;	   by	   one-­‐way	   ANOVA	   followed	   by	   Dunnett’s	  Multiple	  Comparison	  test.	  (C)	  Cell	  death	  was	  quantified	  by	  assessing	  LDH	  release	  into	   culture	   supernatants	   from	   HMDM	   infected	   with	   S.	   Typhimurium.	   Data	  (mean+range)	  are	  combined	  from	  2	  independent	  experiments.	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5.2.3.	   SAHA	  does	  not	  affect	  bacterial	  proliferation	  Although	  priming	  with	  10	  μM	  SAHA	  appeared	  to	  reduce	  intracellular	  survival	  of	  
E.	  coli	  and	  S.	  Typhimurium	  in	  HMDM,	  there	  was	  a	  possibility	  that	  the	  compound	  itself	  was	  directly	  affecting	  bacterial	  growth	  or	  survival	  (rather	  than	  influencing	  on	  macrophage	   antimicrobial	   responses).	   In	   order	   to	   examine	   this	   possibility,	  the	   effect	   of	   SAHA	   on	   the	   growth	   of	   S.	   Typhimurium	   was	   monitored.	   S.	  Typhimurium	  was	  grown	  overnight	  in	  LB	  broth.	  On	  the	  following	  day,	  1	  AU600nm	  of	  S.	  Typhimurium	  was	  used	  to	   inoculate	  cell	  culture	  media,	  and	  these	  cultures	  were	  grown	   in	   the	  presence	  or	  absence	  of	  30	  μM	  SAHA.	  The	  optical	  density	  of	  bacterial	   cultures	  was	  measured	  by	  spectrophotometry	  over	  a	  period	  of	  7	  h	   to	  monitor	   S.	  Typhimurium	   growth.	   There	   was	   no	   difference	   in	   S.	  Typhimurium	  growth	   in	   cell	   culture	   media	   with	   or	   without	   treatment	   with	   30	   μM	   SAHA,	  indicating	   that	   this	  HDAC	   inhibitor	  was	  not	   exerting	  direct	   effects	   on	  bacterial	  growth	   (Figure	   5.3).	   Thus,	   this	   finding	   supported	   the	   conclusion	   that	   SAHA	  treatment	   reduced	   intracellular	   bacterial	   survival	   by	   enhancing	   macrophage	  antimicrobial	  responses.	  	  
	  
	  
Figure	  5.3:	  SAHA	  treatment	  does	  not	  impair	  S.	  Typhimurium	  growth.	  	  
S.	  Typhimurium	  were	  cultured	   in	  HMDM	  complete	  cell	  media	  alone	  or	  with	  30	  μM	  SAHA	  over	  7	  h.	  Optical	  densities	  of	  cultures	  were	  measured	  as	  an	  indication	  of	  the	  rate	  of	  growth	  of	  S.	  Typhimurium.	  Data	  (mean+SEM)	  are	  combined	  from	  3	  independent	  experiments.	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5.2.4.	   Priming	  or	  co-­‐treatment	  with	  SAHA	  reduces	  intracellular	  survival	  of	  S.	  
Typhimurium	  	  and	  E.	  coli	  in	  HMDM.	  Consequently,	   it	   was	   of	   interest	   to	   examine	   the	   effect	   of	   SAHA	   in	   HMDM	   co-­‐treated	  with	  S.	  Typhimurium	   infection	   to	   see	   if	   acute	   treatment	   also	   enhanced	  antimicrobial	   responses.	   Thus,	   HMDM	  were	   primed	   or	   co-­‐treated	   with	   10	   μM	  SAHA	   and	   infected	   with	   S.	  Typhimurium	   or	   E.	   coli	   at	   MOI	   100.	   Again,	   HMDM	  were	   also	   primed	   with	   5	   ng/mL	   IFNγ	   as	   a	   positive	   control	   for	   activation	   of	  macrophage	   antimicrobial	   mechanisms.	   As	   previously	   observed,	   priming	   with	  SAHA	  resulted	  in	  reduction	  in	  intracellular	  survival	  of	  both	  S.	  Typhimurium	  and	  
E.	  coli	   at	   24	  h	  post-­‐infection	  with	  80-­‐90%	  reduction	   in	  bacterial	   loads	   (Figure	  
5.4A	   to	   D).	   In	   comparison,	   co-­‐treatment	  with	   SAHA	   also	   reduced	   intracellular	  survival,	  but	  this	  regime	  was	  somewhat	  less	  effective	  than	  priming	  with	  SAHA.	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Figure	   5.4:	   Co-­‐treatment	   of	   primary	   human	   macrophages	   with	   SAHA	  
reduces	  intracellular	  survival	  of	  S.	  Typhimurium	  and	  E.	  coli.	  	  HMDM	  were	  primed	  with	  either	  10	  μM	  SAHA	  or	  5	  ng/mL	  IFNγ  for	  18	  h,	  and	  were	  then	   infected	  with	  S.	   Typhimurium	  or	  E.	  coli	   at	  MOI	  100.	  Alternatively,	  HMDM	  were	   co-­‐treated	   with	   10μM	   SAHA	   at	   the	   time	   of	   infection.	   (A-­‐B)	   Intracellular	  survival	   of	   (A)	   S.	   Typhimurium	   and	   (B)	   E.	   coli	   was	   assessed	   at	   24	   h	   post-­‐infection.	  Data	  (mean+SEM)	  are	  combined	  from	  4	  independent	  experiments,	  and	  are	   presented	   as	   fold	   change	   relative	   to	   untreated	   controls.	   ***P<0.001;	  ****P<0.0001;	   by	   one-­‐way	  ANOVA	   followed	   by	  Dunnett’s	  Multiple	   Comparison	  test.	   p	   indicates	   primed	   treatments,	   co	   indicates	   co-­‐treatment.	   (C-­‐D)	  Representative	   experiments	   showing	   intracellular	   survival	   of	   (C)	   S.	  Typhimurium	   and	   (D)	   E.	   coli.	   Data	   (mean+range)	   shows	   technical	   replicates	  from	  1	  experiment.	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5.2.5.	   Comparison	  of	  efficacy	  of	  TSA	  and	  SAHA	  as	  HDAC	  inhibitors	  in	  HMDM	  SAHA	  is	  a	  broad-­‐spectrum	  HDAC	  inhibitor	  that	  targets	  multiple	  Class	  I	  and	  Class	  II	  HDACs.	  However,	   it	  was	   possible	   that	   effects	   on	   non-­‐HDAC	   targets	   could	   be	  responsible	   for	   the	   effects	   on	   bacterial	   clearance	   that	   were	   observed.	   Thus,	  comparison	   with	   another	   broad-­‐spectrum	   HDACi,	   Trichostatin	   A	   (TSA),	   was	  considered	  useful	   to	  determine	  whether	   the	  observed	  phenotype	   likely	   related	  to	  HDAC	  inhibition.	  Moreover,	  comparison	  between	  these	  two	  HDACi	  could	  also	  be	  useful	   for	  future	  investigation	  into	  which	  HDACs	  are	  involved	  in	  modulating	  antimicrobial	   responses.	   Although	   it	   is	   difficult	   to	   completely	   and	   accurately	  characterise	   the	   HDACs	   targeted	   by	   TSA	   and	   SAHA	   due	   to	   difficulties	   in	  producing	   active	   recombinant	   enzymes	   for	   in	   vitro	   assays,	   TSA	   and	   SAHA	   are	  reported	  to	  target	  overlapping	  but	  distinct	  combinations	  of	  HDACs	  (TSA	  targets	  Class	   I	   HDACs:	   HDAC	   1	   and	   3,	   and	   Class	   II	   HDACs:	   HDAC	   4,	   6,	   and	   10	   with	  IC50~20	  nM,	  while	  SAHA	  targets	  Class	  I	  HDACs:	  HDACs	  1,	  2,	  3	  and	  Class	  II	  HDACs:	  HDAC	  6	  with	  IC50<86	  nM)	  providing	  an	  avenue	  for	  narrowing	  down	  the	  HDACs	  involved	  in	  antimicrobial	  mechanisms	  (Miller	  et	  al.,	  2003;	  Xu	  et	  al.,	  0000).	  	  	  To	   determine	   the	   concentrations	   of	   TSA	   and	   SAHA	   that	   have	   approximately	  equal	   effects	   in	   causing	   histone	   hyperacetylation	   (a	   hallmark	   of	   HDAC	  inhibition),	  HMDM	  were	  treated	  with	  varying	  concentrations	  of	  TSA	  and	  SAHA	  to	  compare	  the	  effect	  on	  acetylation	  of	  histone	  H3.	   It	  was	   found	  that	  treatment	  of	  HMDM	  with	  1	  μM	  of	  TSA	   and	  10	  μM	  of	   SAHA	   resulted	   in	   approximately	   equal	  levels	  of	  hyperacetylation	  of	  histone	  H3	  protein	  (Figure	  5.5).	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Figure	   5.5:	   Levels	   of	   acetylated	   histone	   H3	   protein	   in	   primary	   human	  
macrophages	  after	  treatment	  with	  TSA	  or	  SAHA	  is	  comparable.	  	  HMDM	  were	  treated	  with	  1	  µM	  TSA	  or	  10	  µM	  SAHA	  for	  6	  h,	  then	  cell	  lysates	  were	  harvested	   and	   western	   blots	   conducted.	   Data	   shows	   immunoblots	   from	   one	  experiment,	  and	  is	  representative	  of	  3	  independent	  experiments.	  	  	  
5.2.6.	   Priming	   with	   HDAC	   inhibitors	   reduces	   phagocytosis	   of	   S.	  
Typhimurium	  	  and	  E.	  coli	  in	  HMDM,	  whilst	  co-­‐treatment	  with	  HDAC	  inhibitors	  
does	  not.	  Since	   the	   previous	   experiments	   with	   SAHA	   priming	   showed	   reduced	  intracellular	  survival	  even	  at	  2	  h	  post-­‐infection	  (Figure	  5.2B),	  it	  was	  important	  to	   determine	  whether	   the	   HDACi	  was	   having	   an	   effect	   on	   phagocytosis	   rather	  than	   intracellular	  survival.	  This	  was	  particularly	   important	  as	  studies	   in	  mouse	  macrophages	  showed	  that	  18	  h	  priming	  with	  TSA	  and	  another	  broad-­‐spectrum	  HDACi,	  valproic	  acid,	  reduced	  cellular	  uptake	  of	  E.	  coli	  and	  Staphyloccocus	  aureus	  (Mombelli	  et	  al.,	  2011).	  To	  assess	  phagocytosis,	  uptake	  of	  pHrodoTM	  Green	  E.	  coli	  Bioparticles	   was	   measured	   by	   flow	   cytometry.	   These	   non-­‐living	   E.	   coli	   are	  conjugated	   to	   a	   pH-­‐sensitive	   dye	   that	   is	   non-­‐fluorescent	   outside	   the	   cell	   at	  neutral	  pH,	  but	   fluoresces	  under	  acidic	  conditions,	   such	  as	  within	  phagosomes.	  HMDM	  were	  primed	  with	  either	  1	  μM	  TSA,	  10	  μM	  SAHA	  or	  5	  ng/mL	  IFNγ 	  for	  18	  h,	   followed	   by	   treatment	   with	   pHrodoTM	   Green	   E.	   coli	   for	   1.5	   h.	   Alternatively,	  HMDM	  were	  co-­‐treated	  with	  pHrodoTM	  Green	  E.	  coli	  and	  either	  1	  μM	  TSA,	  10	  μM	  SAHA,	   5	   ng/mL	   IFNγ 	   or	   10	   μM	   cytochalasin	   D	   for	   1.5	   h.	   Treatment	   with	  cytochalasin	  D	  was	  conducted	  as	  a	  positive	  control	  for	  inhibition	  of	  phagocytosis,	  as	  this	  agent	   inhibits	  actin	  polymerisation	  and	  thus	  phagocytosis	  (Casella	  et	  al.,	  1981).	   Phagocytic	   uptake	   of	   pHrodoTM	   Green	   E.	   coli	   was	   then	   measured	   by	  median	   fluorescence	   intensity	   as	   assessed	  by	   flow	   cytometry.	   Priming,	   but	   not	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co-­‐treatment	   with	   either	   TSA	   or	   SAHA,	   was	   found	   to	   reduce	   phagocytosis	   of	  pHrodoTM	  Green	  E.	  coli	  by	  50%	  or	  more	  in	  HMDM	  (Figure	  5.6).	  	  	  
	  
Figure	  5.6:	  Priming,	  but	  not	  co-­‐treatment,	  of	  primary	  human	  macrophages	  
with	  HDAC	  inhibitors	  impairs	  phagocytosis	  of	  E.	  coli.	  	  HMDM	  were	   primed	  with	   1	   μM	   TSA,	   10	   μM	   SAHA	   or	   5	   ng/mL	   IFNγ 	   for	   18	   h,	  followed	   by	   treatment	   with	   pHrodoTM	   Green	   E.	   coli	   for	   1.5	   h.	   Alternatively,	  HMDM	  were	  co-­‐treated	  with	  pHrodoTM	  Green	  E.	  coli	  and	  either	  1	  μM	  TSA,	  10	  μM	  SAHA,	  5	  ng/mL	  IFNγ 	  or	  10	  μM	  cytochalasin	  D	  for	  1.5	  h.	  Phagocytic	  uptake	  of	  E.	  
coli	   was	   then	  measured	   by	  median	   fluorescence	   intensity	   as	   assessed	   by	   flow	  cytometry.	   Data	   (mean+SEM,	   combined	   from	   3	   independent	   experiments)	  represents	   fold	  change	  relative	   to	  control	  cells	   treated	  with	  pHrodoTM	  Green	  E.	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bacterial	   survival	   at	   24	   h	   post-­‐infection,	   with	   TSA	   having	   a	  more	   pronounced	  effect	  than	  SAHA	  (Figure	  5.7).	  In	  contrast,	  bacterial	  survival	  at	  1	  h	  post-­‐infection	  was	   not	   affected	   by	   co-­‐treatment	   with	   either	   of	   the	   HDACi.	   These	   findings	  confirm	   that	   co-­‐treatment	   with	   HDACi	   does	   not	   affect	   phagocytosis,	   but	   still	  promotes	  clearance	  of	  intracellular	  bacteria.	  The	  results	  also	  explain	  the	  greater	  effect	   of	   priming	   with	   SAHA,	   as	   compared	   to	   co-­‐treatment,	   in	   affecting	  intracellular	  bacterial	  loads	  in	  earlier	  experiments	  (Figure	  5.4).	  	  
	  
Figure	   5.7:	   Co-­‐treatment	   of	   primary	   human	   macrophages	   with	   TSA	   and	  
SAHA	  reduces	  intracellular	  survival	  of	  S.	  Typhimurium	  and	  E.	  coli.	  	  HMDM	  were	   co-­‐treated	   with	   either	   1	   μM	   TSA	   or	   10	   μM	   SAHA	   at	   the	   time	   of	  infection	  with	  S.	  Typhimurium	  or	  E.	  coli	  at	  MOI	  100.	  Intracellular	  survival	  of	  (A)	  
S.	  Typhimurium	  and	  (B)	  E.	  coli	  was	  assessed	  at	  1	  h	  and	  24	  h	  post-­‐infection.	  Data	  (mean+SEM)	  are	  combined	  from	  3	  independent	  experiments,	  and	  are	  presented	  as	  fold	  change	  relative	  to	  untreated	  controls.	  	  	  ***P<0.001;	  **P<0.01;	  by	  one-­‐way	  ANOVA	   followed	   by	   Dunnett’s	   Multiple	   Comparison	   test.	   co	   indicates	   co-­‐treatment.	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5.2.7.	   Co-­‐treatment	  of	  HMDM	  with	  TSA	  or	  SAHA	  at	  the	  time	  of	  infection	  with	  
S.	  Typhimurium	  increases	  mitochondrial	  ROS	  production	  Since	   treatment	   with	   TSA	   and	   SAHA	   reduced	   intracellular	   survival	   in	   human	  macrophages,	   subsequent	   studies	   investigated	   the	   antimicrobial	   mechanisms	  that	   might	   be	   involved.	   Immediate	   antimicrobial	   responses	   such	   as	   NADPH	  oxidase-­‐dependent	   ROS	   generation	   were	   unlikely	   to	   be	   involved,	   because	  intracellular	   bacterial	   loads	   at	   1	   h	   post-­‐infection	   were	   not	   affected	   by	   co-­‐treatment	   with	   HDACi.	   In	   contrast,	   TLR-­‐inducible	   mitoROS	   production	   was	  previously	  shown	  to	  occur	  as	  a	  late	  response	  in	  mouse	  macrophages,	  and	  to	  have	  an	   important	  role	   in	   the	  clearance	  of	   intracellular	  S.	  Typhimurium	  (West	  et	  al.,	  2011).	   Moreover,	   previous	   studies	   have	   reported	   that	   treatment	   with	   various	  HDACi,	   including	  TSA,	  results	   in	   loss	  of	  mitochondrial	  membrane	  potential	  and	  induction	   of	  mitoROS	   in	   breast	   cancer	   cells	   and	   human	   lymphoma	   U937	   cells	  (Rehman	   et	   al.,	   2014;	   Sun	   et	   al.,	   2014).	   For	   these	   reasons,	   experiments	   were	  conducted	  to	  determine	  whether	  HDACi	  enhanced	  the	  generation	  of	  mitoROS	  by	  HMDM	  upon	  bacterial	  challenge.	  	  To	  measure	  release	  of	  mitoROS,	  HMDM	  were	  co-­‐treated	  with	  1	  μM	  TSA	  or	  10	  μM	  SAHA	  during	   infection	  with	  S.	  Typhimurium	  at	  MOI	   100.	   At	   6	   h	   post-­‐infection,	  MitoSOXTM	  Red	   was	   added	   to	   cells	   and	   10	  minutes	   later,	   median	   fluorescence	  intensity	   was	   measured	   by	   flow	   cytometry.	   MitoSOXTM	   Red	   is	   a	   dye	   that	  possesses	  a	  positive	  charge	  due	  to	  a	  triphosphonium	  group,	  selectively	  targeting	  it	   to	   the	   mitochondria.	   Within	   live	   cells,	   MitoSOXTM	   Red	   is	   oxidised	   by	  mitochondrial	   superoxide	   (but	   not	   by	   other	   ROS	   or	   RNS)	   and	   subsequently	  fluoresces	   red	   upon	   binding	  mitochondrial	   nucleic	   acids.	   No	   fluorescence	   was	  emitted	  from	  S.	  Typhimurium-­‐infected	  cells	  compared	  to	  uninfected	  cells,	  while	  addition	   of	   MitoSOXTM	   Red	   alone	   resulted	   in	   a	   slight	   increase	   in	   median	  fluorescence	  (Figure	  5.8).	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Figure	  5.8:	  Co-­‐treatment	  of	  HMDM	  with	  either	  TSA	  or	  SAHA	  at	  the	  time	  of	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5.2.8.	   Inhibition	   of	   mitochondrial	   ROS	   production	   rescues	   survival	   of	   S.	  
Typhimurium	  in	  HMDM	  co-­‐treated	  with	  TSA	  or	  SAHA.	  	  MitoTracker	   Red	   CMXRos	   (obtained	   as	   a	   kind	   gift	   from	   Dr.	   Markus	   Kerr,	  Teasdale	  Group,	  Institute	  for	  Molecular	  Bioscience)	  is	  a	  mitochondrial	  stain	  that	  is	   commonly	   used	   to	   measure	   mitochondrial	   membrane	   potential	   (MMP).	   It	  binds	   irreversibly	   to	   the	  polarised	  mitochondrial	  membrane,	   is	  retained	  within	  the	  mitochondria	  (Poot	  et	  al.,	  1996)	  and	  thus	  blocks	  generation	  of	  mitoROS.	  To	  determine	  whether	  mitoROS	  contributed	   to	  enhanced	  bacterial	   clearance	  upon	  HDACi	  co-­‐treatment,	  MitoTracker	  Red	  CMXRos	  was	  used	  to	  block	  generation	  of	  mitoROS	  in	  infection	  assays.	  	  	  	  Treatment	   of	   S.	  Typhimurium-­‐infected	   HMDM	   with	   MitoTracker	   Red	   CMXRos	  was	  first	  optimised	  by	  treating	  cells	  with	  varying	  concentrations	  over	  24	  h	  and	  monitoring	   cell	   viability,	   to	   assess	   the	   incidence	   of	   cell	   death	   due	   to	   impaired	  mitochondria	   function.	   It	   was	   found	   that	   these	   cells	   tolerated	   treatment	   of	  HMDM	  for	  24	  h	  with	  MitoTracker	  Red	  CMXRos	  at	  concentrations	  up	  to	  200	  nM,	  whereas	  treatment	  with	  500	  nM	  caused	  significant	  cell	  death	  (data	  not	  shown).	  Following	   these	   initial	   optimisation	   experiments,	   HMDM	   cells	   were	   co-­‐treated	  with	  1	  μM	  TSA	  in	  the	  presence	  or	  absence	  of	  100	  nM	  or	  200	  nM	  MitoTracker	  Red	  CMXRos	   during	   infection	   with	   S.	  Typhimurium	   at	   MOI	   100	   to	   investigate	   the	  effect	   of	   mitoROS	   inhibition	   on	   HDACi-­‐mediated	   bacterial	   clearance.	   In	   these	  experiments,	  the	  effects	  of	  only	  TSA	  only	  were	  investigated,	  since	  this	  compound	  appeared	   to	   be	   somewhat	   more	   active	   than	   SAHA	   in	   the	   co-­‐treatment	  experiments	   (Figure	   5.7).	   As	   expected,	   co-­‐treatment	   with	   1	   μM	   TSA	   reduced	  Salmonella	  survival	  at	  both	  8	  and	  24	  h	  post-­‐infection.	   Interestingly,	  addition	  of	  MitoTracker	   Red	   CMXRos	   blocked	   this	   effect	   at	   both	   time	   points,	   without	   any	  significant	   effect	   on	   cell	   viability	   (Figure	   5.9A	   and	   B).	   This	   supports	   the	  hypothesis	  that	  co-­‐treatment	  with	  HDACi	  promotes	  mitoROS	  generation,	  leading	  to	  enhanced	  clearance	  of	  intracellular	  bacteria.	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Figure	   5.9:	   Inhibition	   of	   mitochondrial	   ROS	   generation	   prevents	   HDACi	  
from	  promoting	  clearance	  of	  S.	  Typhimurium	  from	  HMDM.	  HMDM	  were	  co-­‐treated	  with	  1	  μM	  TSA	  in	  the	  presence	  or	  absence	  of	  100	  or	  200	  nM	  Mitotracker®	  CMXRos	  during	  infection	  with	  S.	  Typhimurium	  at	  MOI	  100.	  (A)	  Intracellular	   survival	   was	   assessed	   at	   8	   and	   24	   h	   post-­‐infection.	   Data	  (mean+SEM)	  are	   combined	   from	  3	   independent	   experiments.	   *P<0.05;	  by	  one-­‐way	  ANOVA	  followed	  by	  Dunnett’s	  Multiple	  Comparison	  test.	  (B)	  Cell	  death	  was	  assessed	   by	   quantifying	   LDH	   release	   from	   24	   h	   culture	   supernatants.	   Data	  (mean+range)	   are	   combined	   from	   2	   independent	   experiments.	   100	   and	   200	  indicates	  concentration	  of	  CMXRos	  in	  nM.	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5.2.9.	   C5a	   co-­‐treatment	   with	   S.	   Typhimurium	   reduces	   IL-­‐6	   release	   and	   S.	  
Typhimurium	  survival	  in	  HMDM.	  	  A	  second	  component	  of	  Chapter	  5	  focused	  on	  exploring	  synergy	  between	  C5aR	  and	   TLR4	   in	   human	  macrophages,	   particularly	   in	   the	   context	   of	   antimicrobial	  responses.	  These	  experiments	  were	  undertaken	  in	  collaboration	  with	  Dr.	  Vernon	  Seow	   (Fairlie	   Lab,	   Institute	   for	   Molecular	   Biosciences,	   The	   University	   of	  Queensland).	  C5a	  was	  initially	  obtained	  as	  a	  kind	  gift	  from	  the	  Fairlie	  Lab	  before	  subsequent	   purchase	   from	   Sino	   Biological	   Inc.	   and	   the	   C5aR	   antagonist,	   3D53	  (licensed	   as	   PMX53)	   used	   in	   these	   experiments	   was	   synthesized	   and	  characterized	  by	  the	  Fairlie	  Lab	  at	  the	  Institute	  for	  Molecular	  Bioscience	  (Reid	  et	  al.,	  2003).	  	  	  Experiments	  by	  Dr.	  Vernon	  Seow	  demonstrated	  that	  crosstalk	  between	  C5aR	  and	  TLR4	   signalling	   resulted	   in	   reduced	   production	   of	   the	   pro-­‐inflammatory	  cytokines	   IL-­‐6	   and	   TNFα.	   However,	   the	   effect	   of	   this	   crosstalk	   on	   human	  macrophage	  antimicrobial	   responses	  was	  unknown.	  To	   investigate	   this,	  HMDM	  were	  co-­‐treated	  with	  30	  nM	  C5a	  and	  infected	  with	  S.	  Typhimurium	  at	  MOI	  100	  with	   and	  without	  priming	  with	  1	  μM	  3D53	   for	  30	  minutes.	   Supernatants	  were	  collected	  at	  8	  h	  post-­‐infection	  to	  assess	   levels	  of	  secreted	  IL-­‐6	  and	  intracellular	  survival	   of	   S.	   Typhimurium	   was	   assessed	   at	   2	   and	   8	   h	   post-­‐infection.	   Co-­‐treatment	   of	   HMDM	   with	   C5a	   during	   S.	   Typhimurium	   infection	   resulted	   in	   a	  trend	   for	  decreased	  secretion	  of	   IL-­‐6,	  consistent	  with	   findings	   from	  Dr.	  Vernon	  Seow	  (Figure	  5.10).	  C5a	  co-­‐treatment	  also	  reduced	  survival	  of	  S.	  Typhimurium	  by	   approximately	   50%	   at	   both	   2	   and	   8	   h	   post-­‐infection	   (Figure	   5.11).	   Pre-­‐treatment	  of	  HMDM	  with	  3D53	  to	  inhibit	  the	  C5aR,	  prior	  to	  treatment	  with	  C5a,	  prevented	   the	   suppression	   in	   IL-­‐6	   release	   (Figure	   5.10)	   and	   the	   clearance	   of	  intracellular	   S.	  Typhimurium	   (Figure	   5.11).	   Therefore,	   activation	   of	   the	   C5aR	  during	   infection	  with	  Salmonella	  dampened	   inflammatory	  responses	   in	  HMDM,	  whilst	  at	  the	  same	  time	  promoting	  bacterial	  clearance	  by	  these	  cells.	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Figure	  5.10:	  Treatment	  of	  HMDM	  with	  C5a	  at	   the	   time	  of	   infection	  with	  S.	  
Typhimurium	  reduces	  IL-­‐6	  secretion	  from	  primary	  human	  macrophages.	  HMDM	  were	   co-­‐treated	  with	   30	   nM	   C5a	   and	   infected	  with	   S.	  Typhimurium	   at	  MOI	   100,	   in	   the	   presence	   or	   absence	   of	   priming	   with	   1	   μM	   C5aR	   antagonist,	  3D53,	   for	  30	  minutes.	   Supernatants	  were	   collected	  8	  h	   following	   infection	   and	  assessed	   for	   IL-­‐6	   levels	  by	  ELISA.	  Data	   (mean+SEM)	  represents	  combined	  data	  from	  3	  independent	  experiments.	  	  
	  
Figure	  5.11:	  Treatment	  of	  HMDM	  with	  C5a	  at	   the	   time	  of	   infection	  with	  S.	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  Although	  treatment	  of	  HMDM	  with	  C5a	  reduced	   intracellular	  bacterial	  survival,	  there	   was	   a	   possibility	   that	   C5a	   was	   either	   adversely	   affecting	   HMDM	   cell	  viability	  or	  having	  direct	  effects	  on	  the	  bacteria	  in	  these	  experiments.	  In	  order	  to	  exclude	  the	  first	  possibility,	  LDH	  release	  assays	  were	  conducted	  within	  the	  same	  experiments,	   using	   supernatants	   harvested	   at	   8	   h	   post-­‐infection.	   C5a	   or	   3D53	  treatment	   of	   cells	   did	   not	   result	   in	   increase	   in	   LDH	   release	   compared	   to	  untreated	  cells,	  indicating	  that	  these	  treatments	  were	  not	  cytotoxic	  to	  the	  cells	  at	  the	   concentrations	   used	   (Figure	   5.12A).	   Growth	   of	   S.	   Typhimurium	   in	   the	  presence	  of	  100	  nM	  C5a	  was	  also	  assessed	  by	  inoculating	  cell	  culture	  media	  with	  1	   AU600nm	   of	   S.	   Typhimurium	   (optical	   density	   as	   measured	   by	  spectrophotometry),	  and	  growing	  the	  resulting	  cultures	  over	  a	  period	  of	  7	  h	  with	  or	  without	  C5a.	  No	  difference	  in	  bacterial	  growth	  was	  observed	  upon	  treatment	  with	   C5a	   (Figure	   5.12B).	   Therefore,	   it	   was	   concluded	   that	   the	   decrease	   in	  intracellular	  survival	  of	  S.	  Typhimurium	  upon	  co-­‐treatment	  with	  C5a	  was	  most	  likely	  due	  to	  promotion	  of	  macrophage	  antimicrobial	  responses,	  and	  was	  not	  due	  to	  either	  adverse	  effects	  on	  HMDM	  viability	  or	  direct	  effects	  on	  bacterial	  growth.	  	  	  
	  
Figure	   5.12:	   C5a	   treatment	   does	   not	   impact	   primary	   human	  macrophage	  
cell	  viability	  or	  growth	  of	  S.	  Typhimurium.	  	  HMDM	   were	   treated	   with	   30	   nM	   C5a	   at	   the	   time	   of	   infection	   with	   S.	  Typhimurium	  at	  MOI	  100,	   in	  the	  presence	  or	  absence	  of	  1	  μM	  C5aR	  antagonist,	  3D53	  for	  30	  minutes.	  (A)	  Cell	  death	  was	  assessed	  by	  measuring	  LDH	  release	  in	  culture	   supernatants	   collected	   at	   8	   h	   post-­‐infection.	   Data	   (mean+SEM)	   are	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combined	  from	  3	  independent	  experiments.	  (B)	  S.	  Typhimurium	  were	  cultured	  in	  HMDM	  complete	  cell	  media	  or	  with	  100	  nM	  hC5a	  over	  7	  h.	  Optical	  density	  of	  cultures	  was	  measured	   as	   an	   indication	  of	   the	   growth	   rate	   of	  S.	  Typhimurium.	  Data	  (mean+SEM)	  are	  combined	  from	  3	  independent	  experiments.	  
	  
5.3.10.	  MEK	   inhibition	   rescues	   intracellular	   survival	   of	   S.	   Typhimurium	   in	  
HMDM	  with	  C5a	  co-­‐treatment.	  Experiments	   by	   Dr.	   Vernon	   Seow	   using	   inhibitors	   against	   Gαi-­‐dependent	  interactions	   	   (pertussis	   toxin,	   PTX),	   MEK1/2	   signalling	   pathway	   (U0126	  monothanolate),	   and	   the	   PI3K	   signalling	   pathway	   (pan-­‐PI3K	   inhibitor,	  wortmannin),	   suggested	   that	   C5aR-­‐mediated	   inhibition	   of	   TLR4-­‐induced	   IL-­‐6	  and	   TNFα	   production	   in	   HMDM	   was	   dependent	   on	   C5aR	   coupling	   with	   Gαi	  protein	   and	   activation	   of	   the	  MAPK	   ERK1/2	   pathway	   (Seow	   et	   al.,	   2013).	   	   Dr.	  Seow	   further	   confirmed	   this	   by	   showing	   that	   C5a	   and	   LPS	   synergistically	  enhanced	  c-­‐Raf	  and	  ERK1/2	  phosphorylation	  in	  HMDM.	  Therefore,	  the	  capacity	  of	   C5a	   to	   suppress	   a	   sub-­‐set	   of	   TLR4-­‐dependent	   responses	   in	   HMDM	   was	  attributed	  to	  the	  activation	  of	  the	  Gai/c-­‐Raf/MEK/ERK	  pathway.	  	  	  In	   order	   to	   investigate	   whether	   this	   signalling	   pathway	   was	   also	   involved	   in	  mediation	   of	   the	   antimicrobial	   effect	   of	   C5aR	   synergy	   with	   TLR4	   signalling,	  HMDM	  were	   co-­‐treated	  with	   30	   nM	   C5a	   and	   infected	  with	   S.	  Typhimurium	   at	  MOI	   100,	   in	   the	   presence	   or	   absence	   of	   10	   μM	   MEK1/2	   inhibitor	   (U0126	  monothanolate),	   which	   specifically	   inhibits	   C5aR	   but	   not	   the	   C5L2	   receptor	  (Seow	  et	  al.,	  2013).	  Intracellular	  survival	  was	  then	  assessed	  at	  2	  and	  24	  h	  post-­‐infection.	  The	  MEK1/2	   inhibitor	   showed	  a	   very	   slight	   trend	   for	   inhibiting	  C5a-­‐mediated	   bacterial	   clearance	   at	   2	   h	   post	   infection,	   and	   by	   24	   h,	   this	   inhibitor	  completely	  abrogated	  the	  antimicrobial	  effects	  of	  C5a	  (Figure	  5.13).	  In	  addition,	  at	  24	  h	  post-­‐infection,	  treatment	  with	  the	  MEK1/2	  inhibitor	  alone	  resulted	  in	  a	  slight	   enhancement	   of	   bacterial	   survival.	   These	   data	   suggest	   that	   although	  synergy	   between	   C5aR	   and	   TLR4	   through	  MEK1/2	   signalling	   suppressed	   pro-­‐inflammatory	   cytokine	   secretion,	   it	   was	   also	   responsible	   for	   promoting	  antimicrobial	  responses	  in	  human	  macrophages.	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Figure	   5.13:	   An	   inhibitor	   of	   the	   ERK	   pathway	   prevents	   C5a-­‐mediated	  
clearance	  of	  intracellular	  S.	  Typhimurium	  by	  primary	  human	  macrophages.	  HMDM	   were	   treated	   with	   30	   nM	   C5a	   at	   the	   time	   of	   infection	   with	   S.	  Typhimurium	  at	  MOI	  100	  either,	   in	   the	  presence	  or	  absence	  of	  10	  μM	  MEK1/2	  inhibitor	   (U0126,	   added	   30	   min	   prior	   to	   C5a	   treatment	   and	   infection).	  Intracellular	   survival	   was	   assessed	   at	   2	   and	   24	   h	   post-­‐infection.	   Data	  	  (mean+SEM,	  combined	  from	  3	  independent	  experiments)	  represents	  fold	  change	  relative	   to	   untreated	   cells.	   ***P<0.001;	   ****P<0.0001;	   by	   one-­‐way	   ANOVA	  followed	  by	  Dunnett’s	  Multiple	  Comparison	  test.	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5.4.	  Discussion	  
5.4.1.	   Priming	  versus	  co-­‐treatment	  with	  HDACi	  HDACi	   have	   been	   in	   clinical	   use	   or	   considered	   for	   the	   treatment	   of	   various	  cancers	  due	  to	  their	  potency	  as	  anti-­‐proliferative	  and	  angiostatic	  agents,	  as	  well	  as	   for	   therapy	   in	  autoimmunity	  and	   transplantation	  due	   their	   ability	   to	   reduce	  inflammation	   (Hancock,	   2011).	   However,	   while	   inhibition	   of	   HDACs	   has	   been	  shown	   to	   exert	   therapeutic	   effects	   in	   certain	   animal	   models	   of	   inflammation-­‐related	   diseases,	   the	   effects	   of	   HDAC	   inhibition	   on	   host	   defence	   were	  comparatively	   less	   studied.	   Two	   studies	   in	   mouse	   models	   reported	   that	   the	  administration	   of	   HDACi	   reduced	   bacterial	   uptake	   and	   activation	   of	  antimicrobial	   mechanisms	   such	   as	   ROS	   and	   RNS	   generation	   in	   mouse	  macrophages	  (Mombelli	  et	  al.,	  2011;	  Roger	  et	  al.,	  2011).	  This	  was	  associated	  with	  increased	   susceptibility	   to	   bacterial	   and	   fungal	   infections,	   but	   reduced	  susceptibility	   to	   septic	   shock	   in	   in	   vivo	   models	   in	   mice	   (Roger	   et	   al.,	   2011).	  Anecdotal	   observations	   of	   patients	   in	   clinical	   trials	   also	   describe	   increased	  susceptibility	   for	   infection	  with	   therapies	   involving	  HDACi	   such	   as	  VPA,	   SAHA,	  MS-­‐275	  and	  ITF2357	  (Candelaria	  et	  al.,	  2007;	  Galli	  et	  al.,	  2010;	  Gojo	  et	  al.,	  2007;	  Kelly	  et	   al.,	   2005;	  Rocca	  et	   al.,	   2009;	  Ryan	  et	   al.,	   2005),	  however	   these	   reports	  typically	   reflect	   individual	   cases	   of	   already	   immunocompromised	   patients.	  Hence,	  it	  is	  currently	  unclear	  as	  to	  whether	  HDACi,	  used	  to	  treat	  cancer	  patients	  and	   possibly	   for	   inflammation-­‐related	   diseases	   in	   the	   future,	   might	   endanger	  patients	   by	   compromising	   host	   defence.	   Therefore,	   in-­‐depth	   studies	   on	   the	  effects	  of	  HDACi	  treatment	  on	  host-­‐defence	  in	  human	  cells	  are	  clearly	  warranted.	  	  	  In	   order	   to	   investigate	   the	   effects	   of	   HDACi	   treatment	   on	   human	  macrophage	  antimicrobial	  responses,	  HMDM	  were	  primed	  for	  18	  h	  or	  co-­‐treated	  with	  SAHA,	  then	   infected	  with	  E.	  coli	   and	  S.	  Typhimurium	   to	   analyse	   intracellular	   survival.	  Surprisingly,	  bacterial	  survival	  was	  reduced	  at	  both	  2	  and	  24	  h	  post-­‐infection	  in	  HMDM	  that	  were	  either	  primed	  or	  co-­‐treated	  with	  HDACi.	  These	  results	  initially	  appeared	  to	  contrast	  with	  previous	  studies	  in	  mouse	  macrophages	  (Mombelli	  et	  al.,	   2011;	   Roger	   et	   al.,	   2011),	   where	   HDACi	   compromised	   the	   ability	   of	   these	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innate	   immune	  cells	   to	   clear	   infections.	  However,	   further	  analysis	   showed	   that	  overnight	   priming	   with	   HDACi	   impaired	   phagocytosis	   by	   HMDM.	   This	   is	  probably	   responsible	   for	   the	   reduced	   bacterial	   loads	   observed	   in	   these	  experiments.	  Reduced	  phagocytosis	  upon	  HDACi	  treatment	  is	  in	  accordance	  with	  the	   previous	   studies	   undertaken	   on	   mouse	   macrophages,	   which	   showed	   that	  HDACi	  treatment	  resulted	  in	  down-­‐regulation	  of	  PRR,	  co-­‐stimulatory	  molecules,	  and	  phagocytic	  receptors	  resulting	  in	  reduced	  bacterial	  uptake	  (Mombelli	  et	  al.,	  2011;	   Roger	   et	   al.,	   2011).	   These	   results	   therefore	   suggest	   that	   long-­‐term	  treatment	   with	   HDACi	   would	   interfere	   with	   human	  macrophage	   antimicrobial	  responses,	   similar	   to	   the	   previous	   studies	   in	  mouse	  macrophages.	   In	   contrast,	  infection	  assays	  performed	  on	  donor-­‐matched	  HMDM	  showed	  that	  co-­‐treatment	  with	   SAHA	   and	   TSA	   did	   not	   reduce	   uptake	   of	   bacteria	   by	   HMDM	   at	   1	   h	   post-­‐infection,	   yet	   still	   reduced	   intracellular	   bacterial	   loads	   at	   24	   h	   post-­‐infection.	  Hence,	  while	  the	  reduced	  survival	  of	  bacteria	  in	  HMDM	  primed	  with	  HDACi	  may	  be	   attributed	   to	   reduced	   phagocytosis,	   it	   seems	   most	   likely	   that	   co-­‐treatment	  with	  HDACi	   increases	  human	  macrophage	  antimicrobial	  responses.	   It	   therefore	  became	  of	  interest	  to	  determine	  mechanisms	  responsible.	  	  
5.4.2.	   HDACi	  increases	  mitochondrial	  ROS	  release	  in	  HMDM	  Production	  of	  mitoROS	  was	  found	  to	  be	  significantly	  increased	  in	  HMDM	  treated	  with	  HDACi	  at	  the	  time	  of	  S.	  Typhimurium	  infection,	  compared	  to	  infected	  HMDM	  without	   HDACi	   treatment.	   Thus,	   it	   appeared	   that	   co-­‐treatment	   with	   HDACi	  enhanced	   S.	   Typhimurium-­‐induced	   mitoROS	   production.	   However,	   direct	  visualisation	  and	  quantification	  of	  enhanced	  mitoROS	  release	  upon	  co-­‐treatment	  of	  HDACi	  and	  bacterial	  infection	  was	  not	  examined,	  and	  such	  experiments	  would	  provide	  further	  confidence	  that	  the	  observed	  effects	  were	  truly	  due	  to	  enhanced	  mitoROS.	   Although	   such	   experiments	   were	   attempted,	   visualisation	   by	  immunofluorescence	  was	  not	  possible	  due	  to	  background	  fluorescence	  from	  cell	  nuclei.	  This	  could	  be	  due	  to	  prolonged	  exposure	  of	  cells	  to	  MitoSOXTM	  Red	  during	  live	   cell	   imaging,	   which	   may	   cause	   accumulation	   of	   MitoSOXTM	   Red	   within	  mitochondria,	   resulting	   in	  mitochondrial	   stress	   and	   relocalisation	   of	   oxidation	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products	   to	  the	  cytosol	  and	  nuclei.	  This	  was	  not	  an	   issue	  with	  FACs	  analysis	   to	  detect	  mitoROS	   release	   through	  MitoSOXTM	  Red	   fluorescence,	   as	   FACs	   analysis	  was	   done	   rapidly	   and	   immediately	   following	   incubation	   with	   MitoSOXTM	   Red	  since	   it	   was	   observed	   during	   protocol	   optimisation	   that	   delayed	   or	   prolonged	  FACs	   analysis	   resulted	   in	   saturated	   emission	   of	   MitoSOXTM	   Red	   fluorescence	  regardless	  of	  treatments.	  In	  addition,	  SYTOX®	  Blue	  nucleic	  acid	  stain	  was	  used	  in	  a	   number	   of	   experiments	   during	   protocol	   optimisation	   to	   compare	   median	  fluorescence	   from	  dead	   and	   live	   cells.	   This	   ensured	   that	   the	   increased	  median	  fluorescence	  detected	  upon	  MitoSOXTM	  Red	  staining	  with	  HDACi	  treatment	  and	  S.	  Typhimurium	   infection	   was	   not	   due	   to	   the	   presence	   of	   dead	   cells	   with	  compromised	  mitochondria	  or	  nuclei.	  FACs	  analysis	  of	  cells	  with	  MitoSOXTM	  Red	  alone	  also	  caused	  minimal	  fluorescence	  that	  was	  slightly	  enhanced	  in	  cells	  with	  
S.	  Typhimurium	   infection,	   in	   accordance	   to	   the	   release	   of	   mitoROS	   to	   combat	  infection	  (West	  et	  al.,	  2011).	  	  	  Although	   HDACi	   are	   involved	   in	   preventing	   deacetylation	   of	   histone	   proteins,	  resulting	   in	   more	   accessible	   chromatin	   and	   therefore	   potentially	   increasing	  exposure	   of	   nucleic	   acids	   to	   the	  MitoSOXTM	  Red	   dye,	   controls	   with	   HDACi	   and	  MitoSOXTM	  Red	   compared	   to	  MitoSOXTM	  Red	   alone	   showed	   that	   treatment	  with	  HDACi	   alone	   did	   not	   substantially	   increase	   fluorescence.	   Therefore	   it	   is	   likely	  that	   increased	   fluorescence	   upon	  HDACi	   treatment	   is	   not	   an	   artefact,	   and	   that	  HDACi	   do	   indeed	   enhance	   mitoROS	   release	   upon	   co-­‐treatment	   with	   bacterial	  infection.	  Nevertheless,	  an	  alternative	  method	  to	  measure	  and	  visualise	  mitoROS	  should	  be	  explored	  in	  the	  future,	  as	  it	  would	  be	  very	  informative	  to	  conduct	  co-­‐localisation	  studies	  of	  mitoROS	  and	  bacteria	  in	  infected	  HMDM	  with	  and	  without	  HDACi	   treatment,	   to	   shed	   further	   light	   on	   whether	   mitoROS	   is	   likely	   to	   be	  directly	  responsible	  for	  increased	  bacterial	  clearance.	  Previous	  findings	  suggest	  that	   this	   is	   likely,	   as	   it	   was	   demonstrated	   that	   mitochondria	   are	   recruited	   to	  phagosomes	   downstream	   of	   TLR1,	   2	   and	   4	   stimulation	   leading	   to	   release	   of	  mitoROS	  and	  enhanced	  killing	  of	  S.	  Typhimurium	  in	  mouse	  macrophages	  (West	  et	   al.,	   2011).	   In	   fact,	   the	  HDACi,	   spiruchostatin	  A	   and	  B	   (SP-­‐A	   and	   SP-­‐B),	  were	  shown	   to	   stimulate	   apoptosis	   in	   human	   lymphoma	   U937	   cells	   through	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stimulating	   the	   loss	   of	   MMP	   leading	   to	   increased	   production	   of	   mitoROS,	  activation	   of	   the	   cell-­‐surface	   death	   receptor,	   Fas,	   and	   subsequent	   activation	   of	  caspase-­‐3	  and	   caspase-­‐8	   (Rehman	  et	   al.,	   2014).	  TSA	  was	  also	   shown	   to	   induce	  cell	  death	  of	  human	  breast	  cancer	  cells,	  MDA-­‐MB-­‐231	  and	  MCF-­‐7,	  dependent	  on	  mitoROS	   induction	   through	   impairment	   of	   the	  mitochondrial	   respiratory	   chain	  (Sun	   et	   al.,	   2014).	   	   This	  was	   abrogated	  with	   the	   use	   of	   antioxidants	   to	   inhibit	  ROS.	  	  Treatment	  with	  MitoTracker	  Red	  CMXRos,	  during	  infection	  assays	  abrogated	  the	  ability	   of	   TSA	   to	   promote	   bacterial	   clearance	   by	   HMDM.	   Whilst	   there	   are	   no	  reported	  studies	  on	  the	  capacity	  of	  MitoTracker	  Red	  CMXRos	  to	  quench	  mitoROS	  or	  inhibit	  their	  generation,	  this	  stain	  was	  shown	  to	  passively	  distribute	  into	  the	  mitochondrial	  matrix,	  due	  to	  its	  cationic	  lipophilic	  structure,	  causing	  monovalent	  substitution	  of	   thiols,	  and	  thereby	  preventing	  changes	   in	  the	  MMP	  (Kroemer	  et	  al.,	  1997;	  Marchetti	  et	  al.,	  1997).	  As	  generation	  of	  mitoROS	  requires	  changes	   in	  the	  MMP	   (Go	   et	   al.,	   2010),	   it	   is	   possible	   that	   treatment	  with	  MitoTracker	   Red	  CMXRos	   reduces	   generation	   of	   mitoROS.	   Indeed,	   treatment	   of	   cells	   with	   non-­‐toxic	  levels	  of	  the	  MitoTracker	  Red	  CMXRos	  stain	  blocked	  the	  ability	  of	  HDACi	  to	  reduce	  bacterial	   loads	  within	  HMDM,	  suggesting	  that	  HDACi-­‐mediated	  bacterial	  clearance	   is	   indeed	  due	   to	  enhanced	  mitoROS	  release.	  This	   stain	  has	  also	  been	  reported	   to	   act	   as	   a	   photosensitiser	  when	   treated	   at	   high	   concentrations	  with	  laser	  irradiation,	  causing	  formation	  of	  the	  mitochondrial	  permeability	  transition	  pore	  (MPT)	  and	  swelling	  of	  mitochondria	  leading	  to	  release	  of	  cytochrome	  c	  and	  subsequent	   apoptosis	   (Lum	   et	   al.,	   2002;	   Minamikawa	   et	   al.,	   1999;	   Poot	   et	   al.,	  1996).	   However,	   in	   these	   experiments	   HMDM	   were	   not	   irradiated	   and	   LDH	  assays	   revealed	   no	   adverse	   effect	   of	   the	   concentrations	   of	   MitoTracker	   Red	  CMXRos	  used	  to	  treat	  cells.	  Previous	  literature	  also	  reports	  that	  MitoTracker	  Red	  CMXRos	  is	  not	  toxic	  at	  100-­‐250	  nM	  in	  human	  osteosarcoma	  cell	  lines	  unless	  cells	  were	  irradiated	  (Minamikawa	  et	  al.,	  1999).	  However,	  it	  cannot	  be	  excluded	  that	  this	  mitochondrial	   stain	  may	  have	  affected	  antimicrobial	   responses	   through	  an	  alternate	   way,	   for	   example	   reducing	   cell	   metabolism	   and	   activity	   resulting	   in	  decreased	   antimicrobial	   responses.	   Therefore,	   experimentation	  with	   inhibitors	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of	  ROS,	  such	  as	  NecroX,	  which	  is	  a	  mitoROS	  and	  peroxynitrite	  scavenger	  (Kim	  et	  al.,	  2010),	  or	  the	  antioxidants	  N-­‐acetyl	  cysteine	  (NAC),	  glutathione,	  and	  Vitamin	  C,	  which	  are	  reported	  to	  inhibit	  mitoROS	  production	  by	  up	  to	  65.8%	  (Sun	  et	  al.,	  2014),	   is	   critical	   before	   concluding	   that	   mitoROS	   is	   indeed	   the	   mechanism	  whereby	  HDACi	  promotes	  bacterial	  clearance	  in	  HMDM.	  	  
5.4.3.	   Crosstalk	  between	  C5aR	  and	  TLR4	  in	  human	  macrophages	  Crosstalk	   between	   C5aR	   and	   TLRs	   has	   been	   reported	   in	   studies	   in	   mice	  (Hajishengallis	   and	  Lambris,	  2010;	  Hajishengallis	   and	  Lambris,	  2011;	  Krishnan	  and	  Choi,	  2012)	  as	  well	  as	  in	  the	  context	  of	  TLR4-­‐induced	  cytokine	  production	  in	  human	  macrophages	   (Seow	   et	   al.,	   2013).	   To	   investigate	   this	   in	   the	   context	   of	  infections,	   HMDM	   were	   co-­‐treated	   with	   C5a	   at	   the	   time	   as	   infection	   with	   S.	  Typhimurium.	  This	  resulted	  in	  reduced	  IL-­‐6	  cytokine	  secretion,	  consistent	  with	  recent	  findings	  (Seow	  et	  al.,	  2013).	   	  Although	  pro-­‐inflammatory	  cytokines	  were	  reduced,	   intracellular	   S.	  Typhimurium	   loads	   were	   reduced	   at	   both	   2	   and	   8	   h	  post-­‐infection.	  The	  enhanced	  clearance	  of	   intracellular	  S.	  Typhimurium	  was	  not	  due	   to	   direct	   killing	   of	   the	  bacteria	   by	  C5a,	   as	   proliferation	   of	  S.	  Typhimurium	  was	   not	   affected	   in	   the	   presence	   of	   C5a.	   This	   is	   in	   accordance	   with	   previous	  studies	  that	  report	  that	  human	  C3a	  and	  C4a	  are	  directly	  antimicrobial	  against	  P.	  
aeruginosa	  and	  Enterococcus	  faecalis,	  but	  that	  C5a	  is	  not,	  due	  to	  it	  evolving	  as	  a	  paralog	  and	  possessing	  a	  C-­‐terminal	  receptor	  binding	  peptide	  region	  in	  place	  of	  a	  typical	   antimicrobial	   peptide	   sequence	   (Pasupuleti	   et	   al.,	   2007).	   Thus,	   C5aR	  signalling	  may	   enhance	  macrophage	   antimicrobial	  mechanisms.	   Since	   bacterial	  survival	  was	  reduced	  as	  early	  as	  2	  h	  post-­‐infection,	  C5aR	  signalling	  may	  promote	  rapidly	  acting	  antimicrobial	  responses	  such	  as	  ROS	  generation	  and/or	  hydrolytic	  activity	  within	  the	  phagolysosome	  (Section	  1.1.4.1	  and	  1.1.4.2).	  Indeed,	  C5a	  has	  been	  shown	   to	  be	   critical	   for	   synthesis	  and	  delivery	  of	  ROS	   to	  phagosomes	   for	  clearance	  of	  M.	  tuberculosis	   in	  mouse	  macrophages	  as	  C5aR-­‐/-­‐	  macrophages	  had	  impaired	  co-­‐localisation	  of	  phox	  proteins	  to	  the	  phagosome	  (Daniel	  et	  al.,	  2006)	  and	   for	   ROS	   generation	   in	   response	   to	   E.	   coli	   in	   human	   whole	   blood	   models	  (Mollnes	   et	   al.,	   2012).	   C5a	   was	   also	   shown	   to	   promote	   degranulation	   of	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lysosomal	   enzymes	   in	   phagocytic	   cells	   (Goldstein	   and	   Weissmann,	   1974).	  However,	   the	  reduction	   in	  bacterial	  survival	  at	  2	  h	  post-­‐infection	  could	  also	  be	  explained	   by	   impaired	   phagocytosis	   rather	   than	   promotion	   of	   antimicrobial	  mechanisms,	  as	  was	  observed	  in	  the	  HDACi	  priming	  experiments.	  Although	  C5a	  has	   been	   noted	   to	   impair	   phagocytosis	   in	   neutrophils	   in	   experimental	   sepsis	  (Riedemann	   et	   al.,	   2003),	   it	   was	   essential	   for	   phagocytosis	   of	   E.	   coli	   by	  granulocytes	   and	   monocytes	   (Mollnes	   et	   al.,	   2012).	   Thus,	   future	   experiments	  should	  investigate	  the	  effect	  of	  C5a	  signalling	  on	  phagocytic	  capacity	  of	  HMDM.	  	  	  
5.4.4.	   MEK	  inhibition	  rescues	  survival	  of	  S.	  Typhimurium	  in	  HMDM	  with	  C5a	  
co-­‐treatment	  Notwithstanding	  the	  caveats	  above	  relating	  to	  effects	  on	  phagocytosis,	  inhibition	  of	   MEK1/2	   signalling	   abrogated	   C5aR-­‐mediated	   clearance	   of	   intracellular	   S.	  Typhimurium	  at	  24	  h	  post-­‐infection.	  This	  therefore	  implicates	  MEK1/2	  signalling	  in	   C5aR-­‐dependent	   antimicrobial	   responses	   in	   human	   macrophages.	   Although	  U0126	  is	  reportedly	  a	  highly	  selective	  inhibitor	  of	  MEK1/2	  activity	  (Favata	  et	  al.,	  1998b),	  direct	  inhibition	  of	  MEK1/2	  by	  U0126	  was	  not	  investigated	  in	  parallel	  in	  these	   experiments.	   As	  with	   any	   pharmacological	   inhibitor	   approach,	   there	   is	   a	  possibility	  that	  off-­‐target	  effects	  account	  for	  the	  observed	  effects.	  Verification	  of	  MEK1/2	   inhibition,	   and	   not	   other	   signalling	   responses,	   by	   U0126	   in	   these	  experiments	  is	  especially	  important,	  since	  this	  compound	  is	  also	  reported	  to	  be	  a	  weak	  inhibitor	  of	  various	  other	  signalling	  pathway	  components	  such	  as	  protein	  kinase	  C,	  Abl,	  Raf,	  MEKK,	  ERK,	   JNK,	  MKK-­‐3,	  MKK-­‐4/SEK,	  MKK-­‐6,	  Cdk2,	  or	  Cdk4	  (Favata	   et	   al.,	   1998a).	   Therefore,	   although	   unlikely,	   it	   is	   possible	   that	   the	  antimicrobial	   mechanisms	   promoted	   by	   C5aR	   do	   not	   involve	   MEK1/2.	  Nevertheless,	   the	  MEK1/2	   signaling	   pathway	   is	   linked	   to	   various	  macrophage	  functions	   including	   activation	   of	   ROS,	   endosomal	   trafficking,	   and	   macrophage	  differentiation	  (Rao,	  2001),	  and	   is	  activated	  upon	  macrophage	   infection	  with	  S.	  Typhimurium	   and	   LPS,	   independently	   of	   bacterial	   phagocytosis	   (Procyk	   et	   al.,	  1999).	   In	   addition,	   activation	  of	   the	  MEK/ERK	  pathway	  and	  generation	  of	  ROS	  was	   shown	   to	   inhibit	   S.	   Typhimurium	   replication	   within	   murine	   RAW264.7	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6.1.	  Thesis	  overview	  The	  development	  of	   therapeutics	   for	   immune-­‐related	  diseases	  and	  disorders	   is	  increasingly	  recognised	  as	  being	  limited	  by	  the	  use	  of	  animal	  models	  for	  studies	  and	   preclinical	   testing.	   This	   is	   because	   small	   differences	   in	   the	   immune	  responses	   of	   rodents	   compared	   to	   humans,	   can	   sometimes	   result	   in	   therapies	  that	   show	   promise	   during	   preclinical	   testing	   to	   be	   ineffective,	   or	   even	  detrimental,	   in	   human	   disease	   settings.	   While	   efforts	   have	   been	   made	   to	  overcome	   such	   limitations	   through	   the	   development	   of	   humanised	   mice	  (Gonzalez	  et	  al.,	  2013;	  Legrand	  et	  al.,	  2009),	  there	  are	  still	  many	  deficiencies	   in	  our	  knowledge	  of	  human	  immune	  responses	  that	  are	  not	  conserved	  in	  rodents.	  Therefore,	   even	   while	   efforts	   are	   made	   to	   model	   the	   human	   immune	   system	  using	   humanised	   mice,	   it	   is	   important	   that	   research	   is	   directed	   towards	  identifying	  and	  deciphering	  human-­‐specific	  immune	  mechanisms,	  as	  it	  would	  not	  be	  possible	  to	  recapitulate	  what	  we	  are	  not	  aware	  of.	  	  	  In	  view	  of	   this,	  Chapter	   3	  of	   this	   thesis	   focused	  on	   investigating	  novel	  human-­‐specific	   TLR4-­‐regulated	   genes	   to	   probe	   for	   potential	   functions	   in	   macrophage	  antimicrobial	  and	  inflammatory	  responses	  against	  Gram-­‐negative	  bacteria.	  This	  resulted	  in	  the	  identification	  of	  RNF144B	  as	  a	  novel	  regulator	  of	  inflammasome	  activation.	  Chapter	  4	  explored	  the	  potential	  regulatory	  mechanism	  mediated	  by	  RNF144B,	  and	   identified	  that	  LPS	   induction	  of	  the	   inflammasome	  substrate,	   IL-­‐1β,	  was	   reliant	   on	   RNF144B.	  Chapter	   4	   also	   examined	   p21WAF1	   as	   a	   potential	  target	   of	   RNF144B	   E3	   ligase	   activity	   for	   mediating	   the	   regulation	   of	   IL-­‐1β.	   In	  
Chapter	   5,	   a	   different	   approach	  was	   used	   to	   investigate	   human	   antimicrobial	  mechanisms.	  In	  this	  chapter,	  pharmacological	  compounds	  identified	  to	  modulate	  inflammatory	   responses	   and	   currently	   under	   study	   or	   in	   use	   as	   therapeutic	  agents	   were	   investigated	   for	   effects	   on	   human	   macrophage	   antimicrobial	  mechanisms.	   While	   HDACi	   such	   as	   TSA	   were	   previously	   reported	   to	   be	  detrimental	   for	   intracellular	   bacterial	   clearance	   in	   mouse	   macrophages	  (Mombelli	   et	   al.,	   2011;	   Roger	   et	   al.,	   2011),	   findings	   from	   this	   chapter	  demonstrate	   that	   the	   reverse	   is	   true	   in	   human	   macrophages,	   revealing	   the	  
Final	  Discussion	  
	  	  	  
148	  
potential	  for	  an	  additional	  use	  of	  HDACi	  as	  therapeutics	  to	  boost	  innate	  immune	  defence.	  The	  GPCR,	  C5aR	  was	  also	   found	   to	  amplify	  antimicrobial	   responses	   in	  human	  macrophages,	  revealing	  an	  interesting	  aspect	  of	  C5aR	  co-­‐stimulation	  with	  TLR4,	   whereby	   inflammatory	   responses	   are	   dampened	  without	   compromising	  host	   defence.	   These	   findings	   as	   well	   as	   some	   preliminary	   data	   in	   relation	   to	  future	  directions	  for	  these	  projects	  are	  presented	  and	  discussed	  below.	  
 
6.2.	  Human-­‐specific	  novel	  TLR4-­‐regulated	  genes	  	  
6.2.1.	   Potential	  roles	  of	  novel	  TLR4-­‐regulated	  genes	  	  in	  human	  	  macrophage	  
function.	  In	   Chapter	   3,	   the	   novel	   human-­‐specific	   TLR4-­‐regulated	   genes,	   RNF144B,	  
TMEM140,	  NKG7,	  BATF3	  and	  G0S2	  were	  verified	  to	  be	  upregulated	  in	  human	  but	  not	   mouse	   macrophages	   in	   response	   to	   LPS	   stimulation,	   validating	   the	  microarray	   data	   from	   a	   gene	   profiling	   study	   on	   divergence	   of	   TLR4-­‐regulated	  genes	   in	   human	   and	   mouse	   macrophages	   (Schroder	   et	   al.,	   2012a).	   However,	  subsequent	   functional	  analysis	  of	  selected	  novel	  genes	  with	  the	  most	  divergent	  expression	   in	   response	   to	   LPS	   in	   human	   and	   mouse	   macrophages	   (RNF144B,	  
NKG7,	   G0S2	   and	   SLC41A2)	   suggested	   that	   these	   genes	   do	   not	   have	   a	   role	   in	  human	  antimicrobial	  mechanisms,	  nor	  in	  inflammatory	  cytokine	  secretion,	  with	  the	   exception	   of	   RNF144B,	   which	   affected	   inflammasome	   activation.	   However,	  only	   a	   limited	  number	  of	   read-­‐outs	  were	   examined,	   and	   it	   is	   still	   possible	   that	  these	  genes	  have	  important	  roles	  in	  macrophage-­‐mediated	  immunity	  or	  cellular	  homeostasis.	   Potential	   roles	   for	   these	   novel	   TLR4-­‐regulated	   genes	   are	   briefly	  discussed	  below,	  with	  the	  exception	  of	  RNF144B,	  which	  will	  be	  addressed	  in	  later	  sections.	  	  
6.2.1.1.	  	  	  NKG7	  The	  NKG7	  gene	  was	  originally	  discovered	  to	  be	  expressed	  by	  natural	  killer	  (NK)	  cells	   and	   T	   cells	   (Turman	   et	   al.,	   1993).	   It	   encodes	   a	   small	   4	   transmembrane	  calcium	  ion	  channel	  protein	  that	  localises	  in	  the	  cytotoxic	  granules	  of	  NK	  cells,	  T	  cells	   and	   neutrophils,	   then	   translocates	   from	   the	   granules	   to	   the	   plasma	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membrane	   upon	   stimulation	   of	   degranulation	   (Medley	   et	   al.,	   1996a).	   Initial	  studies	   on	   NKG7	   associated	   its	   expression	   with	   cytotoxic	   lymphocytes	   and	  apoptotic	   cells	   and	   it	   was	   proposed	   as	   a	   marker	   for	   tissue	   injury	   and	   graft	  rejection	   in	   renal	   (Meehan	   et	   al.,	   1997;	  Rifai	   and	  Dworkin,	   2008;	   van	  Es	   et	   al.,	  2008)	  and	  intestinal	  (Ashokkumar	  et	  al.,	  2011;	  Russell	  et	  al.,	  1993)	  tissues.	  More	  recently,	  NKG7	  was	  reported	  to	  be	  upregulated	  by	  TNFα	  in	  human	  macrophages	  (Donlin	   et	   al.,	   2014)	   and	   to	   be	   induced	   downstream	   of	   STAT4	   and	   IFNγ	   in	  genome-­‐wide	  expression	  profiling	  of	  spleens	  from	  S.	  Typhimurium-­‐infected	  mice	  (Eva	   et	   al.,	   2014).	   Thus,	   it	   may	   be	   that	   NKG7	   expression	   is	   LPS-­‐induced	   in	  macrophages	   in	   response	   to	   infection	  or	   tissue	   injury	   in	   order	   to	  mediate	  Th1	  immune	  responses	  by	  upregulating	  lymphocyte	  activation	  and	  is	  not	  involved	  in	  antimicrobial	   responses	   directly	   mediated	   by	   human	  macrophages.	  NKG7	   was	  induced	  in	  murine	  splenocytes	  in	  response	  to	  S.	  Typhimurium	  (Eva	  et	  al.,	  2014),	  thus	  it	  may	  also	  function	  in	  murine	  immunity,	  though	  it	  was	  not	  LPS-­‐inducible	  in	  mouse	  macrophages	  (Chapter	  3).	  	  	  
	  
6.2.1.2.	  	  	  G0S2	  G0S2	  was	   identified	   as	   a	   cell	   cycle	   regulator	   that	   commits	   blood	  mononuclear	  cells	  in	  G0	  phase	  to	  enter	  the	  G1	  phase,	  but	  has	  since	  been	  implicated	  in	  a	  variety	  of	   cellular	   functions	   including	   proliferation	   of	   hematopoietic	   cells,	   apoptosis,	  inflammation,	  metabolism	  and	  carcinogenesis	  (Heckmann	  et	  al.,	  2013).	  The	  most	  well	   studied	   role	   for	   G0S2	   is	   as	   a	   regulator	   of	   lipid	   metabolism	   by	   inhibiting	  adipose	   triglyceride	   lipase	   (ATGL),	   an	   enzyme	   that	   hydrolyses	   triacylglycerol	  (TAG)	   stored	   within	   lipid	   droplets	   (Yang	   et	   al.,	   2010).	   G0S2	   regulates	   ATGL	  through	  modulation	  of	   its	  enzyme	  activity	  and	  intracellular	  co-­‐localisation	  with	  lipid	  droplets	  (Schweiger	  et	  al.,	  2012).	  G0S2	  mRNA	  and	  protein	  was	  reduced	  in	  patients	  with	  poorly	  controlled	  type	  2	  diabetes	  that	  is	  associated	  with	  increased	  ATGL,	   metabolic	   dysregulation	   and	   increase	   in	   serum	   free	   fatty	   acids	   (FFA).	  Thus,	  it	  was	  suggested	  that	  G0S2	  is	  protective	  against	  increased	  lipolysis	  of	  TAG	  into	   FFAs,	   which	   contributes	   to	   several	   metabolic	   disorders	   such	   as	   obesity-­‐linked	  insulin	  resistance	  (Nielsen	  et	  al.,	  2012).	  In	  Chapter	  3,	  G0S2	  was	  shown	  to	  be	  upregulated	  by	  LPS	   in	  human	  macrophages	  but	  not	   in	  mouse	  macrophages.	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This	   is	   in	   accordance	   with	   another	   study	   that	   identified	   G0S2	   among	   genes	  upregulated	  in	  human	  macrophages	  infected	  with	  P.	  gingivalis,	  or	  its	  purified	  cell	  wall	  components,	  LPS	  or	  fimbrial	  protein	  (FimA)	  (Zhou	  and	  Amar,	  2007).	  It	  was	  also	   recently	   shown	   that	  TLR	  stimulation	  enhanced	  FFA	  uptake	  and	  storage	  as	  TAG	   in	   HMDM	   (Huang	   et	   al.,	   2014).	   Thus,	   it	   is	   possible	   that	   G0S2	   may	   be	   a	  human-­‐specific	  regulator	  of	  lipid	  metabolism	  that	  promotes	  macrophage	  uptake	  and	  lipid-­‐storage	  in	  response	  to	  LPS	  stimulation,	  thus	  regulating	  the	  formation	  of	  foam	  cells	  and	  subsequent	  inflammatory	  responses.	  	  
	  
6.2.1.2.	  	  	  	  SLC41A2	  Little	   is	   known	   about	   the	   role	   of	   SLC41A2,	   besides	   its	   function	   in	  magnesium	  uptake	   as	   a	   plasma	  membrane	  magnesium	   transporter	   (Goytain	   and	  Quamme,	  2005;	  Sahni	  et	  al.,	  2007).	  Limiting	  concentrations	  of	  magnesium	  in	  macrophage	  vacuolar	  compartments	  are	  known	  to	  be	  detrimental	  to	  bacterial	  growth	  (Blanc-­‐Potard	   and	   Groisman,	   1997).	   For	   example,	   mutants	   of	   S.	   Typhimurium,	   M.	  
tuberculosis	   and	   B.	   suis	   that	   lack	   an	   acquired	   virulence	   gene,	   mgtC,	   encoded	  within	   pathogenicity	   islands	   are	   unable	   to	   proliferate	   and	   survive	   within	  macrophages	   (Buchmeier	   et	   al.,	   2000;	   Lavigne	   et	   al.,	   2005).	   Nonetheless,	  knockdown	   of	   SLC41A2	   did	   not	   result	   in	   any	   difference	   in	   E.	   coli	   and	   S.	  Typhimurium	   survival.	   It	   is	   possible	   that	   SLC41A2	   may	   not	   be	   involved	   in	  mechanisms	  for	  direct	  killing	  of	  bacteria	   in	  macrophages,	  but	   it	   is	  also	  possible	  that	  significant	  knock-­‐down	  of	  SLC41A2	  protein	  levels	  were	  not	  achieved	  or	  that	  SLC41A2	   has	   a	   role	   in	   direct	   killing	   of	   bacteria	   other	   than	   E.	   coli	   and	   S.	  Typhimurium.	   Alternatively,	   SLC41A2	   may	   be	   important	   for	   cellular	  homeostasis,	   and	   for	   metabolic	   and	   biochemical	   processes,	   that	   may	   be	  increased	  upon	  macrophage	  activation.	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6.2.2.	   Species-­‐specific	  regulation	  of	  RNF144B.	  	  Since	   RNF144B	   knockdown	   attenuated	   inflammasome	   activation,	   subsequent	  analysis	   focused	   on	   investigating	   its	   function	   in	   macrophages.	   However,	  mechanisms	  by	  which	  it	  is	  regulated	  are	  also	  of	  interest.	  As	  LPS	  is	  able	  to	  trigger	  both	   the	   TRIF	   and	   MyD88	   signalling	   pathways,	   the	   pathways	   regulating	  
RNF144B	  expression	  were	  assessed	  by	  analysing	  RNF144B	  expression	  in	  HMDM	  treated	  with	   either	   Poly(I:C)	   or	   imiquimod,	  which	   respectively	   stimulate	   TLR3	  signalling	   through	   the	   TRIF	   pathway,	   or	   TLR7	   signalling	   through	   the	   MyD88	  pathway.	   RNF144B	   was	   very	   modestly	   upregulated	   by	   both	   Poly(I:C)	   and	  imiquimod,	  although	  the	  effect	  was	  much	  less	  pronounced	  than	  was	  observed	  for	  induction	   by	   LPS	   (Appendix	   1,	  Supplementary	   Figure	   2).	   This	   suggests	   that	  both	   TRIF	   and	   MyD88	   signalling	   may	   synergize	   to	   enable	   inducible	   RNF144B	  expression,	   although	   it	   is	   also	   possible	   that	   TLR4-­‐specific	   signalling	   pathways,	  not	  conserved	  with	  TLR3	  or	  TLR7	  are	  involved.	  Prior	  to	  this	  analysis,	  RNF144B	  expression	  had	  only	  been	  shown	  to	  be	  induced	  downstream	  of	  the	  p53	  family	  of	  transcription	  factors	   in	  HCT116	  (human	  colorectal	  carcinoma),	  SAOS-­‐2	  (human	  osteosarcoma),	  H1299	  (human	  lung	  carcinoma,	  U-­‐373	  MG	  (human	  glioblastoma)	  and	  MCF-­‐7	   (human	   breast	   cancer)	   cell	   lines	   and	  mouse	   embryonic	   fibroblasts	  (Conforti	  et	  al.,	  2013;	  Ho	  et	  al.,	  2014;	  Huang	  et	  al.,	  2006;	  Nakamura	  et	  al.,	  2006;	  Ng	  et	  al.,	  2003;	  Sayan	  et	  al.,	  2010).	  	  	  Since	  RNF144B	  was	  LPS-­‐inducible	  only	  in	  human	  macrophages,	  it	  was	  of	  interest	  to	  analyse	  the	  promoter	  regions	  of	  human	  and	  mouse	  RNF144B.	  Cap	  analysis	  of	  gene	   expression	   (CAGE)	   data	   (Carninci	   et	   al.,	   2005;	   Forrest	   et	   al.,	   2014)	  (http://fantom.gsc.riken.jp/zenbu/),	   which	   identifies	   transcription	   start	   sites	  (TSS),	   revealed	   that	   there	   are	   two	  major	   TSS	   regions	   for	   the	   human	  RNF144B	  gene,	   one	   of	   which	   is	   annotated	   as	   the	   TSS	   in	   Ensembl	   (Appendix	   1,	  
Supplementary	   Figure	   4).	   For	   both	  TSS	   regions,	  most	   CAGE	   tags	   are	   derived	  from	  LPS-­‐stimulated	  macrophages	  (Appendix	  1,	  Supplementary	  Figure	  4,	  red	  bars).	   The	   major	   TSS	   in	   the	   mouse	   RNF144B	   gene,	   as	   identified	   by	   CAGE	  mapping,	  was	  ~160	  bp	  upstream	  of	  the	  TSS	  that	  is	  annotated	  in	  Ensembl,	  and	  is	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in	  a	  similar	  position	  to	  the	  upstream	  TSS	  of	  the	  human	  gene.	  However,	  few	  CAGE	  tags	   were	   macrophage-­‐derived	   for	   this	   TSS;	   instead,	   CAGE	   tags	   were	   mostly	  derived	   from	   specific	   tissues	   such	   as	   heart	   and	   testis	   (Appendix	   1,	  
Supplementary	   Figure	   4,	   black	   bars).	   This	   is	   consistent	  with	   the	   observation	  that	  RNF144B	   is	   very	   weakly	   expressed	   by	  mouse	  macrophages,	   either	   in	   the	  basal	  state	  or	  upon	  LPS	  stimulation	  (Figure	  3.2).	  Despite	  the	  clear	  difference	  in	  macrophage-­‐directed	  transcription	  between	  human	  and	  mouse,	  both	  the	  human	  and	   mouse	   genes	   are	   controlled	   by	   highly	   conserved,	   TATA-­‐containing	  promoters	   (Appendix	   1,	   Supplementary	   Figure	   4).	   These	   features	   are	  consistent	   with	   a	   previous	   analysis	   of	   LPS	   target	   genes	   that	   are	   divergently	  regulated	  between	  human	  and	  mouse	  (Schroder	  et	  al.,	  2012a).	  Analysis	  of	  human	  and	   mouse	   proximal	   promoter	   regions	   using	   the	   ECR	   browser	  (http://ecrbrowser.dcode.org)	  revealed	  66.3	  %	  identity	  within	  -­‐1000	  to	  +200bp	  of	   the	   TSS	   (Needleman-­‐Wunsch	   Global	   Sequence	   Alignment),	   and	   conserved	  predicted	   binding	   sites	   for	   known	   LPS-­‐responsive	   transcription	   factors	  (ETS/PU.1,	  HIF	  and	  NF-­‐κB,	  Appendix	  1,	  Supplementary	  Figure	  4).	  However,	  a	  predicted	  p53	  (-­‐173	  to	  -­‐146,	  +26	  to	  +36)	  binding	  site,	  previously	  determined	  by	  CHIP	  analysis	   to	  be	  a	   true	  p53-­‐responsive	  site	  (Ng	  et	  al.,	  2003),	  and	   	  a	  STAT	  (-­‐203	   to	   -­‐195)	   binding	   site	   are	   present	   in	   the	   human	   promoter,	   but	   are	   absent	  from	   the	   mouse	   promoter	   region	   (Appendix	   1,	   Supplementary	   Figure	   4).	  Given	   that	  STAT	   family	  members,	  particularly	  STAT1,	  play	   central	   roles	   in	  LPS	  signal	   transduction	   (Schroder	   et	   al.,	   2006),	   it	   is	   possible	   that	   such	   differences	  account	  for	  the	  lack	  of	  LPS	  responsiveness	  of	  the	  mouse	  RNF144B	  gene,	  though	  it	  is	   also	   possible	   that	   other	   mechanisms	   (e.g.	   distal	   regulatory	   elements,	   trans	  factors)	  contribute	  to	  the	  divergent	  regulation	  of	  RNF144B	  between	  mouse	  and	  human	  macrophages.	  	  Intriguingly,	   HIF1α	   TFBSs	   were	   found	   on	   the	   RNF144B	   human	   promoter	  sequence	  both	  upstream	  and	  downstream	  of	  the	  TSS,	  and	  upstream	  of	  the	  TSS	  in	  the	  mouse	  promoter.	  HIF1α	  is	  a	  transcription	  factor	  that	  is	  induced	  by	  hypoxia,	  upregulated	  by	  LPS	  (Frede	  et	  al.,	  2006),	  stabilised	  by	  succinate	  and	  ROS	  (Chandel	  et	  al.,	  2000;	  Sumbayev,	  2008)	  and	  directly	  targets	  IL-­‐1β	  in	  mouse	  macrophages	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and	  human	  peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  (Tannahill	  et	  al.,	  2013)	  for	   sustained	   IL-­‐1β	   expression	   (Peyssonnaux	   et	   al.,	   2007;	   Zhang	   et	   al.,	   2006).	  Thus,	   these	   potential	  HIF1α	  TFBS	   suggests	   that	   the	  HIF1α	   transcription	   factor	  may	   be	   involved	   in	   RNF144B-­‐dependent	   LPS	   induction	   of	   IL-­‐1β	   in	   human	  macrophages	   (Chapter	   4).	   Possible	   implications	   for	   HIF1α	   regulation	   of	  RNF144B	  are	  discussed	  further	  in	  Section	  6.2.4.2.	  	  	  In	  summary,	  although	  the	  human	  RNF144B	  promoter	  and	  coding	  region	  shows	  high	   conservation	   with	   its	   murine	   ortholog	   (Benard	   et	   al.,	   2010),	   human	  RNF144B	   is	  most	   likely	   divergently	   regulated	   between	   the	   two	   species	   due	   to	  inter-­‐species	  differences	   in	  promoter	   regulatory	  elements,	  particularly	   the	   lack	  of	   a	   TATA	  box	   in	   the	  mouse	   promoter.	   This	   is	   in	   accordance	  with	   the	   original	  study	   from	   this	   laboratory	   showing	   that	   genes	   particularly	   susceptible	   to	  evolutionary	   change	   have	   high	   sequence	   conservation	   within	   cis-­‐regulatory	  elements	  and	   typically	   contain	  TATA	  elements	   in	   their	  promoters	   (Schroder	  et	  al.,	  2012a).	  Such	  promoters	  are	  subjected	  to	  multiple	  regulatory	  inputs,	  thus	  loss	  of	   one	   key	   motif	   such	   as	   a	   TATA	   element,	   in	   one	   species,	   can	   profoundly	  influence	  gene	  expression.	  	  
6.2.3.	   The	   role	   of	   RNF144B	   in	   inflammasome	   activation	   and	   p21WAFI	   as	   a	  
potential	  binding	  partner.	  As	   RNF144B	   was	   required	   for	   LPS-­‐inducible	   expression	   of	   IL-­‐1β	   mRNA	   and	  protein	  but	  not	  all	  TLR4	  target	  genes	  (Section	  4.2.5)	  or	  IL-­‐6	  and	  TNFα	  cytokine	  secretion	  (Section	  3.2.4),	  RNF144B	  appears	  to	  have	  at	  least	  some	  specificity	  in	  selective	   regulation	   of	   IL-­‐1β.	   Given	   the	   pro-­‐inflammatory	   functions	   of	   IL-­‐1β,	   it	  was	  also	  of	  interest	  to	  determine	  whether	  RNF144B	  was	  differentially	  regulated	  in	   GM-­‐CSF-­‐derived	   HMDM,	   as	   compared	   to	   CSF-­‐1-­‐derived	   HMDM	   (since	   the	  former	  have	  an	  enhanced	   inflammatory	  phenotype,	   see	  Section	   1.1.2).	   Indeed,	  RNF144B	   mRNA	   expression	   was	   LPS-­‐inducible	   in	   both	   GM-­‐CSF-­‐	   and	   M-­‐CSF-­‐derived	   HMDM,	   but	   there	   was	   a	   trend	   for	   more	   sustained	   up-­‐regulation	   in	  donor-­‐matched	   GM-­‐CSF-­‐derived	   macrophages	   as	   compared	   to	   CSF-­‐1-­‐derived	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macrophages	   (Appendix	   1,	   Supplementary	   Figure	   1).	   This	   could	   potentially	  contribute	   to	   the	   heightened	   inflammatory	   phenotype	   of	   GM-­‐CSF-­‐derived	  macrophages,	  and	  is	  also	  in	  accordance	  with	  the	  recent	  association	  of	  RNF144B	  with	   endometriosis,	   which	   is	   accompanied	   by	   inflammation	   (Albertsen	   et	   al.,	  2013).	  	  	  Prior	   to	   this	   thesis,	   only	   LUBAC	   had	   been	   identified	   as	   an	   E3	   ubiquitin	   ligase	  required	  for	  inflammasome	  activation	  (Section	  1.2.2).	  Despite	  being	  conserved	  throughout	  eukaryotes,	  the	  RBR	  family	  of	  E3	  ubiquitin	  ligases	  is	  not	  well	  studied.	  Among	  the	  14	  RBRs	  expressed	  in	  humans	  (Smit	  and	  Sixma,	  2014),	  Parkin,	  HHARI	  and	   HOIP,	   are	   the	   best	   characterised.	   Parkin	   and	   HHARI	   both	   have	   a	   RING1	  domain	  that	  recruits	  a	  charged	  E2	  ubiquitin	  ligase,	  a	  RING2	  domain	  that	  contains	  a	  catalytic	  cysteine	  that	  mediates	  ubiquitination	  transfer	  in	  a	  HECT-­‐like	  manner,	  and	   auto-­‐inhibitory	   forms	   that	   prevent	  E3	   ligase	   activity,	   though	   the	  modes	   of	  auto-­‐inhibition	  vary	  between	   the	   two	   (Berndsen	  and	  Wolberger,	  2014).	  Parkin	  possesses	  an	  extra	  RING	  domain,	  RING0,	  which	  blocks	  the	  active	  site	  cysteine	  of	  RING2,	   preventing	   its	   activity,	   while	   HHARI	   has	   a	   C-­‐terminal	   Ariadne	   domain	  that	  also	  masks	  the	  RING2	  active	  site	  cysteine.	  However,	  there	  is	  no	  resemblance	  between	   the	   Ariadne	   domain	   and	   the	   RING0	   domain	   of	   Parkin.	   It	   is	   also	  unknown	   how	   a	   conformational	   change	   is	   triggered,	   and	   whether	   it	   involves	  phosphorylation,	   post-­‐translational	   modifications,	   or	   protein	   interactions.	  	  Analysis	   of	   the	   structure	   of	   RNF144B	   using	   Swiss	   Model	  (http://swissmodel.expasy.org/),	  led	  to	  the	  generation	  of	  a	  putative	  model	  based	  on	  the	  structure	  of	  HHARI	  (Protein	  Data	  Bank:	  4kc9.1A),	  which	  was	  determined	  by	  x-­‐ray	  crystallography.	  HHARI	  was	  automatically	  chosen	  as	  the	  template	  as	  it	  had	   the	   highest	   identity	   (31%)	   and	   coverage	   (66%)	   of	   the	   other	   50	   available	  templates	  for	  RNF144B	  (Appendix	  1,	  Supplementary	  Figure	  5).	  The	  predicted	  structure	   of	   RNF144B	   based	   on	   HHARI	   shows	   the	   residues	   predicted	   to	   be	  important	  for	  Zn2+	  co-­‐factors.	  Further	  analysis	  is	  required	  to	  determine	  whether	  RNF144B	  also	  has	  an	  auto-­‐inhibitory	  form,	  and	  to	  precisely	  pinpoint	  the	  cysteine	  residues	  required	  for	  its	  E3	  ubiquitin	  ligase	  activity.	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The	  potential	  for	  RNF144B-­‐mediated	  degradation	  of	  p21WAF1	  as	  the	  mechanism	  by	   which	   it	   regulates	   IL-­‐1β	   was	   investigated	   in	   Chapter	   4,	   with	   inconclusive	  results,	  as	  RNF144B	  knockdown	  did	  not	  affect	  p21WAF1	  protein	  levels.	  Other	  than	  RNF144B,	   other	   RNF	   E3	   ubiquitin	   ligases	   are	   reported	   to	   regulate	   p21WAF1.	  RNF115/BCA2	  (Wang	  et	  al.,	  2013)	  and	  RNF126	  (Zhi	  et	  al.,	  2013)	  were	  shown	  to	  ubiquitinate	  p21WAF1	  for	  proteasomal	  degradation	  to	  promote	  breast	  cancer	  cell	  proliferation.	   In	   these	   studies,	   knockdown	   of	   the	   RNFs	   resulted	   in	   increased	  p21WAF1	   protein	   levels,	   but	   not	   mRNA	   levels,	   and	   overexpression	   resulted	   in	  accumulation	  of	  ubiquitinated	  p21WAF1	  protein.	  Therefore,	  the	  fact	  that	  RNF144B	  knockdown	  did	  not	  reduce	  p21WAF1	  protein	  levels,	  but	  still	  reduced	  LPS-­‐inducible	  IL-­‐1β	  expression	  (Section	  4.2.7),	  suggests	  that	  the	  situation	  is	  more	  complex	  in	  the	   context	   of	   macrophage-­‐mediated	   inflammation.	   It	   is	   also	   possible	   that	  RNF144B	  ubiquitinates	  p21WAF1	  with	  ubiquitin	   that	  does	  not	   target	  p21WAF1	  for	  degradation,	   but	   which	   changes	   its	   localisation	   or	   signalling	   ability,	   thereby	  preventing	   it	   mediating	   the	   repression	   of	   IL-­‐1β	   transcription.	   Thus,	   it	   is	  important	   to	   investigate	   the	   interaction	   of	   RNF144B	   and	   p21WAF1	   in	   future	  studies	   by	   attempting	   co-­‐immunoprecipitation	   of	   p21WAF1.	   Although	   RNF144B	  interaction	   with	   p21WAF1	   was	   shown	   in	   other	   cell-­‐types,	   it	   has	   not	   been	  demonstrated	   in	  macrophages,	   and	   attempts	   to	   do	   so	   in	   this	   project	  were	   not	  completed	  due	  to	  time	  constraints.	  	  	  
6.2.4.	   Potential	  mechanisms	  for	  RNF144B	  regulation	  of	  IL-­‐1β.	  
6.2.4.1.	  RNF144B	  regulation	  of	  IL-­‐1β	  through	  p21WAF1.	  In	   previous	   reports,	   IL-­‐1β	   release	   was	   increased	   in	   human	   and	   mouse	  macrophages	   upon	   knockdown	   of	   p21WAF1	   expression	   (Scatizzi	   et	   al.,	   2009;	  Trakala	   et	   al.,	   2009).	   However,	   in	   the	   study	   by	   Trakala	   et	   al.	   (2009),	   p21WAF1	  knockdown	  not	   only	   enhanced	   IL-­‐1β,	   but	   also	   IL-­‐6	   and	  TNFα	   levels	   in	  mice	   in	  
vivo	  and	  in	  peritoneal	  macrophages.	  This	  was	  attributed	  to	  p21WAF1	  acting	  as	  an	  early	   inhibitor	   of	   NFκB	   activation	   to	   dampen	   inflammation	   and	   macrophage	  activation,	   since	   NFκB	   activation	   was	   increased	   upon	   p21WAF1	   knockdown	  (Trakala	   et	   al.,	   2009).	  However,	   in	   human	  macrophages,	   RNF144B	  knockdown	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did	  not	  reduce	  IL-­‐6	  and	  TNFα	  levels	  (Section	  3.2.4).	  Thus,	  despite	  the	  evidence	  that	   RNF144B	   is	   able	   to	   ubiquitinate	   p21WAF1	   (Conforti	   et	   al.,	   2013;	   Ng	   et	   al.,	  2003),	   it	  may	  be	  that	  RNF144B	  does	  not	  regulate	  IL-­‐1β	  levels	  through	  p21WAF1.	  Nevertheless,	   as	   the	   experiments	   by	   Trakala	   et	   al.	   (2009)	   were	   conducted	   in	  mice,	   it	   is	   also	   possible	   that	   in	   humans,	   p21WAF1	   has	   a	   more	   specific	   role	   in	  regulating	  only	  IL-­‐1β	  and	  not	  other	  inflammatory	  mediators.	  	  NLRP3	  was	  recently	  shown	  to	  inhibit	  p21WAF1	  protein	  expression	  in	  murine	  DCs,	  as	  NLRP3	  knockdown	  resulted	   in	  accumulation	  of	  p21WAF1	  protein	   (Licandro	  et	  al.,	  2013).	  This	  study	  also	  showed	  that	  NLRP3	  was	  required	   for	  stabilisation	  of	  p53	   and	   increased	   cell	   death	   in	   response	   to	   oxidative	   stress	   in	   murine	   DCs.	  p21WAF1	  protein	  protects	  against	  p53-­‐induced	  apoptosis	  by	  promoting	  cell	  cycle	  arrest	  and	  repair	  in	  macrophages	  (Gartel	  and	  Tyner,	  2002;	  Ozaki	  and	  Hanazawa,	  2001;	  Xaus	  et	  al.,	  1999).	  Thus,	  the	  NLRP3	  inflammasome	  was	  suggested	  to	  favour	  programmed	  cell	  death	  and	  restrict	   cell	   repair	  pathways,	   such	  as	  DNA	  damage	  repair,	   through	   activation	   of	   pro-­‐apoptotic	   p53	   signalling	   (Haasken	   and	  Sutterwala,	  2013;	  Licandro	  et	  al.,	  2013).	  Therefore,	  instead	  of	  directly	  regulating	  just	  IL-­‐1β,	  p21WAF1	  may	  instead	  be	  involved	  in	  balancing	  cell	  responses	  between	  inflammation,	   cell	   death	   and	   cell	   repair,	   where	   reduced	   p21WAF1	  and	   thus,	   cell	  repair,	   assists	   in	  promoting	   continuous	  and	  enhanced	   inflammation,	  ultimately	  leading	  to	  cell	  death.	  	  	  
6.2.4.2.	  RNF144B	  regulation	  of	  IL-­‐1β	  through	  HIF1α	  or	  cellular	  stress.	  Alternative	  to	  p21WAF1-­‐mediated	  regulation	  of	  IL-­‐1β,	  RNF144B	  may	  be	  affecting	  other	  pathways	  involved	  in	  IL-­‐1β	  regulation	  (Figure	  6.1).	  	  As	  shown	  in	  Section	  
6.2.2	  above,	  putative	  p53	  and	  HIF1α	  TFBS	  were	   found	   in	   the	  human	  RNF144B	  promoter.	  Both	  of	  these	  transcription	  factors	  crosstalk	  and	  interact	  in	  response	  to	   oxygen	   stress	   (Robertson	   et	   al.,	   2014),	   which	   is	   often	   a	   hallmark	   in	  inflammation.	  Levels	  of	  p53	  and	  HIF1α	  are	  normally	  controlled	  by	  proteasomal	  degradation	   mediated	   by	   the	   E3	   ubiquitin	   ligases,	   mouse	   double	   minute	   2	  homolog	   (MDM2)	   (Tergaonkar	   et	   al.,	   2002),	   and	   von	   Hippel	   Landau	   (VHL),	  respectively	   (Ke	   and	   Costa,	   2006).	   MDM2	   transcription	   is	   induced	   by	   p53,	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forming	   an	   auto-­‐regulatory	   loop	   to	   control	   p53	   levels	   to	   prevent	   unwarranted	  apoptosis.	   During	   excessive	   cellular	   stress,	   such	   as	   DNA	   damage	   or	   extreme	  hypoxic	   conditions,	   both	   p53	   and	   HIF1α	   levels	   increase	   through	   distinct	  interactions	  with	  MDM2.	  Under	   these	   conditions,	   p53	   is	   no	   longer	   targeted	   by	  MDM2	  for	  degradation	  and	  is	  upregulated	  and	  stabilised	  (Kubbutat	  et	  al.,	  1997;	  Wu	   et	   al.,	   1993).	   p53	   then	   translocates	   to	   the	   mitochondria	   to	   promote	  permeabilisation	  of	  mitochondrial	  outer	  membranes	  for	  release	  of	  pro-­‐apoptotic	  factors	  (Moll	  et	  al.,	  2006).	  During	  cellular	  stress,	  MDM2	  interacts	  with	  HIF1α	  by	  stabilising	  it,	  leading	  to	  its	  translocation	  to	  the	  nucleus	  to	  regulate	  transcription	  of	  genes	  (Ke	  and	  Costa,	  2006)	  such	  as	  induction	  of	  IL-­‐1β	  (Tannahill	  et	  al.,	  2013).	  HIF-­‐1α	   is	   also	   reported	   to	   associate	   with	   mitochondria,	   dependent	   on	  stabilisation	  by	  MG132	   treatment,	   indicating	   that	  mitochondrial	  HIF1α	  may	  be	  regulated	  by	  ubiquitination	   (Briston	  et	  al.,	  2011;	  Rane	  et	  al.,	   2009).	  Thus,	  both	  p53	  and	  HIF1α	  localise	  to	  mitochondria	  upon	  cellular	  stress.	  	  	  
	  
Figure	   6.1:	   Diagram	   summarising	   RNF144B	   regulation	   in	   human	   and	  
mouse	  macrophages	  and	  potential	  mechanisms	  for	  IL-­‐1β	  regulation.	  	  
RNF144B	  is	  LPS-­‐inducible	  in	  human	  (Left)	  but	  not	  mouse	  macrophages	  (Right).	  LPS	   upregulates	   p21WAF1	   (Figure	   4.7)	   and	   IL-­‐1β	   in	   both	   human	   and	   mouse	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macrophages.	   In	   human	   macrophages,	   RNF144B	   may	   modulate	   IL-­‐1β	   mRNA	  expression	   (Figure	   4.6),	   via	   negative	   regulation	   of	   p21WAF1,	   which	   has	   been	  shown	   to	   negatively	   regulate	   IL-­‐1β	   (Scatizzi	   et	   al.,	   2009;	   Trakala	   et	   al.,	   2009).	  Alternatively,	   RNF144B	   may	   be	   recruited	   to	   the	   mitochondria	   upon	   cellular	  stress	  (Benard	  et	  al.,	  2010),	  and	  modulate	  IL-­‐1β	  through	  interaction	  with	  HIF1α	  (Tannahill	  et	  al.,	  2013)	  or	  p53,	  or	  by	  affecting	  production	  of	  mitoROS	  (Chandel	  et	  al.,	  2000).	  	  	  As	  mentioned	  above,	  cellular	  stress,	  inflammasome	  activation	  and	  cell	  death	  and	  repair	   appear	   to	   be	   linked	   through	   pro-­‐apoptotic	   p53	   signalling	   and	  inflammasome	   activation.	   This	   is	   supported	   by	   a	   previous	   study	   showing	   that	  p53	   indirectly	   promotes	   NLRP3	   inflammasome	   activation	   by	   suppressing	  autophagy,	   which	   reduces	   NLRP3	   activation	   and	   restricts	   pro-­‐IL-­‐1β	   synthesis	  (Nakahira	  et	  al.,	  2011;	  Tasdemir	  et	  al.,	  2008).	  p53	  also	   induces	  ASC,	  which	  can	  promote	   apoptosis	   by	   directly	   interacting	   and	   co-­‐localising	   with	   Bax	   to	   the	  mitochondria	  to	  induce	  cytochrome	  c	  release,	  caspase	  activation	  and	  significant	  reduction	   of	   mitochondrial	   membrane	   potential	   (Ohtsuka	   et	   al.,	   2004).	  Inflammasome	  activation	  is	  reported	  to	  be	  induced	  by	  a	  range	  of	  cellular	  stress	  signals	   such	   as	   lysosomal	   damage	   and	   oxygen	   stress	   (Conforti-­‐Andreoni	   et	   al.,	  2011),	  however,	  in	  the	  context	  of	  the	  NLRP3	  inflammasome,	  the	  unifying	  signal	  that	  mediates	   inflammasome	  activation	   in	  response	  to	  several	  stimuli	  has	  been	  hypothesised	   to	   be	   mitochondrial	   ROS	   (Kauppinen	   et	   al.,	   2012;	   Tschopp	   and	  Schroder,	  2010;	  Zhong	  et	  al.,	  2013;	  Zhou	  et	  al.,	  2010).	   In	   support	  of	   this,	   IL-­‐1β	  upregulation	  by	  HIF1α	  in	  macrophages	  was	  shown	  to	  be	  dependent	  on	  mitoROS	  generation	   at	   Complex	   III	   within	   the	   mitochondria,	   which	   was	   required	   to	  stabilise	  HIF1α	  (Chandel	  et	  al.,	  2000).	  mitoROS	  was	  also	  shown	  to	  be	  increased	  during	  hypoxia,	  and	  was	  abrogated	  by	  administration	  of	  antioxidants,	  resulting	  in	   attenuation	   of	   inflammasome	   activation	   (Chandel	   et	   al.,	   2000;	   Nishi	   et	   al.,	  2008;	  Wang	  et	  al.,	  2010a;	  Zhong	  et	  al.,	  2013).	  	  	  Interestingly,	  RNF144B	  is	  also	  reported	  to	  translocate	  to	  the	  mitochondria	  upon	  stress-­‐induced	   apoptosis,	   where	   it	   interacts	   with	   a	   pro-­‐apoptotic	   form	   of	   Bax	  (Benard	   et	   al.,	   2010).	   Thus,	   it	   may	   be	   that	   RNF144B	   functions	   in	   a	   human-­‐
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specific	   regulatory	   role	   for	   IL-­‐1β,	   through	   interaction	   with	   HIF1α	   and/or	   p53	  signalling	   or	   involvement	   in	   regulation	   of	   mitoROS.	   RNF144B	   may	   even	   be	  involved	  in	  regulating	  the	  levels	  of	  both	  HIF1α	  and	  p53,	  such	  as	  with	  MDM2.	  In	  addition,	   as	   potential	  TFBS	   for	   both	  HIF1α	   and	  p53	  were	  predicted	  within	   the	  RNF144B	  promoter	  region,	  RNF144B	  may	  be	  involved	  in	  an	  auto-­‐regulatory	  role,	  as	  has	  been	  reported	  for	  RNF144B	  and	  p63	  (Conforti	  et	  al.,	  2013).	  Thus,	   future	  studies	   may	   investigate	   the	   regulation	   of	   RNF144B	   by	   HIF1α	   and	   p53,	   and	  explore	   potential	   effects	   of	   RNF144B	   knockdown	   or	   overexpression	   on	  HIF1α,	  p53	  and	  IL-­‐1β	  levels	  (Figure	  6.1).	  	  Localisation	  of	  RNF144B	  through	  immunofluorescence	  would	  be	  very	  useful	  for	  determining	  the	  dynamics	  of	  RNF144B	  during	  inflammasome	  activation	  and	  thus	  for	  inferral	  of	  function.	  Preliminary	  results	  obtained	  for	  this	  thesis	  showed	  that	  RNF144B	   appeared	   to	   be	   localised	   in	   a	   vesicular	   compartment	   in	   human	  macrophages	  (data	  not	  shown).	  However,	  due	  to	  the	  presence	  of	  an	  un-­‐identified	  band	  detected	  at	  approximately	  24	  kDa	  (Appendix	  1,	  Supplementary	  Figure	  3)	  by	   the	   RNF144B	   antibody,	   which	   appeared	   more	   often	   than	   the	   predicted	  protein	   band	   of	   RNF144B	   at	   33	   kDa,	   it	   was	   not	   pursued	   further	   due	   to	  uncertainty	  of	  the	  antibody’s	  specificity.	  Although	  the	  protein	  band	  was	  initially	  assumed	   to	   be	   non-­‐specific,	   the	   expression	   pattern	   of	   the	   band	   upon	   LPS	  stimulation	  matched	   the	  mRNA	  expression	  pattern	  of	  RNF144B,	  which	   is	  most	  highly	  induced	  at	  6	  h	  post-­‐LPS	  stimulation	  (Appendix	  1,	  Supplementary	  Figure	  
3	   and	   Figure	   3.2).	   Therefore,	   it	   may	   be	   an	   unidentified	   isoform	   of	   RNF144B.	  Indeed,	  previous	  studies	  have	  reported	  an	  alternative	  splice	  variant	  of	  RNF144B	  that	  is	  missing	  the	  3rd	  exon,	  and	  that	  weighs	  approximately	  25	  kDa	  in	  epithelial	  cells	  (Conforti	  et	  al.,	  2013).	  In	  addition,	  it	  is	  possible	  that	  RNF144B	  may	  be	  in	  an	  auto-­‐inhibitory	   state	   such	   as	   Parkin	   or	   HHARI,	   and	   may	   be	   modulated	   by	  cleavage	  at	  the	  predicted	  caspase-­‐1	  cleavage	  site	  (Section	  4.1	  and	   Figure	  4.1),	  which	  would	  yield	  a	  cleaved	  product	  of	  approximately	  the	  same	  size	  as	  the	  non-­‐specific	   protein	   band.	   Therefore,	   future	   studies	   could	   investigate	   whether	   an	  alternate	   isoform	  of	  RNF144B	   exists	  within	  macrophages	   and/or	   the	   ability	   of	  caspases	  to	  cleave	  RNF144B.	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  One	   limitation	   of	   the	   functional	   studies	   conducted	   on	   RNF144B	   is	   that	   the	  conclusions	   reached	   were	   based	   on	   gene	   silencing	   only.	   Although	   functional	  effects	  were	  observed	  with	  multiple	  independent	  siRNAs,	  alternative	  approaches	  would	   give	   further	   confidence	   in	   the	   findings	   generated.	   Overexpression	   of	  RNF144B	  in	  mouse	  macrophages	  was	  attempted	  via	  a	  retroviral-­‐based	  system	  to	  determine	   whether	   over-­‐expression	   of	   RNF144B	   in	   mouse	   macrophages	  amplified	  LPS-­‐inducible	  IL-­‐1β	  expression,	  however,	  this	  was	  not	  completed	  due	  to	  time-­‐constraints,	  and	  should	  be	  pursued	  in	  future	  studies.	  Future	  studies	  may	  also	   correlate	   RNF144B	   expression	   in	   patients	  with	   autoimmune	   diseases	   and	  mouse	  models	  of	  sepsis,	  to	  validate	  RNF144B	  expression	   in	  vivo	  and	  in	  relation	  to	  LPS	  induction	  and	  IL-­‐1β	  transcription.	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6.3.	   Role	   of	   HDACi	   and	   GPCRs	   in	   human	   macrophage	  
antimicrobial	  and	  inflammatory	  pathways	  
6.3.1.	   The	  role	  of	  HDACi	  in	  promoting	  mitochondrial	  ROS	  in	  HMDM	  	  In	  Chapter	  5,	  treatment	  of	  bacterially	  infected	  HMDM	  with	  HDACi	  was	  found	  to	  reduce	   bacterial	   survival.	   Although	   this	   was	   attributed	   to	   reduction	   in	  phagocytosis	   upon	   HDACi	   priming,	   co-­‐treatment	   with	   HDACi	   did	   not	   affect	  phagocytosis,	   but	   still	   enhanced	   bacterial	   clearance.	   Inhibitor	   data	   suggested	  that	   this	   increased	   microbicidal	   activity	   was	   mediated	   by	   enhanced	   mitoROS	  production	   (Figure	   6.2).	  This	   is	   in	  accordance	  with	   recent	   literature	   reporting	  mitoROS	   as	   a	   TLR-­‐inducible	   antimicrobial	   mechanism	   (West	   et	   al.,	   2011).	  Cellular	   and	   mitochondrial	   ROS	   has	   also	   been	   shown	   to	   be	   important	   for	  antibiotic-­‐mediated	   autophagy-­‐dependent	   clearance	   of	   M.	   tuberculosis	   with	  reliance	  on	  the	  activity	  of	  NOX2	  within	  the	  host	  (Kim	  et	  al.,	  2012).	  	  	  
	  
Figure	   6.2:	   Human	   macrophage	   antimicrobial	   pathways	   promoted	   by	  
HDACi	  and	  C5a.	  
Left:	   Treatment	   of	   HMDM	  with	   HDACi	   promotes	   TLR-­‐inducible	   production	   of	  mitoROS,	  enhancing	  the	  clearance	  of	  S.	  Typhimurium	  and	  E.	  coli	  from	  these	  cells.	  
Right:	  Treatment	  of	  HMDM	  with	  C5a	  promotes	  clearance	  of	  S.	  Typhimurium	  via	  
Final	  Discussion	  
	  	  	  
162	  
a	  MEK/ERK-­‐dependent	  pathway	  that	  could	  potentially	   involve	  NADPH	  oxidase-­‐dependent	  and/or	  mitoROS.	  Dotted	  arrows	  indicated	  signalling	  pathways.	  	  As	  HDACi	  promoted	  mitoROS	  generation,	  it	  would	  be	  beneficial	  to	  utilise	  HDACi	  that	  are	  more	  selective	  for	  individual	  HDACs,	  to	  investigate	  which	  HDAC	  proteins	  are	   involved	   in	   the	   induction	  of	  mitoROS	   in	  HMDM.	  This	  might	  allow	   for	  more	  specific	   control	   in	   induction	   of	   mitoROS,	   and	   other	   antimicrobial	   responses	  induced	   by	   mitoROS	   such	   as	   autophagy,	   to	   promote	   intracellular	   pathogen	  clearance.	   It	   would	   also	   be	   useful	   to	   assess	   the	   ability	   of	   HDACi	   treatment	   to	  clear	   bacterial	   infections	   in	   pre-­‐infected	   macrophages.	   If	   similarly	   enhanced	  antimicrobial	  responses	  were	  observed	  as	  with	  co-­‐treatment	  with	  infection,	  this	  would	  suggest	  that	  more	  specific	  HDACi	  could	  potentially	  be	  developed	  as	  anti-­‐infective	  strategies.	  In	  an	  age	  of	  ever-­‐increasing	  antibiotic	  resistance,	  alternative	  approaches	  to	  combat	  infections	  are	  clearly	  of	  interest.	  However,	  further	  careful	  investigation	  would	   be	   required	   to	   determine	   proper	   timing	   of	   administration	  and	  to	   identify	  more	  selective	  HDACi,	  as	   findings	  reported	  here	  clearly	  showed	  an	  effect	  of	  broad-­‐spectrum	  HDACi	  on	  phagocytosis	  (Section	  5.2.6).	  In	  addition,	  since	  HDACi	  suppress	  inflammation,	  the	  use	  of	  HDACi	  to	  promote	  antimicrobial	  responses	   could	   be	   detrimental	   for	   in	   vivo	   treatments,	   as	   HDACi	   may	   still	  compromise	  host	  defence	  pathways.	  Thus,	  it	  is	  important	  to	  analyse	  the	  effect	  of	  administering	  HDACi	  as	  antimicrobial	  therapeutics	  in	  vivo.	  	  	  HDACi	   have	   also	   recently	   been	   investigated	   for	   use	   to	   curb	   many	   parasitic	  infections	  such	  as	  malaria	  and	  leishmaniasis,	  which	  are	  increasingly	  a	  threat	  due	  to	  the	  emergence	  of	  multi-­‐drug	  resistant	  strains	  and	  the	  susceptibility	  of	  human	  immunodeficiency	   virus	   (HIV)-­‐infected	   patients	   to	   opportunistic	   infections	  (Andrews	  et	  al.,	  2009;	  Patil	  et	  al.,	  2010;	  Rotili	  et	  al.,	  2009).	  	  In	  recent	  years,	  new	  classes	  of	  HDACi	  (aroyl-­‐pyrrolyl-­‐hydroxyamides	  and	  aryltriazolylhydroxamates-­‐based	  HDACi)	  have	  been	  developed	  and	  shown	  in	  vitro	  to	  be	  several	  times	  more	  effective	  against	  plasmodium	  and	  leishmania	  as	  standard	  HDACi,	  and	  to	  be	  even	  as	   effective	   as	   the	   currently	   available	   oral	   compound,	   miltefosine,	   against	  visceral	   leishmaniasis	   (Mai	   et	   al.,	   2004;	   Patil	   et	   al.,	   2010).	   Administration	   of	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SB939,	   an	   orally	   active	  HDACi,	  was	   also	   found	   to	   be	   effective	   in	   in	  vivo	  mouse	  models	   of	   cerebral	   malaria	   (Andrews	   et	   al.,	   2009).	   These	   findings	   reveal	   the	  potential	  of	  HDACi	  as	  anti-­‐infective	  agents	  against	  parasitic	  infections	  by	  causing	  direct	  killing	  of	  parasites.	  The	  findings	  presented	  in	  this	  thesis	  complement	  these	  studies	  by	  showing	  that,	  in	  addition	  to	  previously	  reported	  direct	  toxicity	  against	  some	  pathogens	  (e.g.	  plasmodium,	  leishmania),	  HDACi	  are	  also	  able	  to	  promote	  antimicrobial	  responses	  of	  human	  macrophages	  against	  intracellular	  bacteria.	  	  
6.3.2.	   The	   effect	   of	   crosstalk	   between	   hC5a	   and	   TLR4	   signalling	   in	  
regulating	  HMDM	  antimicrobial	  activity	  Co-­‐treatment	  of	  HMDM	  with	  C5a	  enhanced	  bacterial	  clearance	  via	  a	  mechanism	  that	  appeared	  to	  be	  dependent	  on	  MEK1/2	  signalling	  (Chapter	   5,	   Figure	   6.2).	  Thus,	   assuming	   that	   C5aR	   signalling	   does	   not	   impair	   phagocytosis	   by	   human	  macrophages,	   it	   would	   be	   of	   interest	   to	   investigate	   specific	   antimicrobial	  mechanisms	   that	   are	   triggered	  by	  C5aR	   in	  human	  macrophages.	   In	   addition	   to	  promoting	  degranulation	  (Goldstein	  and	  Weissmann,	  1974)	  and	  ROS	  generation	  (Riedemann	   et	   al.,	   2003),	   C5a	   has	   been	   reported	   to	   mediate	   autophagy	   in	  alveolar	   macrophages	   (Hu	   et	   al.,	   2014),	   promote	   chemotaxis	   of	   myeloid	   cells	  (Bosmann	  and	  Ward,	  2012),	  induce	  intracellular	  calcium	  mobilisation	  (Lee	  et	  al.,	  2008;	   Roach	   et	   al.,	   2008),	   and	   activate	   MAPK	   signalling	   (Gerard	   and	   Gerard,	  1994;	   Lee	   et	   al.,	   2008).	   It	   has	   previously	   been	   reported	   that	   ERK	   activation	   is	  critically	   involved	   in	   degranulation	   of	   cytotoxic	   lymphocytes	   and	   in	   FcεRI-­‐induced	   degranulation	   in	   mast	   cells	   (Takayama	   et	   al.,	   2013).	   Interestingly,	  inhibition	  of	  the	  MEK/ERK	  signalling	  pathway	  decreased	  ROS	  production	  in	  LPS-­‐stimulated	   human	   and	  mouse	  macrophages	   (Traves	   et	   al.,	   2012).	   Therefore,	   it	  would	   be	   of	   interest	   to	   determine	   whether	   NADPH	   oxidase-­‐dependent	   ROS	  production	  is	  amplified	  by	  C5a	  co-­‐treatment	  with	  infection,	  and	  whether	  this	   is	  responsible	  for	  the	  MEK1/2-­‐dependent	  enhanced	  bacterial	  clearance.	  	  Future	  studies	  could	  also	  investigate	  the	  effects	  of	  C5aR	  crosstalk	  with	  TLR4	  on	  antimicrobial	   responses	  of	  different	  macrophage	  populations,	   for	   example	  GM-­‐
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CSF-­‐derived	   macrophages.	   In	   this	   regard,	   C5a	   had	   similar	   effects	   on	   LPS	  responses	  in	  donor-­‐matched	  GM-­‐CSF-­‐	  and	  M-­‐CSF-­‐derived	  macrophages	  (Seow	  et	  al.,	   2013).	   In	   both	   macrophage	   populations,	   C5a	   treatment	   repressed	   LPS-­‐induced	   IL-­‐6	   and	   TNFα	   cytokine	   secretion,	   while	   enhancing	   IL-­‐10	   secretion,	  though	  GM-­‐CSF-­‐derived	  macrophages	  showed	  higher	  LPS-­‐inducible	  levels	  of	  IL-­‐6	  and	  TNFα.	  However,	  C5a	  co-­‐stimulation	  with	  Poly	  (I:C)	  treatment	  enhanced	  IL-­‐6	  production	   in	   GM-­‐CSF-­‐derived	   macrophages,	   but	   not	   M-­‐CSF-­‐derived	  macrophages,	   which	   were	   unresponsive	   to	   Poly(I:C).	   This	   indicates	   that	  differences	   exist	   in	   the	   responsiveness	   of	   the	   two	  macrophage	   populations	   to	  different	   TLR-­‐ligands	   (Seow	   et	   al.,	   2013).	   Indeed,	   these	   two	   macrophage	  populations	  were	  reported	  to	  differentially	  express	  PRRs.	  For	  example,	  GM-­‐CSF-­‐derived	   macrophages	   have	   a	   higher	   ratio	   of	   TLR4/TLR2	   than	   M-­‐CSF-­‐derived	  macrophages	   (Sauer	   et	   al.,	   2014;	   Wang	   et	   al.,	   2014).	   This	   is	   of	   interest,	  considering	  that	  C5aR	  cross-­‐talks	  with	  both	  TLR2	  and	  TLR4	  (Hajishengallis	  and	  Lambris,	   2010),	   and	   infection	   with	   S.	   Typhimurium	   could	   stimulate	   multiple	  TLRs.	  	  	  Interestingly,	   mouse	   and	   human	   GM-­‐CSF-­‐	   and	   M-­‐CSF-­‐derived	   macrophages,	  respectively,	  were	  shown	  to	  have	  approximately	  20%	  to	  23%	  divergence	  in	  gene	  expression	   (Lacey	   et	   al.,	   2012),	   with	   GM-­‐CSF	   upregulating	   more	   immune	  response	   genes	   in	   both	   human	   and	   mouse	   macrophages	   upon	   stimulation.	  Furthermore,	   previous	   work	   from	   this	   laboratory	   used	   Taqman	   Low	   Density	  Arrays	  (TLDA)	  to	  analyse	  the	  expression	  of	  non-­‐sensory	  GPCRs	  in	  unstimulated	  and	   LPS-­‐stimulated	   human	   primary	   macrophages	   differentiated	   with	   GM-­‐CSF	  and	   M-­‐CSF	   (Hohenhaus	   et	   al.,	   2013).	   This	   analysis	   revealed	   that	   GPCRs	   were	  mostly	   similarly	   regulated	   between	   GM-­‐CSF	   and	   M-­‐CSF-­‐derived	   macrophages.	  However,	  15	  GPCRs	  were	  differentially	  expressed	  between	  the	  two	  macrophage	  populations	  at	  basal	  state,	  and	  14	  GPCRs	  showed	  divergent	  expression	  with	  LPS	  stimulation.	   Thus,	   these	   findings	   indicate	   that	   GM-­‐CSF-­‐	   and	   M-­‐CSF-­‐derived	  macrophages	  have	  overlapping	  but	  non-­‐identical	  functions,	  and	  therefore,	  might	  be	   modulated	   differently	   upon	   TLR	   and	   GPCR	   crosstalk	   in	   the	   context	   of	  microbicidal	   pathways.	   Experiments	   were	   conducted	   to	   compare	   intracellular	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survival	   of	   S.	   Typhimurium	   in	   donor-­‐matched	   GM-­‐CSF-­‐	   and	   M-­‐CSF-­‐derived	  macrophages,	   and	   preliminary	   results	   indicated	   that	   bacterial	   clearance	   was	  similarly	   enhanced	   with	   C5a	   co-­‐treatment	   in	   both	   populations,	   dependent	   on	  MEK1/2	   signaling.	  However,	   as	   this	   comparison	  was	   not	   fully	   explored,	   future	  studies	   could	   focus	   on	   comparing	   the	   efficacy	   of	   bacterial	   clearance	   and	  characterisation	  of	  the	  antimicrobial	  mechanisms	  employed	  by	  both	  macrophage	  populations	  upon	  co-­‐treatment	  with	  C5a.	  	  	  	  
6.4.	  Conclusions	  In	  summary,	  this	  thesis	  has	  revealed	  RNF144B	  as	  a	  novel	  regulator	  of	  IL-­‐1β	  that	  is	   specifically	   induced	   by	   LPS	   in	   human	   but	   not	   mouse	   macrophages.	   I	   also	  identified	   HDACi	   and	   C5a	   as	   being	   able	   to	   enhance	  macrophage	   antimicrobial	  responses.	   Thus,	   the	   findings	   from	   this	   project	   will	   direct	   future	   research	  towards	  a	  better	  understanding	  of	  macrophage	  inflammatory	  and	  antimicrobial	  pathways,	   and	  may	   contribute	   towards	   the	   development	   of	   novel	   strategies	   to	  ameliorate	   inflammation	   and/or	   enhance	   host	   defence	   through	   modulation	   of	  macrophage	  function.	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Appendix	  1	  -­‐	  Supplementary	  Figures	  	  	  
	  
Supplementary	  Figure	  1:	  RNF144B	  mRNA	  is	  LPS-­‐inducible	  in	  both	  GM-­‐CSF-­‐	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Supplementary	  Figure	  2:	  qPCR	  analysis	  of	  LPS-­‐,	  Poly(I:C)-­‐	  and	  imiquimod-­‐
regulated	  mRNA	  expression	  of	  RNF144B	  in	  primary	  human	  macrophages.	  	  Relative	  mRNA	  levels	  of	  RNF144B	  were	  determined	  by	  qPCR	  for	  HMDM	  treated	  with	  10	  ng/mL	  LPS,	  30	  μg	  poly	  (I:C)	  or	  20	  μg	  imiquimod	  	  for	  the	  indicated	  time	  course.	  Data	   (mean+SEM)	  shows	   fold	   change	   relative	   to	  unstimulated	  controls,	  and	   is	   combined	   from	   3	   independent	   donors.	   **P≤0.01;	   by	   one-­‐way	   ANOVA	  followed	  by	  Dunnett’s	  Multiple	  Comparison	  test.	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Supplementary	   Figure	   3:	   Protein	   expression	   of	   a	   potential	   alternative	  
isoform	  of	  RNF144B.	  
(A)	  HMDM	  were	  treated	  with	  100	  ng/mL	  LPS	  over	  the	  indicated	  time	  course.	  Cell	  lysates	  were	  harvested	  and	  analysed	  for	  RNF144B	  and	  GAPDH	  protein	  levels	  by	  western	   blotting.	   Data	   are	   from	   one	   experiment,	   and	   are	   representative	   of	   2	  independent	  experiments.	  (B)	  Relative	  levels	  of	  the	  potential	  RNF144B	  isoform	  were	   quantified	   using	   the	   ChemiDoc	   MP	   system.	   Data	   (1	   representative	  experiment)	  shows	  levels	  of	  protein	  normalised	  to	  GAPDH	  levels.	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Supplementary	   Figure	   4:	   The	   promoter	   region	   of	   human	   and	   mouse	  
RNF144B	  is	  conserved,	  but	  has	  distinct	  regulatory	  elements.	  Schematic	   diagram	   showing	   the	   human	   (top)	   and	   mouse	   (bottom)	   RNF144B	  promoters.	   Tags	   per	  millions	   (tpm)	   from	   FANTOM	   3	   and	   5	   CAGE	   analysis	   are	  indicated	  in	  the	  histogram	  plots	  (blue:	  unstimulated	  macrophage	  samples,	  n=11	  for	  human	  and	  n=9	   for	  mouse;	   red:	  LPS-­‐stimulated	  macrophages	  at	  2	  h	   to	  7	  h,	  n=21	  for	  human	  and	  n=11	  for	  mouse;	  black:	  heart	  and	  testis,	  n=6	  for	  human	  and	  n=8	   for	   mouse).	   The	   graphs	   show	   average	   number	   of	   CAGE	   tags/sample	   to	  correct	   for	  differences	   in	  n.	  The	  annotated	  TSS	   from	   the	  Ensembl	  database	   for	  the	  human	  and	  mouse	  genes	  are	   indicated	  by	  solid	  arrows	  and	  6	  bp	  associated	  sequence.	   Transcription	   factor	   binding	   sites	   (indicated	   relative	   to	   Ensembl-­‐annotated	  TSS)	  were	  predicted	  using	  the	  ECR	  browser.	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Supplementary	   Figure	   5:	   Alignment	   of	   the	   amino	   acid	   sequence	   of	  
RNF144B	  and	  HHARI	  and	  the	  predicted	  structure	  of	  RNF144B.	  	  The	   amino	   acid	   sequence	   of	   RNF144B	   was	   analysed	   by	   Swiss	   Model	  	  (http://swissmodel.expasy.org/)	   and	   its	   structure	   predicted	   using	   the	   protein	  structure	   of	   HHARI	   as	   a	   template.	   (A)	   The	   amino	   acid	   sequence	   of	   RNF144B	  aligned	   to	   HHARI.	   Orange	   and	   Purple	   boxes	   indicate	   the	   locations	   of	   residues	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predicted	   to	   co-­‐ordinate	   Zn2+	   within	   the	   RING1	   and	   RING2	   domains.	   (B)	   The	  predicted	  structure	  of	  RNF144B.	  Boxes	  indicate	  where	  the	  residues	  predicted	  to	  co-­‐ordinate	  Zn2+	  (C153,	  C155,	  C156,	  D158,	  H161,	  C166	  within	  RING1	  and	  C219,	  Y221,	  C222	  within	  RING2)	  are	  located	  within	  the	  predicted	  structure.	  Sequence	  in	  bold	  indicates	  alignment	  matched	  with	  HHARI.	  Rectangles	  around	  amino	  acid	  sequences	   indicate	   predicted	   alpha-­‐helix	   secondary	   structure,	   while	   arrows	  indicate	   beta-­‐sheets.	   Regions	   highlighted	   in	   blue	   indicate	   the	   positions	   of	  conserved	  cysteines.	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Appendix	  2	  -­‐	  Standard	  Solutions	  
Solution	   Components	  LIFT	  buffer	   25	  mM	  EDTA,	  0.1%	  azide,	  PBS	  PBS	   	  	   	   	   137	  mM	  NaCl,	  2.7	  mM	  KCl,	  10	  mM	  buffered	  phosphate	  solution	  pH	  7.4	  TBST	   10	  mM	  Tris-­‐HCl	  pH	  8.0,	  150	  mM	  NaCl,	  0.05%	  Tween-­‐20	  MACS	  buffer	   0.5%	  FCS,	  2	  mM	  EDTA	  in	  sterile	  PBS	  MTT	  reagent	  	   	   	   5X	  stock:	  	  5	  mg/mL	  MTT	  (3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐	  diphenyltetrazoliumbromide)	  in	  1X	  PBS.	  	  Made	  to	  1X	  in	  complete	  media	  and	  filtered	  with	  0.45	  μM	  Millex-­‐HA	  sterile	  filters	  immediately	  prior	  to	  use.	  Phosphatase	  Inhibitor	   1	  mM	  sodium	  vanadate,	  1	  mM	  sodium	  pyrophosphate,	  1	  mM	  sodium	  molybdate,	  10	  mM	  sodium	  fluoride	  RIPA	  Buffer	   50	  mM	  Tris-­‐HCl	  pH	  7.4,	  150	  mM	  NaCl,	  0.1%	  SDS,	  1%	  Sodium	  Deoxycholate,	  1%	  NP-­‐40	  Western	   Transfer	  Buffer	   10X	  stock:	  	  30.3	  g/L	  Tris,	  144	  g/L	  glycine	  Transfer	  buffer	  was	  diluted	  in	  water	  to	  1X	  working	  solution	  with	  addition	  of	  methanol	  at	  a	  final	  concentration	  of	  10%.	  
Table	  A.1:	  Standard	  solutions	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Appendix	  3	  -­‐	  Review	  Publication	  A	  portion	  of	   the	   following	   review	  published	   in	  Current	  Opinion	   in	  Microbiology	  was	  included	  in	  Chapter	  1	  of	  this	  thesis	  and	  is	  appended	  here	  for	  reference.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Differences in the repertoire, regulation and function of Toll-like
Receptors and inflammasome-forming Nod-like Receptors
between human and mouse
Juliana K Ariffin and Matthew J Sweet
Ilya Metchnikoff’s use of starfish larvae to discover
phagocytosis, and Bruno Lemaitre’s and Jules Hoffmann’s
identification of host defence functions for Drosophila Toll
provide compelling examples of the utility of model organisms
for discovery of human innate immune pathways. Bruce
Beutler’s mapping of lipopolysaccharide non-responsiveness
in C3H/HeJ mice to the Toll-like Receptor 4 gene similarly
highlights the power of the mouse as a model. Models have
limitations however, and characterising the functional
relevance of human innate immune responses not conserved in
the mouse presents both a challenge and an opportunity. Here
we review differences between human and mouse Toll-like
Receptors and inflammasome-forming Nod-like Receptors in
repertoire, regulation and function, highlighting the significance
of these differences for human innate immunity.
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As a system designed to maintain homeostasis, the innate
immune system is intimately linked to many disease
processes. Studies of mouse innate immune genes and
pathways have paved the way for the development of new
or emerging therapies, for example, anti-TNFa and anti-
IL-6 therapy for rheumatoid arthritis, and IL-1
antagonists for gout and type II diabetes [1]. Along with
success stories, there are also failures; for severe sepsis/
septic shock, for example, several therapies effective in
the mouse LPS shock model have shown no clinical
benefit or actually increased morbidity and mortality in
humans (Table 1). Such lack of translation reflects many
factors that limit the utility of mouse models in replicating
human sepsis/septic shock. This condition is extremely
heterogeneous, typically involving multiple infectious
agents acting through distinct sites of infection, with
patients varying in genetics, sex, age and time of pres-
entation. In contrast, these variables are usually carefully
controlled for in many mouse sepsis models, for example,
through the use of in-bred mouse strains and defined
infectious agents or bacterial products. However, evol-
utionary differences between humans and mice may also
be a contributing factor to failures in the clinic. Thus,
knowledge of species differences between human and
mouse immunity is vital for understanding limitations of
the mouse model, and for pioneering new therapeutic
approaches that cannot be studied with traditional mouse
models.
Humans and mice diverged from a common ancestor
more than 60 million years ago [2], and there are numer-
ous phenotypic differences between the immune systems
of these species [3]. At a genetic level, phenotypic differ-
ences are driven by evolution of non-orthologous genes
through several mechanisms, as well as divergence in the
functions of orthologous genes (e.g. expression, alterna-
tive splicing, biological roles) [4]. Innate immune genes
are particularly susceptible to evolutionary divergence
[5], consistent with the evolutionary arms race between
host and pathogen. It follows that such differences are
likely important for host defence, and thus infectious and
inflammatory disease processes.
PRRs
The innate immune system recognises invariant
microbial motifs and endogenous molecules that indicate
organismal ‘danger’. The sensing of these pathogen-
associated molecular patterns and danger-associated mol-
ecular patterns by immune cells is facilitated by cell
surface and intracellular pattern recognition receptors
(PRRs) including the Toll-like Receptors (TLRs),
nucleotide-binding oligomerisation domain-like recep-
tors (NLRs), retinoic acid-inducible gene I-like receptors,
C-type lectin receptors and the pyrin and HIN domain-
containing protein receptor family [6,7]. Although the
various PRR families are often conserved across species,
there is substantial species diversity in the repertoire
within individual families [5]. This likely reflects
species-specific receptor expansion and reshuffling,
resulting in parallel evolution and conservation of key
domain architectures due to functional constraints [8].
The TLRs and NLRs are the most widely studied PRRs.
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TLRs primarily act by regulating gene expression,
whereas NLRs can have diverse functions including
acting as transcriptional co-activators (CIITA), NF-kB-
activating signalling platforms that are triggered by bac-
terial products such as muramyl dipeptide (NOD1,
NOD2), and initiators of the inflammasome pathway.
Inflammasomes  are large multi-protein complexes that
activate caspase-1-dependent pro-inflammatory cyto-
kine production and cell death, often in co-operation
with the ASC adaptor protein (Apoptosis-associated
Speck-like protein containing a Caspase activation and
recruitment domain (CARD)). Below, we review recent
studies highlighting differences between human and
mouse in the repertoire, regulation or function of TLRs
and inflammasome-forming NLRs. In doing so, we
acknowledge that the majority of genetic and functional
analyses of these PRRs in the mouse utilise the C57Bl/6
in-bred strain, and that some apparent ‘species differ-
ences’ may actually reflect in-bred mouse strain vari-
ation. Because of space limitations, we do not cover other
PRR families or the many other innate immune gene
families with documented differences between these
species.
Human:mouse differences arising from
distinct TLR repertoires
The human genome contains ten functional TLRs
(TLR1–10), whereas the mouse genome contains 12
(Tlr1–9, Tlr11–13) [9]. TLR10 is present in human but
is a pseudogene in mouse, whilst Tlr11, 12 and 13 are
present in mouse but are represented by a pseudogene in
human [9,10]. Like TLR1/2, TLR10/2 senses triacylated
lipopeptides, but this receptor complex does not trigger
conventional TLR signalling programs in response to
these ligands [10]. Thus, although both mouse and
human cells can respond to triacylated lipopeptides, there
are likely to be differences in signalling and gene expres-
sion outputs, at least in B cells and plasmacytoid dendritic
cells where TLR10 is expressed. Differences in the TLR
repertoire may also permit species-specific pathogen
recognition, for example, uropathogenic Escherichia coli
and Toxoplasma gondii recognition by mTlr11 [11,12].
mTlr13 was shown to confer responsiveness to vesicular
stomatitis virus [13], and more recently, to RNA from
Gram-positive bacteria [14,15]. Intriguingly, it detects
a conserved sequence within 23S rRNA, and methylation
of this region confers both bacterial resistance to a group
of antibiotics that includes erythromycin, as well as eva-
sion of detection by Tlr13 [14]. The authors thus
propose that widespread microbial resistance to anti-
biotics, prevalent in ancient times, has led to effective
subversion of this recognition pathway, leading to its loss
from humans. It is of course quite likely that humans and
other Tlr13-devoid species utilise other nucleic acid
sensing TLRs, or perhaps alternative PRRs, to detect
bacterial 23S rRNA.
Orthologous TLRs and human:mouse
differences
Differences in ligand specificity for strict human:mouse
TLR orthologs is common. For example, hTLR8 but not
mTlr8 recognises the imidazoquinoline compound R848
[16], prompting initial speculation that mTlr8 is not
functional. However, mTlr8 does confer responsiveness
to vaccinia virus DNA in murine plasmacytoid dendritic
cells [17], and to the combination of polyT DNA and
hTLR8-activating ligands [18]. Thus, mTlr8 is func-
tional, but displays differences in ligand specificity to
hTLR8. Similarly, mTlr1/2 and mTlr2/6 heterodimers
both detect Aspergillus fumigatus, whereas in humans this
fungal pathogen is detected by TLR1/2, but not TLR2/6
[19]. Differences in ligand specificity between the human
and mouse TLR4/MD2 lipopolysaccharide (LPS) recep-
tor complex also exist [20], which may contribute to the
increased sensitivity of humans to LPS, as compared to
mice.
Differences in cell-specific expression of human:mouse
TLR orthologous are prevalent [21], and it is often the
case that a specific human immune cell population will
respond to a distinct set of TLR ligands to its mouse
counterpart. The same is true for regulated TLR expres-
sion. For example, LPS upregulates mTlr3 and mTlr6
expression in mouse but not in human macrophages
[22,23]. Consequently, LPS priming amplifies mouse
but not human macrophage responses to the TLR2/
TLR6 agonist FSL-1 [22]. Moreover, regulatory diver-
gence is common not only for the TLRs themselves, but
also for their target genes; there is widespread divergence
in LPS/TLR4-regulated expression of orthologous genes
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Table 1
Examples of therapeutic strategies effective in mouse sepsis models but not in subsequent human clinical studies
Therapeutic strategy Outcome of clinical trials References
TNFa blockade No improvement or dose-dependent increase in mortality, though some trials have
also reported beneficial effects in seriously ill septic patients
[52–54]
IL-1 receptor antagonism No significant reduction in mortality in two phase III trials, although a slight increase
in survival rates or survival time was reported in patients with organ dysfunction
and/or 24% risk of mortality
[53,55,56]
Anti-endotoxin Numerous large scale trials conducted, with no consistent therapeutic benefit [53,54]
Nitric oxide synthase inhibition Increased mortality, possibly due to cardiovascular effects, in a phase III trial [57]
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in primary human versus mouse macrophages, and sev-
eral of the divergently regulated genes have key anti-
microbial functions [22] (Table 2). Divergently
regulated genes often encode inputs (e.g. cell surface
receptors) and outputs (e.g. secreted proteins) (Table 2)
[22], predicting substantial functional differences be-
tween human and mouse TLR4 responses. In fact,
deficiencies in the key TLR signalling molecules
MyD88 and IRAK-4, cause susceptibility to a broad
range of pathogens in mice, whereas their loss in humans
results in profound susceptibility to a limited number of
pyogenic bacterial infections, and only in childhood
[24]. Similarly, TLR3 signalling has a restricted anti-
viral role in providing protection against herpes simplex
virus encephalitis in humans [25–27], in contrast to its
much broader functions in the mouse. Thus, TLRs
appear to have a narrower range of protective functions
against infectious diseases in humans, or greater redun-
dancy with other PRR families, as compared to mice.
Nonetheless, these receptors clearly have critical func-
tions in human immunity as evidenced by: first, the
severe susceptibility to specific pathogens that results
from genetic deficiencies in TLR signalling arms
(above); second, the fact that nucleic acid sensing TLRs
have been subjected to strong purifying selection [28],
and the fact that certain TLRs, for example, the TLR10–
TLR1–TLR6 gene cluster, show clear evidence of
positive selection [24,28].
Human:mouse differences arising from
distinct NLR repertoires
Apart from NLRP10, NLR family members contain a
nucleotide-binding domain that is N-terminal to a leucine
rich-repeat domain. NLRs have been partitioned into the
NLRA, NLRB, NLRC, NLRP and NLRX1 subfamilies
on the basis of additional domains [29], or into the NOD,
IPAF and NLRP subfamilies through phylogenetics [30].
NLR genes display species-specific expansion and/or loss
during mammalian evolution [31]; in the case of human
versus mouse, there are 22 hNLR, but >30 mNlr genes.
Interestingly, the divergence in gene repertoire is appar-
ent for the inflammasome-forming NLRP and IPAF sub-
families, rather than the NOD subfamily [30]. Multiple
paralogs of the human gene encoding the IPAF subfamily
member Apoptosis Inhibitory Protein (NAIP) exist in
mouse [32], and hNLRP1, hNLRP4 and hNLRP9 also
share one-to-many orthology relationships with mouse
[29,30]. In contrast, there are no orthologs of hNLRP7,
hNLRP8, hNLRP11 and hNLRP13 in mice. For NLRP8
and NLRP13, this likely reflects the loss of these genes
during rodent evolution, since orthologs are present across
other mammalian species. In the case of NLRP7 and
NLRP11, the absence from mouse reflects primate-
specific evolution; hNLRP7 is thought to have arisen from
duplication of an ancestral NLRP2 gene during primate
evolution, and a similar scenario is likely for hNLRP11,
which is related to hNLRP4 and hNLRP9 [31]. However a
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Table 2
Examples of human:mouse differences in TLR4-regulated expression of mRNAs encoding inputs, outputs and proteins involved in direct
antimicrobial functions. Table based on data from Schroder et al. [22], or references within. Fold regulation of mRNA levels indicates




LPS regulation in human
macrophages
LPS regulation in mouse macrophages Functions in host defence and immunity
NOS2a Not regulated Strongly upregulated (>100 fold) Catalyses production of nitric oxide, a key antimicrobial
effector molecule
LCN2a,c Not regulated Strongly upregulated (>100 fold) Interferes with iron acquisition by bacterial siderophores




Not regulated Rate limiting enzyme in tryptophan catabolism, providing
a nutrient starvation mechanism of host defence
CYP27B1a Strongly upregulated
(>30 fold)
Not regulated Enzyme required for Vitamin D synthesis, enabling








Not regulated Receptor for the IL-7 cytokine
CXCR4b Moderately upregulated
( 5 fold)




Not regulated Adipokine linked to glucose and lipid metabolism
CCL20c Strongly upregulated
(750 fold)
Not regulated Chemokine attracting CCR6+ leukocytes, particularly
lymphocytes
a Role in direct antimicrobial pathways.
b Input (e.g. cell surface receptor).
c Output (e.g. secreted molecule).
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recent study has proposed that mNlrp2 is more closely
related to hNLRP7 than hNLRP2 [33]. The authors
therefore argue that an Nlrp7-like gene actually
represents the ancestral gene and that the mNlrp2 anno-
tation is misleading, with mNlrp2/7 or mNlrp2/7-like being
a more appropriate reflection of orthology relationship.
The diversity between human and mouse in the NLR
repertoire predicts functional differences in danger sen-
sing pathways. The specific absence of Nlrp8 and Nlrp13
from rodents indicates that the functions of these genes
must be pursued in the future using human cells, genetic
association studies, and perhaps alternate animal models
to the mouse. A recent study identified an NLRP7
inflammasome triggering ASC-dependent caspase-1 acti-
vation and IL-1b and IL-18 maturation in response to
microbial acylated lipopeptides in human macrophages
[34]. NLRP7 also restricted intracellular growth of
Staphylococcus aureus and Listeria monocytogenes in infected
human macrophages, although NLRP7-dependent pyr-
optosis was not observed [34]. This suggests that
NLRP7 selectively promotes cytokine maturation, but
not cell death. The lack of a direct murine homolog
implies either that this pathway to IL-1/IL-18 processing
and intracellular pathogen control is absent in mice, or
that an alternative PRR fulfills this role. Given its phy-
logenetic relationship with hNLRP7, one candidate for a
functional equivalent is mNlrp2. Other investigators
have reported roles for NLRP7 in negatively regulating
inflammasome function by inhibiting pro-IL-1b syn-
thesis, but promoting LPS-induced  IL-1b and TNFa
secretion; human NLRP7 mutations cause recurrent
hydatidiform moles and peripheral blood mononuclear
cells from these patients secreted reduced amounts of
IL-1b and TNFa in response to LPS [35,36]. However,
Khare et al. [34] have shown that, in the absence of IL-1
signalling, knockdown of NLRP7 in human macro-
phages did not affect TNFa and IL-6 secretion in
response to a crude LPS preparation, which signals via
both TLR2 and TLR4. Thus, the exact role of NLPR7
in regulating TLR4 and other TLR responses requires
further investigation. At present, little is known of the
other primate-specific NLR, NLRP11, although it has
been linked with susceptibility to Crohn’s Disease [37].
Future studies on these two NLRs are likely to yield
important insights into human innate immunity. There
are also several primate-specific negative regulators of
inflammasomes, suggesting that there has been selective
pressure to ensure tight control of inflammasome func-
tion in human. One example is the Pyrin-only protein 2
(POP2), an inhibitor of ASC-dependent inflammasome
activation. POP2 is present in Old World primates but
appears to be absent from New World primates, indi-
cating that it likely emerged as a functional gene less
than 40 million years ago [33]. Hence, some mechan-
isms for limiting inflammasome activation are absent in
the mouse.
Multiple mouse Naip family members promote Nlrc4
inflammasome formation by recognition of specific bac-
terial proteins. mNaip5 and mNaip6 recognise flagellin
from several bacterial species, while mNaip2 recognises
inner rod proteins such as Salmonella PrgJ and Burkhol-
deria BsaK of bacterial Type III secretion systems
[38,39]. In contrast, hNAIP does not recognise flagel-
lin or PrgJ; rather it initiates NLRC4 inflammasome
formation by detecting the needle subunit from Type
III secretion systems of various bacteria [39]. However,
all of these bacterial ligands present similar structural
motifs to their cognate receptor. Thus, there appears to be
broad conservation between human NAIP and the mouse
Naips in terms of structural recognition and biological
functions, even though the exact activating ligands and
receptors differ. Nonetheless, the rapid expansion of
mNaip genes may have increased the spectrum of patho-
gens that can be detected by mNlrc4, as compared to
hNLRC4. NLRP1, which contains a C-terminal CARD
that enables ASC-independent inflammasome formation,
provides another example of species differences for
NLRs with a non-1:1 orthology relationship. hNLRP1
contains an N-terminal pyrin domain and its capacity to
activate caspase-1 is enhanced by ASC [40], whilst the
pyrin domain is not present in mNlrp1 proteins. Using a
mouse strain with an activating mutation in Nlrp1a, as
well as mice with a knockout of the entire Nlrp1 locus, a
recent study showed that mNlrp1 acts as a sensor of
haematopoietic progenitor cell stress triggered by che-
motherapy and lymphocytic choriomeningitis virus
[41]. Thus, in humans, ASC may partially contribute
to NLRP1-dependent haematopoietic progenitor cell
responses such as IL-1b maturation, whereas this does
not appear to be the case in mouse.
Orthologous NLRs and human:mouse
differences
Some of the most widely studied NLRs, for example,
NLRP3, NOD1 and NOD2 share 1:1 orthology relation-
ships between human and mouse, but this does not
preclude differences in activation signals or function.
For example, hNLRP3 but not mNlrp3 is activated by
Francisella tularensis [42], whereas both hAIM2 and
mAim2 are able to sense this pathogen [42,43]. Sequence
differences between hNLRP3 and mNlrp3, or pathways
to their activation, are likely responsible and could con-
tribute to species differences in detection of other danger
signals. There are also indications of human:mouse differ-
ences for NLRP10, an NLR that lacks a leucine rich-
repeat domain. This NLR has been reported to nega-
tively regulate inflammasome function in human and
mouse, but through differing mechanisms; hNLRP10
inhibited procaspase-1 and pro-IL-1b processing and
ASC aggregation, while mNlrp10 inhibited IL-1b pro-
duction but not caspase-1 processing and ASC aggrega-
tion [44]. However, recent gene knockout studies do not
support a role for mNlrp10 as a negative regulator of the
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inflammasome; rather, mNlrp10 was required for dendri-
tic cell migration and CD4+ T cell-dependent immune
responses [45]. Interestingly, there is evidence for recent
evolutionary divergence in hNLRP10; this gene has a 2.7-
kb deletion in exon 2, which arose after evolutionary
divergence of humans and chimpanzees [46]. This results
in the loss of 30 amino acids from the C-terminus that are
conserved in other primates, and also generates an
alternative 30UTR. Such differences could confer differ-
ential regulation and function to hNLRP10 as compared
to orthologs in primates, and also mouse. In fact, there is
some evidence of different expression patterns of
NLRP10, as well as other NLR family members, between
human and mouse [47]. Finally, there are also differences
in the regulation of genes implicated in activation of
NLRPs. LPS, a classic priming signal for inflammasome
activation, upregulates the mRNA levels of Syk, Nox1 and
Cybb in primary mouse but not human macrophages [48].
These have been directly implicated, or suggested to be
involved, in the activation of NLRP3. This suggests that
there may be differences in the control points for priming
of NLRP3-dependent inflammasome formation in
human versus mouse.
Conclusions
There are substantial differences in TLRs and inflam-
masome-forming NLRs between humans and mice, ran-
ging from divergence in gene repertoire to differences in
regulation, ligand specificity and function (Figures 1 and
2). These are not presented with the intention of dis-
counting the mouse as a model for human innate immu-
nity. In fact, the ultimate biological outcomes initiated by
specific danger signals are often conserved between
human and mouse, even though the precise TLR/NLR
recognition and/or control mechanisms may differ. Un-
derstanding these differences is important however,
because a comprehension of pathways at the molecular
level is essential for devising new therapeutic strategies
for innate immune-driven disease processes, and for un-
derstanding differences between human and mouse with
respect to the pathogenicity of some microorganisms.
One obvious challenge that lies ahead is to understand
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Figure 1
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Human:mouse TLR differences. Mechanisms for differences in TLR repertoire or function between human and mouse are shown. Specific examples
for each mechanism are provided, along with possible functional consequences of these differences.
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the in vivo relevance of human PRR genes or functions
that are not conserved in the mouse. Recent improve-
ments in reconstituting the myeloid compartment in
humanised mice provide one obvious avenue forward
[49,50], as does the utilisation of alternative animal
models [51] in those cases where a particular human
PRR gene or function is conserved in that species.
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Inflammatory Responses Induced by Lipopolysaccharide Are
Amplified in Primary Human Monocytes but Suppressed in
Macrophages by Complement Protein C5a
Vernon Seow, Junxian Lim, Abishek Iyer, Jacky Y. Suen, Juliana K. Ariffin,
Daniel M. Hohenhaus, Matthew J. Sweet, and David P. Fairlie
Monocytes and macrophages are important innate immune cells equipped with danger-sensing receptors, including complement
and Toll-like receptors. Complement protein C5a, acting via C5aR, is shown in this study to differentially modulate LPS-induced
inflammatory responses in primary human monocytes versus macrophages. Whereas C5a enhanced secretion of LPS-induced IL-6
and TNF from primary human monocytes, C5a inhibited these responses while increasing IL-10 secretion in donor-matched
human monocyte-derived macrophages differentiated by GM-CSF or M-CSF. Gai/c-Raf/MEK/ERK signaling induced by C5a was
amplified in macrophages but not in monocytes by LPS. Accordingly, the Gai inhibitor pertussis toxin and MEK inhibitor U0126
blocked C5a inhibition of LPS-induced IL-6 and TNF production from macrophages. This synergy was independent of IL-10,
PI3K, p38, JNK, and the differentiating agent. Furthermore, C5a did not inhibit IL-6 production from macrophages induced by
other TLR agonists that are selective for Toll/IL-1R domain–containing adapter inducing IFN-b (polyinosinic-polycytidylic acid)
or MyD88 (imiquimod), demonstrating selectivity for C5a regulation of LPS responses. Finally, suppression of proinflammatory
cytokines IL-6 and TNF in macrophages did not compromise antimicrobial activity; instead, C5a enhanced clearance of the
Gram-negative bacterial pathogen Salmonella enterica serovar Typhimurium from macrophages. C5aR is thus a regulatory
switch that modulates TLR4 signaling via the Gai/c-Raf/MEK/ERK signaling axis in human macrophages but not monocytes.
The differential effects of C5a are consistent with amplifying monocyte proinflammatory responses to systemic danger signals, but
attenuating macrophage cytokine responses (without compromising microbicidal activity), thereby restraining inflammatory
responses to localized infections. The Journal of Immunology, 2013, 191: 000–000.
C
omplement is an important cascading network of .30
soluble plasma and insoluble membrane-bound proteins
that cooperate in innate immunity in the recognition,
opsonization, destruction, and removal of pathogens and infected
or damaged cells. Complement activation by classical, alternative,
and lectin pathways and other routes is tightly controlled, pro-
ducing the lytic membrane attack complex, as well as opsonins
such as C3b and proinflammatory anaphylatoxins C3a, C4a, and
C5a. Elevated plasma levels of C5a or its receptor are associated
with inflammatory diseases such as rheumatoid arthritis, inflam-
matory bowel diseases, respiratory distress syndrome, ischemia–
reperfusion injury, and sepsis (1). C5a binds to and signals through
the receptor C5aR (CD88), a class A G protein–coupled rhodopsin-
like receptor (2), and to a second receptor C5L2, which does not
couple G proteins and may be nonsignaling, but may also mod-
ulate C5aR (3, 4). C5aR couples to the pertussis toxin (PTX)–sen-
sitive Gai and in some cells such as monocytes to the PTX-insensitive
Ga16, and it recruits b-arrestins-1,2 to the plasma membrane (1, 5).
C5a activates several downstream signaling pathways, including
Akt, MEK, PI3K, phosphokinase A, phospholipase C (PLC), and
NF-kB (1).
The TLRs are an important family of type I transmembrane
proteins that respond to infectious organisms and danger signals by
initiating inflammatory responses, activating microbial killing and
clearance mechanisms, and priming the adaptive immune response
(6). Of 10 known human TLRs, TLR4 responds to LPS from
Gram-negative bacterial cell walls. TLR4 can signal through two
different pathways dependent on, and modulated by, separate
adaptor proteins MyD88 or Toll/IL-1R domain–containing adapter
inducing IFN-b (TRIF) (7). MyD88 activates IL-1R–associated
kinases (IRAKs) and TNFR-associated factor 6 (TRAF6), as well
as transcription factors NF-kB, AP-1, and IFN regulatory factor 5
(IRF5) further downstream. TRIF signals the induction of type I
IFNs by recruiting TRAF3 and receptor interacting protein 1 (RIP1)
to activate transcription factor IFN regulatory factor 3 (IRF3), NF-kB,
and AP-1. Both MyD88 and TRIF activate AP-1 via downstream
MAPK activation (8), although NF-kB and MAPK activation by
TRIF occurs later than for MyD88 (9).
In the present study, crosstalk between C5aR and TLR4 was
investigated in human monocytes and human monocyte–derived
macrophages (HMDMs) using the respective ligands C5a and
LPS. Crosstalk between different signaling pathways in mam-
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malian cells can result in unexpected and unique functional out-
comes (10). Some pathogens have evolved to evade or exploit host
microbial-killing by targeting C5aR and TLRs specifically. For
example, virulence proteins secreted by Staphylococcus aureus
bind to C5aR with potent antagonist activity, preventing recruit-
ment of phagocytes to sites of infection (11). Porphyromonas
gingivalis exploits the C5aR/TLR2 crosstalk by increasing cAMP
production in macrophages, which suppresses macrophage im-
mune function and enhances pathogen survival (12). Clearly, these
pathogens have evolutionarily adapted to exploit complement/
TLR crosstalk to their advantage. Although C5aR and TLR4
signaling have been separately investigated in many studies, there
is comparatively little reported about their interplay (13). Among
recent reports on C5aR/TLR4 crosstalk, C5a has been found to
downregulate TLR4-induced IL-12 production via PI3K-dependent
(14) and PI3K-independent (15) pathways in mouse macrophages;
to signal via the PI3K-Akt pathway to enhance LPS-induced IL-17F
cytokine production (16); and to suppress LPS-induced IL-17A and
IL-23 cytokine production in mouse macrophages (17). C5a-induced
suppression of the LPS-inducible IL-17A/IL-23 axis was reported
to occur via enhanced IL-10 production and ERK1/2 phosphoryla-
tion. However, most studies reporting C5a modulation of TLR4
signaling had been performed with murine rather than human cells
(18, 19). Some interpretations of human disease mechanisms have
been made based on extrapolating from observations of mouse
studies. However, there are important differences in LPS-induced
TLR4 signaling between humans and mice (20–22), necessitating
careful assessment of C5aR/TLR4 crosstalk in human cells.
Monocytes and macrophages are important cellular mediators
of innate immunity and are targets for C5a and LPS. Some features
of LPS signaling are also distinctly different between human mono-
cytes and macrophages (23). Monocytes act as danger sensors in the
circulation and typically generate a more rapid, heightened inflam-
matory response than do macrophages to danger signals. For exam-
ple, LPS alone can trigger inflammasome activation in monocytes,
whereas an additional activation signal such as ATP is required
in macrophages (24). The present study compares effects of C5a
on LPS responses in primary human monocytes versus donor-
matched macrophages derived through differentiating monocytes
with either GM-CSF or M-CSF. Surprisingly, we found that C5a
differentially modulated LPS responses depending upon the cell
type, that C5a activated the Gai/c-Raf/MEK/ERK axis to selec-
tively downregulate proinflammatory cytokine production from
macrophages but not monocytes, and that effects on macrophages
do not compromise but instead stimulate pathogen killing. Thus, it
is proposed that C5a has distinctly different regulatory effects on




Recombinant human GM-CSF, M-CSF, and IL-10 were purchased from
PeproTech. LPS from Salmonella enterica (serotype Minnesota RE 595),
U0126 monothanolate, wortmannin, and PTX were purchased from
Sigma-Aldrich. Imiquimod R837 (IMQ) and polyinosinic-polycytidylic
acid (poly(I:C)) were purchased from InvivoGen. Human C5a was pur-
chased from Sino Biological. Goat neutralizing Ab against human IL-10
(AB-217-NA) was purchased from R&D Systems. C5aR antagonist (3D53
also licensed as PMX53) (1, 25) was synthesized and characterized (an-
alytical HPLC, mass spectroscopy, and nuclear magnetic resonance spec-
troscopy) in-house as described (26). Abs against phosphorylated c-Raf
and total c-Raf were purchased from Cell Signaling Technology. All cell
culture reagents were purchased from Invitrogen, and all analytical-grade
chemical reagents were obtained from Sigma-Aldrich, unless otherwise
stated.
Isolation of human monocytes and macrophages
PBMCs were isolated from buffy coats of anonymous donors (Australian
Red Cross Blood Service, Kelvin Grove, QLD, Australia) by density
centrifugation using Ficoll-Paque Plus (GE Healthcare) following the
manufacturer’s instructions. Contaminating erythrocytes were removed by
repeated ice-cold sterile water. CD14+ MACS MicroBeads (Miltenyi
FIGURE 1. C5a acting via C5aR dose-de-
pendently modulates LPS-induced IL-6, TNF,
and IL-10 cytokine production in human mono-
cytes and macrophages (GM-Mf and M-Mf)
via C5aR. (A–C) Human CD14+ monocytes
(gray) and HMDMs (GM-Mf, black; M-Mf,
white) were serum-deprived for at least 8 h be-
fore treatment with LPS (5 ng/ml) in the ab-
sence or presence of various concentration of
C5a (0.03–300 nM) for 24 h. (D–F) For antag-
onism of C5aR, cells were pretreated with 3D53
(1 mM, 30 min) prior to C5a and LPS stimu-
lation. ELISA was used to detect levels of se-
creted (A, D) IL-6, (B, E) TNF, and (C, F) IL-10
in culture media. Error bars are means 6 SEM
of three independent experiments (n = 3). *p ,
0.05, **p , 0.01, ***p , 0.001 by Student t
test.
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Biotec) were used to positively select monocytes from isolated PBMCs
according to the manufacturer’s instructions. CD14+ monocytes were
seeded at 1 3 106 cells/ml in IMDM supplemented with 10% FBS, 100
U/ml penicillin, 100 mg/ml streptomycin, and 2 mM GlutaMAX at 37˚C
in presence of 5% CO2. To generate HMDMs, CD14
+ monocytes were
cultured in the presence of either 10 ng/ml GM-CSF (GM-Mf) or M-CSF
(M-Mf) for at least 6 d.
Quantitative cytokine ELISA
Cells were seeded at 1 3 106 cells/ml and serum-deprived overnight in the
incubator prior to treatment. LPS and C5a treatments were premixed prior
to 24 h stimulation. Cell culture supernatants were collected and cytokine
levels were determined using specific ELISA sets from BD Pharmingen,
according to the manufacturer’s instructions.
Isolation of mRNA and RT-PCR
Total RNA was extracted from cells using an RNeasy Mini Plus kit
(Qiagen), according to the manufacturer’s instructions. Total cellular RNA
(2–10 mg) was reverse transcribed to cDNA using oligo(dT) primer (1 mg)
and SuperScript III (Invitrogen), according to the manufacturer’s instruc-
tions. cDNA samples were stored at 220˚C until further use.
Gene expression analysis by real-time PCR
Gene-specific primers were designed using the free Web-based software
Primer-BLAST (National Center for Biotechnology Information). Quan-
titative real time-PCR was performed using an ABI Prism 7900 real-time
PCR system (Applied Biosystems), cDNA (50 ng), SYBR Green PCR
Master Mix (Applied Biosystems), and gene-specific primers. Relative gene
expression was normalized against 18S rRNA expression and then converted to
fold change against control samples. All samples were analyzed in duplicate.
Primer sequences used are: CD68, 59-TTTGGGTGAGGCGGTTCAG-39 and
39-CCAGTGCTCTCTGCCAGTA-59; 18S, 59-ACCACGGGTGACGGGGA-
ATC-39 and 39-CCGGGTCGGGAGTGGGTAAT-59.
Quantification of MEK1, ERK1/2, p38, and JNK
phosphorylation
Cells were seeded at 4000 cells/well in white ProxiPlate-384 (PerkinElmer)
overnight. On the following day, cells were serum-deprived for 2 h prior
to stimulation with C5a (30 nM), LPS (5 ng/ml), or both over a stated
time course. Alphascreen SureFire assays (PerkinElmer) were performed
according to the manufacturer’s instructions.
Western blot analysis
Equal amounts of total cell lysates (10 mg) were subjected to SDS-PAGE,
transferred to polyvinylidene difluoride membranes, and proteins were
detected using appropriate Abs according to the manufacturer’s instructions.
Bacterial clearance assay
Intracellular survival of Salmonella enterica serovar Typhimurium
(S. Typhimurium) strain SL1344 within HMDMs was monitored in gen-
tamicin exclusion assays (27). M-Mf were seeded at 200,000 cells/well in
penicillin/streptomycin-free media containing M-CSF (10 ng/ml). On the
following day, cells were infected with S. Typhimurium at a multiplicity of
infection (MOI) of 100. One hour after infection, cells were washed with
gentamicin (200 mg/ml) in penicillin/streptomycin-free media and further
incubated (1 h) to kill extracellular bacteria in the same media. Additional
incubations beyond this 2 h time point were carried out in media con-
taining 20 mg/ml gentamicin. At specific time points, cells were washed
twice and lysed with 0.01% Triton X-100 in PBS, after which lysates were
cultured overnight on Luria–Bertani agar. Colony counts were performed
to assess intracellular bacterial loads. The MOI was also confirmed by
plating out inoculum on Luria–Bertani agar plates and performing colony
counts. Treatments with C5a (30 nM) were conducted by cotreatment with
bacteria upon infection. For antagonism assays, cells were pretreated with
the C5a inhibitor 3D53 (1 mM) 30 min prior to infection. 3D53 was also
added back following the washing with gentamicin-containing media.
Statistical analysis
Data were plotted and analyzed using GraphPad Prism version 5.0c for
Mac OS X (GraphPad Software). Statistically significant differences were
assessed using a Student t test for paired comparison. All values of inde-
pendent parameters are shown as means6 SEM of at least three independent
experiments, unless otherwise stated. A p value , 0.05 was considered
statistically significant.
Results
C5a acting via C5aR differentially modulates LPS signaling in
human CD14+ monocytes versus macrophages
In light of recent discoveries linking crosstalk between TLRs and
the complement system as possible control points for regulation
of host defense (13), this study compared C5aR/TLR4 crosstalk
between human monocytes and macrophages, given their different
roles in responding to inflammatory stimuli. C5a decreased
LPS-induced secreted levels of IL-6 and TNF in both GM-Mf
and M-Mf, but it increased the levels of the same proinflammatory
cytokines in monocytes (Fig. 1A, 1B). Alternatively, C5a enhanced
LPS-induced IL-10 production from macrophages, but it had no
effect on this response in monocytes (Fig. 1C). This suggests that
the regulatory effects of C5aR on TLR4 depend on cellular context,
for example differentiation status. Although C5aR mediates C5a-
dependent responses, a second C5a receptor, C5L2, has also been
reported to exhibit anti-inflammatory functions (3, 28). However,
FIGURE 2. Temporal study of C5aR/TLR4 crosstalk in monocytes and
macrophages. Human CD14+ monocytes were differentiated to HMDMs
with either GM-CSF (10 ng/ml) (GM-Mf, black) or M-CSF (10 ng/ml)
(M-Mf, white) in 10% FBS/IMDM during a 6-d time course. Macrophage
marker (A) CD68 gene expression was monitored during differentiation in
the presence of GM-CSF (black) or in the presence of M-CSF (white) on
days 0, 2, 4, and 6. Genes were detected by quantitative RT-PCR, normalized
against 18S rRNA expression, and converted to fold change relative to day 0.
These cells were also treated with LPS (5 ng/ml) with and without C5a (30
nM) for 24 h in 10% FBS/IMDM on days 0, 2, 4, and 6 to monitor sup-
pression by C5a of LPS-induced IL-6 and TNF in HMDMs. ELISAwas used
to detect (B) IL-6, (C) TNF, and (D) IL-10 secreted in culture media. Error
bars are means6 SEM of three independent experiments (n = 3). *p, 0.05,
**p , 0.01, ***p , 0.001 by Student t test.
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the biological roles of C5L2 in inflammation are highly contro-
versial. Our group has previously developed 3D53, a potent, in-
surmountable, and selective antagonist of C5aR that does not bind
C5L2 (1, 29, 30). 3D53 blocked the immunomodulatory effects of
C5a on TLR4 signaling in both macrophages and monocytes (Fig.
1D–F), thus demonstrating that the observed responses of C5a
were mediated via C5aR rather than C5L2.
Temporal study of C5aR/TLR4 crosstalk in HMDMs
To further characterize the phenotypic switch in C5a responsive-
ness during monocyte to macrophage differentiation, time course
experiments were performed. As expected, mRNA levels of the
macrophage marker CD68 were increased after 4 d of differenti-
ation in the presence of either GM-CSF or M-CSF (Fig. 2A). The
suppressive effect of C5a on LPS-induced cytokine production
was apparent by day 4 for TNF, and by day 6 for IL-6 (Fig. 2B,
2C). Increased IL-10 production was also observed by day 4 (Fig.
2D). The suppressive effects of C5a on LPS-induced IL-6 and
TNF production in macrophages correlated with increased C5AR
and TLR4 expression during monocyte to macrophage differentia-
tion (Supplemental Fig. 1A, 1B). Levels of C5AR and TLR4 mRNA
were not affected by C5a treatment, but LPS decreased C5AR ex-
pression by ∼30% (Supplemental Fig. 1C, 1D), consistent with a
previous study (31).
C5a suppresses LPS-induced IL-6 and TNF via Gai- and
MEK-dependent signaling
C5a-dependent C5aR signaling involves coupling to Gai proteins
(5, 32). We used PTX, which specifically interferes with Gai
protein signaling, to investigate whether the blockade of Gai
signaling would reverse inhibition by C5a of TLR4 responses. As
expected, all modulatory effects of C5a on LPS-induced cytokine
production from monocytes and macrophages was sensitive to
PTX (Fig. 3). These results further confirmed involvement of
C5aR and not C5L2 signaling in this crosstalk, as C5aR, but not
C5L2, employs Gai signaling (1, 3). We also pharmacologically
targeted downstream signaling of C5aR signaling and found that
the MEK inhibitor U0126, a selective inhibitor of the ERK pathway
(33), prevented immunomodulation by C5a of LPS-induced IL-6
and TNF production in macrophages, but not monocytes (Fig. 3A,
3B). In monocytes, the enhancement of LPS-induced IL-6 pro-
duction by C5a was altered by the presence of MAPK p38 and
PLCb inhibitors SB203580 and U73122, respectively, whereas the
enhancement of LPS-induced TNF production was affected by
phosphokinase A inhibitor PKI 14-22 (Supplemental Fig. 2A, 2D).
Collectively, these data suggest that C5a-dependent ERK1/2 phos-
phorylation selectively suppresses LPS-induced IL-6 and TNF
production in macrophages. Interestingly, although the literature
suggests that ERK1/2 is involved in TLR-induced IL-10 production
from human macrophages (15, 34), we found in the present study
that C5a enhanced LPS-mediated IL-10 production in an ERK1/2-
independent, but Gai-dependent, manner (Fig. 3C). Similarly,
LPS-induced IL-10 production from monocytes, as well as from
GM-Mf and M-Mf, was ERK-independent (Fig. 3C).
C5a and LPS synergize for Raf/MEK/ERK phosphorylation in
macrophages
The data for PTX and U0126 inhibitors showed that C5a-modulated
suppression of LPS-mediated inflammatory responses was de-
pendent on Gai coupling and MAPK ERK1/2 phosphorylation.
Therefore, we further investigated additional checkpoints in the
signaling pathway between Gai signaling and upstream of ERK
phosphorylation (Gai/Raf/MEK/ERK) signaling cascade to fur-
ther map the crosstalk signaling mechanisms between C5aR and
TLR4. Interestingly, C5a phosphorylated c-Raf only in macro-
phages (both GM-Mf and M-Mf) but not in monocytes (Fig. 4A).
Co-treatment of GM-Mf or M-Mf with LPS and C5a synergis-
tically promoted c-Raf phosphorylation. This synergy was not
observed in monocytes. LPS triggered MEK1 phosphorylation in
macrophages (Fig. 4B). Although C5a and LPS each induced
MEK1 phosphorylation in monocytes and macrophages, the syn-
ergistic effect of LPS and C5a cotreatment was only observed in
FIGURE 3. C5a suppression of LPS-induced IL-6
and TNF in macrophages is sensitive to PTX and
MEKi (U0126) treatment. To inhibit Gai-dependent
interactions, cells were pretreated with PTX (200 ng/ml,
overnight) or, for MEK1/2 inhibition, U0126 (1 mM,
30 min) prior to LPS (5 ng/ml) with and without C5a
(30 nM) stimulation of monocytes (gray) and HMDMs
(GM-Mf, black; M-Mf, white). ELISA was used to
detect (A) IL-6, (B) TNF, and (C) IL-10 secreted cy-
tokines relative to the LPS response (100%) at 24 h
after stimulation. Error bars are means 6 SEM of three
independent experiments (n = 3). *p, 0.05, **p, 0.01,
***p , 0.001 by Student t test.
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macrophages. Consistent with this, cotreatment of GM-Mf or
M-Mf with LPS and C5a synergistically promoted ERK1/2
phosphorylation, whereas this synergy was not observed for
monocytes (Fig. 4C).
C5a and LPS synergize for phosphorylation of ERK1/2 but not
p38 or JNK in macrophages
Because C5a together with LPS potentiates ERK1/2 in macro-
phages, we next investigated the temporal profile of ERK1/2 ac-
tivation together with other MAPKs (p38 and JNK) in response to
C5a versus C5a plus LPS. C5a induced a transient peak in ERK1/2
phosphorylation within 5 min in monocytes (Fig. 5A) and mac-
rophages (Fig. 5B, 5C), but as we previously observed (Fig. 4C),
LPS amplified this response only in macrophages. C5a appeared
to have little or no effect on p38 and JNK phosphorylation (Fig.
5D–I) and did not amplify LPS-mediated activation of these sig-
naling responses. Although LPS at 5 ng/ml concentration induced
p38 and JNK phosphorylation, at the same concentration, LPS did
not stimulate ERK1/2 phosphorylation in HMDMs; however, at
a higher concentration (1 mg/ml), ERK1/2 phosphorylation was
detected after 20 min (Supplemental Fig. 2G). Although there was
no synergistic effect for p38 phosphorylation in monocytes, the
C5a-mediated amplification of LPS-induced IL-6 production
(Supplemental Fig. 2A), but not TNF production (Supplemental
Fig. 2B), from these cells was affected by the p38 inhibitor
SB203580. Furthermore, SB203580 did not block the suppression
by C5a of LPS-induced IL-6 and TNF production in macrophages
(Supplemental Fig. 2B, 2C, 2E, 2F).
C5a-mediated suppression of LPS-induced IL-6 and TNF is
IL-10 and PI3K independent
C5a has been previously reported to enhance LPS-induced IL-10
cytokine production from macrophages (15), and it has also
been reported to suppress IL-17A and IL-23 by enhancing IL-10
production (17). Consistent with such a mechanism, C5a upreg-
ulated LPS-induced IL-10 production from macrophages, but it
did not alter this response in monocytes (Fig. 1C). However, the
ability of the MEK inhibitor to block C5a-mediated suppression of
IL-6 and TNF production, without affecting enhancement of IL-10
production in macrophages, implied that the inhibitory effects on
IL-6 and TNF were IL-10–independent (Fig. 3C). We therefore
examined this hypothesis. LPS-induced IL-6 and TNF production
was suppressed with increasing concentrations of IL-10 (Supple-
mental Fig. 3A, 3B). This is consistent with literature indicating
that IL-10 attenuates IL-6 and TNF production from activated
macrophages (34, 35). A neutralizing Ab against human IL-10
(10 mg/ml) completely blocked the effect of exogenously added
IL-10 (2 ng/ml) in macrophages (Supplemental Fig. 3C, 3D), and
its addition prior to LPS stimulation resulted in increased TNF
production in GM-Mf and M-Mf (Fig. 6B). However, C5a still
suppressed IL-6 and TNF production in the presence of the neu-
tralizing Ab against human IL-10 (Fig. 6A, 6B), thus demon-
strating that the immunomodulation by C5a was independent of
IL-10. Therefore, C5a-enhanced LPS-induced IL-10 production
does not account for the inhibition of inducible IL-6 and TNF
production by C5a. Apart from IL-10, we also found that the
immunomodulation by C5a was also independent of LPS-induced
PI3K signaling in GM-Mf (Fig. 6C, 6D) and in M-Mf (Fig. 6E,
6F). The presence of the pan-PI3K inhibitor wortmannin at the
highest concentration (100 nM) did not abolish C5a-mediated
suppression of LPS-inducible IL-6 and TNF release, although
wortmannin on its own appears to enhance LPS-induced IL-6 and
TNF production from macrophages at 100 nM concentration.
C5a attenuation of LPS-induced IL-6 is selectively TLR4
mediated in macrophages
TLR4 signaling involves two major pathways, the Mal/MyD88-
and the TRAM/TRIF-dependent pathways (7). To determine
whether C5a affected responses through multiple TLRs in primary
human macrophages, poly(I:C) (TLR3 agonist signaling via TRIF)
and IMQ (TLR7 agonist signaling via MyD88) were used. In con-
trast to TLR4 activation by LPS, C5a amplified poly(I:C)-induced
(TRIF-dependent) IL-6 production from GM-Mf (Fig. 7B),
whereas it did not induce detectable levels of this cytokine in
monocytes and M-Mf (Fig. 7A, 7C). In the case of IMQ-induced
(MyD88-dependent) IL-6 production, C5a enhanced this response
in monocytes, as well as in both macrophage populations. C5a
also increased poly(I:C)-induced and IMQ-induced IL-10 pro-
duction in monocytes and M-Mf (Fig. 7D, 7F), but it did not
modulate this response in GM-Mf (Fig. 7E). These results sug-
gest that suppression of inducible IL-6 production by C5a in GM-
Mf and M-Mf is selective for TLR4 signaling.
C5a enhances clearance of S. Typhimurium from HMDMs
There is evidence in support of C5aR/TLR crosstalk being exploited
by some pathogens for host subversion (12, 35). Therefore, the
FIGURE 4. C5a induced Raf/MEK/ERK phosphorylation is amplified in
macrophages but not in monocytes by LPS. To quantify c-Raf, MEK1, and
ERK1/2 phosphorylation, monocytes (gray) GM-Mf (black), and M-Mf
(white) were treated with LPS (5 ng/ml) with and without C5a (30 nM) for
5 min, after which cells were lysed. (A) c-Raf phosphorylation was detected
by Western blot and probed with Abs against phosphorylated c-Raf and total
c-Raf. Bands were visualized by an ECL method and quantified by densi-
tometry measurements of phosphorylated c-Raf normalized with total c-Raf
against control. Levels of phosphorylated (B) MEK1 and (C) ERK1/2 were
measured by AlphaScreen SureFire assays. Error bars are means 6 SEM of
three independent experiments (n = 3). *p , 0.05, **p , 0.01, ***p ,
0.001 by Student t test.
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impact of C5a on the ability of HMDMs to clear S. Typhimurium
was examined. As expected, C5a alone did not have any bacte-
ricidal effect on S. Typhimurium (Fig. 8A). Instead, C5a promoted
the clearance of this bacterial pathogen from M-Mf, an effect that
was reversed by the C5aR antagonist 3D53 (Fig. 8B). In cytotoxicity
assays monitoring lactate dehydrogenase release, infection assay
FIGURE 5. C5a-induced ERK1/2 phosphory-
lation is amplified in macrophages but not mono-
cytes by LPS. To quantify (A–C) ERK1/2, (D–F)
p38, and (G–I) JNK phosphorylation, cells
(monocytes, GM-Mf, and M-Mf) were treated
with LPS (5 ng/ml) with and without C5a (30 nM)
for 10 min, after which cells were lysed. Phos-
phorylated ERK1/2, p38, and JNK were measured
by AlphaScreen SureFire assays. Treatments by
C5a, LPS, or both are represented by broken lines,
dotted lines, and solid lines, respectively. Error
bars are means 6 SEM of three independent
experiments (n = 3). **p , 0.01, ***p , 0.001
by student t test.
FIGURE 6. C5a suppression of LPS-induced IL-6
and TNF in macrophages is IL-10– and PI3K-inde-
pendent. To determine dependency of IL-10, GM-Mf
(black) and M-Mf (white) were pretreated with neu-
tralizing Ab against human IL-10 (10 mg/ml, 30 min),
or for dependency of PI3K signaling, wortmannin (1–
100 nM, pretreated for 1 h) prior to LPS (5 ng/ml) with
and without C5a (30 nM) stimulation, after which (A,
C, E) IL-6 and (B, D, F) TNF production were moni-
tored at 24 h after stimulation. Error bars are means 6
SEM of three independent experiments (n = 3). *p ,
0.05, **p , 0.01, ***p , 0.001 by Student t test.
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supernatants harvested 8 h after infection showed no differences
in macrophage viability irrespective of treatment (DMSO, SLI344,
hC5a, 3D53, or combinations), thereby indicating that reduced
bacterial loads upon C5a treatment were not a result of increased
macrophage death. Thus, C5a enhances human macrophage antimi-
crobial responses while reducing production of key proinflammatory
cytokines from these cells.
Discussion
Most pathogens trigger both complement and TLR activation,
and crosstalk between these two systems could potentially affect
inflammatory and antimicrobial responses in vivo in infectious
disease. However, studies on C5aR/TLR crosstalk have typically
focused on monocytes or macrophages separately. No previously
reported study has directly compared the impact of crosstalk on the
functional responses of primary human monocytes versus donor-
matched human macrophages. The present study has found that
the myeloid differentiation state is an important variable in de-
termining the impact of C5aR/TLR4 crosstalk on inflammatory
responses of human monocytes and macrophages. New findings in
this study suggest that C5a modulates TLR4 signaling in macro-
phages to favor pathogen clearance while simultaneously limiting
excessive inflammatory responses. This control may be important
during localized infections, whereas C5a detection by monocytes
likely acts as an alarm signal that triggers or amplifies inflammatory
responses during systemic infections.
The mechanisms of C5aR/TLR4 crosstalk are complex and
evidently species- and cell type–dependent. In human monocytes,
C5aR signaling has been reported to both downregulate (36) and
upregulate (37) TLR-induced IL-12 production. Although those
studies were performed on similar IFN-g–primed human blood
monocytes, the second signal used to stimulate the cells was
different. C5a suppressed LPS-induced IL-12 production but up-
regulated S. aureus Cowan I–induced IL-12 production. Although
not addressed in either study, the variations reported are likely due
to different TLRs being activated and differentially affected by
C5aR signaling. The present study emphasizes that C5a suppression
of IL-6 production is specific to LPS/TLR4 signaling in human
FIGURE 7. Suppression by C5a of inducible IL-6
production from macrophages is selective for LPS re-
sponses. Human CD14+ monocytes (gray) and HMDMs
(GM-Mf, black; M-Mf, white) were treated with 1)
LPS (TLR4 agonist, 5 ng/ml) with and without C5a
(30 nM) stimulation, 2) poly(I:C) (TLR3 agonist, 10
mg/ml) with and without C5a (30 nM) stimulation, or 3)
IMQ (TLR7 agonist, 10 mg/ml) with and without C5a
(30 nM) stimulation for 24 h in 10% FBS/IMDM.
ELISAwas used to detect (A–C) IL-6 and (D–F) IL-10
secreted in culture media. Error bars are means6 SEM
of three independent experiments (n = 3). *p , 0.05,
**p , 0.01, ***p , 0.001 by Student t test.
FIGURE 8. C5a decreases S. Typhimurium survival
in M-Mf. (A) Growth of S. Typhimurium was monitored
with and without C5a (100 nM) for 7 h. (B) M-Mf
were infected with S. Typhimurium (MOI of 100) with
and without C5a (30 nM). For antagonism of C5aR,
M-Mf were pretreated with 3D53 (1 mM) for 30 min
prior to C5a stimulation. Intramacrophage survival was
assayed at 2 and 8 h after infection. Graph shows a
representative of three independent experiments. Error
bars are means 6 SEM of experimental triplicates.
**p , 0.01, ***p , 0.001 by Student t test.
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macrophages, because IL-6 production is actually boosted by
C5aR crosstalk with other TLRs, such as TLR3 and TLR7. Similarly,
in mouse macrophages, C5a was reported to selectively crosstalk with
TLR4, but not TLR3, in suppressing IL-27 (p28) production (38).
C5a is thus not only a potent chemotactic agent, attracting immune
cells to site of infection or injury, but it also differentially modulates
host immune responses, possibly tailoring them to match a particular
type of infection.
The differentiating agents GM-CSF andM-CSF have differential
effects on macrophage lineage populations, which contribute to
their functional heterogeneity (39). GM-Mf are often considered
as “M1-like” macrophages, whereas M-Mf are classed as “M2-like”
macrophages, according to their cytokine and gene expression
profiles (40, 41). Whereas LPS-induced inflammatory cytokine
production was clearly enhanced in GM-Mf compared with M-Mf
in the present study, C5a exerted a similar suppressive effect on
inflammatory responses in both human macrophage populations.
Thus, the phenotypic switch in C5a responsiveness during monocyte
to macrophage differentiation occurred irrespective of the differ-
entiating agent. In the future, it will be of interest to determine
whether other macrophage-polarizing factors (e.g., IL-4, IgG)
influence the ability of C5a to suppress TLR4-inducible inflam-
matory mediator production. Although the basal levels of C5AR
and TLR4 increased during the course of differentiating mono-
cytes to macrophages, the differences in the expression levels are
unlikely to be the cause of the phenotypic switch in the crosstalk.
First, C5a treatments did not alter C5AR expression levels. Sec-
ond, C5a had opposing effects on inducible cytokine production
when the macrophages were challenged with poly(I:C) or IMQ,
instead of LPS.
The effects ofC5a onTLR4 responseswere PTX-sensitive in both
monocytes and macrophages, suggesting a Gai-sensitive mecha-
nism. C3a can also bind to a PTX-sensitive receptor, C3aR, that can
recruit GaI coupling when activated. Others have shown that C3a
acting on IFN-g–primed macrophages from C5aR2/2mice (14), as
well as other Gai-specific ligands acting on IFN-g–primed human
monocytes (42), can negatively regulate LPS-induced IL-12 pro-
duction. Also, PI3K signaling has been implicated in C5a regula-
tion of LPS signaling. The pan-PI3K inhibitor wortmannin was
reported by la Sala et al. (42) to block the suppression by C5a of
IL-12p70 production, but this was not the case in the study per-
formed by Hawlisch et al. (14). In our study, wortmannin treatment
had no impact on C5a-mediated suppression of LPS-induced IL-6
and TNF production in human macrophages under the conditions
examined. This suggests that the crosstalk is not only tightly reg-
ulated at multiple checkpoints in the signaling cascade, but that it is
also highly dependent on the activation status of the cells.
As shown previously in human neutrophils, C5a can activate the
Raf/MEK/ERK signaling cascade either directly via Gai activation
or indirectly via Gbϒ/PLCb/PKC pathways (32, 43). We found
that C5a-mediated suppression of LPS-induced IL-6 and TNF was
independent of PLCb signaling (Supplemental Fig. 2). Although
C5a rapidly phosphorylated ERK1/2 in both monocytes and mac-
rophages, consistent with the literature (14, 15), only in macrophages
did C5a increase c-Raf phosphorylation in the presence of LPS,
leading to a further downstream increase in phosphorylation of
MEK and ERK. Because LPS and C5a did not synergize to alter
other MAPKs (p38 and JNK) in monocytes and macrophages, we
attribute the differences in monocytes and macrophages to the
activation of the Gai/c-Raf/MEK/ERK pathway by C5a with LPS
in macrophages versus monocytes.
Low concentrations of LPS failed to stimulate ERK phospho-
rylation. However, only high concentrations of LPS triggered
delayed ERK1/2 activation (20 min after stimulation) by com-
parison with the C5a response, which occurs within 5 min. The
MAP3K tumor progression locus 2 is essential for activation of
ERK1/2 by multiple TLRs, including TLR4, in macrophages (44).
Consistent with this, we observed that LPS triggered MEK1 phos-
phorylation in macrophages independently of activation of another
MAP3K, c-Raf. ERK activation can produce different results,
depending on the stimulus and cell types, especially when com-
paring primary cells versus laboratory cultured cell lines (45). C5a
enhanced ERK1/2 activation in rat neutrophils, and this was as-
sociated with an increase in IL-6 production (46). This contrasts
with our present findings for human macrophages. Complement-
mediated ERK1/2 activation also inhibited IL-12 production in
human monocytes and mouse macrophages (14, 42), whereas the
opposite was observed in mouse dendritic cells (47). Such re-
ported variations in effects of C5a on LPS responses reinforce the
view that observations of complement-mediated effects on TLR
signaling are likely to not only be cell- and species-specific, but
also to vary with the inflammatory readout being monitored.
In summary, in this study we have identified C5aR as a regula-
tory switch that modulates LPS/TLR4 signaling via the Gai/c-Raf/
MEK/ERK signaling axis in primary human macrophages, but not
in monocytes. Extrapolating data from mice to humans, although
convenient, is often not appropriate (48). Regulatory mechanisms
involved in C5aR/TLR4 crosstalk that were previously reported
in mouse studies may not be conserved in humans. Differential
effects of C5a on monocytes versus macrophages have been dem-
onstrated in this study, consistent with a need to either amplify
monocyte proinflammatory responses during systemic danger
recognition or attenuate macrophage proinflammatory cytokine
responses (without compromising microbicidal activity) during
localized infections. Many therapies, including chemotherapy, ra-
diation, cancer vaccines, and small-molecule drugs, already use
immune cell–specific treatment strategies (49), but the rational
basis for targeting specific cell types frequently lacks a level of
understanding necessary to optimize such treatments. Studies such
as this one have the potential to unlock secrets relating to inter-
acting human immunoreceptors and control mechanisms that are
not obvious in studies targeting one particular receptor on a spe-
cific human immune cell type, let alone on immune cells from
other mammalian species.
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